

DESCRIPTION

TITLE OF THE INVENTION

COEXPRESSION PLASMID

Technical Field

[0001]

The present invention relates to a co-expression plasmid characterized by comprising two types of secretory expression cassettes each sequentially comprising a promoter DNA functioning in a bacterium of the genus *Bifidobacterium*; a DNA encoding a secretory signal peptide; a DNA encoding a heterologous polypeptide; and a terminator DNA functioning in the bacterium of the genus *Bifidobacterium*. The present invention also relates to a bacterium of the genus *Bifidobacterium* transformed with the co-expression plasmid; a pharmaceutical composition comprising the bacterium; and the like.

Background Art

[0002]

A great many therapeutic agents have been proposed up to present for treating diseases such as cancer; however the therapeutic agents are all have a limit in effect as pointed out by researchers. Thus, it has been desired to develop therapeutic agents and therapies having higher effects. Recently, development of a therapy using a gene transporting carrier has advanced. For example, a transformed microorganism is proposed (see for example, Patent Document 1), which uses an anaerobic

enterobacterium having a nature of being accumulated in a hypoxic solid tumor when it is systemically administered and the transformant thereof expresses a gene encoding a protein having an antitumor activity or a protein having an activity to convert an antitumor substance precursor to an antitumor substance, in a target diseased site. Further development of this is expected as a new technology for delivering a drug which inevitably produces a side effect when it is systemically administered, to a tumor site effectively in a high concentration.

[0003]

In the meantime, a promoter, a DNA encoding a signal sequence, a DNA encoding a polypeptide or an expression cassette comprising cloning sites for inserting these DNAs (see, for example, Patent Document 2) is proposed.

Prior Art Documents

Patent Documents

[0004]

Patent Document 1: International Publication No. WO2009/128272

Patent Document 2: International Publication No. WO2010/126073

Summary of the Invention

Object to be Solved by the Invention

[0005]

The DNA encoding a signal sequence and proposed in the aforementioned documents is DNA of a signal sequence

found in a membrane protein and a secretory protein. Identification of a signal sequence having more excellent secretion efficiency is expected; at the same time, development of a plasmid expressing a secretory heterologous protein having a higher therapeutic effect and an anaerobic enterobacterium transformed with such a secretory expression plasmid has been desired.

[0006]

An object of the present invention is to provide an anaerobic enterobacterium having a higher therapeutic effect at an anaerobic site such as a solid tumor tissue and an ischemic disease site.

Means to Solve the Object

[0007]

The present inventors found that a bacterium of the genus *Bifidobacterium* transformed with a plasmid, which co-expresses two types of heterologous polypeptides, characterized by comprising two types of secretory expression cassettes each sequentially comprising a promoter DNA functioning in the bacterium of the genus *Bifidobacterium*; a DNA encoding a secretory signal peptide; a DNA encoding a heterologous polypeptide; and a terminator DNA functioning in the bacterium of the genus *Bifidobacterium*, has a significantly high cancer cell proliferation inhibitory activity, compared to single-expression strains of the heterologous polypeptides. Based on the finding, the present invention was accomplished.

[0008]

More specifically, the present invention is as follows.

[1] A co-expression plasmid comprising two types of secretory expression cassettes each sequentially comprising the following DNA (1) to (4) and expressed within a bacterium of the genus *Bifidobacterium*:

(1) a promoter DNA functioning in the bacterium of the genus *Bifidobacterium*;

(2) a DNA encoding a secretory signal peptide;

(3) a DNA encoding a heterologous polypeptide; and

(4) a terminator DNA functioning in the bacterium of the genus *Bifidobacterium*.

[2] The co-expression plasmid according to [1], wherein a DNA encoding a linker peptide is ligated downstream of the DNA encoding a secretory signal peptide.

[3] The co-expression plasmid according to [1] or [2], wherein the promoter functioning in the bacterium of the genus *Bifidobacterium* is one or two promoters selected from P30 promoter, P54 promoter and Hu promoter.

[4] The co-expression plasmid according to any one of [1] to [3], wherein the terminator functioning in the bacterium of the genus *Bifidobacterium* is one or two terminators selected from Hu terminator and T2 terminator.

[5] The co-expression plasmid according to any one of [1] to [4], wherein the secretory signal peptide has the following amino acid sequence a) or b):

a) an amino acid sequence represented by any one of SEQ ID Nos: 57, 59, 61, 63, 65, 67, 69, 71, 73, 75 and 77,

b) an amino acid sequence obtained by deleting, substituting or adding one or several amino acids in the

amino acid sequence represented by any one of SEQ ID Nos. 57, 59, 61, 63, 65, 67, 69, 71, 73, 75 and 77, and wherein a peptide consisting of the amino acid sequence serves as a secretory signal peptide in the bacterium of the genus *Bifidobacterium*.

[6] The co-expression plasmid according to any one of [1] to [5], wherein the heterologous polypeptide is a single-chain antibody.

[7] The co-expression plasmid according to [6], wherein the single-chain antibody is an anti-PD-1 antibody.

[8] The co-expression plasmid according to [6], wherein the single-chain antibody is an anti-CTLA-4 antibody.

[9] The co-expression plasmid according to [6], wherein the single-chain antibody is an anti-HER2 antibody.

[10] The co-expression plasmid according to any one of [1] to [5], wherein the heterologous polypeptide is a cytokine.

[11] The co-expression plasmid according to [10], wherein the cytokine is TNF- α .

[12] The co-expression plasmid according to [10], wherein the cytokine is IFN- γ .

[13] The co-expression plasmid according to any one of [1] to [5], wherein the heterologous polypeptide is a combination of the anti-PD-1 antibody and the anti-CTLA-4 antibody.

[14] The co-expression plasmid according to any one of [1] to [5], wherein the heterologous polypeptide is a combination of TNF- α and IFN- γ .

[15] The co-expression plasmid according to any one of [1] to [5], wherein the heterologous polypeptide is a combination of an anti-HER2 antibody and IFN- γ .

[16] A bacterium of the genus *Bifidobacterium* transformed with the co-expression plasmid according to any one of [1] to [15].

[17] The bacterium of the genus *Bifidobacterium* according to [16], wherein the bacterium is *Bifidobacterium longum*.

[18] A pharmaceutical composition comprising the bacterium of the genus *Bifidobacterium* according to [16] or [17].

Effect of the Invention

[0009]

According to the present invention, it is possible to provide a bacterium of the genus *Bifidobacterium* capable of efficiently secreting two types of heterologous polypeptides outside the bacterial cell by using two types of expression cassettes enabling excellent secretion of a heterologous polypeptide in combination in the same plasmid. If the two types of heterologous polypeptides are e.g., antibodies having an anticancer effect, such as an anti-PD-1 antibody and an anti-CTLA-4 antibody, a synergetic effect of the two types of heterologous polypeptides are obtained. Due to this, such a bacterium of the genus *Bifidobacterium* is extremely useful as an anticancer drug.

Brief Description of Drawings

[0010]

[Figure 1] The figure is a diagram showing the constitution of plasmid pSP3B-TNF α .

[Figure 2] The figure is a diagram showing the constitution of plasmid pHG-2.

[Figure 3] The figure is a diagram showing the constitution of plasmid pTNF11.

[Figure 4] The figure (a) is a diagram showing the constitution of plasmid pHFNg33; and the figure (b) is a diagram showing the constitution of plasmid pHFNg33TL.

[Figure 5] The figure is a graph showing cell proliferation inhibitory activity of a culture-supernatant crude purified product of an AG8TL strain to KPL-1 cell.

[Figure 6] The figure is a graph showing cell proliferation inhibitory activity of a culture-supernatant crude purified product of an AG8TL strain to MIA PaCa-2 cell.

[Figure 7] The figure is a graph showing an effect of the neutralization antibody added for neutralizing the cell proliferation inhibitory activity of the culture-supernatant crude purified product of an AG8TL strain.

[Figure 8] The figure (A) is a diagram showing the constitution of plasmid pHuSP7L20-hPD-1scFv03; (B) the constitution of pHuSP7L20-hCTLA-4scFv02; and (C) the constitution of pHuSP7L20-hCTLA-4scFv02FLAG.

[Figure 9] The figure (a) is a diagram showing the constitution of plasmid pPC1; and (b) the constitution of plasmid pCP1.

[Figure 10] The figure (A) is an electrophoretogram for checking the expression of anti-hPD-1scFv; and (B) is

an electrophoretogram for checking the expression of anti-hCTLA-4scFv.

[Figure 11] The figure is a graph showing the specific binding of anti-hPD-1scFv03 to a human PD-1 immobilized plate.

[Figure 12] The figure is a graph showing the specific binding of anti-hCTLA-4scFv02 to a human CTLA-4 immobilized plate.

[Figure 13] The figure is a graph showing competitive (binding) inhibition of the binding reaction between human PD-1 and human PD-L1 by anti-hPD-1scFv03.

[Figure 14] The figure is a graph showing competitive (binding) inhibition of the binding reaction between human CTLA-4 and human CD80 by anti-hCTLA-4scFv02.

[Figure 15] The figure is a graph showing competitive (binding) inhibition of the binding reaction between human CTLA-4 and human CD86 by anti-hCTLA-4scFv02.

[Figure 16] The figure is a graph showing binding of anti-hPD-1scFv03 purified from PC1 strain to a human PD-1 overexpressing cell.

[Figure 17] The figure is a graph showing binding of anti-hCTLA-4scFv02 purified from PC1 strain to a human CTLA-4 overexpressing cell.

[Figure 18] The figure is an electrophoretogram of western analysis for checking secretion of anti-HER2scFv and hIFN- γ by HG-2 strain.

[Figure 19] The figure is a graph showing proliferation inhibitory activity to HER2 positive cell by anti-HER2scFv in a concentrate of HG-2 strain culture supernatant.

[Figure 20] The figure is a graph showing cell proliferation inhibitory activity to HER2 positive cells by a concentrate of HG-2 strain culture supernatant.

[Figure 21] The figure (A) is a picture showing gram staining of HG-2 strain; and (B) is a picture showing gram staining of Beshuttle strain.

[Figure 22] The figure (A) is a picture showing immunohistochemical staining of HG-2 strain with an anti-hIFN- γ antibody; and (B) is a picture showing immunohistochemical staining of Beshuttle strain with anti-hIFN- γ antibody.

[Figure 23] The figure (A) is a picture showing immunohistochemical staining of HG-2 strain with an anti-histidine tag antibody; and (B) is a picture showing immunohistochemical staining of Beshuttle strain with an anti-histidine tag antibody.

[Figure 24] The figure is a schematic diagram showing the constitution of a co-expression plasmid (pPC2-pPC8).

[Figure 25] The figure is a diagram schematically showing a method for constructing a co-expression plasmid (pPC2-pPC8).

[Figure 26] The figure is a diagram schematically showing a method for constructing anti-human CTLA-4scFv02 expression plasmid.

[Figure 27] The figure is a diagram schematically showing a method for constructing pP30SPxLy-hCTLA-4scFv01-His.

[Figure 28] The figure is a diagram schematically showing a method for constructing pP30SPxLy-hCTLA-4scFv01-FLAG (pC1F-pC3F).

[Figure 29] The figure is a schematic diagram showing the constitution of a co-expression plasmid (pPC2TL-pPC8TL).

[Figure 30] The figure is a diagram schematically showing a method for constructing a co-expression plasmid (pPC2TL-pPC8TL).

[Figure 31] The figure is an electrophoretogram of western analysis for checking secretion of anti-hPD-1scFv03-His (a) and anti-hCTLA-4scFv01-FLAG (b) in individual strains.

[Figure 32] The figure is a diagram schematically showing a method for constructing an anti-hCTLA-4scFv01 single-expression strain (pC1TLB, pC2TLB, pC3TLB).

[Figure 33] The figure is a flow-cytometric analysis chart showing the binding of scFv derived from C1F strain, C2F strain and C3F strain to a human CTLA-4 expressing cell.

[Figure 34] The figure is a flow-cytometric analysis chart showing the binding of scFv derived from C1TLB strain, C2TLB strain and C3TLB strain to a human CTLA-4 expressing cell.

[Figure 35] The figure is a flow-cytometric analysis chart showing the binding of scFv derived from P1H strain, P2H strain and P3H strain to a human PD-1 expressing cell.

[Figure 36] The figure is a flow-cytometric analysis chart showing the binding of scFv derived from P1TL strain,

P2TL strain and P3TL strain to a human PD-1 expressing cell.

[Figure 37] The figure (a) is a flow-cytometric analysis chart showing the binding of an anti-human PD-1 antibody (EH12.2H7) to a human PD-1 expressing cell, (b) binding of an anti-human CTLA-4 antibody (L3D10) to a human CTLA-4 expressing cell; (c) binding of PC4-derived scFv to a human PD-1 expressing cell; and (d) binding of PC4-derived scFv to a human CTLA-4 expressing cell.

[Figure 38] The figure is a graph showing (binding) inhibitory activity of hPD-L1 to the binding between hPD-1scFv03-His purified from PC4 strain and hPD-1.

[Figure 39] The figure is a graph showing (binding) inhibitory activity of hCD80 to the binding between hCTLA-4scFv01-FLAG purified from PC4 strain and hCTLA-4.

[Figure 40] The figure is a graph showing (binding) inhibitory activity of hCD86 to the binding between hCTLA-4scFv01-FLAG purified from PC4 strain and hCTLA-4.

Mode of Carrying Out the Invention

[0011]

The co-expression plasmid of the present invention is not particularly limited as long as it is a plasmid comprising two types of secretory expression cassettes each sequentially comprising (1) a promoter DNA functioning in a bacterium of the genus *Bifidobacterium*; (2) a DNA encoding a secretory signal peptide; (3) a DNA encoding a heterologous polypeptide; and (4) a terminator DNA functioning in the bacterium of the genus *Bifidobacterium*, and capable of co-expressing two types of

heterologous polypeptides in the bacterium of the genus *Bifidobacterium* transformed with the plasmid. The 3' end of each of the above DNA fragments and the 5' end of the DNA fragment present immediately downstream may not be directly connected as long as the advantageous effect of the present invention can be obtained; however, the two ends are preferably directly connected.

[0012]

The promoter DNA of the present invention is not particularly limited as long as it is promoter DNA functioning in a bacterium of the genus *Bifidobacterium*. Examples thereof may include Hu promoter DNA, which is a promoter relating to expression of a gene encoding histone-like DNA binding protein derived from *Bifidobacterium longum*; P30 promoter DNA (J. Microbiology, 2012, 638-643); P54 promoter DNA, which is a promoter relating to expression of a gene encoding Elongation Factor Tu protein (J. Bacteriology, 2005, 5799-5808, J. Microbiology, 2012, 638-643); promoter DNA of Gap gene derived from *Bifidobacterium breve* (Biotechnol. Lett. 2008 30: 1983-1988); promoter DNA of AmyB gene derived from *Bifidobacterium longum* (Biotechnol. Lett. 2006 28: 163-168); 16SrRNA promoter DNA (Biotechnol. Lett. 2008 30: 165-172); promoter DNA of GAPDH (pr-BL1363) gene (Appl Environ Microbiol. 2006 72 (11): 7401-7405); P_RP_L promoter DNA (Cancer Gene Ther. 2007 14: 151-157); promoter DNA of p572 (β -glycosidase from *B. animalis* subsp *lactis*) gene (J. Microbiol Biotechnol. 2012 Dec; 22 (12): 1714-23); promoter (rplM promoter) DNA of p919 gene (J. Microbiol. 2012 Aug; 50 (4): 638-43); and promoter (rplR promoter)

DNA of p895 gene (J. Microbiology, 2012, 638-643). The promoters of individual expression cassettes excellent in secretion of the heterologous polypeptides are preferably different from each other. More specifically, a combination of Hu promoter DNA and P30 promoter DNA, a combination of Hu promoter DNA and P54 promoter DNA and a combination of P54 promoter DNA and P30 promoter DNA can be preferably mentioned.

[0013]

As the secretory signal peptide of the present invention, a) a peptide consisting of the amino acid sequence represented by any one of SEQ ID Nos. 57, 59, 61, 63, 65, 67, 69, 71, 73, 75 and 77 more specifically, any one of SP7, SP45, SP50, SP52, SP55, SP58, SP64, SP66, SP67, SP68 and SP69 can be mentioned. Of them, SP7 represented by SEQ ID No. 56 and SP69 represented by SEQ ID No. 66 can be preferably mentioned. Furthermore, b) a peptide consisting of an amino acid sequence obtained by deleting, substituting or adding one or several amino acids in the amino acid sequence represented by any one of SEQ ID Nos. 57, 59, 61, 63, 65, 67, 69, 71, 73, 75 and 77, and functioning as a secretory signal peptide in a bacterium of the genus *Bifidobacterium* (mutated secretory signal peptide) can be mentioned. The "amino acid sequence obtained by deleting, substituting or adding one or several amino acids" refers to an amino acid sequence obtained by deleting, substituting or adding, for example 1 to 5, preferably 1 to 3, more preferably 1 to 2 and further preferably one amino acid. The amino acid sequence of the mutated secretory signal peptide has a

sequence identity of preferably 90% or more, more preferably 95% or more and further preferably 98% or more, with the amino acid sequence represented by any one of SEQ ID Nos. 57, 59, 61, 63, 65, 67, 69, 71, 73, 75 and 77.

[0014]

The DNA encoding a secretory signal peptide consisting of the amino acid sequence as specified in a) is not particularly limited as long as it is DNA having a nucleotide sequence corresponding to the amino acid sequence specified in a). Accordingly, examples thereof, although different DNA due to degeneracy of codon may be included, may include DNA consisting of a nucleotide sequence (sequence listing, upper stage) represented by any one of SEQ ID Nos. 56, 58, 60, 62, 64, 66, 68, 70, 72, 74 and 76. These DNAs can be prepared by a method known to those skilled in the art, such as chemical synthesis and genetic engineering technique.

[0015]

The DNA encoding a secretory signal peptide consisting of the amino acid sequence as specified in b) is not particularly limited as long as it is a DNA having a nucleotide sequence corresponding to the amino acid sequence specified in b). Accordingly, although different DNAs due to degeneracy of codon are included, these DNAs can be prepared in accordance with a method known to those skilled in the art, such as chemical synthesis, genetic engineering technique and mutagenesis. Mutated DNA can be obtained, for example, by introducing a mutation into DNA in accordance with a method of bringing a drug serving as a mutagen into contact with DNA consisting of the

nucleotide sequence represented by any one of SEQ ID Nos. 56, 58, 60, 62, 64, 66, 68, 70, 72, 74 and 76; a method of irradiating the DNA with ultraviolet rays; or a method of applying a genetic engineering technique to the DNA. A genetic engineering technique, i.e., site-specific mutagenesis, is useful since it is a technique of introducing a predetermined mutation into a predetermined site, and is carried out in accordance with the method described in, e.g., Molecular Cloning: A laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY., 1989., Current Protocols in Molecular Biology, Supplement 1 to 38, John Wiley & Sons (1987-1997).

[0016]

The secretory signal peptide is preferably ligated to a linker peptide and used as a signal peptide-linker conjugate in view of expression/secretion efficiency of a heterologous polypeptide. Such a linker peptide is not particularly limited as long as it can be connected to the C terminal of the secretory signal peptide of the present invention and enhance expression/secretion efficiency of a heterologous polypeptide. A peptide consisting of an amino acid sequence having 0 to 30 amino acid residues is preferably mentioned as an example. More specifically, of the following 11 types of amino acid sequences, which follow the aforementioned individual secretory signal peptides identified from *Bifidobacterium longum* 105-A strain, amino acid sequences consisting of any number of amino acids within the range from 0 to 30th amino acid can be mentioned as the linker peptides.

[0017]

1) Linker peptide sequence represented by SEQ ID No.
79 (downstream of SP7);

2) Linker peptide sequence represented by SEQ ID No.
81 (downstream of SP45);

3) Linker peptide sequence represented by SEQ ID No.
83 (downstream of SP50);

4) Linker peptide sequence represented by SEQ ID No.
85 (downstream of SP52);

5) Linker peptide sequence represented by SEQ ID No.
87 (downstream of SP55);

6) Linker peptide sequence represented by SEQ ID No.
89 (downstream of SP58);

7) Linker peptide sequence represented by SEQ ID No.
91 (downstream of SP64);

8) Linker peptide sequence represented by SEQ ID No.
93 (downstream of SP66);

9) Linker peptide sequence represented by SEQ ID No.
95 (downstream of SP67);

10) Linker peptide sequence represented by SEQ ID No.
97 (downstream of SP68);

11) Linker peptide sequence represented by SEQ ID No.
99 (downstream of SP69).

The number of amino acid residues in the linker peptides mentioned above can be 0 to 30 residues, preferably, 0 to 25 residues, more preferably 0 to 20 residues, further preferably 0 to 15 residues, further more preferably 0 to 10 residues, and particularly preferably 1 to 10 residues.

[0018]

As the DNA sequences encoding linker peptides consisting of amino acid sequences consisting of any number of amino acids within the range from 0 to 30th amino acid of the above individual sequences, the following sequences can be mentioned:

- 1) DNA sequence represented by SEQ ID No. 78 (downstream of SP7);
- 2) DNA sequence represented by SEQ ID No. 80 (downstream of SP45);
- 3) DNA sequence represented by SEQ ID No. 82 (downstream of SP50);
- 4) DNA sequence represented by SEQ ID No. 84 (downstream of SP52);
- 5) DNA sequence represented by SEQ ID No. 86 (downstream of SP55);
- 6) DNA sequence represented by SEQ ID No. 88 (downstream of SP58);
- 7) DNA sequence represented by SEQ ID No. 90 (downstream of SP64);
- 8) DNA sequence represented by SEQ ID No. 92 (downstream of SP66);
- 9) DNA sequence represented by SEQ ID No. 94 (downstream of SP67);
- 10) DNA sequence represented by SEQ ID No. 96 (downstream of SP68);
- 11) DNA sequence represented by SEQ ID No. 98 (downstream of SP69).

[0019]

The DNA region encoding the secretory signal peptide-linker peptide conjugate of the present invention

refers to a DNA region from the 5' end of the DNA encoding each of the secretory signal peptides to the 3' end of the DNA encoding the linker peptide downstream of the secretory signal peptide (including both ends). Since the 3' end of the DNA encoding the secretory signal peptide and the 5' end of the DNA encoding the linker peptide are connected, the secretory signal peptide-linker peptide conjugate of the present invention is sometimes represented by SPxLy (where x is the number of a secretory signal peptide assigned in the specification and y is the number of amino acid residues of the linker peptide). Examples of the secretory signal peptide-linker peptide conjugate may include SP7L20, SP45L20, SP50L20, SP52L20, SP55L20, SP58L20, SP64L20, SP66L20, SP67L20, SP68L20 and SP69L20. For example, SP67L20 represents the secretory signal peptide-linker peptide conjugate obtained by connecting the first 20 amino acids of the sequence represented by SEQ ID No. 95 to the amino acid sequence represented by SEQ ID No. 73. Of the secretory signal peptide-linker peptide connected bodies, SP50L1 to L15, SP67L1 to L15, SP68L1 to L15 and SP69L1 to L15 are preferable; SP50L1 to L10, SP67L1 to L10, SP68L1 to L10 and SP69L1 to L10 are preferable; and SP50L5, SP67L1, SP67L10, SP68L1 and SP69L1 are particularly preferable. Note that, L1 to L15 represent L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14 and L15 and L1 to L10 represent L1, L2, L3, L4, L5, L6, L7, L8, L9 and L10.

[0020]

DNA encoding a heterologous polypeptide as mentioned above is not particularly limited as long as it is DNA

which encodes a polypeptide not derived from a bacterium of the genus *Bifidobacterium* and can be expressed by the secretory expression cassette of the present invention. Examples thereof may include DNA encoding a cytokine such as interferon (IFN)- α , β , γ , a granulocyte macrophage colony stimulating factor (GM-CSF), interleukin (IL)-1 α , IL-1 β , IL-2, IL-3, IL-4, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, IL-18, IL-21, IL-22, IL-27, a tumor necrosis factor (TNF)- α , lymphotoxin (LT)- β , a granulocyte colony stimulating factor (G-CSF), a macrophage colony stimulating factor (M-CSF) and a macrophage migration inhibitory factor (MIF); and DNA encoding an angiogenesis inhibitor such as endostatin, angiostatin and kringle (NH4). Besides these, DNA encoding cytosine deaminase, which is an enzyme of converting of 5-fluorocytosine (a prodrug of 5-fluorouracil) into 5-fluorouracil; and DNA encoding nitroreductase, which is an enzyme of reducing a nitro group of a prodrug of an anticancer agent having a nitroaromatic skeleton to activate it, can be preferably mentioned. In addition, DNA encoding an antibody polypeptide can be advantageously used. To such DNA encoding a heterologous polypeptide, DNA encoding an affinity tag such as histidine (His) tag and FLAG tag can be appropriately attached in order to facilitate an isolation treatment of the polypeptide.

[0021]

Examples of the antibody may include an antibody for use in a rheumatoid therapeutic agent targeting an interleukin-6 (IL-6) receptor; an antibody for use in a therapeutic agent for multiple sclerosis targeting α 4-

integrin; an antibody having an anticancer effect targeting CD20, CD33, PD-1, CTLA-4, PD-L1, CD80, CD86, LAG3, TIM3 or KIR; an agonist antibody targeting e.g., OX40, CD137 or ICOS; and an antibody specifically binding to HER2, EGFR, CEA, HGF, EpCAM (CD326), cMET or CCR4.

[0022]

Of them, the anti-PD-1 antibody can be preferably mentioned as an example, because it binds to a PD-1 receptor expressed on an activated lymphocyte (T cell, B cell) to inhibit the binding of PD-L1 and PD-L2 expressed by a cancer cell to the PD-1 receptor, with the result that the immune reaction to the tumor cell is enhanced. Furthermore, the anti-CTLA-4 antibody suppresses the function of CTLA-4, which is known as an autoimmune function suppression molecule, thereby enhancing an antitumor immune response. More specifically, the anti-CTLA-4 antibody can be preferably mentioned as an example, because the anti-CTLA-4 antibody is considered to enhance the antitumor immune response by inhibiting the binding of CTLA-4 to CD80 and CD86 expressed in an antigen presenting cell to inhibit negative down-regulation of an immune response induced by the interaction between these molecules. Moreover, the anti-HER-2 (human EGFR-related2) antibody can be preferably mentioned as an example, because it is considered to specifically bind to HER2 protein, which is a gene product of oncogene HER2/neu (c-erbB-2), to suppress a proliferation signal, thereby exerting an anti-tumor effect.

[0023]

As the DNA encoding an antibody polypeptide as mentioned above, DNA encoding e.g., a chimeric antibody, a humanized antibody, Fab, Fab', F (ab')₂, and a single-chain antibody (scFv: single chain Fv) can be mentioned; however, DNA encoding a single-chain antibody, capable of recognizing and binding a target substance by itself, having an appropriate (not too big) molecular weight, and expressible when it is introduced into a bacterium of the genus *Bifidobacterium*, is preferable. DNAs encoding heterologous polypeptides including these antibodies can be also prepared by a method known in the art such as chemical synthesis and genetic engineering technique based on their sequence information appropriately obtained from published documents or database such as GenBank.

[0024]

As the aforementioned combination of heterologous polypeptides of the present invention, it is preferable to employ a combination of heterologous polypeptides which are expected to produce a synergistic combinational effect at an anaerobic disease site when locally expressed. This is because when a bacterium of the genus *Bifidobacterium* is systemically administered, it does not proliferate in a normal tissue but is selectively distributed and colonized at an anaerobic site such as a solid tumor tissue and an ischemic disease site. Specific examples of the combination may include a combination of TNF- α and IFN- γ ; a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody; a combination of an anti-HER2 antibody and IFN- γ ; a combination of an anti-PD-1 antibody and IFN- γ ; a combination of an anti-PD-1 antibody and an anti-HER2

antibody; and a combination of an anti-PD-1 antibody and an anti-EpCAM antibody.

[0025]

The terminator DNA is not particularly limited as long as it is terminator DNA that functions in a bacterium of the genus *Bifidobacterium*. Specific examples thereof may include Hu terminator DNA derived from *Bifidobacterium longum*; d0013terminator DNA, which is a terminator of a lactate dehydrogenase gene derived from *Bifidobacterium longum*; T572terminator DNA derived from *Bifidobacterium animaris* (J. Microbiol Biotechnol. 2012 Dec; 22 (12): 1714-23); and BBa_B0015 (T2) terminator DNA, which is an artificially designed terminator. It is preferable to use different terminators for respective expression cassettes excellent in secretion of a heterologous polypeptide as mentioned above. Specific examples thereof may include Hu terminator DNA and d0013 terminator DNA in combination; Hu terminator DNA and T572 terminator DNA in combination; Hu terminator DNA and T2 terminator DNA in combination; d0013 terminator DNA and T572 terminator DNA in combination; d0013 terminator DNA and T2 terminator DNA in combination; and T572 terminator DNA and T2 terminator DNA in combination.

[0026]

As a method for producing a secretory expression cassette of the present invention, preferably a secretory expression cassette comprising a DNA encoding a linker peptide, it is possible to mention a method of sequentially connecting the following DNAs:

(1) a promoter DNA functioning in a bacterium of the genus *Bifidobacterium*;

(2) a DNA encoding a secretory signal peptide consisting of the amino acid sequence described in a) or b) below:

a) an amino acid sequence represented by any one of SEQ ID Nos. 57, 59, 61, 63, 65, 67, 69, 71, 73, 75 and 77;

b) an amino acid sequence obtained by deleting, substituting or adding one or several amino acids in the amino acid sequence represented by any one of SEQ ID Nos. 57, 59, 61, 63, 65, 67, 69, 71, 73, 75 and 77, wherein a peptide consisting of the amino acid sequence serves as a signal peptide in the bacterium of the genus *Bifidobacterium*;

(3) a DNA encoding a linker peptide;

(4) a DNA encoding a heterologous polypeptide; and

(5) a terminator DNA functioning in the bacterium of the genus *Bifidobacterium*,

in the order of (1) to (5) from upstream to downstream. The secretory expression cassette of the present invention can be prepared in accordance with a method described in a commercially available experimental technique, for example, Gene Manual (Kodansha Ltd.); Gene Manipulation Experimental Technique, edited by Yasutaka Takagi, Kodansha Ltd.; Molecular Cloning [Cold Spring Harbor Laboratory (1982)]; Molecular cloning second edition [Cold Spring Harbor Laboratory (1989)]; Methods in enzymology 194 (1991); and Gene experimental technique by yeast, Experimental Medicine, supplemental vol., YODOSHA CO., LTD. (1994).

[0027]

The plasmid vector that can be used for producing a co-expression plasmid comprising two types of secretory expression cassettes of the present invention is not particularly limited, as long as it is a plasmid vector into which two types of expression cassettes of the present invention can be inserted and as long as two types of secretory heterologous polypeptides are expressed when a bacterium of the genus *Bifidobacterium* is transformed with the plasmid vector. A shuttle plasmid vector further having an origin of replication such as a pUCori, which can function also in a bacterium other than a bacterium of the genus *Bifidobacterium*, for example, in *E. coli*, can be advantageously used.

[0028]

Examples of the plasmid vector having a plasmid replication unit functioning in a bacterium of the genus *Bifidobacterium* include pTB6 (Biosci Biotechnol Biochem. 2005 Feb; 69 (2): 422-5); pMB1 (Lett Appl Microbiol. 1990 Oct; 11 (4): 220-3); pTB4 (structural analysis and application of *Bifidobacterium longum*-derived plasmid pTB4, general subject of speech, poster presentation program, Molecular Biology Society of Japan, 1994); pFI2576 (J Microbiol Biotechnol. 2009 Apr; 19 (4): 403-8); pCIBAO (Appl Environ Microbiol. 2007 Dec; 73 (24): 7858-66); pBC1 (Plasmid. 2007 Mar; 57 (2): 165-74); pDOJH10S (Appl Environ Microbiol. 2006 Jan; 72 (1): 527-35); and PKJ50 (Microbiology 1999 Mar; 145 (Pt): 585-92). As the replication unit, pTB6rep unit consisting of a pTB6-derived OriV region and RepB gene can be preferably

mentioned. A shuttle plasmid vector further having an origin of replication such as a pUCori, which can function also in a bacterium other than a bacterium of the genus *Bifidobacterium*, for example in *E. coli*, can be used.

[0029]

The plasmid may contain a marker gene such as a drug resistance gene. Examples of the drug resistance marker gene include spectinomycin, chloramphenicol, erythromycin and ampicillin resistance genes.

[0030]

As a method for introducing the plasmid of the present invention into a bacterium of the genus *Bifidobacterium*, a gene introduction method known in the art, such as electroporation, may be mentioned.

[0031]

Examples of the bacterium of the genus *Bifidobacterium* in the present invention include *Bifidobacterium longum*, *Bifidobacterium breve* (*B. breve*), *Bifidobacterium adolescentis* (*B. adolescentis*), *Bifidobacterium bifidum* (*B. bifidum*), *Bifidobacterium pseudolongum* (*B. pseudolongum*), *Bifidobacterium thermophilum* (*B. thermophilum*), *Bifidobacterium infantis* (*B. infantis*), *Bifidobacterium animalis* (*B. animalis*), *Bifidobacterium angulatum* (*B. angulatum*), *Bifidobacterium asteroides* (*B. asteroides*), *Bifidobacterium boum* (*B. boum*), *Bifidobacterium catenulatum* (*B. catenulatum*), *Bifidobacterium choerinum* (*B. choerinum*), *Bifidobacterium coryneforme* (*B. coryneforme*), *Bifidobacterium cuniculi* (*B. cuniculi*), *Bifidobacterium denticolens* (*B. denticolens*), *Bifidobacterium dentium* (*B. dentium*), *Bifidobacterium*

gallicum (*B. gallicum*), *Bifidobacterium gallinarum* (*B. gallinarum*), *Bifidobacterium globosum* (*B. globosum*), *Bifidobacterium indicum* (*B. indicum*), *Bifidobacterium inopinatum* (*B. inopinatum*), *Bifidobacterium lactis* (*B. lactis*), *Bifidobacterium lactentis* (*B. lactentis*), *Bifidobacterium magnum* (*B. magnum*), *Bifidobacterium merycicum* (*B. merycicum*), *Bifidobacterium minimum* (*B. minimum*), *Bifidobacterium Mongolia Enns* (*B. Mongolia Enns*), *Bifidobacterium parvulorum* (*B. parvulorum*), *Bifidobacterium pseudocatenulatum* (*B. pseudocatenulatum*), *Bifidobacterium psychraerophilum* (*B. psychraerophilum*), *Bifidobacterium pullorum* (*B. pullorum*), *Bifidobacterium ruminale* (*B. ruminale*), *Bifidobacterium ruminantium* (*B. ruminantium*), *Bifidobacterium saeculare* (*B. saeculare*), *Bifidobacterium scardovii* (*B. scardovii*), *Bifidobacterium subtile* (*B. subtile*), *Bifidobacterium suis* (*B. suis*), and *Bifidobacterium thermacidophilum* (*B. thermacidophilum*). Of them, *Bifidobacterium longum*, *Bifidobacterium breve*, *Bifidobacterium adolescentis*, *Bifidobacterium bifidum* and *Bifidobacterium infantis*, which are known to be habitually present within the human intestine regardless of age, are preferably used as a host cell, and *Bifidobacterium longum* is more preferably used. These bacteria all can be commercially available or can be easily obtained from e.g., a depository.

[0032]

The strain of each bacterium is not particularly limited. Examples of the strain of *Bifidobacterium longum* include *Bifidobacterium longum* 105-A strain, *Bifidobacterium longum* aE-194b strain, *Bifidobacterium*

longum bs-601 strain, *Bifidobacterium longum* M101-2 strain and *Bifidobacterium longum* ATCC-15707 strain. Of them, *Bifidobacterium longum* 105-A strain is preferable. As to *Bifidobacterium breve*, for example, *Bifidobacterium breve* standard strain (JCM1192), *Bifidobacterium breve* aS-1 strain and *Bifidobacterium breve* I-53-8W strain may be mentioned. Of them, *Bifidobacterium breve* standard strain and *Bifidobacterium breve* aS-1 strain are preferable. As to *Bifidobacterium infantis*, for example, *Bifidobacterium infantis* standard strain (JCM1222) and *Bifidobacterium infantis* I-10-5 strain may be mentioned. As to *Bifidobacterium lactentis*, for example, *Bifidobacterium lactentis* standard strain (JCM1210) may be mentioned. As to *Bifidobacterium bifidum* strain, for example, *Bifidobacterium bifidum* ATCC-11863 strain may be mentioned.

[0033]

The plasmid and transformed bacterium of the genus *Bifidobacterium* of the present invention can be prepared in accordance with a method described in a published experimental text, for example, Gene Manual (Kodansha Ltd.); Gene Manipulation Experimental Technique, edited by Yasutaka Takagi, Kodansha Ltd.; Molecular Cloning [Cold Spring Harbor Laboratory (1982)]; Molecular cloning second edition [Cold Spring Harbor Laboratory (1989)]; Methods in enzymology 194 (1991); and Gene experimental technique by yeast, Experimental medicine, supplemental vol., YODOSHA CO., LTD. (1994).

[0034]

The transformed bacterium of the genus *Bifidobacterium* does not proliferate in a normal tissue

but proliferates only in a tumor tissue under an anaerobic environment and can express two types of heterologous polypeptides useful for therapy within the tumor tissue.

[0035]

Accordingly, the transformed bacterium of the genus *Bifidobacterium* can be used in a pharmaceutical composition, in particular, an anticancer drug effective for treating a tumor under an anaerobic environment, preferably a solid tumor. Accordingly, the pharmaceutical composition of the present invention is not particularly limited as long as it contains the bacterium of the genus *Bifidobacterium* of the present invention capable of secreting heterologous polypeptides, preferably cytokines and antibodies having an anticancer effect, as an active ingredient, and may contain an optional ingredient such as a pharmacologically acceptable carrier, an excipient and a diluent as long as it does not prevent the action and effect of the polypeptide to be secreted.

[0036]

The administration target of the pharmaceutical composition of the present invention is a mammalian, preferably a human. Examples of the applicable target of the pharmaceutical composition of the present invention include colon carcinoma, head and neck cancer, breast cancer, lung cancer, esophageal carcinoma, gastric carcinoma, liver carcinoma, gallbladder carcinoma, cholangiocarcinoma, pancreatic cancer, pancreatic islet cell carcinoma, choriocarcinoma, colon carcinoma, renal cell carcinoma, adrenal cortical carcinoma, bladder carcinoma, testicular carcinoma, prostate cancer, testis

cancer, ovarian cancer, uterine cancer, choriocarcinoma, thyroid cancer, squamous cell carcinoma, skin cancer, brain tumor, malignant carcinoid tumor, osteosarcoma, soft tissue sarcoma, neuroblastoma, Wilms tumor, retinoblastoma and melanoma.

[0037]

As the dosage form of the pharmaceutical composition of the present invention, a liquid formulation or a solid formulation can be mentioned. The liquid formulation can be prepared by purifying the culture of the bacterium of the genus *Bifidobacterium* of the present invention, applicably adding, if necessary, saline, a replacement fluid or a pharmaceutical additive(s) and charging e.g., ampoules or vials with the resultant suspension. The solid formulation can be prepared by adding a protecting agent to the liquid formulation, charging ampoules or vials with the mixture, and freezing the mixture to obtain a frozen formulation or freeze-drying the mixture to obtain a lyophilized formulation. As a method of administering the pharmaceutical composition of the present invention, oral administration and parenteral administration both can be employed; however, parenteral administration is preferable; for example, intravenous administration and local administration can be mentioned.

[0038]

The dose of the pharmaceutical composition of the present invention is not particularly limited as long as a bacterium of the genus *Bifidobacterium* can grow in a diseased site and as long as it is a sufficient amount for the bacterium of the genus *Bifidobacterium* to express a

therapeutically effective amount of e.g., a cytokine or active antibody. The dose of the pharmaceutical composition can be appropriately selected depending upon the severity of disease and the weight, age and sex of the patient, and appropriately increased or decreased depending upon the degree of improvement. From an economic point of view and in order to avoid a side effect as much as possible, the dose is preferably as low as possible within the range where a requisite therapeutic effect is obtained.

[0039]

For example, in the case of intravenous administration, it is required to reduce a risk, in particular, e.g., embolization caused by bacterial mass. Thus, it is preferable that an injectable solution prepared to have a concentration as low as possible, is injected in a plurality of times by dividing the dose into the plural portions or continuously administered by diluting it with an appropriate replacement fluid. For example, in the case of an adult, the bifidobacterial cell of the present invention, a daily dose of 10^4 to 10^{12} cfu per body weight (1 kg), is divided in a plurality of times and administered for one to several days continuously or non-continuously at appropriate time intervals. More specifically, a formulation comprising the bifidobacterial cell of the present invention in a concentration of 10^4 to 10^{10} cfu/mL is directly administered or by diluting it with an appropriate replacement fluid, in a dose of 1 to 1000 mL per adult, once a day or by dividing the dose in a

plurality of times per day continuously for one to several days.

[0040]

For example, in the case of local administration, i.e., direct administration to a diseased tissue, a high-concentration injectable solution is desirably injected in a plurality of sites of the diseased tissue, since a bacterial cell is required to colonize and grow over the entire diseased tissue as much as possible. For example, in the case of an adult, the bifidobacterial cell of the present invention, more specifically, a daily dose of 10^4 to 10^{12} cfu per body weight (1 kg), is administered once or in a plurality of times per day, if necessary, for one to several days, continuously or non-continuously at appropriate time intervals. More specifically, a formulation comprising the bifidobacterial cell of the present invention in a concentration of 10^4 to 10^{10} cfu/mL is directly administered in a dose of 0.1 to 100 mL per adult, several times per day, if necessary, for one to several consecutive days.

[0041]

Now, the present invention will be more specifically described by way of Examples below; however, the technical scope of the present invention is not limited by these examples.

[0042]

[Example 1]

[Preparation of human TNF- α and human IFN- γ co-expression *Bifidobacterium*, AG8TL strain]

(Outline)

A co-expression plasmid, pAG8TL was prepared, which contains an expression cassette for secretory human TNF- α (human TNF- α secretory expression cassette) and an expression cassette for secretory human IFN- γ (human IFN- γ secretory expression cassette) and which serves as an *E. coli*-*Bifidobacterium* shuttle vector. *Bifidobacterium longum* 105-A strain was transformed with pAG8TL thus prepared by electroporation to obtain a human TNF- α and human IFN- γ co-expression *Bifidobacterium*, AG8TL strain. The primers used in Examples 1 to 3 are shown in the following Table 1.

[0043]

[Table 1]

Primer Name	DNA sequence (5' -> 3')	SEQ ID No.
GA1_primer	gagcagaaggTCACTGGGAGGCGCGACGGCCAC	SEQ ID No. 18
GA2_primer	AGTGAaccttctgctcgtacg	SEQ ID No. 19
GA5_primer_rev	ggtatgtaggcgggtgctacag	SEQ ID No. 20
GA6_primer	caccgectacatacctcget	SEQ ID No. 21
GA100_primer	cgggtGTGCGCTCCTCCTCCCGTAC	SEQ ID No. 22
GA101_primer	TCACAGGGCGATGATGCC	SEQ ID No. 23
GA103_primer	AGGAGCGCACcaccgaactcgccttcgg	SEQ ID No. 24
GA104_primer	ATCATCGCCCTGTGAAACCGCTTCTCATTTCATTGCG	SEQ ID No. 25
GA113_primer	CGGTGCACACTAGTctctcaggacctc	SEQ ID No. 26
GA116_primer	gACTAGTGTGCACCGAATCGCGCTG	SEQ ID No. 27
IFNG1_primer	gaaggatgctttATGCAGGACCCGTACGTCAAGG	SEQ ID No. 28
IFNG2_primer	CATCATCACCACCACTGAccttctgctcgtacg	SEQ ID No. 29
IFNG3_primer	GTGGTGGTGATGATGGTGTCTGGGAGGCGCGACGGCC	SEQ ID No. 30
hIFNG4_primer	caggaccgtacgtcAAGG	SEQ ID No. 31
SP69-ins_F1_primer	caagaaggatgctttATGAATTATTTACGACAAAAAATTTTCGG	SEQ ID No. 32
SP69-ins_R2_primer	gacgtacgggtcctgACCGCTATCAGTCGTGGTGTAAC	SEQ ID No. 33
pCDshuttle_R1_primer	cataaagcatccttcttgggtcag	SEQ ID No. 34
Hu-mCCL21-vecR1_primer	AAAGCATCCTTCTTGGGTCAGG	SEQ ID No. 35

[0044]

(Constitution of human TNF- α secretory expression cassette)

As the human TNF- α secretory expression cassette, a cassette sequentially comprising (1) a P30 promoter DNA, (2) a DNA encoding a signal peptide-linker conjugate, SP7L20, (3) a DNA encoding the amino acid sequence of a human TNF- α protein and (4) a d0013 terminator DNA, was prepared such that DNA (1) was placed upstream (the 5' end) and DNA (4) downstream (the 3' end).

[0045]

(Constitution of human IFN- γ secretory expression cassette)

As the human IFN- γ secretory expression cassette, a cassette sequentially comprising (1) a Hu promoter DNA, (2) a DNA encoding a signal peptide-linker conjugate, SP69L20, (3) a DNA encoding the amino acid sequence of human IFN- γ protein and (4) a Hu terminator DNA (derived from *Bifidobacterium longum*) was prepared such that DNA (1) was placed upstream (the 5' end) and DNA (4) downstream (the 3' end).

[0046]

(Preparation of plasmid pAG8TL)

In preparing plasmid pAG8TL, plasmid pAG8 was first prepared.

[0047]

(Preparation of plasmid pAG8)

(Preparation of hTNF- α insert fragment)

PCR amplification was carried out using plasmid pSP3B-TNF α (see, Figure 1) (1 ng) described in International Publication No. WO2011/093465, as a template

and a primer set of GA100_primer (forward) and GA101_primer (reverse) listed in Table 1. Each of the primer sequences was designed such that an insert fragment was overlapped with a vector fragment at the end of 15 bp. The PCR amplification was carried out by specifying the concentration of each primer as 0.2 μ M and the reaction volume as 20 μ L and using PrimeSTAR HS (Premix) kit (manufactured by Takara Bio Inc.) (hereinafter referred to as "STAR kit"). As the amplification program, a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 65°C for 5 seconds and a reaction at 75°C for 40 seconds was repeated 30 times and then an elongation reaction was carried out at 72°C for 30 seconds to prepare a h (human) TNF- α insert fragment amplified product of about 0.5 kbp.

[0048]

(Preparation of vector fragment comprising DNA encoding the amino acid sequence of human IFN- γ protein)

PCR amplification was carried out using a linearized fragment (SEQ ID No. 1) of plasmid pHG-2 (Figure 2) as a template and a primer set of GA104_primer (forward) and GA103_primer (reverse) listed in Table 1. Each of the primer sequences was designed such that an insert fragment was overlapped with a vector fragment at the end of 15 bp. The PCR amplification was carried out by specifying the concentration of each primer as 0.2 μ M and the reaction volume as 20 μ L, and using STAR kit. As the amplification program, a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 65°C for 5 seconds and a reaction at 75°C for 5 minutes was repeated 30 times and then an

elongation reaction at 72°C for 30 seconds was carried out to prepare a 5'-Hu promoter-SP69L20-human IFN-γ protein-His tag-Hu terminator-pTB rep unit-SPCM^r-pUCori-P30 promoter-SP7L20-3' vector fragment amplified product of about 5 kbp.

[0049]

The plasmid pHG-2 linearized fragment is a nucleotide sequence from 1st nucleotide to 4975th nucleotide of SEQ ID No. 1 and constituted as follows.

d0013 terminator: a nucleotide sequence from 16th nucleotide to 129th nucleotide of SEQ ID No. 1,

Hu promoter: a nucleotide sequence from 136th nucleotide to 496th nucleotide of SEQ ID No. 1,

SP69L20: a nucleotide sequence from 497th nucleotide to 646th nucleotide of SEQ ID No. 1,

human IFN-γ protein: a nucleotide sequence from 647th nucleotide to 1075th nucleotide of SEQ ID No. 1,

His tag: a nucleotide sequence from 1076th nucleotide to 1093rd nucleotide of SEQ ID No. 1,

Hu terminator: a nucleotide sequence from 1097th nucleotide to 1210th nucleotide of SEQ ID No. 1,

a bacterium of the genus *Bifidobacterium*, origin of replication pTB6 rep unit: a nucleotide sequence from 1217th nucleotide to 2812nd nucleotide of SEQ ID No. 1,

spectinomycin resistance gene SPCMr: a nucleotide sequence from 2819th nucleotide to 3897th nucleotide of SEQ ID No. 1,

E. coli origin of replication, pUCori: a nucleotide sequence from 3904th nucleotide to 4571st nucleotide of SEQ ID No. 1,

P30 promoter: a nucleotide sequence from 4572nd nucleotide to 4806th nucleotide of SEQ ID No. 1, and

SP7L20: a nucleotide sequence from 4807th nucleotide to 4965th nucleotide of SEQ ID No. 1.

[0050]

(In-fusion reaction 1)

The vector fragment amplified product and insert fragment amplified product prepared above were ligated by use of In-Fusion (registered trademark) HD Cloning kit (manufactured by Takara Bio Inc.) (hereinafter referred to as "HD kit "). More specifically, in a micro tube, the vector fragment amplified product (50 ng) and the insert fragment amplified product (13 ng) were added, and 5X In-Fusion HD Enzyme premix (2 μ L) and Cloning Enhancer (1 μ L) contained in the kit were further added. The volume of the reaction solution was adjusted with 0.1X TE buffer (1mM Tris-HCl, 0.1mM EDTA, pH7.5) to be 10 μ L. The reaction solution was kept warm at 37°C for 15 minutes and further kept warm at 50°C for 15 minutes. The procedure other than this was carried out in accordance with the product manual of the kit to prepare in-fusion reaction solution 1.

[0051]

(Transformation of *E. coli* and determination of DNA sequence of plasmid pAG8)

Using in-fusion reaction solution 1 (1 μ L), *E. coli* HST16CR competent cells (manufactured by Takara Bio Inc.)

were transformed in accordance with the product manual. After the transformation, the bacterial suspension was spread onto LB agar medium containing 75 µg/mL spectinomycin and cultured at 37°C overnight with shaking. *E. coli* colony formed on the agar medium was cultured in LB liquid medium containing 75 µg/mL spectinomycin at 37°C overnight. From this, a plasmid was extracted by use of QIAprepSpin Miniprep kit (manufactured by QIAGEN). In the plasmid extracted, the sequence of region 1 (5'-P30 promoter-SP7L20-human TNF-α protein-d0013 terminator-Hu promoter-SP69L20-human IFN-γ protein-His tag-Hu terminator-3') comprising the human TNF-α secretory expression cassette and the human IFN-γ secretory expression cassette, was determined by a sequencing reaction using Big Dye (registered trademark) Terminator v3.1 Cycle Sequencing kit (manufactured by Applied Biosystems). The plasmid extracted was designated as pAG8. The sequence of region 1 comprising the human TNF-α secretory expression cassette and the human IFN-γ secretory expression cassette of pAG8 is represented by SEQ ID No. 2.

[0052]

(Preparation of pAG8TL strain)

PCR amplification was carried out using pAG8 obtained above as a template and a primer set of GA2_primer (forward) and GA6_primer (reverse) listed in Table 1. The same procedure as in the above section (Preparation of plasmid pAG8) was repeated except that the amplification program, which is a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 65°C for 5

seconds and a reaction at 75°C for 3 minutes and 15 seconds, was repeated 30 times and then an elongation reaction was carried out at 72°C for 30 seconds, to prepare PCR amplification product A of about 3.3 kbp.

[0053]

PCR amplification was carried out using pAG8 mentioned above as a template and a primer set of GA5_primer_rev (forward) and GA1_primer (reverse) listed in Table 1. The same procedure as in the above section (Preparation of plasmid pAG8) was repeated except that the amplification program, which is a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 65°C for 5 seconds and a reaction at 75°C for 2 minutes and 10 seconds, was repeated 30 times, and then an elongation reaction was carried out at 72°C for 30 seconds to prepare PCR amplification product B of about 2.2 kbp.

[0054]

(In-fusion reaction 2)

The same procedure as in the above section (In-fusion reaction 1) was repeated except that PCR amplification product A (50 ng) and PCR amplification product B (33 ng) were used, to ligate PCR amplification product A and PCR amplification product B. In this manner, in-fusion reaction solution 2 was prepared.

[0055]

(Transformation of *E. coli* and determination of DNA sequence of plasmid pAG8TL)

Transformation of the *E. coli* HST16CR competent cells by using in-fusion reaction solution 2 obtained above and extraction of a plasmid from the recombinant *E.*

coli. were carried out in the same procedure as in the above section (Transformation of *E. coli* and determination of DNA sequence of plasmid pAG8). In the plasmid extracted, the sequence of region 2 (5'-P30 promoter-SP7L20-human TNF- α protein-d0013 terminator-Hu promoter-SP69L20-human IFN- γ protein-Hu terminator-3') comprising the human TNF- α secretory expression cassette and human IFN- γ secretory expression cassette was determined in the same procedure as above. The plasmid extracted was designated as pAG8TL. The sequence of region 2 comprising the human TNF- α secretory expression cassette and human IFN- γ secretory expression cassette of pAG8TL is represented by SEQ ID No. 3.

[0056]

(Transformation 1 of bacterium of the genus *Bifidobacterium*)

Bifidobacterium longum 105-A strain was transformed with plasmid pAG8TL (250 ng) extracted from the transformed *E. coli* by an electroporation system (Gene Pulser II, manufactured by Bio-Rad laboratories). Immediately after electric shock (2 kV, 25 μ F, 200 Ω), a mixture of 800 μ L of IMR liquid medium and 50 μ L of vitamin C solution was added to a cuvette (2 mm gap) and collected in (transferred to) in a sterilized 2 mL-micro tube. The 2 mL (micro) tube with the cap loosen was placed together with a deoxygen/carbon dioxide generator (AnaeroPack (registered trademark) Kenki manufactured by Mitsubishi Gas Chemical Company, Inc.) in an airtight container and kept warm for 3 hours in an incubator set at 37°C.

[0057]

After kept warm, individual bacterial suspensions were each spread onto IMR agar medium containing 75 µg/mL spectinomycin. These plates were placed in an airtight container together with the deoxygen/carbon dioxide generator mentioned above and cultured in an incubator set at 37°C for 2 days.

[0058]

The colony formed on the IMR agar medium containing spectinomycin was determined as a transformant, *Bifidobacterium longum* 105-A/pAG8TL strain (hereinafter referred to as AG8TL strain).

[0059]

[Example 2]

[Preparation of Human TNF-α single-expression strain TNF11]

Human TNF-α single-expression strain TNF11 to be compared with co-expression *Bifidobacterium* AG8TL strain was prepared as follows.

[0060]

PCR amplification was carried out using pAG12 as a template and a primer set of GA113_primer (forward) and GA6_primer (reverse) listed in Table 1. The same procedure as in the above section (Preparation of plasmid pAG8) was repeated except that the amplification program, which is a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 65°C for 5 seconds and a reaction at 75°C for 3 minutes and 50 seconds was repeated 30 times and then an elongation reaction was carried out at 72°C

for 30 seconds to prepare PCR amplification product 60 of about 3.2 kbp.

[0061]

PCR amplification was carried out using pAG12 as a template and a primer set of GA5_primer_rev (forward) and GA116_primer (reverse) listed in Table 1. The same procedure as in the above section (Preparation of plasmid pAG8) was repeated except that the amplification program, which is a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 65°C for 5 seconds and a reaction at 72°C for one minute and 15 seconds, was repeated 30 times, and then an elongation reaction was carried out at 72°C for 30 seconds to prepare PCR amplification product 61 of about 1.2 kbp. Note that, the plasmid pAG12 used as a template was obtained by replacing SP/Linker of hIFN- γ of pAG8TL, i.e., SP69L20, by SP56L20.

[0062]

(In-fusion reaction 3)

The same procedure as in the above section (In-fusion reaction 1) was repeated except that PCR amplification product 60 (50 ng) and PCR amplification product 61 (20 ng) were used to ligate the PCR amplification product 60 and the PCR amplification product 61. In this manner, in-fusion reaction solution 3 was prepared.

[0063]

(Transformation of *E. coli* and determination of DNA sequence of plasmid pTNF11)

The same procedure as in the above section (Transformation of *E. coli* and determination of DNA

sequence of plasmid pAG8) was repeated by using in-fusion reaction solution 3 obtained above to carry out transformation of the *E. coli* HST16CR competent cells obtained above and extraction of a plasmid from the recombinant *E. coli*. In the plasmid extracted, the sequence of the human TNF- α secretory expression cassette (5'-P30 promoter-SP7L20-human TNF- α protein-d0013 terminator) was determined. The plasmid extracted was designated as pTNF11. The constitution of pTNF11 plasmid is shown in Figure 3.

[0064]

(Transformation 2 of bacterium of the genus *Bifidobacterium*)

Bifidobacterium longum 105-A strain was transformed by the electroporation system in the same procedure as in the above section (Transformation 1 of bacterium of the genus *Bifidobacterium*) except that plasmid pTNF11 (500 ng) extracted from the transformed *E. coli* mentioned above was used. The transformant obtained was designated as *Bifidobacterium longum* 105-A/pTNF11 strain (hereinafter referred to as TNF11 strain).

[0065]

[Example 3]

[Preparation of human IFN- γ single-expression strain hIFNg33TL]

Human IFN- γ single-expression strain hIFNg33TL to be compared with co-expression *Bifidobacterium* AG8TL strain was prepared as follows.

[0066]

Human IFN- γ single-expression strain hIFNg33TL to be compared with co-expression AG8TL strain was prepared. In preparation of plasmid phIFNg33TL, plasmid phIFNg33 was first prepared.

[0067]

(Artificial DNA synthesis of hIFN- γ gene)

Synthesis of hIFN- γ gene was ordered to GenScript Japan Inc. The codons of the hIFN- γ sequence were optimized for *Bifidobacterium longum* NCC2705 based on the amino acid sequence (Gln24-Gln166) of the mature protein of Accession#CAA31639 (plasmid delivered: pUC57-hIFNg). The DNA sequence of artificial synthesized hIFN- γ is represented by SEQ ID No. 4.

[0068]

PCR amplification was carried out using pBEshuttle (SEQ ID No. 5) as a template and a primer set of pCDshuttle_R1_primer (reverse) and IFNG2_primer (forward) listed in Table 1. The same procedure as in the above section (Preparation of plasmid pAG8) was repeated except that the amplification program, which is a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 55°C for 5 seconds and a reaction at 75°C for 3 minutes and 50 seconds, was repeated 30 times, and then an elongation reaction was carried out at 72°C for 30 seconds to prepare PCR amplification product, vector 1 of about 3.9 kbp.

[0069]

PCR amplification was carried out using pUC57-hIFNg (hIFNg in pUC57) mentioned above as a template and a primer set of IFNG1_primer (forward) and IFNG3_primer

(reverse) listed in Table 1. The same procedure as in the above section (Preparation of plasmid pAG8) was repeated except that the amplification program, which is a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 55°C for 5 seconds and a reaction at 75°C for 30 seconds, was repeated 30 times, and then an elongation reaction was carried out at 72°C for 30 seconds to prepare PCR amplification product, insert 1 of about 0.5 kbp.

[0070]

(In-fusion reaction 4)

The same procedure as in the above section (In-fusion reaction 1) was repeated except that PCR amplification product, vector 1 (50 ng) and PCR amplification product, insert 1 (12 ng) were used to ligate PCR amplification product, vector 1 and PCR amplification product, insert 1. In this manner, in-fusion reaction solution 4 was prepared.

[0071]

(Transformation of *E. coli* and determination of DNA sequence of non-secretory plasmid phIFNg)

E. coli HST16CR was transformed in the same manner as in the above section (Transformation of *E. coli* and determination of DNA sequence of plasmid pAG8) by using the in-fusion reaction solution 4 (2 µL). A plasmid was extracted from the recombinant *E. coli* and the sequence of full-length plasmid DNA was determined. The plasmid extracted was designated as phIFNg (non-secretory plasmid).

[0072]

(Preparation of secretory plasmid hIFNg33)

PCR amplification was carried out using phIFNg mentioned above as a template and a primer set of hIFNG4_primer (forward) and Hu-mCCL21-vecR1_primer (reverse) listed in Table 1. The same procedure as in the above section (Preparation of plasmid pAG8) was repeated except that the amplification program, which is a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 55°C for 5 seconds and a reaction at 75°C for 4 minutes and 20 seconds, was repeated 30 times, and then an elongation reaction was carried out at 72°C for 30 seconds to prepare PCR amplification product, vector 2 of about 4.3 kbp.

[0073]

PCR amplification was carried out using *Bifidobacterium longum* 105-A strain genomic DNA as a template and a primer set of SP69-ins_F1_primer (forward) and SP69-ins_R2_primer (reverse) listed in Table 1. The same procedure as in the above section (Preparation of plasmid pAG8) was repeated except that the amplification program, which is a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 55°C for 5 seconds and a reaction at 75°C for 15 seconds, was repeated 30 times, and then an elongation reaction was carried out at 72°C for 30 seconds to prepare PCR amplification product, insert 2 of about 0.2 kbp.

[0074]

(In-fusion reaction 5)

The same procedure as in the above section (In-fusion reaction 1) was repeated except that PCR amplification product, vector 2 (50 ng) and PCR

amplification product, insert 2 (5 ng) were used to ligate PCR amplification product, vector 2 and PCR amplification product, insert 2. In this manner, in-fusion reaction solution 5 was prepared.

[0075]

(Transformation of *E. coli* and determination of DNA sequence of plasmid phIFNg33)

The same procedure as in the above section (Transformation of *E. coli* and determination of DNA sequence of plasmid pAG8) was repeated by using in-fusion reaction solution 3 (2 μ L) obtained above to carry out transformation of the *E. coli* HST16CR competent cells obtained above and extraction of a plasmid from the recombinant *E. coli*. In the plasmid extracted, the sequence of human IFN- γ secretory expression cassette (5'-Hu promoter-SP69L20-human IFN- γ protein-His tag-Hu terminator-3') was determined. The plasmid extracted was designated as phIFNg33. The constitution of plasmid phIFNg33 is shown in Figure 4 (a).

[0076]

(Transformation 3 of bacterium of the genus *Bifidobacterium*)

Bifidobacterium longum 105-A strain was transformed by the electroporation system in the same procedure as in the above section (Transformation 1 of bacterium of the genus *Bifidobacterium*) except that plasmid phIFNg33 (605 ng) extracted from the transformed *E. coli* mentioned above was used. The transformant obtained was designated as *Bifidobacterium longum* 105-A/ phIFNg33 strain (hereinafter referred to as hIFNg33 strain).

[0077]

PCR amplification was carried out using phIFNg33 mentioned above as a template and a primer set of GA5_primer_rev (forward) and GA1_primer (reverse) listed in Table 1. The same procedure as in the above section (Preparation of plasmid pAG8) was repeated except that the amplification program, which is a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 65°C for 5 seconds and a reaction at 75°C for 1 minute and 20 seconds, was repeated 30 times, and then an elongation reaction was carried out at 72°C for 30 seconds to prepare PCR amplification product C of about 1.2 kbp.

[0078]

PCR amplification was carried out using phIFNg33 mentioned above as a template and a primer set of GA2_primer (forward) and GA6_primer (reverse) listed in Table 1. The same procedure as in the above section (Preparation of plasmid pAG8) was repeated except that the amplification program, which is a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 65°C for 5 seconds and a reaction at 75°C for 3 minutes and 20 seconds, was repeated 30 times, and then an elongation reaction was carried out at 72°C for 30 seconds to prepare PCR amplification product D of about 3.3 kbp.

[0079]

(In-fusion reaction 6)

The same procedure as in the above section (In-fusion reaction 1) was repeated except that PCR amplification product C (18 ng) and PCR amplification product D (50 ng) were used to ligate PCR amplification

product C and PCR amplification product D. In this manner, in-fusion reaction solution 6 was prepared.

[0080]

(Transformation of *E. coli* and determination of DNA sequence of plasmid phIFNg33TL)

The same procedure as in the above section (Transformation of *E. coli* and determination of DNA sequence of plasmid pAG8) was repeated by using in-fusion reaction solution 6 obtained above to carry out transformation of the *E. coli* HST16CR competent cells obtained above and extraction of a plasmid from the recombinant *E. coli*. In the plasmid extracted, the sequence of human IFN- γ secretory expression cassette (5'-Hu promoter-SP69L20-human IFN- γ protein-Hu terminator-3') was determined. The plasmid extracted was designated as phIFNg33TL. The constitution of plasmid phIFNg33TL is shown in Figure 4 (b).

[0081]

(Transformation 4 of bacterium of the genus *Bifidobacterium*)

Bifidobacterium longum 105-A strain was transformed by the electroporation system in the same procedure as in the above section (Transformation 1 of bacterium of the genus *Bifidobacterium*) except that plasmid phIFNg33TL (435 ng) extracted from the transformed *E. coli* mentioned above was used. The transformant obtained was designated as *Bifidobacterium longum* 105-A/phIFNg33TL strain (hereinafter referred to as hIFNg33TL strain).

[0082]

[Example 4]

[Verification of hTNF- α and hIFN- γ secretion in AG8TL strain]

The presence or absence of secretion of human TNF- α protein and human IFN- γ protein in the culture supernatant of AG8TL strain was checked by ELISA as follows. A negative control strain, *Bifidobacterium longum* 105A/pBEShuttle strain (hereinafter referred to as BShuttle strain) was subjected to the same analysis.

[0083]

(Culture of recombinant bacterium of the genus *Bifidobacterium*)

AG8TL strain, TNF11 strain, hIFNg33TL strain and BShuttle strain each were inoculated in MRS (manufactured by Becton, Dickinson and Company) liquid medium (10 mL) supplemented with spectinomycin (final concentration 75 μ g/mL) and 100 μ L of a vitamin C solution (solution comprising ascorbic acid (35 g) and L-cysteine hydrochloride monohydrate (2 g) and sodium carbonate (11 g)/100 mL), and anaerobically cultured at 37°C for 24 hours. These were specified as activated culture solutions. Subsequently, to a medium (20 mL) obtained by adding DMEM (Cat No. 11885-084: manufactured by Life Technologies Corporation) and MRS in a ratio of 9: 1, vitamin C solution (100 μ L) and spectinomycin (so as to obtain a 75 μ g/mL), the above activated culture solution (100 μ L) was inoculated. The resultant medium was anaerobically cultured at 37°C for 18 hours.

[0084]

(Collection of culture supernatant and ELISA)

After the anaerobic culture, the culture solutions of the individual strains were centrifuged. The culture supernatants were separately collected and subjected to ELISA. The same operation was applied to the BEshuttle strain and used as a negative control. As the ELISA kit for TNF- α measurement, Quantikine Human TNF α /TNFSF1A Immunoassay (manufactured by R&D systems) was used. As the ELISA kit for hIFN- γ measurement, Quantikine Human IFN- γ Immunoassay (manufactured by R&D systems) was used. The operation of ELISA was carried out in accordance with the product manual of each ELISA kit. The results are shown in Table 2.

[0085]

[Table 2]

(ng/mL culture supernatant)

Recombinant Bifidobacterium strain	Amount of hTNF- α secreted	Amount of hIFN- γ secreted
AG8TL	501	376
TNF11	515	N. D.
hIFNg33TL	N. D.	346
BEshuttle	N. D.	N. D.

[0086]

(Results)

As is apparent from Table 2, it was found that hTNF- α protein and hIFN- γ protein are both present in the culture supernatant of AG8TL strain. It was also found that hTNF- α protein is present in the culture supernatant of a positive control, i.e., single-expression strain TNF11; and that human IFN- γ protein is present in the culture supernatant of hIFNg33TL strain.

[0087]

[Example 5]

[Investigation of proliferative inhibitory activity of AG8TL strain on KPL-1 cell]

(Preparation of culture-supernatant crude purified product)

Each (7 mL) of the culture supernatants of AG8TL strain, TNF11 strain and hIFNg33TL strain mentioned above prepared in the same manner as in Example 4 (Culture of recombinant bacterium of the genus *Bifidobacterium*) and (Collection of culture supernatant and ELISA) was concentrated by use of *Amicon Ultra-4*, MWCO: 10k (manufactured by Millipore), washed three times with PBS buffer (pH7.4) and concentrated to prepare 0.5 mL of a culture-supernatant crude purified product. A crude purified product from the culture-supernatant of the negative control strain, i.e., *Bifidobacterium longum* 105A/pBEShuttle strain, was prepared in the same manner. The crude purified products from individual strains were subjected to measurement of cell proliferation inhibitory activity. The concentrations of hTNF- α and hIFN- γ were estimated by use of an ELISA kit for TNF- α measurement and an ELISA kit hIFN- γ measurement.

[0088]

(Preparation of KPL-1 cell and addition of test sample)

Cell proliferation inhibitory activity was measured by using a human breast cancer cell strain, i.e., KPL-1 cell (provided by Prof. Junichi Kurebayashi, Kawasaki Medical School). KPL-1 cells were cultured in 10% fetal

bovine serum (manufactured by EQUITECH-BIO)/Dulbecco's modified eagle medium (high glucose) (manufactured by Sigma Aldrich) in a 100-mm petri dish. After the (test) medium was removed, the cells were washed with PBS (-) (manufactured by Wako Pure Chemical Industries Ltd.). To the cells, 0.25% Trypsin-EDTA (manufactured by Life Technologies Corporation) was added. The cells were collected and centrifuged. The supernatant was removed and the cells were suspended in the test medium so as to obtain 6×10^3 cells/mL. In this manner, a cell suspension was prepared.

[0089]

The cell suspension was dispensed in individual wells of a 96-well plate in an amount of 0.1 mL per well and cultured in a CO₂ incubator set at 37°C. In the following day, exchange was made with the medium prepared by further adding a crude purified product from culture-supernatant of AG8TL strain (comprising 20 ng/mL hIFN- γ and 51.1 ng/mL hTNF- α) to the test medium mentioned above. In this way, stimulation was started. Medium were prepared by separately adding crude purified products from culture-supernatant of TNF11 strain and hIFNg33TL strain so as to obtain the same concentration in the case of AG8TL strain and subjected to the same treatment as positive controls. Four days after initiation of stimulation, the medium was removed and exchanged for a medium (1/10 volume) supplemented with Cell Counting kit-8 (manufactured by Dojindo Molecular Technologies, Inc.) and the reaction was further carried out for 3 hours. After the reaction, absorbance at 450 nm and 630 nm (reference

wavelength) was measured by a multi-mode plate reader (manufactured by DS Pharma Biomedical Co., Ltd.). The blank was calculated by subtracting the absorbance of a well comprising the medium and Cell Counting kit-8 alone and no cells. Note that, the value obtained from a test medium in which KPL-1 cells were continuously cultured without adding any one of the aforementioned culture-supernatant crude purified products was regarded as absorbance (100%) of an untreated district. The proliferation rate of KPL-1 cells in individual mediums was calculated. The results are shown in Figure 5.

[0090]

(Results)

As is apparent from Figure 5, a secretion from AG8TL strain, significantly suppressed proliferation of KPL-1 cell, compared to a secretion from TNF11 strain alone or hIFNg33TL strain alone. More specifically, TNF11 strain secreting hTNF- α exhibited a proliferation rate of 89.9%; hIFNg33TL strain secreting hIFN- γ exhibited a proliferation rate of 83%; whereas AG8TL strain secreting hTNF- α and hIFN- γ , exhibited a relative cell viability of 35.5%. It was verified that AG8TL strain has a strong proliferation inhibitory effect on a human breast cancer cell strain. Such a result is conceivably due to a combinational effect of the hTNF- α secretion and the hIFN- γ secretion.

[0091]

[Example 6]

[Investigation on proliferation inhibitory activity of AG8TL strain to MIA PaCa-2 cell]

Cell proliferation inhibitory activity to MIA PaCa-2 cell was investigated in the same procedure as in Example 5 except that a human pancreas cancer-derived cell, i.e., MIA PaCa-2 cell (obtained from the independent administrative institution, RIKEN Bio Resource Center) was used in place of KPL-1 cell. Note that, the concentration of MIA PaCa-2 cells suspension dispensed and seeded in 96-well plates was specified as 1×10^4 cells/mL. The results are shown in Figure 6.

[0092]

(Results)

As is apparent from Figure 6, a secretion from AG8TL strain, significantly suppressed proliferation of MIA PaCa-2 cell, compared to a secretion from TNF11 strain alone or hIFNg33TL strain alone. More specifically, TNF11 strain secreting hTNF- α exhibited a proliferation rate of 51.6%; hIFNg33TL strain secreting hIFN- γ exhibited a proliferation rate of 75.4%; whereas AG8TL strain secreting hTNF- α and hIFN- γ , exhibited a proliferation rate of 24.2%. It was verified that AG8TL strain has a strong proliferation inhibitory effect on the human pancreas cancer cell strain. Such a result is conceivably due to a combinational effect of the hTNF- α secretion and the hIFN- γ secretion.

[0093]

[Example 7]

[Investigation of the specificity in cell proliferation inhibitory activity of AG8TL strain by using neutralizing antibodies]

To verify that the cell proliferation inhibitory activity by crude purified product from the culture-supernatant of an AG8TL strain is due to secretion of hTNF- α and hIFN- γ , investigation using a neutralizing antibody, i.e., Human IFN- γ Antibody and Human TNF- α Antibody (both are manufactured by R&D systems) was made as follows.

[0094]

In the same procedure as in Example 6, MIA PaCa-2 cells were seeded onto a 96-well plate. On the following day, exchange was made with a medium comprising any one of the crude purified products from culture-supernatant of AG8TL strain, TNF11 strain, hIFNg33TL strain and BEshuttle strain (negative control) and the antibody shown in the following Table 3, in combination. The materials added to the medium are shown in the following Table 3. Cell proliferation rate was calculated in the same procedure as in Example 5. The results are shown in Figure 7.

[0095]

[Table 3]

Medium	culture-supernatant crude purified product	Secretion	Antibody
1)	AG8TL strain	h I F N - γ (20 ng/mL) h T N F - α (51.1 ng/mL)	
2)	AG8TL strain	h I F N - γ (20 ng/mL) h T N F - α (51.1 ng/mL)	Anti-hTNF- α antibody (6 μ g/mL) Anti-hIFN- γ antibody (1 μ g/mL)
3)	AG8TL strain	h I F N - γ (20 ng/mL) h T N F - α (51.1 ng/mL)	Anti-hTNF- α antibody (6 μ g/mL)
4)	AG8TL strain	h I F N - γ (20 ng/mL) h T N F - α (51.1 ng/mL)	Anti-hIFN- γ antibody (1 μ g/mL)
5)	TNF11 strain	h T N F - α (51.1 ng/mL)	
6)	hIFNg33TL strain	h I F N - γ (20 ng/mL)	
7)	BEShuttle strain		
8)	BEShuttle strain		Anti-hTNF- α antibody (6 μ g/mL) Anti-hIFN- γ antibody (1 μ g/mL)

[0096]

(Results)

As is apparent from Figure 7, MIA PaCa-2 cell proliferation rate was 15.3% at the time when the culture-supernatant crude purified product of an AG8TL strain was added; however, the cell proliferation rates at the time when the anti-hIFN- γ antibody alone and the anti-hTNF- α

antibody alone were added increased to 31.8% and 44.4%, respectively. The cell proliferation rate increased to 74.1% at the time when both anti-hIFN- γ antibody and anti-hTNF- α antibody were added. This is because the bioactivities of hTNF- α and hIFN- γ secreted from AG8TL strain were neutralized by these antibodies. It is considered that proliferation inhibition of MIA PaCa-2 cell is due to hTNF- α and hIFN- γ secreted by AG8TL strain.

[0097]

[Example 8]

[Preparation of anti-hPD-1scFv03 and anti-hCTLA-4scFv02 co-expression *Bifidobacterium* PC1 strain and CP1 strain]

(Outline)

Co-expression plasmids pPC1 and pCP1 were prepared, which contain an expression cassette for secretory anti-hPD-1scFv03 (anti-human PD-1scFv03 secretory expression cassette) and an expression cassette for secretory anti-hCTLA-4scFv02FLAG (anti-human CTLA-4scFv02FLAG secretory expression cassette), respectively and which serve as *E. coli*-*Bifidobacterium* shuttle vector. *Bifidobacterium longum* 105-A strain was transformed with these plasmids pPC1 and pCP1 in accordance with electroporation to obtain anti-hPD-1scFv03 and anti-hCTLA-4scFv02 co-expression *Bifidobacterium* PC1 strain and CP1 strain. The primers used in Example 8 are shown in the following Table 4.

[0098]

[Table 4]

Primer Name	DNA sequence (5' -> 3')	SEQ ID No.
Ins-hPD-1 scFv03-F1	CAGGTCCAGCTGGTCGAATCGGGCGGCGGC	SEQ ID No. 36
Ins-hPD-1 scFv03-R1	ACGAGCAGAAGGTCAGTGGTGGTGATGATGGTGCTT	SEQ ID No. 37
TGA-Hu-Terminator-F	TGACCTTCTGCTCGTAGCGATTAC	SEQ ID No. 38
vec-SP7L20-R1	GACCAGCTGGACCTGCACCGAACTCGCCTTCGGGAA	SEQ ID No. 39
Ins-hCTLA-4 scFv02-F1	CAGGTCCAGCTGGTCGAATCGGGCGGCGGC	SEQ ID No. 40
Ins-hCTLA-4 scFv02-R1	ACGAGCAGAAGGTCAGTGATGATGATGATGATGCTT	SEQ ID No. 41
hCTLA-4 scFv02-FLAG-F1	GACTACAAGGACGACGACGACAAGTGACCTTCTGCTCGTAGCGAT	SEQ ID No. 42
hCTLA-4 scFv02-FLAG-R1	GTCGTCCTTGTAAGTCCTTGATTTCCACCTTGGT	SEQ ID No. 43
InF_pTB6 rep_F1	ACTAGTCCTCCAGGACCTCGTCTACGAGGC	SEQ ID No. 44
InF_Hu Prom_F1	GTCTTCCTGCTGGCCTATGCATTGGGTTCC	SEQ ID No. 45
InF_Hu Term-Hu Prom_R1	GGCCAGCAGGAAGACCCGGAATAATACGGTTGGAC	SEQ ID No. 46
InF_Hu Term-pTB6_R1	TCCTGGAGGACTAGTCCGGAATAATACGGTTGGAC	SEQ ID No. 47

[0099]

(Preparation of anti-human PD-1scFv03 secretion plasmid pHuSP7L20-hPD-1scFv03)

In preparing pPC1 and pCP1, anti-human PD-1scFv03 secretion plasmid pHuSP7L20-hPD-1scFv03 was first prepared.

[0100]

(Constitution of anti-human PD-1scFv03 secretory expression cassette)

As an anti-human PD-1scFv03 secretory expression cassette, a cassette sequentially comprising (1) a Hu promoter DNA, (2) a DNA encoding a signal peptide-linker conjugate, SP7L20, (3) a DNA encoding the amino acid sequence of anti-hPD-1scFv03 (comprising a heavy chain sequence, a linker (GGGGS)₃ and a light chain sequence), (4) a DNA encoding a His tag sequence and (5) a Hu

terminator DNA was prepared such that DNA (1) was placed upstream (the 5' end) and DNA (5) downstream (the 3' end). As to the nucleotide sequence of DNA encoding the amino acid sequence of anti-hPD-1scFv03 (comprising a heavy chain sequence, a linker (GGGS)₃ and a light chain sequence), the document shown in Table 5 (1) was referred to.

[0101]

(Artificial DNA synthesis of anti-hPD-1scFv03)

Anti-hPD-1scFv03 represented by SEQ ID No. 11 was sub-cloned to *E. coli* plasmid pUC57 by GenScript Japan Inc. and used as artificially synthesized plasmid, pUC57-hPD-1scFv03.

[0102]

[Table 5]

Antibody		Reference document
(1) Anti-hPD-1 scFv03	SEQ ID No. 11 (729 nucleotide sequence) Heavy chain sequence (1-342 nucleotides) (GGGS) ₃ linker (343-387 nucleotides) Light chain sequence (388-708 nucleotides) Histidine tag (709-726 nucleotides)	Japanese Patent No. 5028700
(2) Anti-hCTLA-4 scFv02	SEQ ID No. 12 (747 nucleotide sequence) Heavy chain sequence (1-357 nucleotides) (GGGS) ₃ linker (358-402 nucleotides) Light chain sequence (403-726 nucleotides) Histidine tag (727-744 nucleotides)	Japanese Patent No. 4093757
(3) Anti-hCTLA-4 scFv02FLAG	SEQ ID No. 13 (753 nucleotide sequence) Heavy chain sequence (1-357 nucleotides) (GGGS) ₃ linker (358-402 nucleotides) Light chain sequence (403-726 nucleotides)	Japanese Patent No. 4093757

	FLAG tag (727-750 nucleotides)	
--	--------------------------------	--

[0103]

(Preparation 1 of anti-hPD-1scFv03 insert fragment)

PCR amplification was carried out using plasmid, pUC57-hPD-1scFv03 (500 pg) as a template and a primer set of Ins-hPD-1scFv03-F1 primer (forward) and Ins-hPD-1scFv03-R1 primer (reverse) listed in Table 4. Each of the primer sequences was designed such that an insert fragment was overlapped with a vector fragment at the end of 15 bp. The PCR amplification was carried out by specifying the concentration of each primer as 0.2 μ M and the reaction volume as 30 μ L and using STAR kit. As the amplification program, a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 55°C for 5 seconds and a reaction at 72°C for 60 seconds was repeated 30 times. The insert PCR product amplified was electrophoresed on a 2% agarose gel and then purified by QIAquick Gel Extraction kit (hereinafter referred to as "QIAGel", manufactured by QIAGEN) to prepare an anti-hPD-1scFv03 insert fragment (1) of about 0.7 kbp.

[0104]

(Preparation of vector fragment (1) comprising DNA encoding the amino acid sequence of SP7L20)

PCR amplification was carried out using the vector linearized fragment (500 pg) represented by SEQ ID No. 14 as a template and a primer set of TGA-Hu-terminator-F primer (forward) and vec-SP7L20-R1 primer (reverse) listed in Table 4. The PCR amplification was carried out by specifying the concentration of each primer as 0.2 μ M and

the reaction volume as 30 μ L and using STAR kit. As the amplification program, a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 55°C for 5 seconds and a reaction at 72°C for 5 minutes, was repeated 30 times. The PCR product amplified was electrophoresed on a 0.8% agarose gel and then purified by QIAGel to prepare a 5'-Hu terminator-pTB6rep unit-SPCMr-pUCori-Hu promoter-SP7L20-3' vector fragment (1) of about 4.0 kbp.

[0105]

(In-fusion reaction 7)

The vector fragment (1) prepared above and the anti-hPD-1scFv03 insert fragment (1) were ligated by use of In-Fusion (registered trademark) HD Cloning kit. More specifically, the vector (fragment) and the insert (fragment) in the kit were added in a molar ratio of 1: 5 in a micro tube; then, 2 μ L of 5X In-Fusion HD Enzyme premix was added; and the volume of the reaction solution was adjusted to be 10 μ L. The reaction solution was kept warm at 50°C for 15 minutes. The procedure other than this was carried out in accordance with the product manual of the kit to prepare in-fusion reaction solution 7.

[0106]

(Transformation of *E. coli* and determination of DNA sequence of pHuSP7L20-hPD-1scFv03)

The same procedure as in the above section (Transformation of *E. coli* and determination of DNA sequence of plasmid pAG8) was repeated except that 5 μ L of in-fusion reaction solution 7 was used to carry out transformation of the *E. coli* HST16CR competent cell obtained above and extraction of a plasmid from the

recombinant *E. coli*. Note that, after the transformation, *E. coli* colony formed on an agar medium was picked up and cultured in LB liquid medium containing 75 µg/mL spectinomycin while shaking at 30°C overnight. The sequence of anti-human PD-1scFv03 secretory expression cassette (5'-Hu promoter-SP7L20-anti-hPD-1scFv03-His tag-Hu terminator-3') in the plasmid extracted was determined in the same procedure as above. The plasmid extracted was designated as pHuSP7L20-hPD-1scFv03. The constitution of pHuSP7L20-hPD-1scFv03 is shown in Figure 8 (A) and the sequence thereof is represented by SEQ ID No. 6.

[0107]

(Transformation 5 of bacterium of the genus *Bifidobacterium*)

Bifidobacterium longum 105-A strain was transformed by the electroporation system in the same procedure as in the above section (Transformation 1 of bacterium of the genus *Bifidobacterium*) except that plasmid pHuSP7L20-hPD-1scFv03 (550 ng) extracted from the transformed *E. coli* mentioned above was used. The transformant obtained was designated as *Bifidobacterium longum* 105-A/pHuSP7L20-hPD-1scFv03 strain (hereinafter referred to as hPD-1scFv03 strain).

[0108]

(Preparation of anti-hCTLA-4scFv02 secretion plasmid pHuSP7L20-hCTLA-4scFv02)

In preparing pPC1 and pCP1, anti-hCTLA-4scFv02 secretion plasmid pHuSP7L20-hCTLA-4scFv02 without FLAG tag was first prepared.

[0109]

(Constitutions of anti-human CTLA-4scFv02 secretory expression cassette and anti-human CTLA-4scFv02FLAG secretory expression cassette)

As an anti-human CTLA-4scFv02 secretory expression cassette, a cassette sequentially comprising (1) a Hu promoter DNA, (2) a DNA encoding a signal peptide-linker conjugate, SP7L20, (3) a DNA encoding the amino acid sequence of anti-hCTLA-4scFv02 (comprising a heavy chain sequence, a linker (GGGGS)₃ and a light chain sequence), (4) a DNA encoding a His tag sequence and (5) a Hu terminator DNA, was prepared such that DNA (1) was placed upstream (the 5' end) and DNA (5) downstream (the 3' end). As to the nucleotide sequence of DNA encoding the amino acid sequence of anti-hCTLA-4scFv02 (comprising a heavy chain sequence, a linker (GGGGS)₃ and a light chain sequence), the document shown in Table 5 (2) was referred to.

[0110]

As an anti-human CTLA-4scFv02FLAG secretory expression cassette, a cassette sequentially comprising (1) a Hu promoter DNA, (2) a DNA encoding a signal peptide-linker conjugate, SP7L20, (3) a DNA encoding the amino acid sequence of anti-hCTLA-4scFv02 (comprising a heavy chain sequence, a linker (GGGGS)₃ and a light chain sequence), (4) a DNA encoding a FLAG tag sequence and (5) a Hu terminator DNA, was prepared such that DNA (1) was placed upstream (the 5' end) and DNA (5) downstream (the 3' end). As to the nucleotide sequence of DNA encoding the amino acid sequence of anti-hCTLA-4scFv02 (comprising a heavy chain sequence, a linker (GGGGS)₃ and a light

chain sequence), the document shown in Table 5 (3) was referred to.

[0111]

(Artificial DNA synthesis of hCTLA-4scFv02)

The fragment, hCTLA-4scFv02 represented by SEQ ID No. 12 was subcloned to *E. coli* plasmid pUC57 by GenScript Japan Inc. and used as artificially synthesized plasmid pUC57-hCTLA-4scFv02.

[0112]

(Preparation of anti-hCTLA-4scFv02 insert fragment)

The same procedure as in the above section (Preparation 1 of anti-hPD-1scFv03 insert fragment) was repeated except that the plasmid pUC57-hCTLA-4scFv02 as a template and a primer set of Ins-hCTLA-4scFv02-F1 (forward) and Ins-hCTLA-4scFv02-R1 (reverse) listed in Table 4 were used to prepare anti-hCTLA-4scFv02 insert fragment of about 0.8 kbp.

[0113]

(In-fusion reaction 8)

An in-fusion reaction solution was prepared in the same procedure as in the in-fusion reaction in the above section (In-fusion reaction 7) except that the vector fragment (1) and the anti-hCTLA-4scFv02 insert fragment were used.

[0114]

(Transformation of *E. coli* and determination of DNA sequence of pHuSP7L20-hCTLA-4scFv02)

The same procedure as in the above section (Transformation of *E. coli* and determination of DNA sequence of plasmid pHuSP7L20-hPD-1scFv03) was repeated

except that 5 μ L of in-fusion reaction solution 8 was used to carry out transformation of *E. coli* HST08 competent cell. A sequencing reaction was carried out for determining the sequence of anti-human CTLA-4scFv02 secretory expression cassette (5'-Hu promoter-SP7L20-anti-hCTLA-4scFv02-His tag-Hu terminator-3') in the plasmid extracted. The plasmid extracted was designated as pHuSP7L20-hCTLA-4scFv02. The constitution of pHuSP7L20-hCTLA-4scFv02 is shown in Figure 8 (B) and the sequence thereof is represented by SEQ ID No. 7.

[0115]

[Preparation of anti-hCTLA-4scFv02FLAG single expression *Bifidobacterium* strain]

(Preparation of vector fragment comprising anti-hCTLA-4scFv02FLAG secretory expression cassette)

PCR amplification was carried out using plasmid pHuSP7L20-hCTLA-4scFv02 (500 pg) mentioned above as a template and a primer set of hCTLA-4scFv02-FLAG-F1 (forward) and hCTLA-4scFv02-FLAG-R1 (reverse) listed in Table 4. The primer sequences were designed such that both ends (15 bp.) of the PCR products were overlapped. The PCR amplification was carried out by specifying the concentration of each primer as 0.2 μ M and the reaction volume as 30 μ L and using the STAR kit. As the amplification program, a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 55°C for 5 seconds and a reaction at 72°C for 5 minutes, was repeated 30 times to prepare a vector fragment amplified product of about 4.8 kbp comprising an anti-hCTLA-4scFv02FLAG secretory expression cassette.

[0116]

(In-fusion reaction 9)

The vector fragment amplified product comprising the anti-human CTLA-4scFv02FLAG secretory expression cassette prepared above was subjected to an in-fusion reaction by use of In-Fusion (registered trademark) HD Cloning kit to close the ring by itself. More specifically, a reaction solution was prepared by mixing the vector fragment amplified product (5 μ L) and Cloning Enhancer (2 μ L), placed in a micro tube and kept warm at 37°C for 15 minutes, subsequently at 80°C for 15 minutes. Then, 0.5 μ L of the reaction solution and 2 μ L of 5X In-Fusion HD Enzyme premix were blended and the volume of the resultant reaction solution was adjusted to be 10 μ L. The reaction solution was kept warm at 50°C for 15 minutes. The procedure other than this was carried out in accordance with the production manual of the kit to prepare in-fusion reaction solution 9.

[0117]

(Transformation of *E. coli* and determination of DNA sequence of pHuSP7L20-hCTLA-4scFv02FLAG)

The same procedure as in the above section (Transformation of *E. coli* and determination of DNA sequence of plasmid pHuSP7L20-hPD-1scFv03) was repeated except that 5 μ L of in-fusion reaction solution 9 was used to carry out transformation of the *E. coli* HST08 competent cell obtained above and extraction of a plasmid from the recombinant *E. coli*. The sequence of anti-human CTLA-4scFv02FLAG secretory expression cassette (5'-Hu promoter-SP7L20-anti-human CTLA-4scFv02-FLAG tag-Hu terminator-3')

in the plasmid extracted was determined in the same procedure as above. The plasmid extracted was designated as pHuSP7L20-hCTLA-4scFv02FLAG. The constitution of pHuSP7L20-hCTLA-4scFv02FLAG is shown in Figure 8 (C) and the sequence thereof is represented by SEQ ID No. 8.

[0118]

(Transformation 6 of bacterium of the genus *Bifidobacterium*)

Bifidobacterium longum 105-A strain was transformed by the electroporation system in the same procedure as in the above section (Transformation 1 of bacterium of the genus *Bifidobacterium*) except that plasmid pHuSP7L20-hCTLA-4scFv02FLAG (256 ng) was used. The transformant obtained was designated as *Bifidobacterium longum* 105-A/pHuSP7L20-hCTLA-4scFv02FLAG strain (hereinafter referred to as hCTLA-4scFv02 strain).

[0119]

[Preparation of anti-hPD-1scFv03 and anti-hCTLA-4scFv02 co-expression strain]

PC1 strain and CP1 strain secreting both anti-hPD-1scFv03 and anti-hCTLA-4scFv02 were prepared. As is shown in Figure 9 (a), PC1 strain has a plasmid having a secretory expression cassette following the 3' end side of the origin of replication, pUCori, of *E. coli*. This secretory expression cassette is anti-human PD-1scFv03 secretory expression cassette, which is followed by anti-human CTLA-4scFv02 secretory expression cassette. As shown in Figure 9 (b), CP1 strain has a plasmid having a secretory expression cassette following the 3' end side of the origin of replication, pUCori, of *E. coli*. This

secretory expression cassette is anti-human CTLA-4scFv02 secretory expression cassette which is followed by anti-human PD-1scFv03 secretory expression cassette.

[0120]

[Preparation of PC1 strain]

(Preparation of anti-hCTLA-4scFv02FLAG insert fragment)

PCR amplification was carried out using plasmid pHuSP7L20-hCTLA-4scFv02FLAG (500 pg) (SEQ ID No. 8) as a template and a primer set of InF_Hu Prom_F1 (forward) and InF_Hu Term-pTB6_R1 (reverse) listed in Table 4. Each of the primer sequences was designed such that an insert fragment was overlapped with a vector fragment at the end of 15 bp. The PCR amplification was carried out by specifying the concentration of each primer as 0.2 μ M and the reaction volume as 30 μ L and using STAR kit. As the amplification program, a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 55°C for 5 seconds and a reaction at 72°C for 2 minutes, was repeated 30 times. The insert PCR product amplified was electrophoresed on a 0.8% agarose gel and then purified by use of QIAGel to prepare an anti-human CTLA-4scFv02FLAG insert fragment of about 1.4 kbp.

[0121]

(Preparation of vector fragment comprising anti-hPD-1scFv03 secretory expression cassette)

PCR amplification was carried out using plasmid pHuSP7L20-hPD-1scFv03 (500 pg) (SEQ ID No. 6) mentioned above as a template and a primer set of InF_pTB6rep_F1 (forward) and InF_HuTerm-HuProm_R1 (reverse) listed in

Table 4. Each of the primer sequences was designed such that an insert fragment was overlapped with a vector fragment at the end of 15 bp. The PCR amplification was carried out by specifying the concentration of each primer as 0.2 μ M and the reaction volume as 30 μ L and using PrimeSTAR HS (Premix) kit mentioned above. As the amplification program, a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 55°C for 5 seconds and a reaction at 72°C for 5 minutes, was repeated 30 times. The insert PCR product amplified was electrophoresed on a 0.8% agarose gel and then purified by QIAquick Gel Extraction kit to prepare a vector fragment (2) of about 4.7 kbp comprising anti-hPD-1scFv03 secretory expression cassette.

[0122]

(In-fusion reaction 10)

The vector fragment (2) prepared in the above and the anti-human CTLA-4scFv02FLAG insert fragment were ligated by use of In-Fusion (registered trademark) HD Cloning kit mentioned above. More specifically, the vector (fragment) and the insert (fragment) in the kit were added in a molar ratio of 1:3 in a micro tube; and then, 2 μ L of 5X In-Fusion HD Enzyme premix was added; and the volume of the reaction solution was adjusted to be 10 μ L. The reaction solution was kept warm at 50°C for 15 minutes. The procedure other than this was carried out in accordance with the product manual of the kit to prepare in-fusion reaction solution 10.

[0123]

(Transformation of *E. coli* and determination of DNA sequence of pPC1)

The same procedure as in the above section (Transformation of *E. coli* and determination of DNA sequence of plasmid pHuSP7L20-hPD-1scFv03) was repeated except that 2 μ L of in-fusion reaction solution 10 was used to carry out transformation of the *E. coli* HST16CR competent cell obtained above and extraction of a plasmid from the recombinant *E. coli*. The sequences of anti-human PD-1scFv03 secretory expression cassette (5'-Hu promoter-SP7L20-anti-hPD-1scFv03-His tag-Hu terminator-3') and anti-human CTLA-4scFv02FLAG secretory expression cassette (5'-Hu promoter-SP7L20-anti-hCTLA-4scFv02-FLAG tag-Hu terminator-3') in the plasmid extracted were determined in the same procedure as above. The plasmid extracted was designated as pPC1. The constitution of pPC1 is shown in Figure 9 (a) and the DNA sequence thereof is represented by SEQ ID No. 9.

[0124]

(Transformation 7 of bacterium of the genus *Bifidobacterium*)

Bifidobacterium longum 105-A strain was transformed by the electroporation system in the same procedure as in the above section (Transformation 1 of bacterium of the genus *Bifidobacterium*) except that plasmid pPC1 (250 ng) mentioned above was used. The transformant obtained was designated as *Bifidobacterium longum* 105-A/pPC1 strain (hereinafter referred to as PC1 strain).

[0125]

[Preparation of CP1 strain]

(Preparation 2 of anti-hPD-1scFv03 insert fragment)

PCR amplification and purification by a gel extraction kit were carried out in the same procedure as in the above section (Preparation of anti-human CTLA-4scFv02FLAG insert fragment) except that plasmid pHuSP7L20-hPD-1scFv03 (500 pg) (SEQ ID No. 6) mentioned above was used as a template and a primer set of InF_HuProm_F1 (forward) and InF_HuTerm-pTB6_R1 (reverse) listed in Table 4 were used to prepare anti-hPD-1scFv03 insert fragment (2) of about 1.4 kbp.

[0126]

(Preparation of vector fragment comprising anti-human CTLA-4scFv02FLAG secretory expression cassette)

PCR amplification and purification by a gel extraction kit were carried out in the same procedure as in the above section (Preparation 2 of anti-hPD-1scFv03 insert fragment) except that plasmid pHuSP7L20-hCTLA-4scFv02FLAG (SEQ ID No. 8) mentioned above was used as a template and a primer set of InF_pTB6rep_F1 (forward) and InF_HuTerm-HuProm_R1 (reverse) listed in Table 4 were used to prepare a vector fragment (3) of about 4.8 kbp comprising anti-human CTLA-4scFv02FLAG secretory expression cassette.

[0127]

(In-fusion reaction 11)

In-fusion reaction solution 11 was prepared in the same procedure as in the above section (In-fusion reaction 10) except that the vector fragment (3) prepared above and the anti-hPD-1scFv03 insert fragment (2) were used.

[0128]

(Transformation of *E. coli* and determination of DNA sequence of pCP1)

Transformation of *E. coli* HST16CR competent cell and plasmid extraction from recombinant *E. coli* were carried out in the same procedure as in the above section (Transformation of *E. coli* and determination of DNA sequence of plasmid pHuSP7L20-hPD-1scFv03) except that 2 μ L of in-fusion reaction solution 11 was used. The sequences of anti-human PD-1scFv03 secretory expression cassette (5'-Hu promoter-SP7L20-anti-hPD-1scFv03-His tag-Hu terminator-3') and anti-human CTLA-4scFv02FLAG secretory expression cassette (5'-Hu promoter-SP7L20-anti-hCTLA-4scFv02-FLAG tag-Hu terminator-3') in the plasmid extracted were determined in the same procedure as the above section (Transformation of *E. coli* and determination of DNA sequence of pCP1). The plasmid extracted was designated as pCP1. The constitution of pCP1 is shown in Figure 9 (b) and the DNA sequence of pCP1 is represented by SEQ ID No. 10.

[0129]

(Transformation 8 of bacterium of the genus *Bifidobacterium*)

Bifidobacterium longum 105-A strain was transformed by the electroporation system in the same procedure as in the above section (Transformation 1 of bacterium of the genus *Bifidobacterium*) except that plasmid pCP1 (250 ng) mentioned above was used. The transformant obtained was designated as *Bifidobacterium longum* 105-A/pCP1 strain (hereinafter referred to as CP1 strain).

[0130]

[Example 9]

[Verification of anti-hPD-1scFv and anti-hCTLA-4scFv secretion in PC1 strain and CP1 strain]

The presence or absence of anti-hPD-1scFv03 (labeled with a histidine tag) and anti-hCTLA-4scFv02 (labeled with FLAG tag) in the culture supernatants of PC1 strain and CP1 strain was checked by western blotting as follows. As a negative control strain, a Beshuttle strain was subjected to the same analysis.

[0131]

(Culture of recombinant bacterium of the genus *Bifidobacterium*)

Bifidobacterium strains, i.e., PC1 strain, CP1 strain, hPD-1scFv03 strain, hCTLA-4scFv02 strain and Beshuttle strain were cultured in the same procedure as in Example 4 (Culture of recombinant bacterium of the genus *Bifidobacterium*) and the culture supernatants were collected. The proteins in the culture supernatants were precipitated with trichloroacetic acid (TCA, manufactured by Wako Pure Chemical Industries Ltd.), washed with acetone, dissolved in a buffer for SDS-PAGE and treated with heat at 95°C for 3 minutes to obtain culture supernatant concentrates.

[0132]

(Western analysis)

Each of the culture supernatant concentrates (corresponding to about 0.1 mL of the culture solution) was electrophoresed by Mini-PROTEAN (registered trademark) TGX™ gel (4 to 20%) (manufactured by Bio-Rad). The resultant gel was transferred to PVDF membrane (iBlot

Transfer Stacks, manufactured by Life Technologies Corporation) by use of iBlot transfer device (manufactured by Life Technologies Corporation). After completion of blotting, the PVDF membrane was blocked with 2%ECL Prime Blocking agent (manufactured by GE Healthcare Japan) in TTBS. Electrophoresis and blotting to the membrane were carried out double. One of the PVDF membranes was used for detection of anti-hPD-1scFv03 using an anti-histidine antibody (THE His Tag Antibody, mAb, Mouse) (manufactured by GenScript) as a primary antibody and ECL peroxidase labelled anti-mouse antibody (manufactured by GE Healthcare) as a secondary antibody. The other PVDF membrane was used for detection of anti-hCTLA-4scFv02 using anti-FLAG antibody Monoclonal ANTI-FLAG M2 Antibody (produced in mouse) (manufactured by Sigma) as a primary antibody and an ECL peroxidase labelled anti-mouse antibody (manufactured by GE Healthcare) as a secondary antibody. After completion of the antibody reactions, the membranes were illuminated by Western Lightning Ultra (manufactured by PerkinElmer Co., Ltd.). These were analyzed by imaging equipment, MYECL Imager (manufactured by Thermo Scientific). The results are shown in Figure 10.

[0133]

(Results)

As is apparent from Figure 10, both anti-hPD-1scFv03 and anti-hCTLA-4scFv02 were detected in the culture supernatants of PC1 strain (lane 1 both in A and B) and CP1 strain (lane 2 both in A and B) comprising anti-human PD-1scFv03 secretory expression cassette having a His tag fused to the C terminal of the anti-hPD-1scFv03 and anti-

human CTLA-4scFv02FLAG secretory expression cassette having a FLAG tag fused to C terminal of the anti-hCTLA-4scFv02. The sizes of hPD-1scFv secretory proteins from PC1 strain (A: lane 1) and CP1 strain (A: lane 2) were the same as the size of hPD-1scFv secretory protein from hPD-1scFv03 single-expression strain (A: lane 3); and the sizes of hCTLA-4scFv secretory proteins from PC1 strain (B: lane 1) and CP1 strain (B: lane 2) were the same as the size of hCTLA-4scFv secretory protein from hCTLA-4scFv02 single-expression strain (B: lane 4). Accordingly, it was verified that co-expression *Bifidobacterium* strains, i.e., PC1 strain and CP1 strain, are recombinant *Bifidobacterium* strains capable of secreting both anti-hPD-1scFv and anti-hCTLA-4scFv in the culture supernatant.

[0134]

[Example 10]

[Verification of binding of antibody secreted from PC1 strain to hPD-1 and hCTLA-4]

The presence or absence of binding activity of anti-hPD-1scFv03, which was purified from the culture supernatant of co-expression strain PC1, to human PD-1 (hPD-1); and the presence or absence of binding activity of anti-hCTLA-4scFv02 to human CTLA-4 were checked by ELISA.

[0135]

To 96-well plates, hPD-1 (Recombinant Human hPD-1 Fc Chimera, manufactured by R&D systems); hCTLA-4 (Recombinant Human CTLA-4-Fc Chimera, manufactured by Biolegend); mPD-1 (Recombinant Human hPD-1 Fc Chimera, manufactured by R&D systems); and mCTLA-4 (Recombinant

mouse CTLA-4-Fc Chimera, manufactured by Biolegend), which were adjusted to be 1 µg/mL with 1X PBS, were dispensed in an amount of 100 µL for each and incubated at 4°C overnight for immobilization. After the liquid was removed, 1X PBS (350 µL) for each was dispensed and the liquid was removed. This operation was repeated three times for washing. To each of the plates, 1% BSA solution (350 µL) was dispensed at room temperature and incubated for 2 hours for blocking. After the liquid was removed, 1X PBS (350 µL) for each was dispensed and the liquid was removed. This operation was repeated three times for washing.

[0136]

Anti-hPD-1scFv03 and anti-hCTLA-4scFv02 were adjusted to be 1000 ng/mL, 100 ng/mL, 10 ng/mL and 1 ng/mL with a signal enhancing reagent (Signal Enhancer HIKARI, manufactured by Nacalai Tesque) and dispensed to the plates each in an amount of 100 µL after completion of the blocking. To blank wells, the signal enhancing reagent alone was dispensed in an amount of 100 µL. A seal was attached to the plates and the plates were incubated at room temperature for 2 hours to allow anti-hPD-1scFv03 to react with immobilized hPD-1, mPD-1 and hCTLA-4. Similarly, anti-hCTLA-4scFv02 was allowed to react with immobilized hCTLA-4, mCTLA-4 and hPD-1. After the liquid was removed, 1X PBS (350 µL for each) was dispensed and the liquid was removed. This operation was repeated three times for washing.

[0137]

The secondary antibody (Anti-Histag-Biotin, manufactured by MBL) was diluted with the signal enhancing reagent to 2000 fold. The dilution (100 μ L) was dispensed to wells reacted with anti-hPD-1scFv03. Similarly, secondary antibody (THE (registered trademark) DYKDDDDK Tag Antibody [Biotin], mAb, mouse, manufactured by GenScript) was diluted with the signal enhancing reagent to 2500 fold. The dilution (100 μ L) was dispensed to wells and allowed to react with anti-hCTLA-4scFv02. A seal was attached to the plates and the plates were incubated at room temperature for 2 hours. After the liquid was removed, 1X PBS (350 μ L) was dispensed for each and the liquid was removed. This operation was repeated three times for washing.

[0138]

Three drops of each of solution A and solution B serving as the avidin-biotin marker enzyme complex (VECTASTAIN ABC kit, manufactured by Vector) were added to the signal enhancing reagent (7.5 mL). The mixture was dispensed in an amount of 100 μ L for each plate. Thereafter, a seal was attached to the plates and the plates were incubated at room temperature for 30 minutes. After the liquid was removed, 1X PBS (350 μ L for each) was dispensed and the liquid was removed. This operation was repeated three times for washing.

[0139]

A detection reagent was prepared by adding Color Solution A and Color Solution B (manufactured by R&D systems) in equal amounts, and dispensed in an amount of 200 μ L for each. The plates were shielded from light and

incubated at room temperature for 20 minutes. Accurately 20 minutes later, Stop Solution (R&D Systems) was added in an amount of 50 μ L for each to terminate the coloring reaction. Absorbance was measured at 450 nm and 570 nm (reference wavelength). The results of binding of anti-hPD-1scFv03 to a human PD-1 immobilized plate determined by ELISA are shown in the following Table 6 and Figure 11. Similarly, the results of binding of anti-hCTLA-4scFv02 to a human CTLA-4 immobilized plate are shown in the following Table 7 and Figure 12.

[0140]

[Table 6]

Binding of anti-hPD-1scFv03 to human PD-1 immobilized plate (OD value)

Concentration of anti-hPD-1scFv03	hPD-1 immobilized	hCTLA-4 immobilized	mPD-1 immobilized
1ng/mL	-0.030	-0.062	-0.059
10ng/mL	0.373	-0.055	-0.057
100ng/mL	3.774	-0.018	-0.049
1000ng/mL	3.788	0.341	0.107

[0141]

[Table 7]

Binding of anti-hCTLA-4scFv02 to human CTLA-4 immobilized plate (OD value)

Concentration of anti-hCTLA-4scFv02	hPD-1 immobilized	hCTLA-4 immobilized	mCTLA-4 immobilized
1ng/mL	-0.018	0.009	0.026
10ng/mL	-0.031	0.026	0.005
100ng/mL	-0.038	0.255	0.001
1000ng/mL	-0.001	1.419	0.051

[0142]

(Results)

As is apparent from Table 6 and Figure 11, anti-hPD-1scFv03 which was purified from the culture supernatant of co-expression strain PC1, bound to hPD-1. As is apparent from Table 7 and Figure 12, anti-hCTLA-4scFv02 bound to hCTLA-4. In contrast, anti-hPD-1scFv03 bound to neither hCTLA-4 nor mPD-1; and anti-hCTLA-4scFv02 bound to neither hPD-1 nor mCTLA-4. From these, it was verified that anti-hPD-1scFv03 and anti-hCTLA-4scFv02 secreted from co-expression strain PC1, specifically bind to the corresponding antigen proteins.

[0143]

[Example 11]

[Competitive inhibitory activity of anti-hPD-1scFv in binding reaction of human PD-L1 to human PD-1]

It is said that when ligand PD-L1 binds to PD-1, a negative signal is transmitted to T cell to suppress an immune response (immune tolerance). Then, Competitive inhibitory activity of anti-hPD-1scFv in binding reaction of human PD-L1 to human PD-1 was investigated.

[0144]

Whether anti-hPD-1scFv03 purified from the culture supernatant of co-expression strain PC1 has a competitive binding inhibition activity in binding of human PD-L1 (hPD-L1) to human PD-1 (hPD-1) was checked by ELISA. As a negative control, anti-hCTLA-4scFv02 was used.

[0145]

To 96-well plates, hPD-1 (Recombinant HumanPD-1 Fc Chimera, manufactured by R&D systems), the concentration

of which was adjusted to be 1 µg/mL with 1X PBS, was dispensed in an amount of 100 µL for each and incubated at 4°C overnight for immobilization. After the liquid was removed, 1X PBS (350 µL) was dispensed and the liquid was removed. This operation was repeated three times for washing.

[0146]

To the plates, 1% BSA solution (350 µL for each) was dispensed and incubated at room temperature for 2 hours for blocking. After the liquid was removed, 1X PBS (350 µL) for each was dispensed and the liquid was removed. This operation was repeated three times for washing. Ligand, hPD-L1 (R&D Systems, Recombinant HumanB7-H1/PD-L1 FcChimera) was adjusted to be 2000 ng/mL with the signal enhancing reagent.

[0147]

Anti-hPD-1scFv03 purified from a bacterium of the genus *Bifidobacterium* was adjusted to be 20000 ng/mL, 2000 ng/mL, 200 ng/mL and 20 ng/mL with the signal enhancing reagent and mixed with hPD-L1 in equal amounts (120 µL). The resultant solutions was each (100 µL) dispensed to plates after completion of blocking. As a negative control, anti-hCTLA-4scFv02 purified from a bacterium of the genus *Bifidobacterium* was subjected to the same operation. To blank wells, the signal enhancing reagent alone (100 µL) was dispensed. A seal was attached to the plate and the plate was incubated at room temperature for 2 hours to allow hPD-L1 mixed with anti-hPD-1scFv03 to react with immobilized hPD-1. After the liquid was removed, 1X PBS (350 µL) was dispensed and the liquid was

removed. This operation was repeated three times for washing. A secondary antibody (Biotinanti-human CD274, manufactured by Biolegend) to hPD-L1 was adjusted to be 0.2 µg/mL with the signal enhancing reagent and dispensed in an amount of 100 µL for each. A seal was attached to the plate and the plate was incubated at room temperature for 30 minutes. After the liquid was removed, 1X PBS (350 µL) was dispensed and the liquid was removed. This operation was repeated three times for washing.

[0148]

One drop of solution A and solution B serving as the avidin-biotin marker enzyme complex were added to the signal enhancing reagent (2.5 mL). This was dispensed in an amount of 100 µL for each. Then, a seal was attached to the plate and the plate was incubated at room temperature for 30 minutes. After the liquid was removed, 1X PBS (350 µL) was dispensed and the liquid was removed. This operation was repeated three times for washing. A detection reagent was prepared by adding Color Solution A and Color Solution B (manufactured by R&D systems) in equal amounts and dispensed in an amount of 200 µL for each. The plate was shielded from light and incubated at room temperature for 20 minutes. Accurately 20 minutes later, 50 µL of Stop Solution (R&D Systems) for each was added to terminate the coloring reaction. Absorbance was measured at 450 nm and 570 nm (reference wavelength). The measurement results are shown in the following Table 8 and Figure 13.

[0149]

[Table 8]

Competitive inhibitory activity of anti-hPD-1scFv03 in binding reaction of human PD-L1 to human PD-1

Concentration of scFv	Binding (OD) to hPD-L1 (1000 ng/mL) and Inhibition rate (%)	
	Anti- hPD-1 scFv03	Anti- hCTLA-4 scFv02
10ng/mL	3.479 (-0.7%)	3.697 (-7.0%)
100ng/mL	3.503 (-1.4%)	3.473 (-0.5%)
1000ng/mL	3.309 (4.2%)	3.555 (-2.9%)
10000ng/mL	1.062 (69.3%)	3.596 (-4.1%)
Non-scFv	3.455 (0%)	

[0150]

(Results)

As is apparent from Table 8 and Figure 13, the inhibition rate of anti-hPD-1scFv03 (10000 ng/mL) to the binding of hPD-L1 (1000 ng/mL) to hPD-1 was 69.3%. From the result, it was demonstrated that anti-hPD-1scFv03 competitively inhibits the binding of hPD-L1 (1000 ng/mL) to hPD-1 at a concentration of 10000 ng/mL or more.

[0151]

[Example 11-1]

[Verification of competitive inhibitory activity of hCTLA-4scFv in binding reactions of human CD80 and human CD86 to human CTLA-4]

Using anti-hCTLA-4scFv02 purified from the culture supernatant of co-expression strain PC1 mentioned above, competitive inhibitory activity thereof in binding of each of human CD80 (hCD80) and human CD86 (hCD86) to human CTLA-4 (hCTLA-4) was checked by ELISA. As a negative control, anti-hPD-1scFv03 was used.

[0152]

To 96-well plates, hCTLA-4 (Recombinant Human CTLA-4-Fc Chimera, carrier-free, manufactured by BioLegend) adjusted to be 1 µg/mL with 1X PBS was dispensed in an amount of 100 µL for each and incubated at 4°C overnight for immobilization. After the liquid was removed, 1X PBS (350 µL for each) was dispensed and the liquid was removed. This operation was repeated three times for washing.

[0153]

To the plates, 1% BSA solution (350 µL for each) was dispensed, incubated at room temperature for 2 hours for blocking. After the liquid was removed, 1X PBS (350 µL for each) was dispensed and the liquid was removed. This operation was repeated three times for washing. Ligand hCD80 (R&D Systems, Recombinant Human B7-1/CD80 Fc Chimera) and hCD86 (R&D Systems, Recombinant Human B7-2/CD86 Fc Chimera) were separately adjusted to be 2000 ng/mL with the signal enhancing reagent.

[0154]

Anti-hCTLA-4scFv02 purified from a bacterium of the genus *Bifidobacterium* was adjusted to be 20000 ng/mL, 2000 ng/mL, 200 ng/mL and 20 ng/mL with the signal enhancing reagent, mixed with each of the hCD80 and hCD86 in equal amounts (120 µL). The resultant mixtures was each (100 µL) dispensed to the plates after completion of blocking. Anti-hPD-1scFv03 purified from a bacterium of the genus *Bifidobacterium* as a negative control was subjected to the same preparation. To blank wells, the signal enhancing reagent alone (100 µL) was dispensed. A seal was attached to the plates and the plates were incubated at room

temperature for 2 hours. Each of hCD80 and hCD86, which were separately mixed with anti-hCTLA-4scFv02, was allowed to react with the hCTLA-4 immobilized. After the liquid was removed, 1X PBS (350 μ L for each) was dispensed and the liquid was removed. This operation was repeated three times for washing.

[0155]

A secondary antibody (R&D Systems, Human B7-1/CD80 Biotinylated Antibody) to hCD80 and a secondary antibody (R&D Systems, Biotinylated Anti-human B7-2 Antibody) to hCD86 were separately adjusted to be 2.5 μ g/mL and 0.5 μ g/mL with the signal enhancing reagent and each dispensed in an amount of 10 μ L. A seal was attached to the plates and the plates were incubated at room temperature for 30 minutes. After the liquid was removed, 1X PBS (350 μ L for each) was dispensed and the liquid was removed. This operation was repeated three times for washing.

[0156]

Three drops of solution A and solution B mentioned above serving as the avidin-biotin marker enzyme complex were added to the signal enhancing reagent (7.5 mL). This was dispensed in an amount of 100 μ L for each. Then, a seal was attached to the plates and the plates were incubated at room temperature for 30 minutes. After the liquid was removed, 1X PBS (350 μ L for each) was dispensed and the liquid was removed. This operation was repeated three times for washing. A detection reagent was prepared by adding Color Solution A and Color Solution B (R&D) in equal amounts and dispensed in an amount of 200 μ L for each. The plate was shielded from light and incubated at

room temperature for 20 minutes. Accurately 20 minutes later, 50 μ L of Stop Solution (R&D) was added to terminate the coloring reaction. Absorbance was measured at 450 nm and 570 nm (reference wavelength). The results are shown in the following Table 9 and Table 10 and Figure 14 and Figure 15.

[0157]

[Table 9]

Competitive inhibitory activity of anti-hCTLA-4scFv02 in binding reaction of human CD80 to human CTLA-4

Concentration of scFv	Binding (OD) to hCD80 (1000 ng/mL) and Inhibition rate (%)	
	Anti- hCTLA-4 scFv02	Anti- hPD-1 scFv03
10ng/mL	2.656 (15.7%)	2.638 (16.2%)
100ng/mL	2.403 (23.7%)	2.410 (23.5%)
1000ng/mL	1.774 (43.7%)	2.464 (21.8%)
10000ng/mL	0.577 (81.7%)	2.862 (9.1%)
Non-scFv	3.149 (0%)	

[0158]

[Table 10]

Competitive inhibitory activity of anti-hCTLA-4scFv02 in binding reaction of human CD86 to human CTLA-4

Concentration of scFv	Binding (OD) to hCD86 (1000 ng/mL) and Inhibition rate (%)	
	Anti- hCTLA-4 scFv02	Anti- hPD-1 scFv03
10ng/mL	2.085 (0.3%)	1.491 (28.7%)
100ng/mL	1.421 (32.0%)	1.396 (33.2%)
1000ng/mL	0.627 (70.0%)	1.265 (39.5%)
10000ng/mL	0 (100.0%)	1.526 (27.0%)
Non-scFv	2.091 (0%)	

[0159]

(Results)

As is apparent from Table 9 and Table 10 and Figure 14 and Figure 15, the inhibition rates of anti-hCTLA-4scFv02 (1000 ng/mL) to the binding of hCD80 and hCD86 (1000 ng/mL) to hCTLA-4 are as follows. In the case of anti-hCTLA-4scFv02 (1000 ng/mL), the inhibition rates thereof were 43.7% and 70.0%, respectively. In the case of anti-hCTLA-4scFv02 (10000 ng/mL), the inhibition rates thereof were 81.7% and 100.0%, respectively. It was demonstrated that anti-hCTLA-4scFv02 competitively inhibits the binding of each of hCD80 and hCD86 (1000 ng/mL) to hCTLA-4 at a concentration of 1000 ng/mL or more.

[0160]

[Example 12]

[Investigation on binding of each of anti-hPD-1scFv and anti-hCTLA-4scFv purified from a co-expression

Bifidobacterium to cells by using antigen overexpressing cell strain]

The presence or absence of binding of anti-hPD-1scFv purified from the culture supernatant of co-expression strain PC1 mentioned above to a human PD-1 (hPD-1) expressing cells, and the presence or absence of binding of anti-hCTLA-4scFv to a human CTLA-4 (hCTLA-4) expressing cells were checked by using the following antigen-protein overexpressing cells in accordance with flow cytometry.

[0161]

HEK293T cells overexpressing hPD-1 (hPD-1 and rat CD2 are bicistronically expressed) and HEK293T cells overexpressing hCTLA-4 (hCTLA-4 and rat CD2 are bicistronically expressed) were used. HEK293T cells overexpressing hPD-1 and HEK293T cells overexpressing hCTLA-4 were each cultured in DMEM medium containing inactivated 10% fetal bovine serum and seeded in a 100-mm dish (manufactured by Greiner Japan). After the culture supernatants of hPD-1 overexpressing HEK293T cells and hCTLA-4 overexpressing HEK293T cells were removed, these cells were separately washed twice with PBS (Ca^{2+} , Mg^{2+} -free phosphate buffer). A trypsin/EDTA solution (1 mL) (manufactured by Wako Pure Chemical Industries Ltd.) diluted 10 fold with PBS was added. The cells were incubated at room temperature for one minute. Thereafter, 10 mL of DMEM medium containing inactivated 10% fetal bovine serum was added. The resultant cells were transferred to 15 mL-centrifuge tubes (manufactured by BD FALCON) and spun by a low-speed centrifuge (manufactured by TOMY SEIKO CO., LTD.) at 1000 rpm for 5 minutes. After

centrifugation, the supernatant was removed. DMEM medium (1 mL) containing inactivated 10% fetal bovine serum was added and the number of cells was counted. Further, the DMEM medium was added to prepare a cell suspension of 1×10^5 cells/mL and dispensed in 1.5-mL tubes (manufactured by Ina-optika Corporation) so as to contain 1×10^5 cells/mL/tube. The hPD-1 overexpressing HEK293T cells and hCTLA-4 overexpressing HEK293T cells dispensed in 1.5-mL tubes were each spun by a micro refrigerated centrifuge (manufactured by TOMY SEIKO CO., LTD.) at 5000 rpm and 4°C for one minute and then the supernatants were removed. The remaining cell pellets in the tube were washed twice with 0.5 mL of PBS. Thereafter, anti-hPD-1scFv03 and anti-hCTLA-4scFv02 (100 μ L for each), which were purified from a recombinant bacterium of the genus *Bifidobacterium* and prepared to be 10 μ g/mL, were added to respective tubes and incubated on ice for 30 minutes. Thirty minutes later, FACS buffer (PBS containing 1% BSA and 0.1%NaN₃) was added in the tubes (500 μ L). After centrifugation was carried out by a micro refrigerated centrifuge at 5000 rpm and 4°C for one minute, the supernatants were removed and washing operation was carried out. The same operation was repeated once more and the washing operation was carried out twice. Anti-His-tag Alexa Fluor 488 antibody (manufactured by MBL) and anti-DDDDK-tag Alexa Fluor 488 antibody (manufactured by MBL) diluted with FACS buffer to be 0.5 μ g/mL were added in an amount of 100 μ L to the 1.5-mL tubes, sufficiently mixed by pipetting and incubated on ice for 30 minutes. Thirty minutes later, the FACS buffer was added to the tubes (500 μ L), centrifuged by a micro

refrigerated centrifuge at 5000 rpm and 4°C for one minute. After the supernatants were removed, a washing operation was carried out. The same operation was repeated once more and the washing operation was carried out twice. After the FACS buffer (500 µL) was added, the cells suspended with the FACS buffer were transferred to 5 mL polystyrene round-bottom tubes (manufactured by Becton, Dickinson and Company). A propidium iodide solution (5 µL) diluted with the FACS buffer to be 5 µg/mL was added and analysis was carried out by use of BD FACS canto II flow cytometer (manufactured by Becton, Dickinson and Company) and flow cytometry analysis software Kaluza ver 1.2 (manufactured by Beckman Coulter, Inc.). The binding results of anti-PD-1scFv03 purified from PC1 strain to human PD-1 overexpressing cells are shown in Figure 16. Similarly, the binding results of anti-CTLA-4scFv02 purified from co-expression strain PC1 to human CTLA-4 overexpressing cells are shown in Figure 17.

[0162]

(Results)

As is apparent from Figure 16, it was verified that anti-PD-1scFv03 purified from PC1 strain specifically binds to human PD-1 high expressing cells (rat CD2 high expressing cells). Similarly, as is apparent from Figure 17, it was verified that anti-CTLA-4scFv02 purified from PC1 strain specifically binds to a human CTLA-4 high expressing cells (rat CD2 high expressing cell). From these results, it was verified that the scFv purified from co-expression strain PC1, specifically binds to human PD-1 and human CTLA-4 overexpressing cells.

[0163]

[Example 13]

[Preparation of anti-HER2scFv and hIFN- γ co-expression *Bifidobacterium* strain, HG-2]

(Outline)

A co-expression plasmid, pHG-2, which contains an expression cassette for secretory anti-HER2scFv (anti-HER2scFv secretory expression cassette) and an expression cassette for secretory hIFN- γ (human IFN- γ secretory expression cassette), and which serves as an *E. coli*-*Bifidobacterium* shuttle vector, was prepared (Figure 2). *Bifidobacterium longum* 105-A strain was transformed with pHG-2 thus prepared by electroporation to obtain an anti-HER2scFv and hIFN- γ co-expression *Bifidobacterium*, HG-2 strain. The primers used in Example 13 are shown in the following Table 11.

[0164]

[Table 11]

Primer Name	DNA sequence (5' -> 3')	SEQ ID No.
pTB6_Vec_F1	ACTAGTCCTCCAGGACCTCGTCTAC	SEQ ID No. 48
Hu-term_Vec_R1	CCGGAATAATACGGTTGGACAAC	SEQ ID No. 49
Hu-HuT_ins_F1	accgtattattccggGGATCCGTCTTCCTGCTGG	SEQ ID No. 50
HuT-pTB6_ins_R1	tcctggaggactagtCCGGAATAATACGGTTGGA CAAC	SEQ ID No. 51
Hu_Vec_F1	GGATCCGTCTTCCTGCTGG	SEQ ID No. 52
bHER2-His_Vec_R1	TCAGTGATGATGATGATGATGCTTG	SEQ ID No. 53
d0013+T_ins_F1	catcatcatcactgaAACCGCTTCTCATTTCATT TG	SEQ ID No. 54
d0013+T_ins_R1	caggaagacggatccGTGCACCGAATCGCGCT	SEQ ID No. 55

[0165]

As the anti-HER2scFv secretory expression cassette, a cassette sequentially comprising (1) a P30 promoter DNA, (2) a DNA encoding a signal peptide-linker conjugate, SP7L20, (3) a DNA encoding the amino acid sequence of anti-HER2scFv, (4) a DNA encoding a His tag sequence and (5) a d0013 terminator DNA was prepared such that DNA (1) was placed upstream (the 5' end) and DNA (5) downstream (the 3' end).

[0166]

(Preparation of plasmid pHG-2)

In preparing plasmid pHG-2, plasmid pHG-1 was first prepared.

[0167]

(Preparation of plasmid pHG-1)

(Preparation of hIFNg insert fragment)

PCR amplification was carried out using a plasmid phIFNg33 (SEQ ID No. 16) as a template and a primer set of Hu-HuT_ins_F1 (forward) and HuT-pTB6_ins_R1 (reverse) listed in Table 11. Each of the primer sequences was designed such that an insert fragment was overlapped with a vector fragment at the end of 15 bp. The PCR amplification was carried out by specifying the concentration of each primer as 0.2 μ M and the reaction volume as 20 μ L and using STAR kit. As the amplification program, a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 65°C for 5 seconds and a reaction at 72°C for 72 seconds, was repeated 30 times and then an elongation reaction was carried out at 72°C for 30 seconds to prepare hIFNg insert fragment amplified product of about 1.1 kbp.

[0168]

(Preparation of vector fragment comprising DNA encoding the amino acid sequence of anti-HER2scFv protein)

PCR amplification was carried out using pP30SP7L20-bHER2 (SEQ ID No. 15) as a template and a primer set of pTB6_Vec_F1 (forward) and Hu-term_Vec_R1 (reverse) listed in Table 11. Each of the primer sequences was designed such that an insert fragment was overlapped with a vector fragment at the end of 15 bp. The PCR amplification was carried out by specifying the concentration of each primer as 0.2 μ M and the reaction volume as 20 μ L and using STAR kit. As the amplification program, a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 65°C for 5 seconds and a reaction at 72°C for 4 minutes 45 seconds, was repeated 30 times and then an elongation reaction was carried out at 72°C for 30 seconds to prepare a vector fragment amplified product of about 4.6 kbp.

[0169]

(In-fusion reaction 12)

The vector fragment amplified product of 4.6 kbp and the insert fragment amplified product of about 1.1 kbp prepared above were ligated by use of In-Fusion (registered trademark) HD Cloning kit (manufactured by Takara Bio Inc.). First, in the website of Clontech: In-Fusion (registered trademark) Molar Ratio Calculator (<http://bioinfo.clontech.com/infusion/molarRatio.do>), the requisite insert amount and vector amount were calculated and the molar ratio of the vector to the insert was specified as 1:2. Two μ L of 5X In-Fusion HD Enzymes premix, Cloning Enhancer (1 μ L) and the requisite amounts

of insert and vector were mixed and the total amount of the reaction system was adjusted with 0.1X TE buffer (1 mM Tris-HCl, 0.1 mM EDTA, pH7.5) to be 10 μ L. The reaction was carried out at 37°C for 15 minutes and then 50°C for 15 minutes. The reaction solution was incubated at 4°C. The procedure other than this was carried out in accordance with the product manual of the kit to prepare in-fusion reaction solution 12.

[0170]

(Transformation of *E. coli* and determination of DNA sequence of plasmid pHG-1)

The same procedure as in the above section (Transformation of *E. coli* and determination of DNA sequence of plasmid pAG8) was repeated by using in-fusion reaction solution 12 obtained above to carry out transformation of the *E. coli* HST16CR competent cell obtained above and extraction of a plasmid from the recombinant *E. coli*. In the plasmid extracted, the sequences of anti-HER2scFv secretory expression cassette and human IFN- γ secretory expression cassette were determined in the same procedure as above. The plasmid extracted was designated as pHG-1. The DNA sequence of plasmid pHG-1 is represented by SEQ ID No. 17.

[0171]

(Preparation of pHG-2 strain)

The terminator of anti-HER2scFv expression secretion cassette of plasmid pHG-1 was changed from Hu terminator to d0013 terminator. PCR amplification was carried out using pHG-1 mentioned above as a template and a primer set of Hu_Vec_F1 (forward) and bHER2-His_Vec_R1 (reverse)

listed in Table 11. As the amplification program, a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 65°C for 5 seconds and a reaction at 72°C for 5 minutes 45 seconds, was repeated 30 times, and then an elongation reaction was carried out at 72°C for 30 seconds. Other than this, the same procedure as in the above section (Preparation of plasmid pAG8) was repeated to obtain a vector fragment amplified product of about 5.6 kbp.

[0172]

PCR amplification was carried out using genomic DNA of *Bifidobacterium longum* 105-A as a template and a primer set of d0013+T_ins_F1 (forward) and d0013+T_ins_R1 (reverse) listed in Table 11. As the amplification program, a cycle consisting of a reaction at 98°C for 10 seconds, a reaction at 65°C for 5 seconds and a reaction at 72°C for 35 seconds, was repeated 30 times, and then an elongation reaction was carried out at 72°C for 30 seconds. Other than this, the same procedure as in the above section (Preparation of plasmid pAG8) was repeated to obtain an insert fragment amplified product of about 144 bp.

[0173]

(In-fusion reaction 13)

The same procedure as in the above (In-fusion reaction 10) was repeated except that the vector fragment and the insert fragment prepared above were used to prepare in-fusion reaction solution 13.

[0174]

(Transformation of *E. coli* and determination of DNA sequence of plasmid pHG-2)

The same procedure as in the above section (Transformation of *E. coli* and determination of DNA sequence of plasmid pAG8) was repeated by using in-fusion reaction solution 13 to carry out transformation of the *E. coli* HST16CR competent cell obtained above and extraction of a plasmid from the recombinant *E. coli*. In the plasmid extracted, the DNA sequences of anti-HER2scFv secretory expression cassette and human IFN- γ secretory expression cassette were determined in the same procedure. The plasmid extracted was designated as pHG-2. The DNA sequence of plasmid pHG-2 is represented by SEQ ID No. 100. [0175]

(Transformation 9 of bacterium of the genus *Bifidobacterium*)

Bifidobacterium longum 105-A strain was transformed by the electroporation system in the same procedure as in the above section (Transformation 1 of bacterium of the genus *Bifidobacterium*) except that plasmid pHG-2 (500 ng) extracted from the transformed *E. coli* was used. The transformant obtained was designated as *Bifidobacterium longum* 105-A/pHG-2 (hereinafter referred to as HG-2 strain).

[0176]

[Example 14]

[Verification of anti-HER2scFv and hIFN- γ secretion in HG-2 strain]

The presence or absence of anti-HER2scFv and hIFN- γ in the culture supernatant of HG-2 strain was verified by western blotting as follows.

[0177]

(Culture of recombinant bacterium of the genus *Bifidobacterium*)

Bacteria of the genus *Bifidobacterium*, i.e., HG-2 strain; a single-expression strain P30SP7L20-bHER2 (plasmid pP30SP7L20-bHER2 introduced strain) having one of the human IFN- γ secretory expression cassettes; and hIFNg33 strain; were cultured in the same procedure as in Example 4, (Culture of recombinant bacterium of the genus *Bifidobacterium*) and the culture supernatants were collected. The proteins in the culture supernatants were precipitated by trichloroacetic acid (TCA, manufactured by Wako Pure Chemical Industries Ltd.), washed with acetone, dissolved in a buffer for SDS-PAGE and treated with heat at 95°C for 3 minutes to obtain culture supernatant concentrates.

[0178]

(Western analysis)

Each of the culture supernatant concentrates (corresponding to 0.1 mL of the culture solution) was treated in the same manner as in Example 9, (Western analysis). After blotting, the membrane was treated with blocking reagent. Thereafter, using an anti-histidine antibody, namely, THE His Tag Antibody, mAb, Mouse as a primary antibody and ECL peroxidase labelled anti-mouse antibody (mentioned above) as a secondary antibody, an antibody reaction was carried out. After the reaction,

the membrane was illuminated by Western Lightning Ultra. This was analyzed by imaging equipment, Fluor-S Max (manufactured by BIO-RAD). The results are shown in Figure 18.

[0179]

(Results)

As is apparent from Figure 18, both anti-HER2scFv and hIFN- γ in HG-2 strain were detected. The sizes of these proteins were the same as those of the proteins separately secreted from the corresponding single-expression strains. Note that, lane M shows a marker; lane 1 shows a protein secreted from anti-HER2scFv single-expression strain (P30SP7L20-bHER2 strain); lane 2 shows a protein secreted from hIFN- γ single-expression strain (hIFNg33 strain); and lane 3 shows proteins secreted from anti-HER2scFv and hIFN- γ co-expression strain (HG-2 strain).

[0180]

[Example 15]

[Investigation on physiological activity of secretion from HG-2 strain]

(Preparation of culture supernatant concentrate and determination of hINF- γ protein expression-level)

Each of HG-2 strain, P30SP7L20-bHER2 strain, hIFNg33 strain, and BEshuttle strain was inoculated in MRS liquid medium (75 μ g/mL spectinomycin and 1% vitamin C-added liquid) in a ratio of 1% and anaerobically cultured at 37°C for 24 hours (activation culture). The activated culture solution (0.5%) was inoculated in DMEM/MRS (75 μ g/mL spectinomycin, 0.5% vitamin C-added liquid) medium, which

was prepared by adding MRS liquid medium (2 mL) to 18 mL of DMEM medium (low glucose, manufactured by Life technologies). This medium was anaerobically cultured (main culture) at 37°C for 18 hours. The culture solution (20 mL) was centrifuged. The culture supernatant (13 mL) was collected and filtered by a filter having a pore size of 0.2 μ m to remove bacterial cells. The culture supernatant (10 mL) was concentrated by Amicon Ultra-4 (manufactured by Millipore) and replaced with PBS (-) to obtain a concentrate of 500 μ L (*Bifidobacterium* culture supernatant concentrate (PBS substitution)). Each of the bacterium culture supernatant concentrates was subjected to hIFN- γ measurement by an ELISA kit in accordance with ELISA to measure the amount of IFN- γ in the culture supernatant. The measurement results are shown in the following Table 12.

[0181]

[Table 12]

Measurement of human IFN- γ concentration in bifidobacterium culture supernatant concentrate

Sample name	hIFN- γ conc. (ng/mL)
Beshuttle strain	0
P30SP7L20-bHER2 strain (anti-HER2scFv single expression strain)	0
hIFNg33 strain (hIFN- γ single expression strain)	3697
HG-2 strain (anti-HER2scFv/hIFN- γ co-expression strain)	6851

[0182]

(Cancer cell proliferation inhibitory activity of anti-HER2scFv in secretion form HG-2 strain)

As the physiological activity of anti-HER2scFv, cell proliferation inhibitory activity thereof was measured by adding anti-HER2scFv (PBS substitution), which was obtained by His-tag purification from the culture supernatant of P30SP7L20-bHER2 strain, to HER2 positive cell (NCI-N87 (stomach cancer) cell). More specifically, NCI-N87 cells were cultured in RPMI 1640 medium (10% (v/v) FBS) at 37°C in the condition of 5% CO₂, and then seeded in a 96-well plate in a ratio of 2×10^4 cells for each and cultured at 37°C in the condition of 5% CO₂ for 24 hours. Thereafter, the old medium was removed by suction and fresh RPMI 1640 medium (10% (v/v) FBS) was added in an amount of 98 μ L for each. Subsequently, measurement samples, PBS (-) and anti-HER2scFv, which were adjusted to have a concentration in the range of 244 ng/mL to 1 mg/mL, were added separately in an amount of 2 μ L for each. This plate was cultured at 37°C in a condition of 5% CO₂ for 5 days.

[0183]

After 5-day culture, the medium was removed by suction, a mixture, which was obtained by adding Cell Counting kit-8 (1 mL) to 9 mL of fresh RPMI 1640 medium (10% (v/v) FBS), was added in an amount of 100 μ L for each. The plate was kept warm for further three hours at 37°C in the condition of 5% CO₂. The absorbance was measured at a wavelength of 450 nm and 630 nm (reference wavelength) to determine cell proliferation inhibitory activity to the HER2 positive cells. The measurement results are shown in Figure 19.

[0184]

(Results)

As is apparent from Figure 19, anti-HER2scFv purified from the *Bifidobacterium longum* Re-105A/pP30SP7L20-bHER2 exhibited cell proliferation inhibitory activity to NCI-N87 stomach cancer cell in a dose dependent manner. Thus, it was verified that anti-HER2scFv secreted from recombinant bacterium of the genus *Bifidobacterium* has a physiological activity.

[0185]

[Example 16]

(Cancer cell proliferation inhibitory activity 1 of anti-HER2scFv and hINF- γ secreted from HG-2 strain)

The physiological activities of anti-HER2scFv and hINF- γ , which were secreted from a co-expression strain, were checked by determining cell proliferation inhibitory activity thereof by adding the concentrate (PBS substitution) of the culture supernatant of a bacterium of the genus *Bifidobacterium* (HG-2 strain) obtained in Example 15 to HER2 positive cell (NCI-N87 cell). More specifically, NCI-N87 cells were cultured in RPMI 1640 medium (10% (v/v) FBS) at 37°C, in the condition of 5% CO₂, seeded in a 96-well plate in an amount of 2×10^4 cells for each and cultured at 37°C in the condition of 5% CO₂ for 24 hours. From the cell culture solution, the old medium was removed by suction and fresh RPMI 1640 medium (10% (v/v) FBS) was added in an amount of 90 μ L for each. Subsequently, as measurement samples, PBS (-), a Beshuttle strain culture supernatant concentrate (negative control), a P30SP7L20-bHER2 strain culture supernatant concentrate, a hINFg33 strain culture supernatant concentrate (prepared

by diluting with PBS so as to have a hIFN- γ concentration of 2000 ng/mL), a HG-2 strain culture supernatant concentrate and recombinant hIFN- γ (positive control, the hIFN- γ concentration was adjusted so as to be 2000 ng/mL) were added in an amount of 10 μ L for each. This plate was subjected to culture at 37°C in the condition of 5% CO₂ for 5 days.

[0186]

The cell proliferation inhibitory activity was measured in the same manner as described in the above section (Cell proliferation inhibitory activity of anti-HER2scFv). The results are shown in Figure 20.

[0187]

As is apparent from Figure 20, the culture supernatant concentrate derived from anti-HER2scFv/hIFN- γ co-expression strain, i.e., HG-2 strain, exhibited extremely strong cell proliferation inhibitory activity to NCI-N87 cell. In contrast, the concentrate derived from the culture supernatant of hIFN- γ single-expression strain, i.e., hINFg33 strain, exhibited the same cell proliferation inhibitory activity as recombinant hIFN- γ (manufactured by PeploTech) used as a standard at a hIFN- γ concentration of 200 ng/mL. The concentrate derived from P30SP7L20-bHER2 strain was determined to have the same cell proliferation inhibitory activity as in Example 15. The cell proliferation inhibitory activity of anti-HER2scFv/hIFN- γ co-expression strain, i.e., HG-2 strain, is higher than the activity of either one of strains: hIFN- γ single-expression strain and P30SP7L20-bHER2 strain, simultaneously checked. This activity is conceivably due

to synergistic combinational effect of both hIFN- γ and anti-HER2scFv proteins secreted together.

[0188]

[Example 17]

[Verification of secretion from anti-HER2scFv and hIFN- γ co-expression strain within tumor]

Using a human stomach cancer cell strain NCI-N87 bearing nude mouse, localization of a bacterium of the genus *Bifidobacterium* within a tumor was checked by gram staining. The localization of anti-HER2scFv and hIFN- γ within the tumor was checked by immunohistochemical staining with an anti-histidine tag antibody and anti-hIFN- γ antibody.

[0189]

Human stomach cancer cell strain NCI-N87 (ATCC) was cultured in RPMI 1640 medium (manufactured by Wako Pure Chemical Industries Ltd.) comprising 10%FBS (manufactured by EQUITECH-BIO, INC.) and transplanted into nude mice (produced by Japan SLC, Inc.) to prepare tumor bearing mice. To mice having a tumor size of about 470 mm³, a simple frozen preparation of an anti-HER2scFv and hIFN- γ co-expression strain (HG-2 strain); and a simple frozen preparation of the BEshuttle strain expressing neither one of them and serving as a control, were administered in a dose of 6×10^8 cfu from the tail vein. Note that, a 10% maltose solution was administered in a dose of 1 mL at a frequency of two times a day for 5 days. On Day 7 after the administration, the tumor was excised out, embedded in O. C. T. compound (manufactured by Sakura Finetek) and frozen. Thin specimens were prepared by Cryostat

microtome Leica CM1900 (manufactured by Leica), separately placed on slides and subjected to tissue staining.

[0190]

(Gram staining)

The thin specimens on slides were dried in air and soaked in 4% PFA (manufactured by Wako Pure Chemical Industries Ltd.) for 10 minutes to fix. After fixation, the thin specimens were pre-stained with Bartholomew & Mittwer M crystal violet solution (manufactured by MUTO PURE CHEMICALS Co., Ltd.) for 2 minutes, and allowed to react with Bartholomew & Mittwer M iodine/sodium hydroxide solution (manufactured by MUTO PURE CHEMICALS Co., Ltd.) for one minute. The thin specimens were decolorized with Bartholomew & Mittwer M acetone/ethyl alcohol mixture (manufactured by MUTO PURE CHEMICALS Co., Ltd.) and stained with Bartholomew & Mittwer M 0.1% fuchsin solution (manufactured by MUTO PURE CHEMICALS Co., Ltd.) for one minute. After staining, the thin specimens were washed with purified water, dewatered with 99.5% ethanol (manufactured by Wako Pure Chemical Industries Ltd.), cleared in Lemosol (manufactured by Wako Pure Chemical Industries Ltd.) and enclosed with Entellan new (manufactured by MERCK KGaA). The results are shown in Figure 21.

[0191]

(Immunohistochemical staining with anti-histidine tag antibody and anti-hIFN- γ antibody)

The thin specimens on slides were dried in air and soaked in 4% PFA (manufactured by Wako Pure Chemical Industries Ltd.) for about 4 hours to fix. After fixation,

the thin specimens were washed with purified water for one minute and three times with 1X PBS (-) for 5 minutes. Moisture around the tissue was wiped out. A line was drawn around the tissue by Dako pen (manufactured by Dako). To the tissue, 3% BSA-PBS was added dropwise and allowed to react for 60 minutes to inhibit non-specific binding. Anti-His-tag mAb-Alexa Fluor (registered trademark) 594 (manufactured by MBL) and FITC Anti-human IFN- γ antibody (manufactured by BioLegend) were mixed and diluted with Can Get Signal (registered trademark) immunostain (manufactured by TOYOBOKO CO., LTD.) to prepare an antibody reaction solution. The antibody reaction solution was added dropwise onto the tissue and allowed to react at 4°C overnight. After the antibody reaction, washing with 1X PBS (-) for 5 minutes was carried out three times. The specimen(s) was enclosed with VECTASHIELD (registered trademark) Mounting Medium with DAPI. The stained slice was observed by a microscope DM5000B (manufactured by Leica) and the image thereof was photographed. The results are shown in Figures 22 and 23.

[0192]

(Results)

As is apparent from Figure 21, in gram staining, bacterial cells, i.e., HG-2 strain (A) and BEshuttle strain (B) (Figure 21 (A) and (B), pointed by the arrow) each were found to be present in the tumor tissue. Also, in immunohistochemical staining with an anti-hIFN- γ antibody, hIFN- γ positive images were found in the tumor tissue of the mouse having a cancer and administered with a co-expression strain, i.e., HG-2 strain (Figure 22,

green color portions pointed by arrows). Furthermore, in immunohistochemical staining with a histidine tag, histidine tag positive images (anti-HER2scFv and hIFN- γ) were found (Figure 23, red color portions pointed by arrows). From these results, it was verified that when HG-2 strain is intravenously administered to a mouse having a human stomach cancer NCI-N87, the HG-2 strain is colonized in the tumor and hIFN- γ and anti-HER2scFv proteins are secreted from the HG-2 strain and simultaneously present in the tumor.

[0193]

[Example 18]

[Preparation of co-expression strain for anti-human PD-1scFv03-His and anti-human CTLA-4scFv01-FLAG]

E. coli-Bifidobacterium shuttle vector secreting anti-human PD-1scFv03-His and anti-human CTLA-4scFv01-FLAG, i.e., co-expression plasmids pPC2, pPC3, pPC4, pPC5, pPC6, pPC7 and pPC8 were prepared. *Bifidobacterium longum* 105-A strain was separately transformed with these 7 types of co-expression plasmids.

[0194]

The constitutions of anti-human PD-1scFv03-His expression cassettes and anti-human CTLA-4scFv01-FLAG expression cassettes in the 7 types of co-expression plasmids pPC2 to pPC8 are shown in Table 13-1 and Table 13-2. To avoid homologous sequences within a plasmid molecule, the promoter DNA, a terminator DNA and DNA sequences encoding a tag and signal peptide-linker peptide conjugate in each expression cassette were designed not to have the same constitution.

[0195]

[Table 13-1]

plasmid	anti-hPD-1 scFv03-His expression cassette				
	promoter	SP/Linker	scFv	tag	terminator
pPC2	Hu	SP50L5	anti-hPD-1 scFv03	His	Hu
pPC3	Hu	SP50L5	anti-hPD-1 scFv03	His	Hu
pPC4	Hu	SP67L10	anti-hPD-1 scFv03	His	Hu
pPC5	Hu	SP67L10	anti-hPD-1 scFv03	His	Hu
pPC6	Hu	SP69L1	anti-hPD-1 scFv03	His	Hu
pPC7	Hu	SP69L1	anti-hPD-1 scFv03	His	Hu
pPC8	Hu	SP69L1	anti-hPD-1 scFv03	His	Hu

[0196]

[Table 13-2]

plasmid	anti-hCTLA-4 scFv01-FLAG expression cassette				
	promoter	SP/Linker	scFv	tag	terminator
pPC2	P30	SP67L1	anti-hCTLA-4 scFv01	FLAG	T2
pPC3	P30	SP68L1	anti-hCTLA-4 scFv01	FLAG	T2
pPC4	P30	SP50L5	anti-hCTLA-4 scFv01	FLAG	T2
pPC5	P30	SP68L1	anti-hCTLA-4 scFv01	FLAG	T2
pPC6	P30	SP50L5	anti-hCTLA-4 scFv01	FLAG	T2
pPC7	P30	SP67L1	anti-hCTLA-4 scFv01	FLAG	T2
pPC8	P30	SP68L1	anti-hCTLA-4 scFv01	FLAG	T2

[0197]

(Constitution of anti-hPD-1scFv03-His secretory expression cassette)

As the anti-hPD-1scFv03-His secretory expression cassette, a cassette sequentially comprising (1) a Hu promoter DNA, (2) a DNA encoding a signal peptide-linker peptide conjugate, (3) a DNA encoding an anti-hPD-1scFv03

amino acid sequence, (4) a DNA encoding a His tag sequence and (5) a Hu terminator DNA was prepared such that DNA (1) was placed upstream (the 5' end) and DNA (5) downstream (the 3' end). As the signal peptide-linker peptide conjugate, SP50L5 (secretory signal peptide-linker peptide conjugate obtained by binding a sequence consisting of the initial five amino acids (Ala Thr Leu Thr Pro) of the amino acid sequence represented by SEQ ID No. 83 to the amino acid sequence represented by SEQ ID No. 61); SP67L10 (secretory signal peptide-linker peptide conjugate obtained by binding a sequence consisting of initial ten amino acids (Ala Gly Val Asp Tyr Leu Pro Thr Ile Gly) of the amino acid sequence represented by SEQ ID No. 95 to the amino acid sequence represented by SEQ ID No. 73); or SP69L1 (secretory signal peptide-linker peptide conjugate obtained by binding the initial amino acid (Asp) of the amino acid sequence represented by SEQ ID No. 99 to the amino acid sequence represented by SEQ ID No. 77) was used. [0198]

(Constitution of anti-hCTLA-4scFv01-FLAG secretory expression cassette)

As the anti-hCTLA-4scFv01-FLAG secretory expression cassette, a cassette sequentially comprising (1) a P30 promoter DNA, (2) a DNA encoding signal peptide-linker peptide conjugate, (3) a DNA encoding an anti-hCTLA-4scFv01 amino acid sequence, (4) a DNA encoding a FLAG tag sequence and (5) a T2 terminator DNA was prepared such that DNA (1) was placed upstream (the 5' end) and DNA (5) downstream (the 3' end). As the signal peptide-linker peptide conjugate, SP50L5 (secretory signal peptide-linker

peptide conjugate obtained by binding a sequence consisting of the initial five amino acids (Ala Thr Leu Thr Pro) of the amino acid sequence represented by SEQ ID No. 83 to the amino acid sequence represented by SEQ ID No. 61); SP67L1 (secretory signal peptide-linker peptide conjugate obtained by binding the initial amino acid (Ala) of the amino acid sequence represented by SEQ ID No. 95 to the amino acid sequence represented by SEQ ID No. 73); or SP68L1 (secretory signal peptide-linker peptide conjugate obtained by binding the initial amino acid (Asp) of the amino acid sequence represented by SEQ ID No. 97 to the amino acid sequence represented by SEQ ID No. 75) was used. [0199]

The basic constitutions of co-expression plasmids pPC2 to pPC8 are shown in Figure 24.

The production method thereof is schematically shown in Figure 25.

(1) In the first step, template plasmids (pHuSPxLy-hPD-1scFv03-His (SPxLy = SP50L5, SP67L10, SP69L1)) to be used in preparation of co-expression plasmids pPC2 to pPC8 was prepared.

(2) In the second step, plasmid pHuSPxLy-hPD-1scFv03-His-T2 (SPxLy = SP50L5, SP67L10, SP69L1) was prepared by inserting T2 terminator fragment downstream of an anti-hPD-1scFv03-His expression cassette of an anti-hPD-1scFv03-His expression plasmid, pHuSPxLy-hPD-1scFv03-His (SPxLy = SP50L5, SP67L10, SP69L1).

(3) In the third step, an anti-hCTLA-4scFv01-FLAG expression cassette (except a terminator) was inserted between Hu terminator and T2 terminator of the plasmid

prepared in the second step to prepare co-expression plasmids pPC2 to pPC8.

[0200]

(First step)

Step A: PCR products of a linear vector (vector) prepared by using plasmid pHuSP7L20-hPD-1scFv03 (histidine tag is added to the 3' end of scFv sequence) prepared in Example 8 as template DNA and SP50 insert (insert), SP67 insert and SP69 insert prepared from 105-A genomic DNA, were prepared. A primer was designed such that terminal 15 bp of a PCR product has the same sequence as that of the terminal 15 bp to the adjacent PCR product to be ligated in the in-fusion reaction of the next step. The elongation reaction time was set assuming that one minute is required for elongation of 1 kbp. The PCR amplification step herein is referred to as "PCR amplification step 1".

[0201]

The linear vector and each of the inserts were ligated by an in-fusion reaction using HD kit. In the same manner as in (Example 1: Transformation of *E. coli* and determination of DNA sequence of plasmid pAG8), the *E. coli* HST16CR competent cells were transformed by using the in-fusion reaction solution; a plasmid was extracted from recombinant *E. coli*; and the sequence of "anti-hPD-1scFv03-His expression cassette region" (including Hu promoter to Hu terminator) in the plasmid extracted, was determined (hereinafter, the step from the in-fusion reaction to the sequence determination will be carried out in the same procedure as this). The plasmids extracted

were designated as pHuSP50L20-hPD-1scFv03-His, pHuSP67L20-hPD-1scFv03-His and pHuSP69L20-hPD-1scFv03-His.

[0202]

Step B: PCR products of SP50L5 insert, SP67L10 insert and SP69L1 insert, which were prepared respectively from the pHuSP50L20-hPD-1scFv03-His, pHuSP67L20-hPD-1scFv03-His and pHuSP69L20-hPD-1scFv03-His, were prepared.

[0203]

The linear vector prepared in Step A and each of the SP50L5 insert, SP67L10 insert and SP69L1 insert prepared above were ligated by the HD kit in the same manner as above and the sequence of the "anti-hPD-1scFv03-His expression cassette region" was determined. The plasmids extracted were designated as pHuSP50L5-hPD-1scFv03-His, pHuSP67L10-hPD-1scFv03-His and pHuSP69L1-hPD-1scFv03-His.

[0204]

(Second step)

(Preparation of T2 terminator)

Synthesis of the sequence (SEQ ID No. 101) was ordered to GenScript Japan Inc. and the sequence was designated as T2 terminator, which was integrated in plasmid vector pUC57 (Bba-B0015 in pUC57) and delivered.

[0205]

Using the pHuSP50L5-hPD-1scFv03-His, pHuSP67L10-hPD-1scFv03-His and pHuSP69L1-hPD-1scFv03-His separately as template DNA and PC1_primer (SEQ ID No. 102) as a forward primer and PC2_primer (SEQ ID No. 103) as a reverse primer, PCR products were prepared in the same manner as in the above step "PCR amplification 1" and designated as A1, A2

and A3 linear vectors. The sizes of the PCR products were 4751 bp, 4697 bp and 4661 bp, respectively.

[0206]

Using the Bba-B0015 in pUC57 as template DNA, and PC3_primer (SEQ ID No. 104) as a forward primer and PC4_primer (SEQ ID No. 105) as a reverse primer, PCR product B (159 bp) was prepared.

[0207]

[Table 14]

Plasmid to be constructed	Combination in in-fusion reaction
pHuSP50L5-hPD-1 scFv03-His-T2	A1 and B
pHuSP67L10-hPD-1 scFv03-His-T2	A2 and B
pHuSP69L1-hPD-1 scFv03-His-T2	A3 and B

[0208]

PCR products were ligated in accordance with the combinations shown in Table 14 by use of the HD kit and the sequence of each of "anti-hPD-1scFv03-His expression cassette-T2 terminator regions" (5'-Hu promoter-SPxLy-human PD-1scFv03-His-T2 terminator-3') was determined. The plasmids extracted were designated as pHuSP50L5-hPD-1scFv03-His-T2, pHuSP67L10-hPD-1scFv03-His-T2 and pHuSP69L1-hPD-1scFv03-His-T2.

[0209]

[Preparation of plasmid phCTLAz]

The Hu promoter of the plasmid pHuSP7L20-hCTLA-4scFv02FLAG prepared in Example 8 was replaced by P30 promoter, as schematically shown in Figure 26.

[0210]

A PCR product (4410 bp) of a linear vector was prepared by using pHuSP7L20-hCTLA-4scFv02FLAG as template DNA, and vec_F5_primer (SEQ ID No. 106) as a forward primer and vec_R2_primer (SEQ ID No. 107) as a reverse primer. A PCR product (245 bp) of an insert was prepared by using 105-A genomic DNA as a template, and P30_F1_primer (SEQ ID No. 108) as a forward primer and P30_R1_primer (SEQ ID No. 109) as a reverse primer. The linear vector and insert thus prepared were ligated as mentioned above by use of the HD kit and the sequence of the full-length plasmid extracted was determined. The plasmid extracted was designated as phCTLA1.

[0211]

(Preparation of plasmid phCTLAz (z = 4, 10, 11))

The signal peptide sequence of the plasmid phCTLA1 prepared above was changed from SP7 to SP50, SP67 and SP68.

[0212]

PCR amplification was carried out in the same manner as in the above step "PCR amplification 1" using template DNA molecules and primers listed in Table 15 to prepare a vector and inserts.

[0213]

[Table 15]

Template and primer used in PCR

PCR product	Template DNA	Fow. Primer (Forward primer)	Rev. primer (Reverse primer)	Size of PCR product
Vector	phCTLA1	hCTLA3_primer (SEQ ID No. 110)	P30_R1_primer (SEQ ID No. 109)	4466 bp
Insert-SP50	<i>B. longum</i> 105A genome	SP50-ins_F2_primer (SEQ ID No. 111)	SP50-ins_R6_primer (SEQ ID No. 112)	258 bp
Insert-SP67	<i>B. longum</i> 105A genome	SP67-ins_F2_primer (SEQ ID No. 113)	SP67-ins_R6_primer (SEQ ID No. 114)	189 bp
Insert-SP68	<i>B. longum</i> 105A genome	SP68-ins_F2_primer (SEQ ID No. 115)	SP68-ins_R6_primer (SEQ ID No. 116)	219 bp

[0214]

The vector and each of the inserts listed in Table 15 were ligated in the same manner as above by using HD kit, and the sequences of "anti-hCTLA-4scFv02-FLAG cassette regions" were determined. The plasmids extracted were designated as phCTLA4 (in the case of SP50), phCTLA10 (in the case of SP67) and phCTLA11 (in the case of SP68).

[0215]

(Preparation of pP30SPx'Ly'-hCTLA-4scFv01-His)

Preparation is schematically shown in Figure 27.

[0216]

(Preparation of anti-CTLA-4 single-chain antibody expression cassette)

Referring to [Preparation of pHuSP7L20-scFv-CTLA-4-1] in WO2015/166640, pHuSP7L20-scFv-CTLA-4-1 was prepared and designated as pHuSP7L20-hCTLA-4scFv01-His in this Example.

[0217]

PCR products were prepared in the same manner as in the above step "PCR amplification 1" by using template DNA molecules and primers listed in Table 16.

[0218]

[Table 16]

PCR product	Template DNA	Fow. primer	Rev. primer	Size of PCR product
A	pHuSP7L20-hCTLA-4scFv01-His	hCTLA3_primer	GA6_primer (SEQ ID No. 117)	4020 bp
B-SP50L5	phCTLA4	GA5_primer_rev (SEQ ID No. 118)	SP50L5-ins_R1_hPD1_03 (SEQ ID No. 128)	671 bp
B-SP67L1	phCTLA10	GA5_primer_rev	SP67L1-ins_R1_hPD1_03 (SEQ ID No. 129)	590 bp
B-SP68L1	phCTLA11	GA5_primer_rev	SP68L1-ins_R1_hPD1_03 (SEQ ID No. 130)	620 bp

[0219]

The PCR product A and each of PCR products B listed in Table 16 were ligated in the same manner as above by using HD kit, and the sequences of "anti-hCTLA-4scFv01-His cassette regions" were determined. The plasmids extracted were designated as pP30SP50L5-hCTLA-4scFv01-His, pP30SP67L1-hCTLA-4scFv01-His and pP30SP68L1-hCTLA-4scFv01-His.

[0220]

[Preparation of plasmid pP30SPx'Ly'-hCTLA-4scFv01-FLAG]

The histidine tag of plasmid pP30SPx'Ly'-hCTLA-4scFv01-His (SPx'Ly' = SP50L5, SP67L1, SP68L1) prepared above was changed to FLAG tag as schematically shown in Figure 28. Hereinafter, in the case of anti-hCTLA-4scFv, expression "SPx'Ly'" may be sometimes employed.

[0221]

PCR products were prepared by using the template DNA molecules and primers listed in Table 17 in the same manner as in the above step "PCR amplification 1".

[0222]

[Table 17]

PCR product	Template DNA	Fow. primer	Rev. primer	Size of PCR product
A	pP30SP50L5-hCTLA-4 scFv01-His	hCTLA15_primer (SEQ ID No. 120)	GA6_primer	3280 bp
B-SP50L5	pP30SP50L5-hCTLA-4 scFv01-His	GA5_primer_rev	hCTLA16_primer (SEQ ID No. 119)	1417 bp
B-SP67L1	pP30SP67L1-hCTLA-4 scFv01-His	GA5_primer_rev	hCTLA16_primer	1336 bp
B-SP68L1	pP30SP68L1-hCTLA-4 scFv01-His	GA5_primer_rev	hCTLA16_primer	1366 bp

[0223]

PCR product A and each of PCR products B listed in Table 17 were ligated by using HD kit in the same manner as mentioned above and the sequences of "anti-hCTLA-4 scFv01-FLAG cassette regions" were determined. The plasmids extracted were designated as pP30SP50L5-hCTLA-4scFv01-FLAG (hereinafter referred to as pC1F), pP30SP67L1-hCTLA-4scFv01-FLAG (hereinafter referred to as pC2F) and pP30SP68L1-hCTLA-4scFv01-FLAG (hereinafter referred to as pC3F).

[0224]

(Third step)

PCR products were prepared by using the template DNA and primers listed in Table 18 in the same manner as in the above step "PCR amplification 1".

[0225]

[Table 18]

PCR product	Template DNA	Fow. primer	Rev. primer	Size of PCR product
A7	pHuSP50L5-hPD-1 scFv03-His-T2	PC5_primer (SEQ ID No. 121)	PC2_primer	4886 bp
A8	pHuSP67L10-hPD-1 scFv03-His-T2	PC5_primer	PC2_primer	4832bp
A9	pHuSP69L1-hPD-1 scFv03-His-T2	PC5_primer	PC2_primer	4796 bp
B1	pC1F	PC6_primer (SEQ ID No. 122)	PC7_primer (SEQ ID No. 123)	1210 bp
B2	pC2F	PC6_primer	PC7_primer	1129 bp
B3	pC3F	PC6_primer	PC7_primer	1159 bp

[0226]

[Table 19]

Plasmid to be constructed	Combination in in-fusion reaction
pPC2	A7 and B2
pPC3	A7 and B3
pPC4	A8 and B1
pPC5	A8 and B3
pPC6	A9 and B1
pPC7	A9 and B2
pPC8	A9 and B3

[0227]

The PCR products listed in Table 18 were ligated in accordance with the combinations listed in Table 19 by using HD kit in the same manner as mentioned above and DNA sequences of the full-length plasmids extracted were determined. The plasmids extracted were designated as pPC2, pPC3, pPC4, pPC5, pPC6, pPC7 and pPC8. The individual plasmids will be outlined below.

[0228]

(pPC2 scFv expression cassette sequences (2618 bp)
(SEQ ID No. 131))

1..1384 Anti-human PD-1scFv03-His expression cassette
1..361 Hu promoter
362..544 SP50L5
545..1249 anti-human PD-1scFv03
1250..1267 His tag
1268..1270 stop codon
1271..1384 Hu terminator

1385..2618 Anti-human CTLA-4scFv01-FLAG
expression cassette

1385..1619 P30 promoter
1620..1721 SP67L1
1722..2462 anti-human CTLA-4scFv01
2463..2486 FLAG tag
2487..2489 stop codon
2490..2618 T2 terminator

[0229]

(pPC3 scFv expression cassette sequences (2648 bp)
(SEQ ID No. 132))

1..1384 Anti-human PD-1scFv03-His expression cassette

1..361	Hu promoter	
362..544	SP50L5	
545..1249	anti-human PD-1scFv03	
1250..1267	His tag	
1268..1270	stop codon	
1271..1384	Hu terminator	
1385..2648	Anti-human	CTLA-4scFv01-FLAG
expression cassette		
1385..1619	P30 promoter	
1620..1751	SP68L1	
1752..2492	anti-human CTLA-4scFv01	
2493..2516	FLAG tag	
2517..2519	stop codon	
2520..2648	T2 terminator	
[0230]		
(pPC4 scFv expression cassette sequences (2645 bp)		
(SEQ ID No. 133))		
1..1330 Anti-human PD-1scFv03-His expression cassette		
1..361	Hu promoter	
362..490	SP67L10	
491.. 1195	anti-human PD-1scFv03	
1196..1213	His tag	
1214..1216	stop codon	
1217..1330	Hu terminator	
1331..2645	Anti-human	CTLA-4scFv01-FLAG
expression cassette		
1331..1565	P30 promoter	
1566..1748	SP50L5	

1749..2489	anti-human CTLA-4scFv01
2490..2513	FLAG tag
2514..2516	stop codon
2517..2645	T2 terminator

[0231]

(pPC5 scFv expression cassette sequences (2594 bp)
(SEQ ID No. 134))

1..1330	Anti-human PD-1scFv03-His expression cassette
1..361	Hu promoter
362..490	SP67L10
491..1195	anti-human PD-1scFv03
1196..1213	His tag
1214..1216	stop codon
1217..1330	Hu terminator

1331..2594	Anti-human	CTLA-4scFv01-FLAG
------------	------------	-------------------

expression cassette

1331..1565	P30 promoter
1566..1697	SP68L1
1698..2438	anti-human CTLA-4scFv01
2439..2462	FLAG tag
2463..2465	stop codon
2466..2594	T2 terminator

[0232]

(pPC6 scFv expression cassette sequences (2609 bp)
(SEQ ID No. 135))

1..1294	Anti-human PD-1scFv03-His expression cassette
1..361	Hu promoter
362..454	SP69L1
455..1159	anti-human PD-1scFv03

1160..1177	His tag	
1178..1180	stop codon	
1181..1294	Hu terminator	
1295..2609	Anti-human	CTLA-4scFv01-FLAG
expression cassette		
1295..1529	P30 promoter	
1530..1712	SP50L5	
1713..2453	anti-human CTLA-4scFv01	
2454..2477	FLAG tag	
2478..2480	stop codon	
2481..2609	T2 terminator	
[0233]		
(pPC7 scFv expression cassette sequences (2528 bp)		
(SEQ ID No. 136))		
1..1294 Anti-human PD-1scFv03-His expression cassette		
1..361	Hu promoter	
362..454	SP69L1	
455..1159	anti-human PD-1scFv03	
1160..1177	His tag	
1178..1180	stop codon	
1181..1294	Hu terminator	
1295..2528	Anti-human	CTLA-4scFv01-FLAG
expression cassette		
1295..1529	P30 promoter	
1530..1631	SP67L1	
1632..2372	anti-human CTLA-4scFv01	
2373..2396	FLAG tag	
2397..2399	stop codon	

2400..2528 T2 terminator

[0234]

(pPC8 scFv expression cassette sequences (2558 bp)
(SEQ ID No. 137))

1..1294 Anti-human PD-1scFv03-His expression cassette

1..361 Hu promoter

362..454 SP69L1

455..1159 anti-human PD-1scFv03

1160..1177 His tag

1178..1180 stop codon

1181..1294 Hu terminator

1295..2558 Anti-human CTLA-4scFv01-FLAG
expression cassette

1295..1529 P30 promoter

1530..1661 SP68L1

1662..2402 anti-human CTLA-4scFv01

2403..2426 FLAG tag

2427..2429 stop codon

2430..2558 T2 terminator

[0235]

(Transformation 10 of bacterium of the genus
Bifidobacterium)

Bifidobacterium longum 105-A strain was transformed by the electroporation system in the same procedure as in the above section (Transformation 1 of bacterium of the genus *Bifidobacterium*) except that the plasmids pPC2, pPC3, pPC4, pPC5, pPC6, pPC7 and pPC8, extracted from the transformed *E. coli* mentioned above were used each in an amount of 5 µL. The transformants obtained were

designated as *Bifidobacterium longum* 105-A/pPC2 (hereinafter referred to as PC2 strain); *Bifidobacterium longum* 105-A/pPC3 (hereinafter referred to as PC3 strain); *Bifidobacterium longum* 105-A/pPC4 (hereinafter referred to as PC4 strain); *Bifidobacterium longum* 105-A/pPC5 (hereinafter referred to as PC5 strain); *Bifidobacterium longum* 105-A/pPC6 (hereinafter referred to as PC6 strain); *Bifidobacterium longum* 105-A/pPC7 (hereinafter referred to as PC7 strain) and *Bifidobacterium longum* 105-A/pPC8 (hereinafter referred to as PC8 strain).

[0236]

[Example 19]

[Preparation of PC2TL strain to PC8TL strain]

In view of clinical development, from the plasmids prepared in Example 18, scFv marker tag (histidine tag/FLAG tag) and a plasmid origin of replication pUCori, working in *E. coli* were removed to prepare anti-human PD-1scFv03 and anti-human CTLA-4scFv01 co-expression plasmids, pPC2TL to pPC8TL. *Bifidobacterium longum* 105-A was transformed with each of these plasmids to obtain co-expression strains, PC2TL strain to PC8TL strain.

[0237]

Basic constitution of the plasmid in co-expression strains, PC2TL strain to PC8TL strain, is shown in Figure 29. In 7 types of non-tagged co-expression plasmids pPC2TL to pPC8TL, the constitutions of anti-human PD-1scFv03 expression cassette and anti-human CTLA-4scFv01 expression cassette are shown in the following Table 20 and Table 21.

[0238]

[Table 20]

Plasmid	Anti-hPD-1 scFv03 expression cassette (not tagged)				
	Promoter	SP/Linker	scFv	Tag	Terminator
pPC2TL	Hu	SP50L5	anti-hPD-1 scFv03	-	Hu
pPC3TL	Hu	SP50L5	anti-hPD-1 scFv03	-	Hu
pPC4TL	Hu	SP67L10	anti-hPD-1 scFv03	-	Hu
pPC5TL	Hu	SP67L10	anti-hPD-1 scFv03	-	Hu
pPC6TL	Hu	SP69L1	anti-hPD-1 scFv03	-	Hu
pPC7TL	Hu	SP69L1	anti-hPD-1 scFv03	-	Hu
pPC8TL	Hu	SP69L1	anti-hPD-1 scFv03	-	Hu

[0239]

[Table 21]

Plasmid	Anti-hCTLA-4 scFv01 expression cassette (not tagged)				
	Promoter	SP/Linker	scFv	Tag	Terminator
pPC2TL	P30	SP67L1	anti-hCTLA-4 scFv01	-	T2
pPC3TL	P30	SP68L1	anti-hCTLA-4 scFv01	-	T2
pPC4TL	P30	SP50L5	anti-hCTLA-4 scFv01	-	T2
pPC5TL	P30	SP68L1	anti-hCTLA-4 scFv01	-	T2
pPC6TL	P30	SP50L5	anti-hCTLA-4 scFv01	-	T2
pPC7TL	P30	SP67L1	anti-hCTLA-4 scFv01	-	T2
pPC8TL	P30	SP68L1	anti-hCTLA-4 scFv01	-	T2

[0240]

(Constitution of anti-hPD-1scFv03 secretory expression cassette)

As anti-hPD-1scFv03 secretory expression cassette, a cassette sequentially comprising (1) a Hu promoter DNA, (2) a DNA encoding a signal peptide-linker peptide conjugate, (3) a DNA encoding an anti-hPD-1scFv03 amino

acid sequence and (4) a Hu terminator DNA was prepared such that DNA (1) was placed upstream (the 5' end) and DNA (4) downstream (the 3' end). As the signal peptide-linker peptide conjugate, SP50L5, SP67L10 or SP69L1 was used.

[0241]

(Constitution of anti-hCTLA-4scFv01 secretory expression cassette)

As anti-hCTLA-4scFv01 secretory expression cassette, a cassette sequentially comprising (1) a P30 promoter DNA, (2) a DNA encoding a signal peptide-linker peptide conjugate, (3) a DNA encoding an anti-hCTLA-4scFv01 amino acid sequence and (4) a T2 terminator DNA was prepared such that DNA (1) was placed upstream (the 5' end) and DNA (4) downstream (the 3' end). As the signal peptide-linker peptide conjugate, SP50L5, SP67L1 or SP68L1 was used.

[0242]

(Method for producing pPC2TL to pPC8TL)

The method for producing a plasmid is constituted of the following 4 steps as schematically shown in Figure 30.

(1) In the first step, a template plasmid, pHuSPxLy-hPD-1scFv03TL to be used in preparation of co-expression plasmids, pPC2TL-pPC8TL was prepared.

(2) In the second step, a T2 terminator fragment was inserted downstream of anti-PD-1scFv03 expression cassette of anti-hPD-1scFv03 (not tagged) expression plasmid to prepare plasmid pHuSPxLy-hPD-1scFv03TL-T2 (SPxLy = SP50L5, SP67L10, SP69L1).

(3) In the third step, anti-hCTLA-4scFv01 (not tagged) expression cassette (note that a terminator is excluded) was inserted between Hu terminator and T2

terminator of the plasmid prepared in the second step to prepare plasmids pPC2TLS to pPC8TLS.

(4) In the fourth step, the fragment of pUCori, which serves as a plasmid origin of replication in *E. coli*, of the plasmid prepared in the third step, was cleaved out with a restriction enzyme(s). Thereafter, the plasmid was allowed to self-close to prepare a co-expression plasmids (not tagged, non-shuttle) pPC2TL to pPC8TL.

[0243]

(First step)

PCR product A-1 (3261 bp) was prepared in the same manner as in the above step "PCR amplification 1" using pHuSP50L5-hPD-1scFv03-His as mentioned above as template DNA, pCDshuttle_F1_ primer (SEQ ID No. 126) as a forward primer and GA6_ primer as a reverse primer. PCR products, B-SP50L5 (1502 bp), B-SP67L10 (1448 bp) and B-SP69L1 (1412 bp) were prepared in the same manner as in the above step "PCR amplification 1" using pHuSP50L5-hPD-1scFv03-His, pHuSP67L10-hPD-1scFv03-His and pHuSP69L1-hPD-1scFv03-His, respectively as template DNA, and GA5_primer_rev primer as a forward primer and hPD1scFv03-1_ primer (SEQ ID No. 127) as a reverse primer.

[0244]

PCR product A-1 and each of B-SP50L5, B-SP67L10 and B-SP69L1 were ligated by using HD kit in the same manner as mentioned above and the sequences of "anti-hPD-1scFv03 expression cassette regions" (including from Hu promoter to Hu terminator) were determined. The plasmids extracted were designated as pHuSP50L5-hPD-1scFv03TL, pHuSP67L10-hPD-1scFv03TL and pHuSP69L1-hPD-1scFv03TL.

[0245]

(Second step)

PCR products were prepared by using the template DNA and primers listed in Table 22, in the same manner as in the above step "PCR amplification 1".

[0246]

[Table 22]

PCR product	Template DNA	Fow. primer	Rev. primer	Size of PCR product
A4	pHuSP50L5-hPD-1 scFv03TL	PC1_primer	PC2_primer	4733 bp
A5	pHuSP67L10-hPD-1 scFv03TL	PC1_primer	PC2_primer	4679 bp
A6	pHuSP69L1-hPD-1 scFv03TL	PC1_primer	PC2_primer	4643 bp
B	Bba-B0015 in pUC57	PC3_primer	PC4_primer	159 bp

[0247]

[Table 23]

Plasmid to be constructed	Combination in in-fusion reaction
pHuSP50L5-hPD-1 scFv03TL-T2	A4 and B
pHuSP67L10-hPD-1 scFv03TL-T2	A5 and B
pHuSP69L1-hPD-1 scFv03TL-T2	A6 and B

[0248]

The PCR products listed in Table 22 were ligated in accordance with the combinations listed in Table 23 by using HD kit in the same manner as mentioned above and the sequence of "anti-hPD-1scFv03 (not tagged) expression cassette-T2 terminator region" (5'-Hu promoter-SPxLy-human PD-1scFv03-Hu terminator-T2 terminator-3') was determined. The plasmids extracted were designated as pHuSP50L5-hPD-

1scFv03TL-T2, pHuSP67L10-hPD-1scFv03TL-T2 and pHuSP69L1-hPD-1scFv03TL-T2.

[0249]

(Third step)

PCR products were prepared by using the template DNA and primers listed in Table 24 in the same manner as in the above step "PCR amplification 1".

[0250]

[Table 24]

PCR product	Template DNA	Fow. primer	Rev. primer	Size of PCR product
A10	pHuSP50L5-hPD-1 scFv03TL-T2	PC8_primer (SEQ ID No. 124)	PC2_primer	4868 bp
A11	pHuSP67L10-hPD-1 scFv03TL-T2	PC8_primer	PC2_primer	4814 bp
A12	pHuSP69L1-hPD-1 scFv03TL-T2	PC8_primer	PC2_primer	4778 bp
B4	pP30SP50L5-hCTLA-4 scFv01-FLAG	PC6_primer (SEQ ID No. 122)	PC9_primer (SEQ ID No. 125)	1186 bp
B5	pP30SP67L1-hCTLA-4 scFv01-FLAG	PC6_primer	PC9_primer	1105 bp
B6	pP30SP68L1-hCTLA-4 scFv01-FLAG	PC6_primer	PC9_primer	1135 bp

[0251]

[Table 25]

Plasmid to be constructed	Combination in in-fusion reaction
pPC2TLS	A10 and B5
pPC3TLS	A10 and B6
pPC4TLS	A11 and B4
pPC5TLS	A11 and B6
pPC6TLS	A12 and B4
pPC7TLS	A12 and B5
pPC8TLS	A12 and B6

[0252]

The PCR products listed in Table 24 were ligated in accordance with the combinations listed in Table 25 by using HD kit in the same manner as mentioned above and DNA sequences of the full-length plasmids extracted were determined in the same manner as above.

The plasmids extracted were designated as pPC2TLS, pPC3TLS, pPC4TLS, pPC5TLS, pPC6TLS, pPC7TLS and pPC8TLS.

[0253]

(Fourth step)

To plasmids pPC2TLS to pPC8TLS (2 μ g for each), which were prepared in the third step of the plasmid preparation, restriction enzymes, BamHI and BglII (manufactured by Thermo Scientific Inc.) were added each in an amount of 10 units. The mixture was kept warm at 37°C for 3 hours to cleave the plasmids. BamHI and BglII recognition sites are present one for each in the adjacent

portions to pUCori, which is the plasmid origin of replication in *E. coli*, as shown in Figure 30. After the treatment with the restriction enzymes, an aliquot was taken from the DNA solution and subjected to 0.8% agarose gel electrophoresis. In this manner, it was verified that the plasmid DNA was cleaved into fragments having predetermined sizes (about 5.3 kbp and about 0.7 kbp).

[0254]

(Separation and purification by agarose gel electrophoresis)

After the treatment with the restriction enzymes, the DNA fragments were separated by agarose gel electrophoresis. DNA band of about 5.3 kbp was cut out and DNA was extracted by use of QIAGel. The concentration of DNA was estimated by agarose gel electrophoresis.

[0255]

(Self-closing of DNA)

The purified DNA mentioned above (about 5.3 kbp) was subjected to a self-ligation reaction using Rapid DNA Ligation kit (manufactured by Thermo Scientific Inc.). After completion of the reaction, the solution was purified by QIAquick PCR Purification Kit (manufactured by QIAGEN) to prepare pPC2TL, pPC3TL, pPC4TL, pPC5TL, pPC6TL, pPC7TL and pPC8TL.

[0256]

(Transformation 11 of bacterium of the genus *Bifidobacterium*)

Bifidobacterium longum 105-A strain was transformed by the electroporation system in the same procedure as in the above section (Transformation 1 of bacterium of the

genus *Bifidobacterium*) except that plasmid pPC2TL, pPC3TL, pPC4TL, pPC5TL, pPC6TL, pPC7TL and pPC8TL prepared in the fourth step of the plasmid preparation were used each in an amount of 5 μ L. The transformants obtained were designated as *Bifidobacterium longum* 105-A/pPC2TL (hereinafter referred to as PC2TL strain); *Bifidobacterium longum* 105-A/pPC3TL (hereinafter referred to as PC3TL strain); *Bifidobacterium longum* 105-A/pPC4TL (hereinafter referred to as PC4TL strain); *Bifidobacterium longum* 105-A/pPC5TL (hereinafter referred to as PC5TL strain); *Bifidobacterium longum* 105-A/pPC6TL (hereinafter referred to as PC6TL strain); *Bifidobacterium longum* 105-A/pPC7TL (hereinafter referred to as PC7TL strain); and *Bifidobacterium longum* 105-A/pPC8TL (hereinafter referred to as PC8TL strain).

[0257]

(Determination of plasmid DNA sequence)

To each of the bacterium of the genus *Bifidobacterium* transformant cells obtained in the above section (Transformation 11 of bacterium of the genus *Bifidobacterium*), 1.5 mL of a lysozyme-Proteinase K mixture, which was prepared by adding lysozyme (manufactured by Wako Pure Chemical Industries Ltd.) and Proteinase K (manufactured by QIAGEN) in a concentration of 40 mg/mL and 0.4 mg/mL, respectively with the addition of 1 mM Tris-HCl-0.1mM EDTA buffer (pH8.0), was added and suspended. Each of the mixtures was kept warm at 37°C for about 1.5 hours. After centrifugal separation was carried out and the supernatant was removed, the resultant bacterial cells were subjected to extraction of plasmid

DNA by QIAprep Spin Miniprep Kit (manufactured by QIAGEN). In the same manner as in the above section (Example 1: Transformation of *E. coli* and determination of DNA sequence of plasmid pAG8), the DNA sequence of the full-length plasmid extracted was determined. The plasmids extracted were designated as plasmid pPC2TL, pPC3TL, pPC4TL, pPC5TL, pPC6TL, pPC7TL and pPC8TL as outlined below. The sequences of expression cassettes of plasmids pPC2TL, pPC3TL, pPC4TL, pPC5TL, pPC6TL, pPC7TL and pPC8TL are the same as in pPC2, pPC3, pPC4, pPC5, pPC6, pPC7 and pPC8 sequences except that neither of the sequences of expression cassettes of anti-hPD-1scFv03 and anti-hCTLA-4scFv01 contain a tag sequence.

[0258]

(pPC2TL: scFv expression cassette sequence (2576 bp)
(SEQ ID No. 138))

1..1366 Anti-human PD-1scFv03 expression cassette

1..361 Hu promoter

362..544 SP50L5

545..1249 anti-human PD-1scFv03

1250..1252 stop codon

1253..1366 Hu terminator

1367..2576 Anti-human CTLA-4scFv01 expression
cassette

1367..1601 P30 promoter

1602..1703 SP67L1

1704..2444 anti-human CTLA-4scFv01

2445..2447 stop codon

2448..2576 T2 terminator

[0259]

(pPC3TL scFv expression cassette sequence (2606 bp)

(SEQ ID No. 139))

1..1366 Anti-human PD-1scFv03 expression cassette

1..361 Hu promoter

362..544 SP50L5

545..1249 anti-human PD-1scFv03

1250..1252 stop codon

1253..1366 Hu terminator

1367..2606 Anti-human CTLA-4scFv01 expression
cassette

1367..1601 P30 promoter

1602..1733 SP68L1

1734..2474 anti-human CTLA-4scFv01

2475..2477 stop codon

2478..2606 T2 terminator

[0260]

(pPC4TL scFv expression cassette sequence (2603 bp)

(SEQ ID No. 140))

1..1312 Anti-human PD-1scFv03 expression cassette

1..361 Hu promoter

362..490 SP67L10

491.. 1195 anti-human PD-1scFv03

1196..1198 stop codon

1199..1312 Hu terminator

1313..2603 Anti-human CTLA-4scFv01 expression
cassette

1313..1547 P30 promoter

1548..1730 SP50L5

1731..2471	anti-human CTLA-4scFv01
2472..2474	stop codon
2475..2603	T2 terminator

[0261]

(pPC5TL scFv expression cassette sequence (2552 bp)

(SEQ ID No. 141))

1..1312 Anti-human PD-1scFv03 expression cassette

1..361	Hu promoter
362..490	SP67L10
491..1195	anti-human PD-1scFv03
1196..1198	stop codon
1199..1312	Hu terminator

1313..2552 Anti-human CTLA-4scFv01 expression
cassette

1313..1547	P30 promoter
1548..1679	SP68L1
1680..2420	anti-human CTLA-4scFv01
2421..2423	stop codon
2424..2552	T2 terminator

[0262]

(pPC6TL scFv expression cassette sequence (2567 bp)

(SEQ ID No. 142))

1..1276 Anti-human PD-1scFv03 expression cassette

1..361	Hu promoter
362..454	SP69L1
455..1159	anti-human PD-1scFv03
1160..1162	stop codon
1163..1276	Hu terminator

1277..2567 Anti-human CTLA-4scFv01 expression
cassette

1277..1511 P30 promoter
1512..1694 SP50L5
1695..2435 anti-human CTLA-4scFv01
2436..2438 stop codon
2439..2567 T2 terminator

[0263]

(pPC7TL scFv expression cassette sequence (2486 bp)
(SEQ ID No. 143))

1..1276 anti-human PD-1scFv03 expression cassette
1..361 Hu promoter
362..454 SP69L1
455..1159 anti-human PD-1scFv03
1160..1162 stop codon
1163..1276 Hu terminator

1277..2486 anti-human CTLA-4scFv01 expression
cassette

1277..1511 P30 promoter
1512..1613 SP67L1
1614..2354 anti-human CTLA-4scFv01
2355..2357 stop codon
2358..2486 T2 terminator

[0264]

(pPC8TL scFv expression cassette sequence (2516 bp)
(SEQ ID No. 144))

1..1276 Anti-human PD-1scFv03 expression cassette
1..361 Hu promoter
362..454 SP69L1

455..1159	anti-human PD-1scFv03
1160..1162	stop codon
1163..1276	Hu terminator
1277..2516	Anti-human CTLA-4scFv01 expression cassette
1277..1511	P30 promoter
1512..1643	SP68L1
1644..2384	anti-human CTLA-4scFv01
2385..2387	stop codon
2388..2516	T2 terminator

[0265]

[Example 20]

[Verification of scFv secretion in co-expression *Bifidobacterium* strain]

The presence or absence of secretions of anti-hPD-1scFv03-His and anti-hCTLA-4scFv01-FLAG in culture supernatants of co-expression strains, PC2 to PC8, was checked by western blotting as follows. The Beshuttle strain mentioned above was used as a negative control strain and subjected to the same analysis.

[0266]

(Culture of recombinant bacterium of the genus *Bifidobacterium*)

PC2 strain to PC8 strain, PC1 strain prepared in Example 8 and Beshuttle strain were cultured in the same procedure as in Example 4 (Culture of recombinant bacterium of the genus *Bifidobacterium*) and the culture supernatants were collected. The culture supernatants were concentrated by TCA in the same procedure as in

Example 9 (Culture of recombinant bacterium of the genus *Bifidobacterium*) to obtain individual culture supernatant concentrates.

[0267]

(Western analysis)

Western analysis using each of the culture supernatant concentrates (corresponding to about 0.01 mL of the culture solution) was carried out in the same manner as in Example 9 (Western analysis). Note that transferring from the gel to membrane was carried out by using Trans-Blot Turbo (manufactured by Bio-Rad) and the 2%ECL Advance Blocking Agent mentioned above was used as a blocking solution. The results for anti-hPD-1scFv03-His are shown in Figure 31 (A) and the results for anti-hCTLA-4scFv01-FLAG are shown in Figure 31 (B).

[0268]

(Results)

As is apparent from Figures 31A and B, both secretions of anti-hPD-1scFv03-His and anti-hCTLA-4scFv01-FLAG were observed in the culture supernatants of PC2 strain (lane 1 both in A and B), PC3 strain (lane 2 both in A and B), PC4 strain (lane 3 both in A and B), PC5 strain (lane 4 both in A and B), PC6 strain (lane 5 both in A and B), PC7 strain (lane 6 both in A and B), PC8 strain (lane 7 both in A and B) and PC1 strain (lane 9 both in A and B) (note that in PC1 strain, anti-hCTLA-4scFv02-FLAG was secreted). The amounts of anti-hPD-1scFv03-His and anti-hCTLA-4scFv01-FLAG secreted from PC2 strain to PC8 strain were each larger than the amount of single-chain antibody secreted from PC1 strain.

[0269]

From the above results, it was verified that co-expression *Bifidobacterium* strains, PC2 strain to PC8 strain, are recombinant *Bifidobacterium* strains that can secrete both anti-hPD-1scFv and anti-hCTLA-4scFv in the culture supernatants and secrete a single-chain antibody in a larger amount than PC1 strain.

[0270]

[Example 21]

[Verification of scFv secretion in co-expression strains, PC2TL strain to PC8TL strain]

The antibodies secreted from the co-expression strains, PC2TL strain to PC8TL strain, were subjected to ELISA for checking the presence or absence of binding activity to human PD-1 (hPD-1) and binding activity to human CTLA-4.

[0271]

(Culture of recombinant bacterium of the genus *Bifidobacterium*)

Co-expression *bifidobacteria*, PC2TL strain to PC8TL strain prepared in Example 19 above and Beshuttle strain were cultured in the same procedure as in Example 4 (Culture of recombinant bacterium of the genus *Bifidobacterium*) and the culture supernatants were collected. The culture supernatants of PC2TL strain to PC8TL strain were appropriately diluted with the culture supernatant of Beshuttle strain and used as samples for ELISA.

[0272]

(Evaluation on secretion of anti-hPD-1scFv03)

To 96-well plates (MaxiSorp, Type C, manufactured by Nunc), 1 µg/mL hPD-1 solution (using Recombinant Human PD-1 Fc Chimera (R&D Systems) as an antigen and prepared with 1X PBS) was dispensed in an amount of 100 µL for each. To the upper portion of the plates, a seal was attached and the plates were incubated at 4°C overnight to immobilize the antigen. After the solution was removed from the plates, 1X PBS was dispensed in an amount of 400 µL for each and the liquid was removed. This operation was repeated three times for washing (hereinafter referred to as "PBS washing").

[0273]

To the plates washed, 1% BSA solution (350 µL for each) was dispensed. The plates were incubated at room temperature for 2 hours for blocking and PBS washing was carried out.

[0274]

To the plates, the samples for ELISA were dispensed. To the blank wells, the culture supernatant (100 µL) of BEshuttle strain was dispensed. As a positive control, a solution (100 µL), which was prepared by adding anti-hPD-1scFv03 purified product to the culture supernatant of BEshuttle strain so as to obtain a concentration of 100 ng/mL, was dispensed. A seal was attached to the upper portions of the plates and the plates were incubated at room temperature for 2 hours to carry out the scFv binding reaction to the antigen immobilized and PBS washing was carried out.

[0275]

After completion of the scFv binding reaction to the antigen immobilized, 100 μ L of 0.2 μ g/mL biotinylated Protein L solution (prepared by diluting Biotinylated Protein L: manufactured by Thermo Scientific with Solution B of Signal Enhancer HIKARI: manufactured by Nacalai Tesque Inc., up to a concentration of 0.2 μ g/mL) was added to the plates. A seal was attached to the upper portions of the plates and the plates were incubated at room temperature for one hour (binding reaction of biotinylated Protein L to scFv light chain, κ chain) and PBS washing was carried out.

[0276]

After the binding reaction of the biotinylated Protein L, 100 μ L of an avidin-biotin marker enzyme complex preparation solution (prepared by adding Solution A and B (30 μ L for each) of avidin-biotin marker enzyme complex VECTASTAIN ABC Kit: manufactured by VECTOR Laboratories, to Solution B (7.5 mL) of Signal Enhancer HIKARI, followed by stirring) was added to the plates. A seal was attached to the upper portions of the plates and the plates were incubated at room temperature for 30 minutes and PBS washing was carried out.

[0277]

To the plates to which the enzyme was bound, 200 μ L of a detection reagent (comprising Color Reagent A and Color Reagent B: both are manufactured by R&D systems and blended in equal amounts) was added. The plates were shielded from light and incubated at room temperature. Accurately 20 minutes later, the stop solution (50 μ L) mentioned above was added to terminate a color reaction.

Absorbance was measured at 450 nm and 570 nm (reference wavelength) by a plate reader.

[0278]

(Evaluation on secretion of anti-hCTLA-4scFv01)

Evaluation was carried out in the same manner as in the above section (Evaluation on secretion of anti-hPD-1scFv03) except the points: 1) the antigen was immobilized to a plate by using a 1 µg/mL hCTLA-4 solution (Recombinant Human CTLA-4-Fc Chimera (manufactured by BioLegend) prepared in the addition of 1X PBS), 2) as the positive control, anti-hCTLA-4scFv01 purified product added in the culture supernatant of BEshuttle strain was used and 3) the concentration of biotinylated Protein L solution was specified as 0.05 µg/mL. The results are shown in Table 26.

[0279]

[Table 26]

Binding activity of scFv to immobilized antigen

Sample	Binding (OD450-570) to immobilized antigen	
	hPD-1 immobilized	hCTLA-4 immobilized
PC2TL	0.812	1.312
PC3TL	0.792	1.286
PC4TL	0.363	1.788
PC5TL	0.305	1.39
PC6TL	0.528	1.116
PC7TL	0.549	1.457
PC8TL	0.733	1.320
P.C. 1 (anti-hPD-1 scFv03)	0.667	n.t.
P.C. 2 (anti-hCTLA-4 scFv01)	n.t.	1.074

n.t.: not treated, P.C.: Positive control

[0280]

(Results)

As is apparent from Table 26, culture supernatants of ELISA co-expression strains, PC2TL strain to PC8TL strain, had binding activities to both of human PD-1 and human CTLA-4 immobilized. Note that it was already verified that the binding activities of such scFv molecules are specific to the corresponding antigens (data are not shown).

[0281]

[Example 22]

Anti-hPD-1scFv03-His single-expression strain and anti-hCTLA-4scFv01-FLAG single-expression strain to be

compared with co-expression *bifidobacteria*, PC2 strain to PC8 strain, are shown in Table 27.

[0282]

[Table 27]

Co-expression strain	Comparable anti-hPD-1scFv03-His single expression strain	Comparable anti-hCTLA-4scFv01-FLAG single expression strain
PC2	P1H	C2F
PC3	P1H	C3F
PC4	P2H	C1F
PC5	P2H	C3F
PC6	P3H	C1F
PC7	P3H	C2F
PC8	P3H	C3F

[0283]

(Transformation 12 of bacterium of the genus *Bifidobacterium*)

Bifidobacterium longum 105-A strain was transformed by the electroporation system in the same procedure as in the above section (Transformation 1 of bacterium of the genus *Bifidobacterium*) by using plasmid pHuSP50L5-hPD-1scFv03-His, pHuSP67L10-hPD-1scFv03-His and pHuSP69L1-hPD-1scFv03-His prepared in Example 18. The transformants obtained were designated as *Bifidobacterium longum* 105-A/pHuSP50L5-hPD-1scFv03-His (hereinafter referred to as P1H strain); *Bifidobacterium longum* 105-A/pHuSP67L10-hPD-1scFv03-His (hereinafter referred to as P2H strain); and *Bifidobacterium longum* 105-A/pHuSP69L1-hPD-1scFv03-His (hereinafter referred to as P3H strain).

[0284]

Similarly, *Bifidobacterium longum* 105-A strain was transformed by using plasmid pC1F, pC2F and pC3F prepared in Example 18 to obtain *Bifidobacterium longum* 105-A/pC1F (hereinafter referred to as C1F strain); *Bifidobacterium longum* 105-A/pC2F (hereinafter referred to as C2F strain); and *Bifidobacterium longum* 105-A/pC3F (hereinafter referred to as C3F strain).

[0285]

[Example 23]

Anti-hPD-1scFv03 single-expression strain and anti-hCTLA-4scFv01 single-expression strain to be compared with co-expression *bifidobacteria* PC2TL-PC8TL strain are shown in Table 28.

[0286]

[Table 28]

Co-expression strain	Comparable anti-hPD-1scFv03 single expression strain	Comparable anti-hCTLA-4scFv01 single expression strain
PC2TL	P1TL	C2TLB
PC3TL	P1TL	C3TLB
PC4TL	P2TL	C1TLB
PC5TL	P2TL	C3TLB
PC6TL	P3TL	C1TLB
PC7TL	P3TL	C2TLB
PC8TL	P3TL	C3TLB

[0287]

(Transformation 13 of bacterium of the genus *Bifidobacterium*)

Bifidobacterium longum 105-A strain was transformed by the electroporation system in the same procedure as in the above section (Transformation 1 of bacterium of the genus *Bifidobacterium*) by using plasmid pHuSP50L5-hPD-1scFv03TL, pHuSP67L10-hPD-1scFv03TL and pHuSP69L1-hPD-1scFv03TL prepared in Example 19. The transformants obtained were designated as *Bifidobacterium longum* 105-A/pHuSP50L5-hPD-1scFv03TL (hereinafter referred to as P1TL strain); *Bifidobacterium longum* 105-A/pHuSP67L10-hPD-1scFv03TL (hereinafter referred to as P2TL strain); and *Bifidobacterium longum* 105-A/pHuSP69L1-hPD-1scFv03TL (hereinafter referred to as P3TL strain).

[0288]

(Preparation of anti-hCTLA-4scFv01 single-expression strain)

A method for producing anti-hCTLA-4scFv01 expression plasmids pC1TLB, pC2TLB and pC3TLB is schematically shown in Figure 32. The method consists of two steps: T2 substitution step of removing FLAG tag from plasmids pC1F, pC2F and pC3F and replacing with T2 terminator; and pUCori removal step of removing pUCori from plasmids pC1TL, pC2TL and pC3TL.

[0289]

(T2 substitution step)

Using the template DNA and primers listed in Table 29, PCR products were prepared in the same manner as in the above step "PCR amplification 1".

[0290]

[Table 29]

PCR product	Template DNA	Fow. primer	Rev. primer	Size of PCR product
A1	pC1F	PC1_primer	PC9_primer	4538 bp
A2	pC2F	PC1_primer	PC9_primer	4457 bp
A3	pC3F	PC1_primer	PC9_primer	4487 bp
B	BBa-B0015 in pUC57	PC8_primer	PC4_primer	150 bp

[0291]

PCR products were used in combination in accordance with the following three types: A1 and B (for preparation of pC1TL), A2 and B (for preparation of pC2TL) and A3 and B (for preparation of pC3TLpreparation) and ligated by using HD kit in the same manner as mentioned above. The DNA sequences of the full-length plasmids extracted were determined in the same procedure as above. The plasmids extracted were designated as pC1TL, pC2TL and pC3TL.

[0292]

(pUCori removal step)

pUCori was removed from pC1TL, pC2TL and pC3TL in the same manner as in the third step of the method for producing co-expression plasmids, pPC2TL to pPC8TL in Example 19 to obtain pC1TLB, pC2TLB and pC3TLB.

[0293]

(Transformation 14 of bacterium of the genus *Bifidobacterium*)

Bifidobacterium longum 105-A strain was transformed by the electroporation system in the same procedure as in the above section (Transformation 1 of bacterium of the genus *Bifidobacterium*) by using plasmid pC1TLB, pC2TLB and

pC3TLB. The transformants obtained were designated as *Bifidobacterium longum* 105-A/pC1TLB (hereinafter referred to as C1TLB strain); *Bifidobacterium longum* 105-A/pC2TLB (hereinafter referred to as C2TLB strain); and *Bifidobacterium longum* 105-A/pC3TLB (hereinafter referred to as C3TLB strain).

[0294]

[Example 24]

(Binding to cell)

Binding of anti-hCTLA-4scFv01-FLAG purified from the anti-hCTLA-4scFv01-FLAG single-expression strain to be compared with co-expression strains, PC2 to PC8 was investigated.

[0295]

Anti-hCTLA-4scFv01-FLAG was purified from each of the culture supernatants of anti-hCTLA-4scFv01-FLAG single expression *Bifidobacterium* C1F strain, C2F strain and C3F strain by Protein L column. The purified scFv (100 μ L) prepared to have a concentration of 1 μ g/mL was added to HEK293T cells, in which intracellular domain deficient hCTLA-4 was overexpressed by use of a retrovirus vector, and incubated on ice for 30 minutes. After the cells were washed, biotinylated Protein L (100 μ L) was added and incubated for 30 minutes to allow protein L to bind to scFv bound to the cell. After the cells were washed, Brilliant Violet 421 Streptavidin (100 μ L) prepared to have a concentration of 0.5 μ g/mL was added and incubated for 30 minutes. The cells were washed and then analysis was carried out by flow cytometry. The results are shown in Figure 33.

[0296]

(Results)

As is apparent from Figure 33, scFv molecules derived from C1F strain, C2F strain and C3F strain all bound to intracellular domain deficient hCTLA-4 expression HEK293T cells. From this, it was presumed that anti-hCTLA-4scFv01-FLAG secreted from each of co-expression strains, PC4 and PC6, which secrete the same scFv as in C1F strain; co-expression strains, PC2 strain and PC7 strain, which secrete the same scFv as in C2F strain; and co-expression strains, PC3 strain, PC5 strain and PC8 strain, which secrete the same scFv as in C3F strain can also bind to hCTLA-4 expressing cells. From Figure 33 (a), binding to a Mock cells not expressing hCTLA-4 was slightly observed; however, binding of anti-hCTLA-4scFv01-FLAG purified from co-expression PC4 strain to the Mock cells were not observed from the results of Figure 37 (d). From this, binding to scFv molecules derived from C1F strain, C2F strain and C3F strain to the Mock cells is considered as non-specific binding.

[0297]

[Example 25]

(Binding of anti-hCTLA-4scFv01 purified from anti-hCTLA-4scFv01 single-expression strain to cells)

Anti-hCTLA-4scFv01 was purified from each of the culture supernatants of anti-hCTLA-4scFv01 single-expression strains, C1TLB, C2TLB and C3TLB to be compared with co-expression strains, PC2TL to PC8TL, by Protein L column. To HEK293T cells in which intracellular domain deficient hCTLA-4 was overexpressed by use of a retrovirus

vector, purified scFv (100 μ L) prepared to have a concentration of 1 μ g/mL was added and incubated on ice for 30 minutes. After the cells were washed, biotinylated Protein L (100 μ L) was added and incubated for 30 minutes to allow protein L to bind to scFv bound to the cells. After the cells were washed, Brilliant Violet 421 Streptavidin (100 μ L) prepared to have a concentration of 0.5 μ g/mL was added and incubated for 30 minutes. The cells were washed and then analysis was carried out by flow cytometry. The results are shown in Figure 34.

[0298]

(Results)

As is apparent from Figure 34, scFv molecules derived from C1TLB strain, C2TLB strain and C3TLB strain all bound to hCTLA-4 expressing cells. From this, it was presumed that anti-hCTLA-4scFv01 secreted from each of co-expression strains, PC4TL strain and PC6TL strain, which secrete the same scFv as in C1TLB strain; co-expression strains, PC2TL strain and PC7TL strain, which secrete the same scFv as in C2TLB strain; and co-expression strains, PC3TL strain, PC5TL strain and PC8TL strain, which secrete the same scFv as in C3TLB strain can also bind to hCTLA-4 expressing cells.

[0299]

[Example 26]

(Binding of anti-PD-1scFv03-His purified from anti-hPD-1scFv03-His single-expression strain to cells)

Anti-PD-1scFv03-His was purified from each of the culture supernatants of anti-PD-1scFv03-His single-expression strains, P1H, P2H and P3H to be compared with

co-expression strains, PC2 to PC8, by Protein L. To HEK293T cells in which hPD-1 was overexpressed by use of a retrovirus vector, purified scFv (100 μ L) prepared to have a concentration of 1 μ g/mL was added and incubated on ice for 30 minutes. After the cells were washed, biotinylated Protein L (100 μ L) was added, incubated for 30 minutes to allow protein L to bind to scFv bound to the cells. After the cells were washed, Brilliant Violet 421 Streptavidin (100 μ L) prepared to have a concentration of 0.5 μ g/mL was added and incubated for 30 minutes. The cells were washed and then analysis was carried out by flow cytometry. The results are shown in Figure 35.

[0300]

(Results)

As is apparent from Figure 35, scFv molecules derived from P1H strain, P2H strain and P3H strain all bound to hPD-1 expressing cells. From this, it was presumed that anti-PD-1scFv03-His secreted from each of co-expression strains, PC2 and PC3, which secrete the same scFv as in P1H strain; co-expression strains, PC4 and PC5, which secrete the same scFv as in P2H strain; and co-expression strains, PC6, PC7 and PC8, which secrete the same scFv as in P3H strain can also bind to hPD-1 expressing cells.

[0301]

[Example 27]

(Binding of anti-hPD-1scFv03 purified from anti-hPD-1scFv03 single-expression strain to cells)

Anti-hPD-1scFv03 was purified from each of the culture supernatants of PD-1scFv03 single expression

bifidobacteria, P1TL strain, P2TL strain and P3TL strain, to be compared with co-expression strains, PC2TL strain to PC8TL strain, by Protein L column. To HEK293T cells in which hPD-1 was overexpressed by use of a retrovirus vector, purified scFv (100 μ L) prepared to have a concentration of 1 μ g/mL was added and incubated on ice for 30 minutes. After the cells were washed, biotinylated Protein L (100 μ L) was added and incubated for 30 minutes to allow protein L to bind to scFv bound to the cells. After the cells were washed, Brilliant Violet 421 Streptavidin (100 μ L) prepared to have a concentration of 0.5 μ g/mL was added and incubated for 30 minutes. The cells were washed and then analysis was carried out by flow cytometry. The results are shown in Figure 36.

[0302]

(Results)

As is apparent from Figure 36, scFv molecules derived from P1TL strain, P2TL strain and P3TL strain all bound to hPD-1 expressing cells. From this, it was presumed that anti-PD-1scFv03 secreted from each of co-expression strains, PC2TL and PC3TL, which secrete the same scFv as in P1TL strain; co-expression strains, PC4TL and PC5TL, which secrete the same scFv as in P2TL strain; and co-expression strains, PC6TL, PC7TL and PC8TL, which secrete the same scFv as in P3TL strain can bind to hPD-1 expressing cells.

[0303]

[Example 28]

(Binding of scFv purified from co-expression strain PC4 to cells)

From the culture supernatant of co-expression strain PC4, anti-hPD-1scFv03-His was purified by use of a purification column for His-tag; and anti-hCTLA-4scFv01-FLAG was purified by use of a purification column for FLAG tag. Binding of anti-hPD-1scFv03 to hPD-1 expressing cells were checked in the same manner as in [Example 26]. Binding of anti-hCTLA-4scFv01 to hCTLA-4 expressing cells were checked in the same manner as in [Example 24]. As positive controls, PE-labeled anti-hPD-1 antibody (clone: EH12.2H7) and PE-labeled anti-hCTLA-4 antibody (clone: L3D10) were used. The results are shown in Figure 37.

[0304]

From Figure 37 (a), it was found that a positive control, i.e., PE-labeled anti-hPD-1 antibody (clone: EH12.2H7) binds to hPD-1 expressing cells and binds to neither Mock cells nor hCTLA-4 expressing cells. From (b), it was found that PE-labeled anti-hCTLA-4 antibody (clone: L3D10) binds to hCTLA-4 expressing cells and binds to neither Mock cells nor hPD-1 expressing cells. As is apparent from Figures 37 (c) and (d), it was found that anti-hPD-1scFv03-His and anti-hCTLA-4scFv01-FLAG purified from co-expression strain PC4 bind to the corresponding antigen expressing cells.

[0305]

[Example 29]

(Affinity of anti-hCTLA-4scFv01-FLAG purified from anti-hCTLA-4scFv01-FLAG single-expression strain for antigen (Biacore))

Anti-hCTLA-4scFv01-FLAG was purified by Protein L column from each of the culture supernatants of anti-

hCTLA-4scFv01-FLAG single expression *bifidobacteria* C1F, C2F and C3F to be compared with co-expression strains, PC2 to PC8. The binding kinetic parameter of each hCTLA-4scFv01-FLAG purified to hCTLA-4 (fusion protein with human IgG1Fc) was measured by surface plasmon resonance using Biacore system (manufactured by GE Healthcare). To a substrate having a carboxyl methyl dextran-coated gold membrane, a mouse anti-human IgG (Fc) monoclonal antibody (manufactured by GE Healthcare) was bound in accordance with amine coupling, and Fc-fused recombinant hCTLA-4 (Biolegend) was captured as a ligand. As an analyte, scFv purified was used. Samples of scFv having a concentration of 0.7404, 2.2222, 6.6667, 20 and 60 nM were prepared and sequentially subjected to binding in order of increasing concentration in accordance with single cycle kinetics. Data obtained were analyzed by BIA evaluation software (manufactured by GE Healthcare). The results are shown in Table 30.

[0306]

[Table 30]

sample	ka (1/Ms)	kd (1/s)	KD (M)
C1F	9.18E+05	9.96E-04	1.08E-09
C2F	4.52E+05	1.03E-03	2.28E-09
C3F	3.47E+05	1.03E-03	2.97E-09
C1TLB	6.61E+05	9.80E-04	1.48E-09
C2TLB	9.81E+05	9.61E-04	9.80E-10
C3TLB	7.73E+05	9.96E-04	1.29E-09

[0307]

(Results)

As is apparent from Table 30, scFvs secreted from each of the single-expression strains C1F, C2F and C3F exhibits a high KD value, meaning that scFvs have affinity for hCTLA-4. It is presumed that anti-hCTLA-4scFv secreted from each of co-expression strains, PC4 and PC6, also has affinity for hCTLA-4, similarly to scFv derived from C1F strain. It is also presumed that scFv secreted from each of co-expression strains, PC2 and PC7, presumably has affinity for hCTLA-4 similarly to scFv derived from C2F strain; and that scFv secreted from each of co-expression strains, PC3, PC5 and PC8, has affinity for hCTLA-4 similarly to scFv derived from C3F strain.

[0308]

[Example 30]

(Affinity of anti-hCTLA-4scFv01 purified from anti-hCTLA-4scFv01 single-expression strain for antigen (Biacore))

Anti-hCTLA-4scFv01 was purified by Protein L column from each of the culture supernatants of anti-hCTLA-4scFv01 single expression *bifidobacteria*, C1TLB strain, C2TLB strain and C3TLB strain to be compared with co-expression strains, PC2TL to PC8TL. The binding kinetic parameter to hCTLA-4 (fusion protein with human IgG1Fc) was measured by surface plasmon resonance using Biacore system. Thereafter, analysis was carried out in the same manner as in Example 29. The results are shown in Table 30.

[0309]

(Results)

As is apparent from Table 30, scFvs secreted from each of single-expression strains, C1TLB, C2TLB and C3TLB exhibits a high KD value, meaning that scFvs have affinity for hCTLA-4. It is presumed that scFv secreted from each of co-expression strains, PC4TL and PC6TL, also has affinity for hCTLA-4, similarly to scFv derived from C1TLB strain. It is also presumed that scFv secreted from each of co-expression strains, PC2TL and PC7TL, has affinity for hCTLA-4 similarly to scFv derived from C2TLB strain; and that scFv secreted from each of co-expression strains, PC3TL, PC5TL and PC8TL, has affinity for hCTLA-4 similarly to scFv derived from C3TLB strain.

[0310]

[Example 31]

(Affinity of anti-hPD-1scFv03-His purified from anti-hPD-1scFv03-His single-expression strain for antigen (Biacore))

Anti-hPD-1scFv03-His was purified by Protein L column from each of the culture supernatants of anti-hPD-1scFv03-His single expression *bifidobacteria*, P1H strain, P2H strain and P3H strain, to be compared with co-expression strains, PC2 to PC8. The binding kinetic parameter with hPD-1 (fusion protein with human IgG1Fc) was measured by surface plasmon resonance using Biacore system. Analysis was carried out in the same manner as in Example 29 except that Fc fused recombinant hPD-1 (R&D) was captured as a ligand. The results are shown in Table 31.

[0311]

[Table 31]

sample	ka (1/Ms)	kd (1/s)	KD (M)
P1H	4.79E+05	1.29E-03	2.69E-09
P2H	4.60E+05	1.86E-03	4.04E-09
P3H	4.33E+05	1.99E-03	4.60E-09
P1TL	3.44E+05	1.34E-03	3.89E-09
P2TL	3.35E+05	1.96E-03	5.85E-09
P3TL	3.03E+05	2.07E-03	6.83E-09

[0312]

(Results)

As is apparent from Table 31, scFvs secreted from each of single-expression strains, P1H, P2H and P3H exhibited a high KD value, meaning that scFvs have affinity for hPD-1. It is presumed that scFv secreted from each of co-expression strains, PC2 and PC3, also has affinity for hPD-1, similarly to scFv derived from P1H strain. It is also presumed that scFv secreted from each of co-expression strains, PC4 and PC5 has affinity for hPD-1, similarly to scFv derived from P2H strain; and that scFv secreted from each of co-expression strains, PC6, PC7 and PC8 has affinity for hPD-1, similarly to scFv derived from P3H strain.

[0313]

[Example 32]

(Affinity of anti-hPD-1scFv03 purified from anti-hPD-1scFv03 single-expression strain for antigen (Biacore))

Anti-hPD-1scFv03 was purified by Protein L column from each of the culture supernatants of anti-hPD-1scFv03 single expression *bifidobacteria*, P1TL strain, P2TL strain and P3TL strain to be compared with co-expression strains, PC2TL to PC8TL. The binding kinetic parameter with hPD-1 (fusion protein with human IgG1Fc) was measured by surface plasmon resonance using Biacore system. Analysis was carried out in the same manner as in Example 29 except that Fc fused recombinant hPD-1 (R&D) was captured as a ligand. The results are shown in Table 31.

[0314]

(Results)

As is apparent from Table 31, scFvs secreted from each of single-expression strains P1TL, P2TL and P3TL exhibited a high KD value, meaning that scFvs have affinity for hPD-1. It is presumed that scFv secreted from each of co-expression strains, PC2TL and PC3TL, also has affinity for hPD-1, similarly to scFv derived from P1TL strain. It is also presumed that scFv secreted from each of co-expression strains, PC4TL and PC5TL has affinity for hPD-1, similarly to scFv derived from P2TL strain; and that scFv secreted from each of co-expression strains, PC6TL, PC7TL and PC8TL has affinity for hPD-1, similarly to scFv derived from P3TL strain.

[0315]

[Example 33]

(Inhibitory activity of scFv derived from co-expression strain PC4 to antigen-ligand binding)

From the culture supernatant of co-expression strain PC4, anti-hPD-1scFv03-His was purified by the purification

column for His-tag and anti-hCTLA-4scFv01-FLAG was purified by the purification column for FLAG-tag. Competitive activities (ELISA) of these with a ligand in binding to the corresponding antigens were evaluated.

[0316]

(Competitive activity of human PD-L1 to binding between anti-hPD-1scFv03 to antigen)

The same operation as in Example 21 (Evaluation on secretion of anti-hPD-1scFv03) was repeated except the sample addition operation. As a sample, a mixture of 2 nM (immobilization concentration) of anti-hPD-1scFv03-His obtained by His-tag purification of the culture supernatant of co-expression strain PC4 and a human PD-L1 solution (Recombinant Human B7-H1/PD-L1Fc Chimera, R&D systems, hereinafter referred to as hPD-L1) different in concentration (640 nM, 320 nM, 160 nM, 80 nM, 40 nM, 20 nM, 5nM, 0.5 nM, 0 nM) was used. In control wells, a sample of 2 nM anti-hCTLA-4scFv01-FLAG (derived from C1F strain) and a sample of 640 nM hPD-L1 were added. The binding inhibition rate of hPD-L1 to binding of hPD-1/anti-hPD-1scFv03-His was calculated in accordance with Expression 1. The resultant (binding) inhibitory activities of hPD-L1 to the binding between hPD-1scFv03 purified from PC4 strain and hPD-1 are shown in Table 32.

[0317]

[Expression 1]

$$\text{Binding inhibition rate (\%)} = 100 - \frac{(\text{Absorbance in the presence of hPD-L1})}{(\text{Absorbance in the absence of hPD-L1})} \times 100 \quad (\text{Formula 1})$$

[0318]

[Table 32]

Sample		Binding	Inhibition rate
hPD-1	scFv03-His	hPD-L1	A450-570 (%)
2 nM		0 nM	1.942 0
2 nM		0.5 nM	1.426 26.6
2 nM		5 nM	1.359 30
2 nM		20 nM	1.481 23.7
2 nM		40 nM	1.021 47.4
2 nM		80 nM	0.851 56.2
2 nM		160 nM	0.649 66.6
2 nM		320 nM	0.396 79.6
2 nM		640 nM	0.272 86
no		640 nM	0 -
hCTLA-4	scFv	no	-0.001 -

[0319]

As is apparent from Table 32, as the hPD-L1 concentration increased, absorbance decreased. Binding of anti-hPD-1scFv03-His to an antigen decreased in a hPD-L1-concentration dependent manner. In contrast, in the case where 2nM anti-hCTLA-4scFv01-FLAG was added, binding to the plate was not observed. From this, binding of anti-hPD-1scFv03-His to human PD-1 immobilized can be said to be specific binding. In the case where hPD-L1 alone was added, binding to the plate was not observed. From this, what was bound to the plate when anti-hPD-1scFv03-His/hPD-L1 mixture was added can be said to be anti-hPD-1scFv03-His. The binding inhibition rate of hPD-L1 against the binding between hPD-1 and anti-hPD-1scFv03-His is shown in Figure 38. The binding between hPD-1 and anti-hPD-1scFv03-His is inhibited by hPD-L1 in a concentration-dependent manner.

[0320]

(Competitive activity of ligand to binding between anti-hCTLA-4scFv01 and antigen)

The same operation as in Example 21 (Evaluation on secretion of anti-hCTLA-4scFv01) was repeated except the sample addition operation. As samples, a mixture of 1 nM anti-hCTLA-4scFv01-FLAG obtained by FLAG-tag purification from co-expression strain PC4 and human CD80 (Recombinant Human B7-1/CD80 Fc Chimera, R&D Systems, hereinafter referred to as hCD80) different in concentration (30 nM, 20 nM, 10 nM, 5 nM, 3 nM and 0 nM); and a mixture of 1 nM anti-hCTLA-4 scFv01-FLAG and human CD86 (Recombinant Human B7-1/CD86 Fc Chimera, R&D Systems, hereinafter referred to as hCD86) different in concentration (100 nM, 80 nM, 60 nM, 40 nM, 20 nM and 0 nM) were used. In control wells, 1 nM anti-hPD-1scFv03-His (derived from P2H strain), 30 nM hCD80 alone, or 100 nM hCD86 alone were added. The binding inhibition rate of hCD80 or hCD86 to binding of hCTLA-4/anti-hCTLA-4scFv01-FLAG was calculated in accordance with Expression 2.

[0321]

[Expression 2]

$$\text{Binding inhibition rate (\%)} = 100 - \frac{(\text{Absorbance in the presence of ligand}^*)}{(\text{Absorbance in the absence of ligand}^*)} \times 100 \quad (\text{Formula 2})$$

*Ligand: hCD80 or hCD86

[0322]

(Results)

The results of competitive ELISA are shown in Table 33 (hCD80 was used as a ligand) and Table 34 (hCD86 was used as a ligand).

[0323]

[Table 33]

Binding inhibitory activity of hCD80 to binding between hCTLA-4scFv01-FLAG purified from PC4 strain and hCTLA-4

Sample		Binding	Inhibition
hCTLA-4scFv01-FLAG	hCD80	A450-570	(%)
1 nM	0 nM	1.027	0
1 nM	3 nM	1.352	-31.6
1nM	5 nM	0.489	52.4
1nM	10 nM	0.407	60.4
1nM	20 nM	0.248	75.9
1nM	30 nM	0.185	82
no	30 nM	0.004	-
hPD-1 scFv	no	-0.020	-

[0324]

[Table 34]

Binding inhibitory activity of hCD86 to binding between hCTLA-4scFv01-FLAG purified from PC4 strain and hCTLA-4

Sample		Binding	Inhibition
hCTLA-4scFv01-FLAG	hCD86	A450-570	(%)
1 nM	0 nM	1.027	0
1 nM	20 nM	1.084	-5.6
1nM	40 nM	0.799	22.2
1nM	60 nM	0.614	40.2
1nM	80 nM	0.521	49.3
1nM	100 nM	0.374	63.6
no	100 nM	0.009	-
hPD-1 scFv	no	-0.020	-

[0325]

As is apparent from Table 33 and Table 34, as the concentration of hCD80 or hCD86 increased, absorbance decreased. Binding of anti-hCTLA-4scFv01-FLAG to an

antigen decreased in a hCD80- or hCD86-concentration dependent manner. In contrast, in the case where 1 nM anti-hPD-1scFv03-His was added, binding to the plate was not observed. From this, the binding of hCTLA-4scFv01-FLAG to human CTLA-4 immobilized can be said to be specific binding. In the case where hCD80 alone or hCD86 alone was added, binding to the plate was not observed. From this, what was bound to the plate when the mixture of anti-hCTLA-4scFv01-FLAG and hCD80 or the mixture of anti-hCTLA-4scFv01-FLAG and hCD86 was added, can be said to be anti-hCTLA-4scFv01-FLAG.

[0326]

The binding inhibition rates of hCD80 and hCD86 to binding between hCTLA-4 and anti-hCTLA-4scFv01-FLAG are shown in Figure 39 and Figure 40, respectively. The binding between hCTLA-4 and anti-hCTLA-4scFv01-FLAG is inhibited by hCD80 or hCD86 in a concentration-dependent manner.

[0327]

From the results mentioned above, it was successfully verified that anti-hPD-1scFv03-His and anti-hCTLA-4scFv01-FLAG secreted from co-expression strain PC4 have activities to competitively bind to the corresponding antigens with the respective ligands.

CLAIMS

1. A co-expression plasmid comprising two types of secretory expression cassettes each sequentially comprising the following DNAs (1) to (4) and expressed within a bacterium of the genus *Bifidobacterium*:

(1) a promoter DNA functioning in the bacterium of the genus *Bifidobacterium*;

(2) a DNA encoding a secretory signal peptide;

(3) a DNA encoding a heterologous polypeptide; and

(4) a terminator DNA functioning in the bacterium of the genus *Bifidobacterium*.

2. The co-expression plasmid according to Claim 1, wherein a DNA encoding a linker peptide is ligated downstream of the DNA encoding a secretory signal peptide.

3. The co-expression plasmid according to Claim 1 or 2, wherein the promoter functioning in the bacterium of the genus *Bifidobacterium* is one or two promoters selected from P30 promoter, P54 promoter and Hu promoter.

4. The co-expression plasmid according to any one of Claims 1 to 3, wherein the terminator functioning in the bacterium of the genus *Bifidobacterium* is one or two terminators selected from Hu terminator and T2 terminator.

5. The co-expression plasmid according to any one of Claims 1 to 4, wherein the secretory signal peptide has the following amino acid sequence a) or b):

a) an amino acid sequence represented by any one of SEQ ID Nos: 57, 59, 61, 63, 65, 67, 69, 71, 73, 75 and 77,

b) an amino acid sequence obtained by deleting, substituting or adding one or several amino acids in the amino acid sequence represented by any one of SEQ ID Nos: 57, 59, 61, 63, 65, 67, 69, 71, 73, 75 and 77, wherein a peptide consisting of the amino acid sequence serves as a secretory signal peptide in the bacterium of the genus *Bifidobacterium*.

6. The co-expression plasmid according to any one of Claims 1 to 5, wherein the heterologous polypeptide is a single-chain antibody.

7. The co-expression plasmid according to Claim 6, wherein the single-chain antibody is an anti-PD-1 antibody.

8. The co-expression plasmid according to Claim 6, wherein the single-chain antibody is an anti-CTLA-4 antibody.

9. The co-expression plasmid according to Claim 6, wherein the single-chain antibody is an anti-HER2 antibody.

10. The co-expression plasmid according to any one of Claims 1 to 5, wherein the heterologous polypeptide is a cytokine.

11. The co-expression plasmid according to Claim 10, wherein the cytokine is TNF- α .

12. The co-expression plasmid according to Claim 10, wherein the cytokine is IFN- γ .

13. The co-expression plasmid according to any one of Claims 1 to 5, wherein the heterologous polypeptide is a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody.

14. The co-expression plasmid according to any one of Claims 1 to 5, wherein the heterologous polypeptide is a combination of TNF- α and IFN- γ .

15. The co-expression plasmid according to any one of Claims 1 to 5, wherein the heterologous polypeptide is a combination of an anti-HER2 antibody and IFN- γ .

16. A bacterium of the genus *Bifidobacterium* transformed with the co-expression plasmid according to any one of Claims 1 to 15.

17. The bacterium of the genus *Bifidobacterium* according to Claim 16, wherein the bacterium is *Bifidobacterium longum*.

18. A pharmaceutical composition comprising the bacterium of the genus *Bifidobacterium* according to Claim 16 or 17.

Sequence Listings_ASCII.txt
SEQUENCE LISTING

<110> Anaeropharma Science Inc.
 <120> coexpression plasmid
 <130> 2015C9105
 <150> JP2014-245424
 <151> 2014-12-03
 <160> 144
 <170> PatentIn version 3.1
 <210> 1
 <211> 4975
 <212> DNA
 <213> Artificial
 <220>
 <223> Linearized pHG-2 fragment
 <220>
 <221> misc_feature
 <223> Inventor:KOSEKI, Koichi; SHIOYA, Koichiro; KOBAYASHI, Satoshi; SH
 IMATANI, Yuko ;MASAKI, Takeshi; SHIMIZU, Hitomi; MATSUMURA, Tomio
 ; OKABE, Masami; INOUE, Kengo
 <400> 1
 atcatcgccc tgtgaaaccg cttctcattt ccatttgcga tatggtctga atacgacgaa 60
 accccggcgc gaggccgggg tttcgtaagc tgtgctgac tatagcacga ccagcgcgat 120
 tcggtgcacg gatccgtctt cctgctggcc tatgcattgg gttccgcagt gccactcca 180
 ggcggtctgg gcggtgtgga agcggcgctg acattcgcgt tcgtggcggg cggagtgccg 240
 cagggcgctg cgctttccgc cactttgctg caccgcgtgg tgttctactg gctgcgcat 300
 ccgctgggcg cggcggccat gaagtggctt gacaagcata atcttgtctg attcgtctat 360
 tttcataccc ctttcgggga aatagatgtg aaaaccctta taaaacgcgg gttttcgag 420
 aaacatgcgc tagtatcatt gatgacaaca tggactaagc aaaagtgcct gtcccctgac 480
 ccaagaagga tgctttatga attatttacg acaaaaaatt tcggctagtgc ctatcgcggt 540
 gttgtcgact tgtgggttga ttttggcgcc aatgccggtc tttgcggatg attcaacgcc 600
 atcttcaacg ccacgcatg gcagttacac cacgactgat agcggtcagg acccgtagct 660
 caaggaagcc gaaaacctga agaagtactt caacgccggc catagcgatg tcgccgataa 720
 cggcaccctg ttcctgggca tcctgaagaa ctggaaggaa gagtccgacc gcaagatcat 780
 gcagtcccag atcgtgagct tctacttcaa gctgttcaag aacttcaagg acgatcagtc 840
 gatccagaag tccgtggaga ccatcaagga agacatgaac gtcaagttct tcaacagcaa 900
 caagaagaag cgcgacgatt tcgagaagct gaccaactac tccgtgaccg atctgaacgt 960
 ccagcgtaag gccatccacg agctgatcca ggtcatggcc gaactgtccc cggccgcaa 1020
 gaccggcaag cgtaagcgtt cccagatgct gttccgtggc cgtcgcgcct cccagcacca 1080
 tcatcaccac cactgacctt ctgctcgtag cgattacttc gagcattact gacgacaaag 1140

Sequence Listings_ASCII.txt

accccgaccg	agatggtcgg	ggtctttttg	ttgtggtgct	gtgacgtggt	gtccaaccgt	1200
attattccgg	actagtcctc	caggacctcg	tctacgaggc	gctgagcgag	gaatggcgca	1260
aaagggacgg	cgagatcagc	gacccatggg	ccaacgacga	ggcggacgga	taccagccgc	1320
cctcatacga	gccggtcaac	cccgaacgca	ggactcccca	gacgccctcc	gatggcctga	1380
tctgacgtcc	gaaaaaaggc	gctgtgcgcc	ctttttaaat	cttttataaa	tctttttaca	1440
ttcttttagc	ccctccgcag	ccttactctc	ccaacggggt	tcagccgaaa	cctacaccaa	1500
aaggggagcg	aacctacacc	aaaaggggag	cgaacctaca	ccaaaagggg	agcgaaccta	1560
cacaaaaagg	ggagctatat	acaccttttg	ttattttaagg	tgcaagttgt	gctatgctga	1620
ggccatgtcc	aatgagatcg	tgaagttcag	caaccagttc	aacaacgtcg	cgctgaagaa	1680
gttcgacgcc	gtgcacctgg	acgtgctcat	ggcgatcgcc	tcaaggggtga	gggagaaggg	1740
cacggccacg	gtggagttct	cgttcgagga	gctgcgcgcc	ctcatgcgat	tgaggaagaa	1800
cctgaccaac	aagcagctgg	ccgacaagat	cgtgcagacg	aacgcgcgcc	tgctggcgct	1860
gaactacatg	ttcgaggatt	cgggcaagat	catccagttc	gcgctgttca	cgaagtctgt	1920
caccgacccg	caggaggcga	ctctcgcggt	tgggggtcaac	gaggagtctg	cgttcctgct	1980
caacgacctg	accagccagt	tcacgcgctt	cgagctggcc	gagttcgccg	acctcaagag	2040
caagtacgcc	aaggagttct	accgcagggc	caagcagtac	cgcagctccg	gaatctggaa	2100
gatcgggccg	gacgagttct	gccgactgct	tggcggtcca	ccgtcggcaa	taaccagac	2160
acgatatctg	aatcagaagg	ttcttcagcc	aattcaggag	gagtgtgggc	ctctccttgg	2220
cctgaagatc	gagcgccagt	acgtgaaacg	caggctgtcg	ggcttcgtgt	tcacattcgc	2280
ccgcgagacc	cctccggtga	tcgacgccag	gcccgtggag	gcgaggaaga	cggacggcga	2340
cggcaagggc	cattggacga	gcgttgccgg	gtacggcgag	gtgttcacga	ccacggcggt	2400
gttcgacgtg	acggccgccc	gggctcactt	cgacggcacc	gttgaagccg	gggagtgccg	2460
tttctgcgcg	tttgacgcgc	gcaaccgcga	acatcatgcg	cggaacgccg	gaaggctggt	2520
ctagcggccg	tgtccgcgcc	tctggggcgg	ttgcgcctgc	catgggtcga	tctgccgctg	2580
ttcggcctca	cgctggtctg	tgcgctgcct	gatctccctg	agcaggctcg	ccttggtcct	2640
gggggcgctt	cgctcctcga	acgggcccgt	ctccccagg	tcctcgggct	cgctcaggtc	2700
caacggctcg	tcaccggacg	gctcgggccc	gttctctccc	tgtgccgggt	tctccgcctg	2760
tgcgcgttgt	tcggccatgc	gcagtgcgag	ggccttcacc	tgttcggggc	ttgtcgactc	2820
gattttcggt	cgtgaataca	tgttataata	actataacta	ataacgtaac	gtgactggca	2880
agagatatatt	ttaaaacaat	gaatagggtt	acacttactt	tagttttatg	gaaatgaaag	2940
atcatatcat	atataatcta	gaataaaaatt	aactaaaata	attattatct	agataaaaaa	3000
tttagaagcc	aatgaaatct	ataaataaac	taaattaagt	ttatttaatt	aacaactatg	3060
gatataaaat	aggtactaat	caaaatagtg	aggaggatat	atgtgaatac	atacgaacaa	3120
attaataaag	tgaaaaaaat	acttcggaaa	cattttaaaaa	ataaccttat	tggtacttac	3180

Sequence Listings_ASCII.txt

```

atgtttggat caggagttga gagtggacta aaaccaaata gtgatcttga ctttttagtc 3240
gtcgtatctg aaccattgac agatcaaagt aaagaaatac ttatacaaaa aattagacct 3300
atttcaaaaa aaataggaga taaaagcaac ttacgatata ttgaattaac aattattatt 3360
cagcaagaaa tgggtaccgtg gaatcatcct cccaaacaag aatttattta tggagaatgg 3420
ttacaagagc tttatgaaca aggatacatt cctcagaagg aattaaattc agatttaacc 3480
ataatgcttt accaagcaaa acgaaaaaat aaaagaatat acggaaatta tgacttagag 3540
gaattactac ctgatattcc attttctgat gtgagaagag ccattatgga ttcgtcagag 3600
gaattaatag ataattatca ggatgatgaa accaactcta tattaacttt atgccgtatg 3660
attttaacta tggacacggg taaaatcata ccaaaagata ttgcgggaaa tgcaagggtc 3720
gaatcttctc cattagaaca tagggagaga attttgtag cagttcgtag ttatcttgga 3780
gagaatattg aatggactaa tgaaaatgta aatttaacta taaactattt aaataacaga 3840
ttaaaaaaat tataaaaaaa ttgaaaaaat ggtggaaaca cttttttcaa tttttttaga 3900
tcttgagcaa aaggccagca aaaggccagg aaccgtaaaa aggccgcgtt gctggcggtt 3960
ttccataggc tccgcccccc tgacgagcat cacaaaaatc gacgctcaag tcagaggtgg 4020
cgaaacccga caggactata aagataccag gcgtttcccc ctggaagctc cctcgtgcgc 4080
tctcctgttc cgaccctgcc gcttaccgga tacctgtccg ctttctccc ttcgggaagc 4140
gtggcgcttt ctcatagctc acgctgtagg tatctcagtt cggtgtaggt cgttcgctcc 4200
aagctgggct gtgtgcacga aaaaaacgtt cagcccgacc gctgcgcctt atccggtaac 4260
tatcgtcttg agtccaaccc ggtaagacac gacttatcgc cactggcagc agccactggt 4320
aacaggatta gcagagcgag gtatgtaggc ggtgctacag agttcttgaa gtggtggcct 4380
aactacggct acactagaag aacagtattt ggtatctgcg ctctgctgaa gccagttacc 4440
ttcggaaaaa gagttggtag ctcttgatcc ggcaaaaaa ccaccgctgg tagcgggtgt 4500
ttttttgttt gcaagcagca gattacgcgc agaaaaaaag gatctcaaga agatcctttg 4560
atcttttcta ctagccggca ttttcgcgat acattccccg gaatgttgcg caacggggaa 4620
cgcgaccac accgcaacca cagtgcgcca cgcccagtcc ggccctgtgc gctataatag 4680
gtcagttatt cgcgcgcgcg tggcgccctc tacaccccga gccgcgagga cacgtggatt 4740
ccggacggcc atgccccaca tggcaaaccg agaaccgcga cacctagcat tacaaggaga 4800
gccattatgg cgttgatgat gagcgtaag actattatct ccacatcagt ggcgattatc 4860
gccacgggtg ccatgtttgc gtgcgtagcc ccgtttgcct ctgccgattc cgcgagacg 4920
agtgtgtgg tgtcctcacg ttctttcccg aaggcgagtt cggtggtgcg ctcct 4975

```

<210> 2
 <211> 2063
 <212> DNA
 <213> Artificial

<220>

Sequence Listings_ASCII.txt

<223> pAG8 hTNF- α ? expression cassette-hIFN- α A expression cassette

<400> 2

tagccggcat	tttcgcgata	cattccccgg	aatgttgcg	aacggggaac	gcgaccaca	60
ccgcaaccac	agtgcgccac	gcccagtcg	gccctgtgcg	ctataatagg	tcagttattc	120
gcgcgcgcgt	ggcgccctct	acaccccgag	ccgcgaggac	acgtggattc	cggacggcca	180
tgccccacat	ggcaaaccga	gaacccgcac	acctagcatt	acaaggagag	ccattatggc	240
gttgatgatg	agcgtaaga	ctattatttc	cacatcagtg	gcgattatcg	ccacgggtgc	300
catgtttg	gcgtagccc	cgtttgctc	tgccgattcc	gcgcagacga	gtgctgtggt	360
gtcctcacgt	tctttcccga	aggcgagttc	ggtgggtgcg	tcctcctccc	gtaccccgctc	420
cgataagccg	gtcgcccatg	tggtcgccaa	cccgcaggcc	gagggccagc	tgagtggtct	480
gaaccgtcgc	gccaacgccc	tgctggccaa	cggcgtggaa	ctgcgcgaca	accagctggt	540
cgtgccgtcc	gagggcctgt	acctgatcta	ctcccaggtg	ctgttcaagg	gccagggctg	600
cccgtccacc	cacgtcctgc	tgaccatac	catctccgcg	atcgccgtgt	cctaccagac	660
caaggtcaac	ctgctgtccg	ccatcaagtc	cccgtgccag	cgtgagacc	cggaggcg	720
cgaggccaag	ccgtggtacg	aaccgatcta	cctgggcggc	gtgttccagc	tggaaaagg	780
cgatcgtctg	tccgccgaga	tcaaccgtcc	ggactacctg	gatttcgccg	agtccggcca	840
ggtctacttc	ggcatcatcg	ccctgtgaaa	ccgcttctca	tttccatttg	cgatatggtc	900
tgaatacgac	gaaaccccg	cgcgaggccg	gggtttcgta	agctgtgcgt	gactatagca	960
cgaccagcgc	gattcggtgc	acggatccgt	cttcctgctg	gcctatgcat	tgggttccgc	1020
agtgccact	ccaggcggtc	tgggcggtgt	ggaagcggcg	ctgacattcg	cgttcgtggc	1080
ggtcggagt	ccgcagggcg	tggcgctttc	cgccactttg	ctgcaccgcg	tgggtgttcta	1140
ctggctgcgc	attccgctgg	gcgcggcggc	catgaagtgg	cttgacaagc	ataatcttgt	1200
ctgattcgtc	tattttcata	cccccttcg	ggaaatagat	gtgaaaacc	ttataaaacg	1260
cgggttttcg	cagaaacatg	cgctagtatc	attgatgaca	acatggacta	agcaaaagt	1320
cttgtccct	gaccaagaa	ggatgcttta	tgaattattt	acgacaaaaa	atttcggcta	1380
gtgctatcgc	ggtgttgctg	acttggtggg	tgattttggc	gccaatgccg	gtctttgcgg	1440
atgattcaac	gccatcttca	acgccatcgg	atggcagtta	caccacgact	gatagcggtc	1500
aggacccgta	cgtcaaggaa	gccgaaaacc	tgaagaagta	cttcaacgcc	ggccatagcg	1560
atgtcgccga	taacggcacc	ctgttcctgg	gcatcctgaa	gaactggaag	gaagagtccg	1620
accgcaagat	catgcagtcc	cagatcgtga	gcttctactt	caagctgttc	aagaacttca	1680
aggacgatca	gtcgatccag	aagtccgtgg	agaccatcaa	ggaagacatg	aacgtcaagt	1740
tcttcaacag	caacaagaag	aagcgcgacg	atttcgagaa	gctgaccaac	tactccgtga	1800
ccgatctgaa	cgtccagcgt	aaggccatcc	acgagctgat	ccaggtcatg	gccgaactgt	1860
ccccggccgc	caagaccggc	aagcgtaagc	gttcccagat	gctgttccgt	ggccgtcgcg	1920
cctcccagca	ccatcatcac	caccactgac	cttctgctcg	tagcgattac	ttcgagcatt	1980

Sequence Listings_ASCII.txt

actgacgaca aagacccccga ccgagatggg cgggggtcttt ttgttggtggg gctgtgacgt 2040
gttgtccaac cgtattattc cgg 2063

<210> 3
<211> 2045
<212> DNA
<213> Artificial

<220>
<223> pAG8TL hTNF-^L? expression cassette-hIFN-^LA expression cassette

<400> 3
tagccggcat tttcgcgata cattccccgg aatgttgcg c aacgggggaac gcgcaccaca 60
ccgcaaccac agtgcgccac gccaggtccg gccctgtgcg ctataatagg tcagttattc 120
gcgcgcgcgt ggcgccctct acacccccgag ccgcgaggac acgtggattc cggacggcca 180
tgccccacat ggcaaaccga gaaccgcac acctagcatt acaaggagag ccattatggc 240
gttgatgatg agcgttaaga ctattatttc cacatcagtg gcgattatcg ccacgggtgc 300
catgtttgcg tgcgtagccc cgtttgcctc tgccgattcc gcgcagacga gtgctgtggg 360
gtcctcacgt tctttcccga aggcgagttc ggtgggtgcgc tcctcctccc gtacccccgtc 420
cgataagccg gtcgcccattg tggtcgccaa cccgcaggcc gagggccagc tgcagtgggt 480
gaaccgtcgc gccaacgccc tgctggccaa cggcgtggaa ctgcgcgaca accagctggg 540
cgtgccgtcc gagggcctgt acctgatcta ctcccagggt ctgttcaagg gccagggtg 600
cccgtccacc cacgtcctgc tgaccatac catctccgc atcgccgtgt cctaccagac 660
caaggtaac ctgctgtccg ccatcaagtc cccgtgccag cgtgagacc cggaaaggcg 720
cgaggccaag ccgtggtacg aaccgatcta cctgggcggc gtgttccagc tggaaaagg 780
cgatcgtctg tccgccgaga tcaaccgtcc ggactacctg gatttcgccg agtccggcca 840
ggtctacttc ggcattcatc ccctgtgaaa ccgcttctca tttccatttg cgatatggc 900
tgaatacgac gaaacccccg gcgcaggccg ggggttcgta agctgtgcgt gactatagca 960
cgaccagcgc gattcgggtgc acggatccgt cttcctgctg gcctatgcat tgggttccgc 1020
agtgccact ccaggcggtc tgggcgggtg ggaagcggcg ctgacattcg cgttcgtggc 1080
ggtcggagtg ccgcaggcg tggcgctttc cgccactttg ctgcaccgcg tgggtgttcta 1140
ctggctgcgc attccgctgg gcgcggcgcc catgaagtgg cttgacaagc ataatcttgt 1200
ctgattcgtc tattttcata ccccttcggt ggaaatagat gtgaaaacc ttataaaacg 1260
cgggttttcg cagaaacatg cgctagtatc attgatgaca acatggacta agcaaaagt 1320
cttgtccctt gaccaagaa ggatgcttta tgaattattt acgacaaaaa atttcggcta 1380
gtgctatcgc ggtgttgctg acttggtggg tgattttggc gccaatgccg gtctttgcgg 1440
atgattcaac gccatcttca acgcatcgg atggcagtta caccagact gatagcggtc 1500
aggaccgta cgtcaaggaa gccgaaaacc tgaagaagta cttcaacgcc ggccatagcg 1560
atgtcgccga taacggcacc ctgttcctgg gcatcctgaa gaactggaag gaagagtccg 1620

Sequence Listings_ASCII.txt

```
accgcaagat catgcagtcc cagatcgtga gcttctactt caagctgttc aagaacttca 1680
aggacgatca gtcgatccag aagtcctgg agaccatcaa ggaagacatg aacgtcaagt 1740
tcttcaacag caacaagaag aagcgcgacg atttcgagaa gctgaccaac tactccgtga 1800
ccgatctgaa cgtccagcgt aaggccatcc acgagctgat ccaggatcatg gccgaactgt 1860
ccccggccgc caagaccggc aagcgtaagc gttcccagat gctgttccgt ggccgtcgcg 1920
cctcccagtg accttctgct cgtacgatt acttcgagca ttactgacga caaagacccc 1980
gaccgagatg gtcggggtct tttgttggtg gtgctgtgac gtgtgtcca accgtattat 2040
tccgg 2045
```

```
<210> 4
<211> 432
<212> DNA
<213> Artificial
```

```
<220>
<223> hIFN- $\gamma$ A
```

```
<400> 4
caggacccgt acgtcaagga agccgaaaac ctgaagaagt acttcaacgc cggccatagc 60
gatgtcgcgcg ataacggcac cctgttcctg ggcattcctga agaactggaa ggaagagtcc 120
gaccgcaaga tcatgcagtc ccagatcgtg agcttctact tcaagctgtt caagaacttc 180
aaggacgatc agtcgatcca gaagtccgtg gagaccatca aggaagacat gaacgtcaag 240
tttttcaaca gcaacaagaa gaagcgcgac gatttcgaga agctgaccaa ctactccgtg 300
accgatctga acgtccagcg taaggccatc cacgagctga tccaggatcat ggccgaactg 360
tccccggccg ccaagaccgg caagcgtaag cgttcccaga tgctgttccg tggccgtcgc 420
gcctcccagt ga 432
```

```
<210> 5
<211> 3863
<212> DNA
<213> Artificial
```

```
<220>
<223> pBEShuttle
```

```
<400> 5
ggatccgtct tcctgctggc ctatgcattg gggtccgcag tgcccactcc aggcgggtctg 60
ggcgggtgtgg aagcggcgct gacattcgcg ttcgtggcgg tcggagtgcc gcagggcgtg 120
gcgctttccg ccactttgct gcaccgcgtg gtgttctact ggctgcgcat tccgtgggc 180
gcggcggcca tgaagtggct tgacaagcat aatcttgtct gattcgtcta tttcataacc 240
cccttcgggg aaatagatgt gaaaaccctt ataaaacgcg ggttttcgca gaaacatgcg 300
ctagtatcat tgatgacaac atggactaag caaaagtgtg tgtcccctga cccaagaagg 360
atgctttatg aagcttatcc tgcagtgacc ttctgctcgt agcgattact tcgagcatta 420
ctgacgacaa agaccccgac cgagatggtc ggggtctttt tggtgtgggtg ctgtgacgtg 480
```

Sequence Listings_ASCII.txt

ttgtccaacc	gtattattcc	ggactagtcc	tccaggacct	cgtctacgag	gcgctgagcg	540
aggaatggcg	caaaagggac	ggcgagatca	gcgacccatg	ggccaacgac	gaggcggacg	600
gataccagcc	gccctcatal	gagccggtca	accccgaacg	caggactccc	cagacgccct	660
ccgatggcct	gatctgacgt	ccgaaaaaag	gcgctgtgcg	ccctttttta	atctttttata	720
aatcttttta	cattctttta	gcccctccgc	agccttactc	tcccaacggg	tttcagccga	780
aacctacacc	aaaaggggag	cgaacctaca	ccaaaagggg	agcgaacct	cacaaaaggg	840
ggagcgaacc	tacaccaaaa	ggggagctat	atacaccttt	tggtatttta	ggtgcaagtt	900
gtgctatgct	gaggccatgt	ccaatgagat	cgtgaagtgc	agcaaccagt	tcaacaacgt	960
cgcgctgaag	aagttcgacg	ccgtgcacct	ggacgtgctc	atggcgatcg	cctcaagggg	1020
gagggagaag	ggcacggcca	cggtggagtt	ctcgttcgag	gagctgcgcg	gcctcatgcg	1080
attgaggaag	aacctgacca	acaagcagct	ggccgacaag	atcgtgcaga	cgaacgcgcg	1140
cctgctggcg	ctgaactaca	tggttcgagga	ttcgggcaag	atcatccagt	tcgctgctgt	1200
cacgaagttc	gtcaccgacc	cgcaggaggc	gactctcgcg	gttggggcca	acgaggagtt	1260
cgcgttcctg	ctcaacgacc	tgaccagcca	gttcacgcgc	ttcgagctgg	ccgagttcgc	1320
cgacctcaag	agcaagtacg	ccaaggagtt	ctaccgcagg	gccaagcagt	accgcagctc	1380
cggaatctgg	aagatcggcc	gcgacgagtt	ctgccgactg	cttggcgctc	caccgtcggc	1440
aataacccag	acacgatata	tgaatcagaa	ggttcttcag	ccaattcagg	aggagtgtgg	1500
gcctctcctt	ggcctgaaga	tcgagcgcca	gtacgtgaaa	cgcaggctgt	cgggcttcgt	1560
gttcacattc	gcccgcgaga	cccctccggt	gatcgacgcc	aggcccgtgg	aggcgaggaa	1620
gacggacggc	gacggcaagg	gccattggac	gagcgttgcc	gggtacggcg	aggtgttcac	1680
gaccacggcg	ttgttcgacg	tgacggccgc	ccgggctcac	ttcgacggca	ccgttgaagc	1740
cggggagtg	cgtttctg	cgtttgacgc	gcgcaaccgc	gaacatcatg	cgcggaacgc	1800
cgggaaggctg	ttctagcggc	cgtgtccg	cctctggggc	ggttgcgct	gccatgggtc	1860
gatctgccgc	tggttcggcct	cacgctgggc	tgtgcgctgc	ctgatctccc	tgagcagggtc	1920
ggccttggtc	ctggggg	ttcgtcctc	gaacggggcg	ctctcccca	gtcctcggg	1980
ctcgtcagg	tccaacggct	cgtcaccgga	cggctcgggc	cggttctctc	cctgtgccgg	2040
gttctccgcc	tgtgcgcgtt	gttcggccat	gcgcagtgcg	agggccttca	cctgttcggg	2100
gcttgctgac	tcgattttcg	ttcgtgaata	catgttataa	taactataac	taataacgta	2160
acgtgactgg	caagagatat	ttttaaaaca	atgaataggt	ttacacttac	tttagtttta	2220
tggaaatgaa	agatcatata	atatataatc	tagaataaaa	ttaactaaaa	taattattat	2280
ctagataaaa	aatttagaag	ccaatgaaat	ctataaataa	actaaattaa	gtttatttta	2340
ttaacaacta	tggatataaa	ataggactata	atcaaaatag	tgaggaggat	atatttgaat	2400
acatacgaac	aaattaataa	agtgaaaaaa	atacttcgga	aacattttaa	aaataacctt	2460
attggtactt	acatgtttgg	atcaggaggt	gagagtggac	taaaaccaa	tagtgatctt	2520

Sequence Listings_ASCII.txt

gacttttttag	tcgtcgtatc	tgaaccattg	acagatcaaa	gtaaagaaat	acttatacaa	2580
aaaatttagac	ctattttcaaa	aaaaatagga	gataaaagca	acttacgata	tattgaatta	2640
acaattatta	ttcagcaaga	aatggtaccg	tggaatcatc	ctcccaaaca	agaattttatt	2700
tatggagaat	ggttacaaga	gctttatgaa	caaggataca	ttcctcagaa	ggaattaaat	2760
tcagatttaa	ccataatgct	ttaccaagca	aaacgaaaaa	ataaaagaat	atacggaat	2820
tatgacttag	aggaattact	acctgatatt	ccattttctg	atgtgagaag	agccattatg	2880
gattcgtcag	aggaattaat	agataattat	caggatgatg	aaaccaactc	tatattaact	2940
ttatgccgta	tgattttaac	tatggacacg	ggtaaaatca	taccaaaga	tattgcggga	3000
aatgcagtgg	ctgaatcttc	tccattagaa	catagggaga	gaattttggt	agcagttcgt	3060
agttatcttg	gagagaatat	tgaatggact	aatgaaaatg	taaatttaac	tataaactat	3120
ttaaataaca	gattaaaaaa	attataaaaa	aattgaaaaa	atgggtggaaa	cacttttttc	3180
aatttttttta	gatcttgagc	aaaaggccag	caaaaggcca	ggaaccgtaa	aaaggccgcg	3240
ttgctggcgt	ttttccatag	gctccgcccc	cctgacgagc	atcacaaaaa	tcgacgctca	3300
agtcagaggt	ggcgaaaccc	gacaggacta	taaagatacc	aggcgtttcc	ccctggaagc	3360
tccctcgtgc	gctctcctgt	tccgaccctg	ccgcttaccg	gatacctgtc	cgcttttctc	3420
ccttcgggaa	gcgtggcgct	ttctcatagc	tcacgctgta	ggtatctcag	ttcgggtgtag	3480
gtcgttcgct	ccaagctggg	ctgtgtgcac	gaaccccccg	ttcagcccga	ccgctgcgcc	3540
ttatccggt	actatcgtct	tgagtccaac	ccggtaaagac	acgacttatc	gccactggca	3600
gcagccactg	gtaacaggat	tagcagagcg	aggatatgtag	gcggtgctac	agagttcttg	3660
aagtgggtggc	ctaactacgg	ctacactaga	agaacagtat	ttggtatctg	cgctctgctg	3720
aagccagtta	ccttcgga	aagagttggt	agctcttgat	ccggcaaaca	aaccaccgct	3780
ggtagcgggtg	gtttttttgt	ttgcaagcag	cagattacgc	gcagaaaaaa	aggatctcaa	3840
gaagatcctt	tgatcttttc	tac				3863

<210>	6
<211>	4727
<212>	DNA
<213>	Artificial

<220>
<223> pHuSP7L20-hPD-1scFv03

<400>	6						
ggatccgtct	tcctgctggc	ctatgcattg	ggttccgcag	tgccactcc	aggcgggtctg		60
ggcgggtgtg	aagcggcgct	gacattcgcg	ttcgtggcgg	tcggagtgcc	gcagggcgctg		120
gcgctttccg	ccactttgct	gcaccgcgtg	gtgttctact	ggctgcgcat	tccgctgggc		180
gcggcggcca	tgaagtggct	tgacaagcat	aatcttgtct	gattcgtcta	ttttcatacc		240
cccttcgggg	aaatagatgt	gaaaaccctt	ataaaacgcg	ggttttcgca	gaaacatgcg		300
ctagtatcat	tgatgacaac	atggactaag	caaaagtgtct	tgtcccctga	ccaagaagg		360

Sequence Listings_ASCII.txt

atgctttatg	gcgttgatga	tgagcgtaa	gactattatt	tccacatcag	tggcgattat	420
cgccacgggt	gcatgtttg	cgtgcgtagc	cccgtttgcc	tctgccgatt	ccgcgcagac	480
gagtgtctgtg	gtgtcctcac	gttctttccc	gaaggcgagt	tcggtgcagg	tccagctggt	540
cgaatcgggc	ggcggcgctg	tccagccggg	ccgttccctg	cgtctggatt	gcaaggcctc	600
gggcatcacc	ttctcgaact	ccggcatgca	ctgggtgcgc	caggccccgg	gcaagggcct	660
ggaatgggtc	gccgtgatct	ggtacgatgg	ctcgaagcgc	tactacgccg	attccgtgaa	720
gggccgcttc	accatctcgc	gcgacaactc	caagaacacc	ctgttcctgc	agatgaactc	780
cctgcgcgcc	gaagacaccg	ccgtgtacta	ctgcgccacc	aacgatgact	actggggcca	840
gggcaccctg	gtcaccgtgt	ccagcggcgg	cggcggctcc	ggcggcggcg	gctcgggcgg	900
cggcggcagc	gaaatcgtgc	tgaccagtc	cccggccacc	ctgtccctgt	ccccgggcga	960
acgtgccacc	ctgtcgtgcc	gcgcctccca	gtcgggtgtcc	agctacctgg	cctggtacca	1020
gcagaagccg	ggccaggccc	cgcgtctgct	gatctacgac	gcctccaacc	gcgccaccgg	1080
catcccggcc	cgcttctccg	gctcgggctc	cggcaccgac	ttcacctga	ccatctcgtc	1140
cctggaaccg	gaggacttcg	ccgtctacta	ctgccagcag	tcctcgaact	ggccgcgcac	1200
cttcggccag	ggcaccaagg	tcgagatcaa	gcaccatcat	caccaccact	gaccttctgc	1260
tcgtagcgat	tacttcgagc	attactgacg	acaaagaccc	cgaccgagat	ggtcggggtc	1320
tttttgttgt	ggtgctgtga	cgtgttgtcc	aaccgtatta	ttccggacta	gtcctccagg	1380
acctcgtcta	cgaggcgctg	agcgaggaat	ggcgcaaaaag	ggacggcgag	atcagcgacc	1440
catgggcaa	cgacgaggcg	gacggatacc	agccgccctc	atacgagccg	gtcaaccccg	1500
aacgcaggac	tccccagacg	ccctccgatg	gcctgatctg	acgtccgaaa	aaaggcgctg	1560
tgcgcccttt	ttaaattctt	tataaatctt	tttacattct	tttagcccct	ccgcagcctt	1620
actctcccaa	cgggtttcag	ccgaaaccta	caccaaaaagg	ggagcgaacc	tacacaaaaa	1680
ggggagcgaa	cctacaccaa	aaggggagcg	aacctacacc	aaaagggggag	ctatatacac	1740
cttttgttat	ttaagggtgca	agttgtgcta	tgctgaggcc	atgtccaatg	agatcgtgaa	1800
gttcagcaac	cagttcaaca	acgtcgcgct	gaagaagttc	gacgccgtgc	acctggacgt	1860
gctcatggcg	atcgcctcaa	gggtgagggg	gaagggcagc	gccacggtgg	agttctcgtt	1920
cgaggagctg	cgcggcctca	tgcgattgag	gaagaacctg	accaacaagc	agctggccga	1980
caagatcgtg	cagacgaacg	cgcgcctgct	ggcgctgaac	tacatgttcg	aggattcggg	2040
caagatcatc	cagttcgcgc	tgttcacgaa	gttcgtcacc	gacccgcagg	aggcgactct	2100
cgcggttggg	gtcaacgagg	agttcgcgtt	cctgctcaac	gacctgacca	gccagttcac	2160
gcgcttcgag	ctggccgagt	tcgccgacct	caagagcaag	tacgccaagg	agttctaccg	2220
cagggccaag	cagtaccgca	gctccggaat	ctggaagatc	ggccgcgacg	agttctgccg	2280
actgcttggc	gttccaccgt	cggcaataac	ccagacacga	tatctgaatc	agaaggttct	2340
tcagccaatt	caggaggagt	gtgggcctct	ccttggcctg	aagatcgagc	gccagtacgt	2400

Sequence Listings_ASCII.txt

gaaacgcagg	ctgtcgggct	tcgtgttcac	attcgccccg	gagacccctc	cggatgatcga	2460
cgccaggccc	gtggaggcga	ggaagacgga	cggcgacggc	aagggccatt	ggacgagcgt	2520
tgccgggtac	ggcgagggtg	tcacgaccac	ggcgttggtc	gacgtgacgg	ccgcccgggc	2580
tcacttcgac	ggcaccgttg	aagccgggga	gtgccgtttc	tgcgcgtttg	acgcgcgcaa	2640
ccgcgaacat	catgcgcgga	acgccggaag	gctgtttctag	cggccgtgtc	cgcgccctctg	2700
gggcgggttg	gcctgccatg	ggtcgatctg	ccgctgttcg	gcctcacgct	ggtctgtgcg	2760
ctgcctgata	tccctgagca	ggtcggcctt	ggtcctgggg	gcgcttcgct	cctcgaacgg	2820
gccgctctcc	cccagggtcct	cgggctcgct	caggccaac	ggctcgtcac	cggacggctc	2880
gggcgggttc	tctccctgtg	ccgggttctc	cgcctgtgcg	cgttggtcgg	ccatgcgcag	2940
tgcgagggcc	ttcacctgtt	cggggcttgt	cgactcgatt	ttcgttcgtg	aatacatgtt	3000
ataataacta	taactaataa	cgtaacgtga	ctggcaagag	atatttttaa	aacaatgaat	3060
aggtttacac	ttactttagt	tttatggaaa	tgaaagatca	tatcatatat	aatctagaat	3120
aaaattaact	aaaataatta	ttatctagat	aaaaaattta	gaagccaatg	aaatctataa	3180
ataaactaaa	ttaagtttat	ttaattaaca	actatggata	taaaataggt	actaatcaaa	3240
atagttagga	ggatatat	gaatacatac	gaacaaatta	ataaagtga	aaaaataactt	3300
cggaaacatt	taaaaaataa	ccttattggg	acttacatgt	ttggatcagg	agttgagagt	3360
ggactaaaac	caaatagtga	tcttgacttt	ttagtcgtcg	tatctgaacc	attgacagat	3420
caaagtaaag	aaatacttat	acaaaaaatt	agacctat	caaaaaaat	aggagataaa	3480
agcaacttac	gatataattga	attaacaatt	attattcagc	aagaaatggg	accgtggaat	3540
catcctccca	aacaagaatt	tatttatgga	gaatgggtac	aagagcttta	tgaacaagga	3600
tacattcctc	agaaggaatt	aaattcagat	ttaaccataa	tgctttacca	agcaaaacga	3660
aaaaataaaa	gaatatacgg	aaattatgac	ttagaggaat	tactacctga	tattccattt	3720
tctgatgtga	gaagagccat	tatggattcg	tcagaggaat	taatagataa	ttatcaggat	3780
gatgaaacca	actctatatt	aactttatgc	cgtatgattt	taactatgga	cacgggtaaa	3840
atcataccaa	aagatattgc	gggaaatgca	gtggctgaat	cttctccatt	agaacatagg	3900
gagagaattt	tgtagcag	tcgtagttat	cttgagagaga	atattgaatg	gactaatgaa	3960
aatgtaaatt	taactataaa	ctatttaaat	aacagattaa	aaaaattata	aaaaaattga	4020
aaaaatgggtg	gaaacacttt	tttcaatttt	tttagatcct	gagcaaaagg	ccagcaaaag	4080
gccaggaacc	gtaaaaaggc	cgcgttgctg	gcgtttttcc	ataggctccg	ccccctgac	4140
gagcatcaca	aaaatcgacg	ctcaagtcag	agggtggcgaa	acccgacagg	actataaaga	4200
taccaggcgt	ttccccctgg	aagctccctc	gtgcgctctc	ctgttccgac	cctgccgctt	4260
accggatacc	tgtccgcctt	tctcccttcg	ggaagcgtgg	cgctttctca	tagctcacgc	4320
tgtaggtatc	tcagttcggg	gtaggtcggt	cgctccaagc	tgggctgtgt	gcacgaaccc	4380
cccgttcagc	ccgaccgctg	cgccttatcc	ggtaactatc	gtcttgagtc	caaccgggta	4440

Sequence Listings_ASCII.txt

```

agacacgact tatcgccact ggcagcagcc actggttaaca ggattagcag agcgaggtat 4500
gtaggcgggtg ctacagagtt cttgaagtgg tggcctaact acggctacac tagaagaaca 4560
gtattttggtg tctgcgctct gctgaagcca gttaccttcg gaaaaagagt tggtagctct 4620
tgatccggca aacaaaccac cgctggtagc ggtgggtttt ttgtttgcaa gcagcagatt 4680
acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctac 4727

```

```

<210> 7
<211> 4745
<212> DNA
<213> Artificial

```

```

<220>
<223> pHuSP7L20-hCTLA-4scFv02

```

```

<400> 7
ggatccgtct tcctgctggc ctatgcattg gggtccgcag tgcccactcc aggcgggtctg 60
ggcgggtgtgg aagcggcgct gacattcgcg ttcgtggcgg tcggagtgcc gcagggcggtg 120
gcgctttccg ccactttgct gcaccgcgtg gtgttctact ggctgcgcat tccgctgggc 180
gcggcggcca tgaagtggct tgacaagcat aatcttgtct gattcgtcta tttcataacc 240
cccttcgggg aaatagatgt gaaaaccctt ataaaacgcg ggttttcgca gaaacatgcg 300
ctagtatcat tgatgacaac atggactaag caaaagtgct tgtcccctga cccaagaagg 360
atgctttatg gcgttgatga tgagcggtta gactattatt tccacatcag tggcgattat 420
cgccacgggt gccatgtttg cgtgcgtagc cccgtttgcc tctgccgatt ccgcgcagac 480
gagtgtgtgt gtgtcctcac gttctttccc gaaggcgagt tcggtgcagg tccagctggt 540
cgaatcgggc ggcggcgctg tccagccggg ccgtagcctg cgtctgtcgt gcgccgcctc 600
gggcttcacc ttctccagct acaccatgca ctgggtgctg caggccccgg gcaagggcct 660
ggagtgggtc accttcatct cctacgacgg caacaacaag tactacgccg attccgtgaa 720
gggccgcttc accatctccc gtgacaacag caagaacacc ctgtacctgc agatgaactc 780
cctgcgcgcc gaagacaccg ccatctacta ctgcgcccgt accggctggc tgggcccgtt 840
cgattactgg ggccagggca ccctggtgac cgtctcgtcg ggcggcggcg gctcgggcgg 900
cggcggctcc ggcggcggcg gcagcgagat cgtgctgacc cagtccccgg gcacctgtc 960
gctgtccccg ggcgaacgcg ccaccctgtc ctgccgtgcc agccagtcgg tcggcagctc 1020
gtacctggcc tgggtaccagc agaagccggg ccaggccccg cgtctgtgta tctacggcgc 1080
cttctcccgt gccaccggca tcccggaccg tttctccggc agcggctcgg gcaccgattt 1140
caccctgacc atctcccgcc tggagccgga agatttcgcc gtctactact gccagcagta 1200
cggctccagc ccgtggacct tcggccaggg caccaaggtg gaaatcaagc atcatcatca 1260
tcatcactga cttctgtctc gtagcgatta cttcgagcat tactgacgac aaagaccccc 1320
accgagatgg tcggggtctt tttgttgtgg tgctgtgacg tgttgtccaa ccgtattatt 1380
ccggactagt cctccaggac ctcgtctacg aggcgctgag cgaggaatgg cgcaaaaggg 1440

```

Sequence Listings_ASCII.txt

acggcgagat	cagcgaccca	tgggccaacg	acgaggcgga	cggataaccag	ccgcccctcat	1500
acgagccggt	caacccccgaa	cgcaggactc	cccagacgcc	ctccgatggc	ctgatctgac	1560
gtccgaaaaa	aggcgctgtg	cgcccttttt	aaatctttta	taaatctttt	tacattcttt	1620
tagccccctc	gcagccttac	tctcccaacg	ggtttcagcc	gaaacctaca	ccaaaagggg	1680
agcgaaccta	caccaaaaagg	ggagcgaacc	tacaccaaaa	ggggagcgaa	cctacaccaa	1740
aaggggagct	atatacacct	tttgttattt	aagggtgcaag	ttgtgctatg	ctgaggccat	1800
gtccaatgag	atcgtgaagt	tcagcaacca	gttcaacaac	gtcgcgctga	agaagttcga	1860
cgccgtgcac	ctggacgtgc	tcatggcgat	cgctcaagg	gtgagggaga	agggcacggc	1920
cacggtggag	ttctcgttcg	aggagctgcg	cggcctcatg	cgattgagga	agaacctgac	1980
caacaagcag	ctggccgaca	agatcgtgca	gacgaacgcg	cgctgctgg	cgctgaacta	2040
catgttcgag	gattcgggca	agatcatcca	gttcgcgctg	ttcacgaagt	tcgtcaccga	2100
cccgaggag	gcgactctcg	cggttggggg	caacgaggag	ttcgcgttcc	tgctcaacga	2160
cctgaccagc	cagttcacgc	gcttcgagct	ggccgagttc	gccgacctca	agagcaagta	2220
cgccaaggag	ttctaccgca	gggccaagca	gtaccgcagc	tccggaatct	ggaagatcgg	2280
ccgcgacgag	ttctgcccga	tgcttgggcg	tccaccgtcg	gcaataaccc	agacacgata	2340
tctgaatcag	aaggttcttc	agccaattca	ggaggagtgt	gggcctctcc	ttggcctgaa	2400
gatcgagcgc	cagtacgtga	aacgcaggct	gtcgggcttc	gtgttcacat	tcgcccgcga	2460
gacccctccg	gtgatcgacg	ccaggccccg	ggaggcgagg	aagacggacg	gcgacggcaa	2520
gggccatttg	acgagcgttg	ccgggtacgg	cgagggtgtc	acgaccacgg	cgttgttcga	2580
cgtgacggcc	gccccgggct	acttcgacgg	caccgttgaa	gccggggagt	gccgtttctg	2640
cgcgtttgac	gcgcgcaacc	gcgaacatca	tgcgcggaac	gccggaaggc	tgttctagcg	2700
gccgtgtccg	cgctcttggg	gcggttgcg	ctgccatggg	tcgatctgcc	gctgttcggc	2760
ctcacgctgg	tctgtgcgct	gcctgatctc	cctgagcagg	tcggccttgg	tcctgggggg	2820
gcttcgctcc	tcgaacgggc	cgctctcccc	caggtcctcg	ggctcgctca	ggtccaacgg	2880
ctcgtcaccg	gacggctcgg	gccggttctc	tccctgtgcc	gggttctccg	cctgtgcgcg	2940
ttgttcggcc	atgcgcagtg	cgagggcctt	cacctgttcg	gggcttgtcg	actcgatttt	3000
cgttcgtgaa	tacatgttat	aataactata	actaataacg	taacgtgact	ggcaagagat	3060
atttttaaaa	caatgaatag	gtttacactt	actttagttt	tatggaaatg	aaagatcata	3120
tcatatataa	tctagaataa	aattaactaa	aataattatt	atctagataa	aaaatttaga	3180
agccaatgaa	atctataaat	aaactaaatt	aagtttat	aattaacaac	tatggatata	3240
aaataggtac	taatcaaaat	agtgaggagg	atatatttga	atacatacga	acaaattaat	3300
aaagtgaana	aaataacttc	gaaacattta	aaaaataacc	ttattggtac	ttacatgttt	3360
ggatcaggag	ttgagagtgg	actaaaacca	aatagtgatc	ttgacttttt	agtcgtcgta	3420
tctgaaccat	tgacagatca	aagtaaagaa	atacttatac	aaaaaattag	acctattttca	3480

Sequence Listings_ASCII.txt

```

aaaaaaatag gagataaaag caacttacga tatattgaat taacaattat tattcagcaa 3540
gaaatggtac cgtggaatca tcctcccaaa caagaattta tttatggaga atgggtacaa 3600
gagctttatg aacaaggata cattcctcag aaggaattaa attcagattt aaccataatg 3660
ctttaccaag caaaacgaaa aaataaaaga atatacggaa attatgactt agaggaatta 3720
ctacctgata ttccattttc tgatgtgaga agagccatta tggattcgtc agaggaatta 3780
atagataatt atcaggatga tgaaaccaac tctatattaa ctttatgccg tatgatttta 3840
actatggaca cgggtaaaat cataccaaaa gatattgcgg gaaatgcagt ggctgaatct 3900
tctccattag aacataggga gagaattttg ttagcagttc gtagttatct tggagagaat 3960
attgaatgga ctaatgaaaa tgtaaattta actataaact atttaaataa cagattaaaa 4020
aaattataaa aaaattgaaa aaatggtgga aacacttttt tcaatttttt tagatcttga 4080
gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc gtttttccat 4140
aggctccgcc cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac 4200
ccgacaggac tataaagata ccaggcgttt ccccttgga gctccctcgt gcgctctcct 4260
gttccgacct tgccgcttac cggatacctg tccgcctttc tcccttcggg aagcgtggcg 4320
ctttctcata gctcacgctg taggtatctc agttcgggtg aggtcgttcg ctccaagctg 4380
ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg cttatccgg taactatcgt 4440
cttgagtcca acccggtaa acacgactta tcgccactgg cagcagccac tggtaacagg 4500
attagcagag cgaggatatgt aggcggtgct acagagttct tgaagtgggt gcctaactac 4560
ggctacacta gaagaacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga 4620
aaaagagttg gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tgggtttttt 4680
gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt 4740
tctac 4745

```

```

<210> 8
<211> 4751
<212> DNA
<213> Artificial

```

```

<220>
<223> pHuSP7L20-hCTLA-4scFv02FLAG

```

```

<400> 8
ggatccgtct tcctgctggc ctatgcattg gggtccgcag tgcccactcc aggcggtctg 60
ggcgggtgtg aagcggcgct gacattcgcg ttcgtggcgg tcggagtgcc gcagggcggt 120
gcgctttccg ccactttgct gcaccgctg gtgttctact ggctgcgcat tccgctgggc 180
gcggcggcca tgaagtggct tgacaagcat aatcttgtct gattcgtcta ttttcatacc 240
cccttcgggg aaatagatgt gaaaaccctt ataaacgcg ggttttcgca gaaacatgcg 300
ctagtatcat tgatgacaac atggactaag caaaagtgct tgtcccctga cccaagaagg 360
atgctttatg gcgttgatga tgagcggtta gactattatt tccacatcag tggcgattat 420

```

Sequence Listings_ASCII.txt

cgccacgggt gccatgtttg cgtgcgtagc cccgtttgcc tctgccgatt ccgcgcagac	480
gagtgtgtgt gtgtcctcac gttctttccc gaaggcgagt tcggtgcagg tccagctggt	540
cgaatcgggc ggcggcgctc tccagccggg ccgtagcctg cgtctgtcgt gcgccgcctc	600
gggcttcacc ttctccagct acaccatgca ctgggtgcgt caggccccgg gcaagggcct	660
ggagtgggtc accttcattt cctacgacgg caacaacaag tactacgccg attccgtgaa	720
gggccgcttc accatctccc gtgacaacag caagaacacc ctgtacctgc agatgaactc	780
cctgcgcgcc gaagacaccg ccatctacta ctgcgcccgt accggctggc tgggcccgtt	840
cgattactgg ggccagggca ccctggtgac cgtctcgtcg ggcggcggcg gctcgggcgg	900
cggcggtcc ggccggcgcg gcagcgagat cgtgctgacc cagtccccgg gcacctgtc	960
gctgtccccg ggcgaacgcg ccacctgtc ctgccgtgcc agccagtcgg tcggcagctc	1020
gtacctggcc tgggtaccagc agaagccggg ccaggccccg cgtctgctga tctacggcgc	1080
cttctcccgt gccaccggca tcccggaccg tttctccggc agcggctcgg gcaccgattt	1140
cacctgacc atctcccgcc tggagccgga agatttcgcc gtctactact gccagcagta	1200
cggctccagc ccgtggacct tcggccaggg caccaagggt gaaatcaagg actacaagga	1260
cgacgacgac aagtgcacct ctgctcgtag cgattacttc gagcattact gacgacaaag	1320
accccgaccg agatggtcgg ggtctttttg ttgtggtgct gtgacgtgtt gtccaaccgt	1380
attattccgg actagtcctc caggacctcg tctacgaggc gctgagcgag gaatggcgca	1440
aaagggacgg cgagatcagc gacccatggg ccaacgacga ggcggacgga taccagccgc	1500
cctcatacga gccgggtcaac cccgaacgca ggactcccca gacgccctcc gatggcctga	1560
tctgacgtcc gaaaaaaggc gctgtgcgcc ctttttaa at cttttataaa tctttttaca	1620
ttcttttagc ccctccgcag cttactctc ccaacgggtt tcagccgaaa cctacaccaa	1680
aaggggagcg aacctacacc aaaaggggag cgaacctaca ccaaagggg agcgaacct	1740
cacaaaagg ggagctatat acaccttttg ttatttaagg tgcaagttgt gctatgctga	1800
ggccatgtcc aatgagatcg tgaagttcag caaccagttc aacaacgtcg cgctgaagaa	1860
gttcgacgcc gtgcacctgg acgtgctcat ggcgatcgcc tcaagggtga gggagaagg	1920
cacggccacg gtggagttct cgttcgagga gctgcgcggc ctcatgcgat tgaggaagaa	1980
cctgaccaac aagcagctgg ccgacaagat cgtgcagacg aacgcgcgcc tgctggcgct	2040
gaactacatg ttcgaggatt cgggcaagat catccagttc gcgctgttca cgaagtctgt	2100
caccgaccg caggaggcga ctctcgcggt tggggtaaac gaggagttcg cgttcctgct	2160
caacgacctg accagccagt tcacgcgctt cgagctggcc gagttcgccg acctcaagag	2220
caagtacgcc aaggagttct accgcagggc caagcagtac cgcagctccg gaatctggaa	2280
gatcgccgc gacgagttct gccgactgct tggcggtcca ccgtcggcaa taaccagac	2340
acgatatctg aatcagaagg ttcttcagcc aattcaggag gagtgtgggc ctctccttgg	2400
cctgaagatc gagcgccagt acgtgaaacg caggctgtcg ggcttcgtgt tcacattcgc	2460

Sequence Listings_ASCII.txt

ccgcgagacc	cctccggtga	tcgacgccag	gcccgtggag	gcgaggaaga	cggacggcga	2520
cggcaagggc	cattggacga	gcgttgccgg	gtacggcgag	gtgttcacga	ccacggcggt	2580
gttcgacgtg	acggccgccc	gggctcactt	cgacggcacc	gttgaagccg	gggagtgccg	2640
tttctgcgcg	tttgacgcgc	gcaaccgcga	acatcatgcg	cggaacgccg	gaaggctggt	2700
ctagcggccg	tgtccgcgcc	tctggggcgg	ttgcgcctgc	catgggtcga	tctgccgctg	2760
ttcggcctca	cgctggtctg	tgcgctgcct	gatctccctg	agcaggctcg	ccttggtcct	2820
gggggcgctt	cgctcctcga	acgggccgct	ctccccagg	tcctcgggct	cgctcaggct	2880
caacggctcg	tcaccggacg	gctcgggccg	gttctctccc	tgtgccgggt	tctccgcctg	2940
tgcgcgttgt	tcggccatgc	gcagtgcgag	ggccttcacc	tggtcggggc	ttgtcgactc	3000
gattttcggt	cgtgaataca	tggtataata	actataacta	ataacgtaac	gtgactggca	3060
agagatatatt	ttaaaacaat	gaatagggtt	acacttactt	tagttttatg	gaaatgaaag	3120
atcatatcat	atataatcta	gaataaaaatt	aactaaaata	attattatct	agataaaaaa	3180
tttagaagcc	aatgaaatct	ataaataaac	taaattaagt	ttatttaatt	aacaactatg	3240
gatataaaat	aggtactaat	caaaatagtg	aggaggatat	atttgaatac	atacgaacaa	3300
attaataaag	tgaaaaaaat	acttcggaaa	catttaaaaa	ataaccttat	tggtacttac	3360
atgtttggat	caggagttga	gagtggacta	aaaccaaata	gtgatcttga	cttttttagtc	3420
gtcgtatctg	aaccattgac	agatcaaagt	aaagaaatac	ttatacaaaa	aattagacct	3480
atttcaaaaa	aaataggaga	taaaagcaac	ttacgatata	ttgaattaac	aattattatt	3540
cagcaagaaa	tggtaccgtg	gaatcatcct	cccaaacaag	aatttattta	tggagaatgg	3600
ttacaagagc	tttatgaaca	aggatacatt	cctcagaagg	aattaaattc	agatttaacc	3660
ataatgcttt	accaagcaaa	acgaaaaaat	aaaagaatat	acggaaatta	tgacttagag	3720
gaattactac	ctgatattcc	attttctgat	gtgagaagag	ccattatgga	ttcgtcagag	3780
gaattaatag	ataattatca	ggatgatgaa	accaactcta	tattaacttt	atgccgtatg	3840
attttaacta	tggacacggg	taaaatcata	ccaaaagata	ttgcgggaaa	tgcagtggct	3900
gaatcttctc	cattagaaca	tagggagaga	attttgttag	cagttcgtag	ttatcttgga	3960
gagaatattg	aatggactaa	tgaaaatgta	aattttaacta	taaactattt	aaataacaga	4020
ttaaaaaaat	tataaaaaaa	ttgaaaaaat	ggtggaaaaca	cttttttcaa	tttttttaga	4080
tcttgagcaa	aaggccagca	aaaggccagg	aaccgtaaaa	aggccgcggt	gctggcggtt	4140
ttccataggc	tccgcccccc	tgacgagcat	cacaaaaatc	gacgctcaag	tcagagggtg	4200
cgaaacccga	caggactata	aagataccag	gcgtttcccc	ctggaagctc	cctcgtgcgc	4260
tctcctgttc	cgaccctgcc	gcttaccgga	tacctgtccg	cctttctccc	ttcgggaagc	4320
gtggcgcttt	ctcatagctc	acgctgtagg	tatctcagtt	cggtgtaggt	cgttcgctcc	4380
aagctgggct	gtgtgcacga	acccccggtt	cagccccgacc	gctgcgctt	atccggtaac	4440
tatcgtcttg	agtccaaccc	ggtaagacac	gacttatcgc	cactggcagc	agccactggg	4500

Sequence Listings_ASCII.txt

```
aacaggatta gcagagcgag gtatgtaggc ggtgctacag agttcttgaa gtgggtggcct 4560
aactacggct acactagaag aacagtatatt ggtatctgcg ctctgctgaa gccagttacc 4620
ttcggaaaaa gagttggtag ctcttgatcc ggcaaaaaa ccaccgctgg tagcgggtgg 4680
ttttttgttt gcaagcagca gattacgcgc agaaaaaaag gatctcaaga agatcctttg 4740
atcttttcta c 4751
```

```
<210> 9
<211> 6111
<212> DNA
<213> Artificial
```

```
<220>
<223> pPC1
```

```
<400> 9
ggatccgtct tcctgctggc ctatgcattg ggttccgcag tgcccactcc aggcgggtctg 60
ggcgggtgtgg aagcggcgct gacattcgcg ttcgtggcgg tcggagtgcc gcagggcgctg 120
gcgctttccg ccactttgct gcaccgcgtg gtgttctact ggctgcgcat tccgctgggc 180
gcggcggcca tgaagtggct tgacaagcat aatcttgtct gattcgtcta tttcataacc 240
cccttcgggg aaatagatgt gaaaaccctt ataaaacgcg ggttttcgca gaaacatgcg 300
ctagtatcat tgatgacaac atggactaag caaaagtgt tgtcccctga cccaagaagg 360
atgctttatg gcgttgatga tgagcggtta gactattatt tccacatcag tggcgattat 420
cgccacgggt gccatgtttg cgtgcgtagc cccgtttgcc tctgccgatt ccgcgcagac 480
gagtgtgtgt gtgtcctcac gttctttccc gaaggcgagt tcggtgcagg tccagctggt 540
cgaatcgggc ggcggcgctg tccagccggg ccgttcccctg cgtctggatt gcaaggcctc 600
gggcatcacc ttctcgaact ccggcatgca ctgggtgcgc caggccccgg gcaagggcct 660
ggaatgggtc gccgtgatct ggtacgatgg ctcgaagcgc tactacgccg attccgtgaa 720
gggccgcttc accatctcgc gcgacaactc caagaacacc ctgttcctgc agatgaactc 780
cctgcgcgcc gaagacaccg ccgtgtacta ctgcgccacc aacgatgact actggggcca 840
gggcaccctg gtcaccgtgt ccagcggcgg cggcggctcc ggcggcggcg gctcgggcgg 900
cggcggcagc gaaatcgtgc tgaccagtc cccggccacc ctgtccctgt ccccgggcga 960
acgtgccacc ctgtcgtgcc gcgcctccca gtcggtgtcc agctacctgg cctggtacca 1020
gcagaagccg ggccaggccc cgcgtctgct gatctacgac gcctccaacc gcgccaccgg 1080
catcccggcc cgcttctccg gctcgggctc cggcaccgac ttcaccctga ccatctcgtc 1140
cctggaaccg gaggacttcg ccgtctacta ctgccagcag tcctcgaact ggccgcgcac 1200
cttcggccag ggcaccaagg tcgagatcaa gcaccatcat caccaccact gaccttctgc 1260
tcgtagcgat tacttcgagc attactgacg acaaagaccc cgaccgagat ggtcggggtc 1320
ttttgtttgt ggtgctgtga cgtgttgtcc aaccgtatta ttccgggtct tcctgctggc 1380
ctatgcattg ggttccgcag tgcccactcc aggcgggtctg ggcgggtgtgg aagcggcgct 1440
```

Sequence Listings_ASCII.txt

gacattcgcg	ttcgtggcgg	tcggagtgcc	gcagggcggtg	gcgctttccg	ccactttgct	1500
gcaccgcgtg	gtgttttact	ggctgcgcat	tccgctgggc	gcggcggcca	tgaagtggct	1560
tgacaagcat	aatcttgtct	gattcgtcta	ttttcatacc	cccttcgggg	aaatagatgt	1620
gaaaaccctt	ataaaacgcg	ggttttcgca	gaaacatgcg	ctagtatcat	tgatgacaac	1680
atggactaag	caaaagtgtt	tgtccccctga	cccaagaagg	atgctttatg	gcgttgatga	1740
tgagcgtaa	gactattatt	tccacatcag	tggcgattat	cgccacgggt	gccatgtttg	1800
cgtgcgtagc	cccgtttgcc	tctgccgatt	ccgcgcagac	gagtgcgtg	gtgtcctcac	1860
gttctttccc	gaaggcgagt	tcggtgcagg	tccagctggt	cgaatcgggc	ggcggcgctc	1920
tccagccggg	ccgtagcctg	cgtctgtcgt	gcgccgcctc	gggcttcacc	ttctccagct	1980
acaccatgca	ctgggtgctg	caggccccgg	gcaagggcct	ggagtgggtc	accttcatct	2040
cctacgacgg	caacaacaag	tactacgccg	attccgtgaa	gggccgcttc	accatctccc	2100
gtgacaacag	caagaacacc	ctgtacctgc	agatgaactc	cctgcgcgcc	gaagacaccg	2160
ccatctacta	ctgcgcccgt	accggctggc	tgggcccgtt	cgattactgg	ggccagggca	2220
ccctggtgac	cgtctcgtcg	ggcggcgggc	gctcggggcg	cgccgggctcc	ggcggcgggc	2280
gcagcgagat	cgtgctgacc	cagtccccgg	gcaccctgtc	gctgtccccg	ggcgaacgcg	2340
ccaccctgtc	ctgccgtgcc	agccagtcgg	tcggcagctc	gtacctggcc	tggtaccagc	2400
agaagccggg	ccaggccccg	cgtctgtcta	tctacggcgc	cttctcccgt	gccaccggca	2460
tcccggaccg	tttctccggc	agcggctcgg	gcaccgattt	caccctgacc	atctcccgcc	2520
tggagccgga	agatttcgcc	gtctactact	gccagcagta	cggctccagc	ccgtggacct	2580
tcggccaggg	caccaagggtg	gaaatcaagg	actacaagga	cgacgacgac	aagtgcacct	2640
ctgctcgtag	cgattacttc	gagcattact	gacgacaaa	accccgaccg	agatggctcg	2700
ggcttttttg	ttgtggtgct	gtgacgtggt	gtccaaccgt	attattccgg	actagtcctc	2760
caggacctcg	tctacgaggc	gctgagcgag	gaatggcgca	aaagggacgg	cgagatcagc	2820
gacccatggg	ccaacgacga	ggcggacgga	taccagccgc	cctcatacga	gccggtcaac	2880
cccgaacgca	ggactcccca	gacgccctcc	gatggcctga	tctgacgtcc	gaaaaaaggc	2940
gctgtgcgcc	ctttttaaat	ctttttataa	tctttttaca	ttcttttagc	ccctccgcag	3000
ccttactctc	ccaacggggt	tcagccgaaa	cctacaccaa	aaggggagcg	aacctacacc	3060
aaaaggggag	cgaacctaca	ccaaaagggg	agcgaacctc	caccaaagg	ggagctatat	3120
acaccttttg	ttatttaagg	tgcaagttgt	gctatgctga	ggccatgtcc	aatgagatcg	3180
tgaagttcag	caaccagttc	aacaacgtcg	cgctgaagaa	gttcgacgcc	gtgcacctgg	3240
acgtgctcat	ggcgatcgcc	tcaaggggtga	gggagaaggg	cacggccacg	gtggagtctt	3300
cgttcgagga	gctgcgcggc	ctcatgcatg	tgaggaagaa	cctgaccaac	aagcagctgg	3360
ccgacaagat	cgtgcagacg	aacgcgcgcc	tgctggcgct	gaactacatg	ttcgaggatt	3420
cgggcaagat	catccagttc	gcgctgttca	cgaagtctgt	caccgacccg	caggaggcga	3480

Sequence Listings_ASCII.txt

ctctcgcggt	tggggtcaac	gaggagttcg	cgttcctgct	caacgacctg	accagccagt	3540
tcacgcgctt	cgagctggcc	gagttcgccg	acctcaagag	caagtacgcc	aaggagttct	3600
accgcagggc	caagcagtac	cgcagctccg	gaatctggaa	gatcggccgc	gacgagttct	3660
gccgactgct	tggcgttcca	ccgtcggcaa	taaccagac	acgatatctg	aatcagaagg	3720
ttcttcagcc	aattcaggag	gagtgtgggc	ctctccttgg	cctgaagatc	gagcgccagt	3780
acgtgaaacg	caggctgtcg	ggcttcgtgt	tcacattcgc	ccgcgagacc	cctccggtga	3840
tcgacgccag	gcccgtggag	gcgaggaaga	cggacggcga	cggcaagggc	cattggacga	3900
gcgttgccgg	gtacggcgag	gtgttcacga	ccacggcggt	gttcgacgtg	acggccgccc	3960
gggctcactt	cgacggcacc	gttgaagccg	gggagtgccg	tttctgcgcg	tttgacgcgc	4020
gcaaccgcga	acatcatgcg	cggaacgccg	gaaggctgtt	ctagcggccg	tgtccgcgcc	4080
tctggggcgg	ttgcgcctgc	catgggtcga	tctgccgctg	ttcggcctca	cgctgggtctg	4140
tgcgctgcct	gatctccctg	agcaggctcg	ccttggtcct	gggggcgctt	cgctcctcga	4200
acgggccgct	ctccccag	tcctcgggct	cgctcaggtc	caacggctcg	tcaccggacg	4260
gctcggggccg	gttctctccc	tgtgccgggt	tctccgcctg	tgcgcgttgt	tcggccatgc	4320
gcagtgcgag	ggccttcacc	tgttcggggc	ttgtcgactc	gattttcggt	cgtgaataca	4380
tgttataata	actataacta	ataacgtaac	gtgactggca	agagatat	ttaaaacaat	4440
gaataggttt	acacttactt	tagttttatg	gaaatgaaag	atcatatcat	atataatcta	4500
gaataaaaatt	aactaaaata	attattatct	agataaaaaa	tttagaagcc	aatgaaatct	4560
ataaataaac	taaattaagt	ttatttaatt	aacaactatg	gatataaaat	aggtactaat	4620
caaaatagtg	aggaggatat	atttgaatac	atacgaacaa	attaataaaag	tgaaaaaaat	4680
acttcggaaa	catttaaaaa	ataaccttat	tggtacttac	atgtttggat	caggagttga	4740
gagtggacta	aaaccaaata	gtgatcttga	cttttttagtc	gtcgtatctg	aaccattgac	4800
agatcaaagt	aaagaaatac	ttatacaaaa	aattagacct	atttcaaaaa	aaataggaga	4860
taaaagcaac	ttacgatata	ttgaattaac	aattattatt	cagcaagaaa	tggtaccgtg	4920
gaatcatcct	cccaaacaag	aatttattta	tggagaatgg	ttacaagagc	tttatgaaca	4980
aggatacatt	cctcagaagg	aattaaattc	agatttaacc	ataatgcttt	accaagcaaa	5040
acgaaaaaat	aaaagaatat	acggaaatta	tgacttagag	gaattactac	ctgatattcc	5100
atcttctgat	gtgagaagag	ccattatgga	ttcgtcagag	gaattaatag	ataattatca	5160
ggatgatgaa	accaactcta	tattaacttt	atgccgtatg	attttaacta	tggacacggg	5220
taaaatcata	ccaaaagata	ttgcgggaaa	tgcagtggct	gaatcttctc	cattagaaca	5280
tagggagaga	atcttggttag	cagttcgtag	ttatcttgga	gagaatattg	aatggactaa	5340
tgaaaatgta	aatttaacta	taaactat	aaataacaga	ttaaaaaaat	tataaaaaaa	5400
ttgaaaaaat	ggtggaaaca	cttttttcaa	tttttttaga	tcttgagcaa	aaggccagca	5460
aaaggccagg	aaccgtaaaa	aggccgcgtt	gctggcgctt	ttccataggc	tccgcccccc	5520

Sequence Listings_ASCII.txt

tgacgagcat	cacaaaaatc	gacgctcaag	tcagagggtgg	cgaaacccga	caggactata	5580
aagataaccag	gcgttttcccc	ctggaagctc	cctcgtgctgc	tctcctgttc	cgaccctgcc	5640
gcttaccgga	tacctgtccg	cctttctccc	ttcgggaagc	gtggcgcttt	ctcatagctc	5700
acgctgtagg	tatctcagtt	cggtgtaggt	cgttcgctcc	aagctgggct	gtgtgcacga	5760
accccccggt	cagccccgacc	gctgctcctt	atccggtaac	tatcgtcttg	agtccaaccc	5820
ggtaagacac	gacttatcgc	cactggcagc	agccactggg	aacaggatta	gcagagcgag	5880
gtatgtaggc	gggtgctacag	agttcttgaa	gtgggtggcct	aactacggct	acactagaag	5940
aacagtattt	ggatatctgcg	ctctgctgaa	gccagttacc	ttcggaaaaa	gagttggtag	6000
ctcttgatcc	ggcaaacaaa	ccaccgctgg	tagcgggtgg	ttttttgttt	gcaagcagca	6060
gattacgcgc	agaaaaaaaag	gatctcaaga	agatcctttg	atcttttcta	c	6111

<210> 10
 <211> 6111
 <212> DNA
 <213> Artificial

<220>
 <223> pCP1

<400> 10						
ggatccgtct	tcctgctggc	ctatgcattg	ggttccgcag	tgcccactcc	aggcggctctg	60
ggcgggtgtg	aagcggcgct	gacattcgcg	ttcgtggcgg	tcggagtgcc	gcagggcgctg	120
gcgctttccg	ccactttgct	gcaccgcgtg	gtgttctact	ggctgcgcat	tccgctgggc	180
gcggcggcca	tgaagtggct	tgacaagcat	aatcttgtct	gattcgtcta	ttttcatacc	240
cccttcgggg	aaatagatgt	gaaaaccctt	ataaaacgcg	ggttttcgca	gaaacatgcg	300
ctagtatcat	tgatgacaac	atggactaag	caaaagtgct	tgtcccctga	ccaagaagg	360
atgctttatg	gcgttgatga	tgagcggtta	gactattatt	tccacatcag	tggcgattat	420
cgccacgggt	gccatgtttg	cgtgcgtagc	cccgtttgcc	tctgccgatt	ccgcgcagac	480
gagtgtctgt	gtgtcctcac	gttctttccc	gaaggcgagt	tcggtgcagg	tccagctggg	540
cgaatcgggc	ggcggcgctg	tccagccggg	ccgtagcctg	cgtctgtcgt	gcgccgcctc	600
gggcttcacc	ttctccagct	acaccatgca	ctgggtgcgt	caggccccgg	gcaagggcct	660
ggagtgggtc	accttcatct	cctacgacgg	caacaacaag	tactacgccg	attccgtgaa	720
gggccgcttc	accatctccc	gtgacaacag	caagaacacc	ctgtacctgc	agatgaactc	780
cctgcgcgcc	gaagacaccg	ccatctacta	ctgcgcccgt	accggctggc	tgggcccgtt	840
cgattactgg	ggccagggca	ccctggtgac	cgtctcgtcg	ggcggcgggc	gctcgggcgg	900
cggcggctcc	ggcggcgggc	gcagcgagat	cgtgctgacc	cagtccccgg	gcaccctgtc	960
gctgtccccg	ggcgaacgcg	ccaccctgtc	ctgccgtgcc	agccagtcgg	tcggcagctc	1020
gtacctggcc	tgggtaccagc	agaagccggg	ccaggccccg	cgtctgctga	tctacggcgc	1080
cttctcccgt	gccaccggca	tcccggaccg	tttctccggc	agcggctcgg	gcaccgattt	1140

Sequence Listings_ASCII.txt

caccctgacc	atctcccgcc	tggagccgga	agatttcgcc	gtctactact	gccagcagta	1200
cggctccagc	ccgtggacct	tcggccaggg	caccaaggtg	gaaatcaagg	actacaagga	1260
cgacgacgac	aagtgacctt	ctgctcgtag	cgattacttc	gagcattact	gacgacaaag	1320
accccgaccg	agatggtcgg	ggtctttttg	ttgtggtgct	gtgacgtggt	gtccaaccgt	1380
attattccgg	gtcttcctgc	tggcctatgc	attgggttcc	gcagtgccca	ctccaggcgg	1440
tctgggcggt	gtggaagcgg	cgctgacatt	cgcgttcgtg	gcggtcggag	tgccgcaggg	1500
cgtggcgctt	tccgccactt	tgctgcaccg	cgtggtgttc	tactggctgc	gcattccgct	1560
gggcgcggcg	gcatgaagt	ggcttgacaa	gcataatctt	gtctgattcg	tctattttca	1620
tacccccctt	ggggaaatag	atgtgaaaac	ccttataaaa	cgcgggtttt	cgagaaaaca	1680
tgcgctagta	tcattgatga	caacatggac	taagcaaaag	tgcttgctcc	ctgaccaag	1740
aaggatgctt	tatggcggtt	atgatgagcg	ttaagactat	tatttccaca	tcagtggcga	1800
ttatcgccac	gggtgccatg	tttgcgctgc	tagccccgtt	tgccctctgc	gattccgcgc	1860
agacgagtgc	tgtggtgtcc	tcacgttctt	tcccgaaggc	gagttcgggt	caggccagc	1920
tggtcgaatc	gggcggcggc	gtcgtccagc	cgggccgttc	cctgctctct	gattgcaagg	1980
cctcgggcat	caccttctcg	aactccggca	tgcactgggt	gcgccaggcc	ccgggcaagg	2040
gcctggaatg	ggtcgccgtg	atctggtacg	atggctcgaa	gcgctactac	gccgattccg	2100
tgaagggccg	cttcaccatc	tcgcgcgaca	actccaagaa	cacctgttcc	ctgcagatga	2160
actccctgcg	cgccgaagac	accgccgtgt	actactgcgc	caccaacgat	gactactggg	2220
gccagggcac	cctggtcacc	gtgtccagcg	gcggcgggcg	ctccggcggc	ggcggctcgg	2280
gcggcgggcg	cagcgaaatc	gtgctgaccc	agtccccggc	cacctgttcc	ctgtcccccg	2340
gcgaacgtgc	cacctgtctg	tgccgcgcct	cccagtcggt	gtccagctac	ctggcctggt	2400
accagcagaa	gccggggccag	gccccgcgtc	tgctgatcta	cgacgcctcc	aaccgcgcca	2460
ccggcatccc	ggcccgcttc	tccggctcgg	gctccggcac	cgacttcacc	ctgaccatct	2520
cgtccctgga	accggaggac	ttcgccgtct	actactgcca	gcagtcctcg	aactggccgc	2580
gcaccttcgg	ccagggcacc	aaggtcgaga	tcaagcacca	tcatcaccac	cactgacctt	2640
ctgctcgtag	cgattacttc	gagcattact	gacgacaaag	accccgaccg	agatggtcgg	2700
ggtctttttg	ttgtggtgct	gtgacgtggt	gtccaaccgt	attattccgg	actagtcctc	2760
caggacctcg	tctacgaggc	gctgagcgag	gaatggcgca	aaagggacgg	cgagatcagc	2820
gacccatggg	ccaacgacga	ggcggacgga	taccagccgc	cctcatacga	gccggtcaac	2880
cccgaacgca	ggactcccca	gacgccctcc	gatggcctga	tctgacgtcc	gaaaaaaggc	2940
gctgtgcgcc	ctttttaaat	ctttttataaa	tcttttttaca	ttcttttagc	ccctccgcag	3000
ccttactctc	ccaacggggt	tcagccgaaa	cctacaccaa	aaaggggagcg	aacctacacc	3060
aaaaggggag	cgaacctaca	ccaaaagggg	agcgaacct	caccaaaggg	ggagctatat	3120
acaccttttg	ttatttaagg	tgcaagttgt	gctatgctga	ggccatgtcc	aatgagatcg	3180

Sequence Listings_ASCII.txt

tgaagttcag	caaccagttc	aacaacgtcg	cgctgaagaa	gttcgacgcc	gtgcacctgg	3240
acgtgctcat	ggcgatcgcc	tcaaggggtga	gggagaaggg	cacggccacg	gtggagtctt	3300
cgttcgagga	gctgcgcggc	ctcatgcgat	tgaggaagaa	cctgaccaac	aagcagctgg	3360
ccgacaagat	cgtgcagacg	aacgcgcgcc	tgctggcgct	gaactacatg	ttcgaggatt	3420
cgggcaagat	catccagttc	gcgctgttca	cgaagtctgt	caccgacccg	caggaggcga	3480
ctctcgcggt	tgggggtcaac	gaggagtctg	cgttcctgct	caacgacctg	accagccagt	3540
tcacgcgctt	cgagctggcc	gagttcgccg	acctcaagag	caagtacgcc	aaggagtctt	3600
accgcagggc	caagcagtac	cgcagctccg	gaatctggaa	gatcggccgc	gacgagtctt	3660
gccgactgct	tggcgttcca	ccgtcggcaa	taaccagac	acgatatctg	aatcagaagg	3720
ttcttcagcc	aattcaggag	gagtgtgggc	ctctccttgg	cctgaagatc	gagcgccagt	3780
acgtgaaacg	caggctgtcg	ggcttcgtgt	tcacattcgc	ccgcgagacc	cctccggtga	3840
tcgacgccag	gcccgtggag	gcgaggaaga	cggacggcga	cggcaagggc	cattggacga	3900
gcgttgccgg	gtacggcgag	gtgttcacga	ccacggcggt	gttcgacgtg	acggccgccc	3960
gggctcactt	cgacggcacc	gttgaagccg	gggagtgcgg	tttctgcgcg	tttgacgcgc	4020
gcaaccgcga	acatcatgcg	cggaaacgcc	gaaggctgtt	ctagcggccg	tgtccgcgcc	4080
tctggggcgg	ttgcgcctgc	catgggtcga	tctgccgctg	ttcggcctca	cgctggtctg	4140
tgcgctgcct	gatctccctg	agcaggctcg	ccttggtcct	gggggcgctt	cgctcctcga	4200
acgggcccgt	ctcccccagg	tcctcgggct	cgctcaggtc	caacggctcg	tcaccggacg	4260
gctcgggccc	gttctctccc	tgtgccgggt	tctccgcctg	tgcgcgttgt	tcggccatgc	4320
gcagtgcgag	ggccttcacc	tgttcggggc	ttgtcgactc	gattttcgtt	cgtaataca	4380
tgttataata	actataacta	ataacgtaac	gtgactggca	agagatatatt	ttaaaacaat	4440
gaataggttt	acacttactt	tagttttatg	gaaatgaaag	atcatatcat	atataatcta	4500
gaataaaatt	aactaaaata	attattatct	agataaaaaa	tttagaagcc	aatgaaatct	4560
ataaataaac	taaattaagt	ttatttaatt	aacaactatg	gatataaaaat	aggtactaat	4620
caaaatagtg	aggaggatat	atttgaatac	atacgaacaa	attaataaag	tgaaaaaaat	4680
acttcggaaa	catttaaaaa	ataaccttat	tgggtacttac	atgtttggat	caggagttag	4740
gagtggacta	aaaccaaata	gtgatcttga	cttttttagtc	gtcgtatctg	aaccattgac	4800
agatcaaagt	aaagaaatac	ttatacaaaa	aattagacct	atttcaaaaa	aaataggaga	4860
taaaagcaac	ttacgatata	ttgaattaac	aattattatt	cagcaagaaa	tgggtaccgtg	4920
gaatcatcct	cccaaacaag	aatttattta	tggagaatgg	ttacaagagc	tttatgaaca	4980
aggatacatt	cctcagaagg	aattaaattc	agatttaacc	ataatgcttt	accaagcaaa	5040
acgaaaaaat	aaaagaatat	acggaaatta	tgacttagag	gaattactac	ctgatattcc	5100
atcttctgat	gtgagaagag	ccattatgga	ttcgtcagag	gaattaatag	ataattatca	5160
ggatgatgaa	accaactcta	tattaacttt	atgccgtatg	attttaacta	tggacacggg	5220

Sequence Listings_ASCII.txt

taaaatcata	ccaaaagata	ttgcgggaaa	tgcagtggct	gaatcttctc	cattagaaca	5280
tagggagaga	attttgttag	cagttcgtag	ttatcttgga	gagaatattg	aatggactaa	5340
tgaaaatgta	aatttaacta	taaactattt	aaataacaga	ttaaaaaaat	tataaaaaaa	5400
ttgaaaaaat	ggtggaaaca	cttttttcaa	tttttttaga	tcttgagcaa	aaggccagca	5460
aaaggccagg	aaccgtaaaa	aggccgcgtt	gctggcggtt	ttccataggc	tccgcccccc	5520
tgacgagcat	cacaaaaatc	gacgctcaag	tcagagggtg	cgaaacccga	caggactata	5580
aagataccag	gcgtttcccc	ctggaagctc	cctcgtgcgc	tctcctgttc	cgaccctgcc	5640
gcttaccgga	tacctgtccg	cctttctccc	ttcgggaagc	gtggcgcttt	ctcatagctc	5700
acgctgtagg	tatctcagtt	cggtgtaggt	cgttcgctcc	aagctgggct	gtgtgcacga	5760
acccccggt	cagcccgacc	gctgcgcctt	atccggtaac	tatcgtcttg	agtccaaccc	5820
ggtaagacac	gacttatcgc	cactggcagc	agccactggt	aacaggatta	gcagagcgag	5880
gtatgtaggc	ggtgctacag	agttcttgaa	gtggtggcct	aactacggct	acactagaag	5940
aacagtattt	ggtatctgcg	ctctgctgaa	gccagttacc	ttcggaaaaa	gagttggtag	6000
ctcttgatcc	ggcaaacaaa	ccaccgctgg	tagcggtggt	ttttttgttt	gcaagcagca	6060
gattacgcgc	agaaaaaaag	gatctcaaga	agatcctttg	atcttttcta	c	6111

<210> 11
 <211> 729
 <212> DNA
 <213> Artificial

<220>
 <223> hPD-1scFv03

<400> 11		
atgcagggtcc	agctgggtcga atcggggcggc ggcgctcgtcc agccggggccg ttccctgcgt 60	
ctggattgca	aggcctcggg catcaccttc tcgaactccg gcatgcaactg ggtgcgccag 120	
gccccgggca	agggcctgga atgggtcgcc gtgatctggt acgatggctc gaagcgctac 180	
tacgccgatt	ccgtgaaggg ccgcttcacc atctcgcgcg acaactccaa gaacaccctg 240	
ttcctgcaga	tgaactccct gcgcgccgaa gacaccgccg tgtactactg cgccaccaac 300	
gatgactact	ggggccaggg caccctgggtc accgtgtcca gcggcgggcg cggtctccggc 360	
ggcggcggt	cgggcggcgg cggcagcgaa atcgtgctga cccagtcccc ggccaccctg 420	
tccctgtccc	cgggcgaacg tgccaccctg tcgtgccgcg cctcccagtc ggtgtccagc 480	
tacctggcct	ggtaccagca gaagccgggc caggccccgc gtctgctgat ctacgacgcc 540	
tccaaccgcg	ccaccggcat cccggccccg ttctccgggt cgggctccgg caccgacttc 600	
accctgacca	tctcgtccct ggaaccggag gacttcgccg tctactactg ccagcagtcc 660	
tcgaactggc	cgcgcacctt cggccagggc accaaggctc agatcaagca ccatcatcac 720	
caccactga		729

Sequence Listings_ASCII.txt

<210> 12
 <211> 747
 <212> DNA
 <213> Artificial

<220>
 <223> hCTLA-4scFv02

<400> 12
 atgcagggtcc agctggtcga atcgggcggc ggcgtcgtcc agccggggccg tagcctgcgt 60
 ctgtcgtgcg ccgcctcggg cttcaccttc tccagctaca ccatgcaactg ggtgcgtcag 120
 gccccgggca agggcctgga gtgggtcacc ttcatctcct acgacggcaa caacaagtac 180
 tacgccgatt ccgtgaaggg ccgcttcacc atctcccgtg acaacagcaa gaacaccctg 240
 tacctgcaga tgaactccct gcgcgccgaa gacaccgcca tctactactg cgcccgtacc 300
 ggctggctgg gcccgttcga ttactggggc cagggcaccc tggtgaccgt ctcgtcgggc 360
 ggcggcggtc cgggcggcgg cggctccggc ggcggcgga gcgagatcgt gctgaccag 420
 tccccgggca ccctgtcgct gtccccgggc gaacgcgcca ccctgtcctg ccgtgccagc 480
 cagtcggtcg gcagctcgta cctggcctgg taccagcaga agccgggcca ggccccgcgt 540
 ctgctgatct acggcgctt ctcccgtgcc accggcatcc cggaccgttt ctccggcagc 600
 ggctcgggca ccgatttcac cctgaccatc tccgcctgg agccggaaga tttcgccgtc 660
 tactactgcc agcagtacgg ctccagcccc tggaccttcg gccagggcac caaggtggaa 720
 atcaagcatc atcatcatca tcaactga 747

<210> 13
 <211> 753
 <212> DNA
 <213> Artificial

<220>
 <223> hCTLA-4 scFv02FLAG

<400> 13
 atgcagggtcc agctggtcga atcgggcggc ggcgtcgtcc agccggggccg tagcctgcgt 60
 ctgtcgtgcg ccgcctcggg cttcaccttc tccagctaca ccatgcaactg ggtgcgtcag 120
 gccccgggca agggcctgga gtgggtcacc ttcatctcct acgacggcaa caacaagtac 180
 tacgccgatt ccgtgaaggg ccgcttcacc atctcccgtg acaacagcaa gaacaccctg 240
 tacctgcaga tgaactccct gcgcgccgaa gacaccgcca tctactactg cgcccgtacc 300
 ggctggctgg gcccgttcga ttactggggc cagggcaccc tggtgaccgt ctcgtcgggc 360
 ggcggcggtc cgggcggcgg cggctccggc ggcggcgga gcgagatcgt gctgaccag 420
 tccccgggca ccctgtcgct gtccccgggc gaacgcgcca ccctgtcctg ccgtgccagc 480
 cagtcggtcg gcagctcgta cctggcctgg taccagcaga agccgggcca ggccccgcgt 540
 ctgctgatct acggcgctt ctcccgtgcc accggcatcc cggaccgttt ctccggcagc 600
 ggctcgggca ccgatttcac cctgaccatc tccgcctgg agccggaaga tttcgccgtc 660
 tactactgcc agcagtacgg ctccagcccc tggaccttcg gccagggcac caaggtggaa 720

Sequence Listings_ASCII.txt

atcaaggact acaaggacga cgacgacaag tga

753

<210> 14
 <211> 4019
 <212> DNA
 <213> Artificial

<220>
 <223> Linearized vector fragment

<400> 14
 tgaccttctg ctcgtagcga ttacttcgag cattactgac gacaaagacc ccgaccgaga 60
 tggctcggggt ctttttggtg tggtgctgtg acgtgttgct caaccgtatt attccggact 120
 agtcctccag gacctcgtct acgaggcgct gagcgaggaa tggcgcaaaa gggacggcga 180
 gatcagcgac ccatgggcca acgacgaggc ggacggatac cagccgccct catacgagcc 240
 ggtcaacccc gaacgcagga ctccccagac gccctccgat ggcctgatct gacgtccgaa 300
 aaaaggcgct gtgcgccctt tttaaactct ttataaatct ttttacattc ttttagcccc 360
 tccgcagcct tactctccca acgggtttca gccgaaacct acacaaaaag gggagcgaac 420
 ctacacaaaa aggggagcga acctacacca aaaggggagc gaacctacac caaaagggga 480
 gctatataca ctttttggtt tttaagggtg aagttgtgct atgctgaggc catgtccaat 540
 gagatcgtga agttcagcaa ccagttcaac aacgtcgcgc tgaagaagtt cgacgccgtg 600
 cacctggacg tgctcatggc gatcgctca agggtgaggg agaagggcac ggccacgggtg 660
 gagttctcgt tcgaggagct gcgcggcctc atgcgattga ggaagaacct gaccaacaag 720
 cagctggccg acaagatcgt gcagacgaac gcgcgcctgc tggcgctgaa ctacatgttc 780
 gaggattcgg gcaagatcat ccagttcgcg ctgttcacga agttcgtcac cgacccgcag 840
 gaggcgactc tcgcggttgg ggtcaacgag gagttcgcgt tcctgctcaa cgacctgacc 900
 agccagttca cgcgcttcga gctggccgag ttcgccgacc tcaagagcaa gtacgccaag 960
 gagttctacc gcagggccaa gcagtaccgc agctccggaa tctggaagat cggccgcgac 1020
 gagttctgcc gactgcttgg cgttccaccg tcggcaataa cccagacacg atatctgaat 1080
 cagaaggttc ttcagccaat tcaggaggag tgtgggcctc tccttggcct gaagatcgag 1140
 cgccagtacg tgaaacgcag gctgtcgggc ttcgtgttca cattcgcccg cgagaccctt 1200
 ccggtgatcg acgccaggcc cgtggaggcg aggaagacgg acggcgacgg caagggccat 1260
 tggacgagcg ttgccgggta cggcgagggtg ttcacgacca cggcgttggt cgacgtgacg 1320
 gccgcccggg ctacttcga cggcaccgtt gaagccgggg agtgccgttt ctgcgcgttt 1380
 gacgcgcgca accgcgaaca tcatgcgcgg aacgccggaa ggctgttcta gcggccgtgt 1440
 ccgcgcctct ggggcgggtt cgcctgccat gggtcgatct gccgctgttc ggcctcacgc 1500
 tggctctgtg gctgcctgat ctccctgagc aggtcggcct tggctcctggg ggcgcttcgc 1560
 tcctcgaacg ggccgctctc ccccagggtc tcgggctcgc tcagggtccaa cggctcgtca 1620
 ccggacgggt cgggcccgtt ctctccctgt gccgggttct ccgcctgtgc gcgttggtcg 1680

Sequence Listings_ASCII.txt

gccatg	cgca	gtg	cgagggc	cttcac	ctgt	tcgggg	ccttg	tcgact	cgat	tttcgt	ttcgt	1740
gaatac	atgt	tataa	taact	ataact	aata	acgta	acgtg	actgg	caaga	gatatt	ttttta	1800
aaaca	atgaa	taggt	tttaca	cttact	tttag	ttttat	ggaa	atgaa	agatc	atatc	atata	1860
taatc	tagaa	taaa	attaac	taaa	ataatt	attat	ctaga	taaaa	aattt	agaag	ccaat	1920
gaaat	ctata	aataa	actaa	atta	agttta	ttta	attaac	aactat	ggat	ataaa	atagg	1980
tacta	atcaa	aatag	tgagg	aggata	tatt	tgaata	acata	cgaac	aaatt	aataa	agtga	2040
aaaaa	atact	tcgga	aacat	ttaaaa	aaata	acctt	atttg	tactt	acatg	tttgg	atcag	2100
gagtt	gagag	tggac	taaaa	ccaat	agtg	atcct	tgactt	tttag	tcgtc	gtatc	tgaac	2160
cattg	acaga	tcaa	agtaaa	gaaata	actta	tacaaaa	aat	tagac	ctatt	tcaaaaa	aaaaa	2220
tagga	gataa	aagca	actta	cgata	tattg	aatta	acaat	tattat	tcag	caaga	aatgg	2280
taccg	tggaa	tcac	tctccc	aaaca	agaat	ttatt	ttatgg	agaat	ggtta	caaga	gcttt	2340
atga	acaagg	atac	attcct	caga	aggaat	taaat	tcaga	ttta	accata	atgct	tttacc	2400
aagca	aaacg	aaaaa	ataaa	agaat	atacg	gaaat	tatga	cttag	aggaa	ttact	acctg	2460
atatt	ccatt	ttct	gatgtg	aga	agagcca	ttat	ggattc	gtcag	aggaa	ttaat	agata	2520
attat	cagga	tgat	gaaacc	aact	ctatat	taact	tttatg	ccgat	tgatt	ttact	atgg	2580
acacg	ggtaa	aatc	atacca	aaag	atattg	cggg	aaatgc	agtgg	ctgaa	tcttc	tccat	2640
taga	acatag	ggag	agaatt	ttgt	tagcag	ttcg	tagtta	tcttg	gagag	aatatt	gaaat	2700
ggact	aatga	aatg	ttaa	atataa	actatt	ttaaa	taac	agatta	aaaaa	attat		2760
aaaaa	attg	aaaaa	atggt	ggaa	acactt	tttt	caattt	ttttag	atct	tgag	caaaag	2820
gccag	caaaa	ggcc	aggaac	cgta	aaaaag	ccgc	gttgct	ggcg	tttttc	catag	gctcc	2880
gcccc	ctga	cgag	catcac	aaaa	atcgac	gctc	aagtca	gaggt	ggcga	aaccc	gacag	2940
gacta	taaag	atacc	aggcg	tttccc	ctg	gaag	ctccct	cg	tcgctct	cctg	ttccga	3000
ccctg	ccgct	tacc	gatac	ctgt	ccgcct	ttct	cccttc	ggga	agcgtg	gcgct	ttctc	3060
atag	ctcacg	ctgt	aggtat	ctcag	ttcgg	tgtag	gtcgt	tcg	ctccaag	ctggg	ctgtg	3120
tgcac	gaacc	cccc	gttcag	cccga	ccgct	gcgc	cttatc	cggt	aactat	cgtct	tgagt	3180
cca	acccggt	aagac	acgac	ttat	cggcac	tggc	agcagc	cact	ggtaac	aggat	tagca	3240
gagc	gaggta	tgtag	gcggt	gctac	agagt	tctt	gaagtg	gtgg	cctaac	tacgg	ctaca	3300
ctaga	agaac	agtatt	tggt	atct	gcgctc	tgct	gaagcc	agtt	accttc	ggaaa	agag	3360
ttggt	tagctc	ttgat	ccggc	aaaca	aaacca	ccgt	tggtag	cggt	gggtttt	tttgt	ttgca	3420
agcag	cagat	tacgc	gcaga	aaaa	aaggat	ctca	agaaga	tcct	ttgatc	tttt	ctacgg	3480
atccg	tcttc	ctgt	tgccct	atgc	attggg	ttcc	gcagtg	cccac	tccag	gcggt	ctggg	3540
cgg	tgtggaa	gcgg	cgctga	catt	cgcg	tt	cggtc	ggag	tgccgc	aggg	cggtggc	3600
gcttt	ccgcc	acttt	gctgc	accg	cg	tggt		gtt	ctactgg	ctgc	gcattc	3660
ggcgg	ccatg	aagt	ggccttg	aca	agcataa	tctt	gtctga	ttcgt	ctatt	ttcata	cccc	3720

Sequence Listings_ASCII.txt

cttcggggaa atagatgtga aaacccttat aaaacgcggg ttttcgcaga aacatgcgct	3780
agtatcattg atgacaacat ggactaagca aaagtgcttg tcccctgacc caagaaggat	3840
gctttatggc gttgatgatg agcgttaaga ctattatttc cacatcagtg gcgattatcg	3900
ccacgggtgc catgtttgcg tgcgtagccc cgtttgcctc tgccgattcc gcgcagacga	3960
gtgctgtggt gtcctcacgt tctttcccga aggcgagttc ggtgcaggtc cagctggtc	4019

<210> 15
 <211> 4616
 <212> DNA
 <213> Artificial

<220>
 <223> pP30SP7L20-bHER2

<400> 15 tagccggcat tttcgcgata cattccccgg aatgttgcg aacggggaac gcgcaccaca	60
ccgcaaccac agtgcgccac gcccagtcg gccctgtgcg ctataatagg tcagttattc	120
gcgcgcgcgt ggcgccctct acaccccgag ccgcgaggac acgtggattc cggacggcca	180
tgccccacat ggcaaaccga gaaccgcac acctagcatt acaaggagag ccattatggc	240
gttgatgatg agcgttaaga ctattatttc cacatcagtg gcgattatcg ccacgggtgc	300
catgtttgcg tgcgtagccc cgtttgcctc tgccgattcc gcgcagacga gtgctgtggt	360
gtcctcacgt tctttcccga aggcgagttc ggtggaagtg cagctggtcg aatcgggcgg	420
cggcctggtg cagccgggcg gctccctgcg tctgtcgtgc gccgcctcgg gcttcaacat	480
caaggatacc tacatccact gggcgcgcca ggccccgggc aagggcctgg aatgggtggc	540
ccgtatctac ccgaccaacg gctacacccg ctacgccgat tccgtgaagg gccgcttcac	600
catctccgcc gataccagca agaacaccgc ctacctgcag atgaactccc tgcgcgccga	660
agataccgcc gtgtactact gctcgcgctg gggcggcgac ggcttctacg ccatggacta	720
ctggggccag ggcaccctgg tgaccgtgtc cagcggcggc ggcggtccg gcggcggcgg	780
ctcgggcggc ggcgggtccg acatccagat gacccagtcc ccgtcgtccc tgagcgcctc	840
ggtgggcgat cgcgtagcca tcacctgccg cgccctccag gatgtgaaca ccgccgtggc	900
ctggtaccag cagaagccgg gcaaggcccc gaagctgctg atctactcgg cctccttcct	960
gtactccggc gtgccgtccc gtttctccgg ctcccgtcgg ggcaccgact tcaccctgac	1020
catctcgtcc ctgcagccgg aagacttcgc cacctactac tgccagcagc attacaccac	1080
cccgccgacc ttcggccagg gcaccaaggt ggaaatcaag catcatcatc atcatcactg	1140
accttctgct cgtagcgatt acttcgagca ttactgacga caaagacccc gaccgagatg	1200
gtcggggctt ttttgttgtg gtgctgtgac gtgttgtcca accgtattat tccggactag	1260
tcctccagga cctcgtctac gaggcgtga gcgaggaatg gcgcaaaagg gacggcgaga	1320
tcagcgaccc atggggccaac gacgaggcgg acggatacca gccgccctca tacgagccgg	1380
tcaacccga acgcaggact cccagacgc cctccgatgg cctgatctga cgtccgaaaa	1440

Sequence Listings_ASCII.txt

aaggcgctgt	gcgccctttt	taaatctttt	ataaatcttt	ttacattctt	ttagcccctc	1500
cgcagcctta	ctctcccaac	gggtttcagc	cgaaacctac	accaaaaagg	gagcgaacct	1560
acaccaaaaag	gggagcgaac	ctacaccaaa	aggggagcga	acctacacca	aaaggggagc	1620
tatatacacc	ttttgttatt	taaggtgcaa	gttggtgctat	gctgaggcca	tgtccaatga	1680
gatcgtgaag	ttcagcaacc	agttcaacaa	cgtcgcgctg	aagaagttcg	acgccgtgca	1740
cctggacgtg	ctcatggcga	tcgcctcaag	ggtgagggag	aagggcacgg	ccacggtgga	1800
gttctcgttc	gaggagctgc	gcggcctcat	gcgattgagg	aagaacctga	ccaacaagca	1860
gctggccgac	aagatcgtgc	agacgaacgc	gcgcctgctg	gcgctgaact	acatgttcga	1920
ggattcgggc	aagatcatcc	agttcgcgct	gttcacgaag	ttcgtcaccg	acccgcagga	1980
ggcgactctc	gcggttgggg	tcaacgagga	gttcgcgttc	ctgctcaacg	acctgaccag	2040
ccagttcacg	cgcttcgagc	tggccgagtt	cgccgacctc	aagagcaagt	acgccaagga	2100
gttctaccgc	agggccaagc	agtaccgcag	ctccggaatc	tggaagatcg	gccgcgacga	2160
gttctgccga	ctgcttggcg	ttccaccgtc	ggcaataacc	cagacacgat	atctgaatca	2220
gaaggttctt	cagccaattc	aggaggagtg	tgggcctctc	cttggcctga	agatcgagcg	2280
ccagtacgtg	aaacgcaggc	tgtcgggctt	cgtgttcaca	ttcgcccgcg	agaccctcc	2340
ggtgatcgac	gccaggcccg	tggaggcgag	gaagacggac	ggcgacggca	agggccattg	2400
gacgagcggt	gccgggtacg	gcgagggtgt	cacgaccacg	gcgttggttcg	acgtgacggc	2460
cgcccgggct	cacttcgacg	gcaccgttga	agccggggag	tgccgtttct	gcgcgtttga	2520
cgcgcgcaac	cgcgaacatc	atgcgcggaa	cgccggaagg	ctgttctagc	ggccgtgtcc	2580
gcgcctctgg	ggcggttgcg	cctgccatgg	gtcgatctgc	cgctgttcgg	cctcacgctg	2640
gtctgtgcgc	tgcctgatct	ccctgagcag	gtcggccttg	gtcctggggg	cgcttcgctc	2700
ctcgaacggg	ccgctctccc	ccaggtcctc	gggctcgctc	aggtccaacg	gctcgtcacc	2760
ggacggctcg	ggccggttct	ctccctgtgc	cgggttctcc	gcctgtgcgc	gttgttcggc	2820
catgcgcagt	gcgagggcct	tcacctgttc	ggggcttgct	gactcgattt	tcgttcgtga	2880
atacatgtta	taataactat	aactaataac	gtaacgtgac	tggcaagaga	tatttttaaa	2940
acaatgaata	ggtttacact	tacttttagt	ttatggaaat	gaaagatcat	atcatatata	3000
atctagaata	aaattaacta	aaataattat	tatctagata	aaaaatttag	aagccaatga	3060
aatctataaa	taaactaaat	taagtttatt	taattaacaa	ctatggatat	aaaataggta	3120
ctaatacaaaa	tagtgaggag	gatataattg	aatacatacg	aacaaattaa	taaagtga	3180
aaaatacttc	ggaaacattt	aaaaaataac	cttattggta	cttacatgtt	tggatcagga	3240
gttgagagtg	gactaaaacc	aaatagtgat	cttgactttt	tagtcgtcgt	atctgaacca	3300
ttgacagatc	aaagtaaaga	aatacttata	caaaaaatta	gacctatttc	aaaaaaaata	3360
ggagataaaa	gcaacttacg	atatattgaa	ttaacaatta	ttattcagca	agaaatggta	3420
ccgtggaatc	atcctcccaa	acaagaattt	atttatggag	aatgggttaca	agagctttat	3480

Sequence Listings_ASCII.txt

gaacaaggat	acatttcctca	gaaggaatta	aattcagatt	taaccataat	gctttaccaa	3540
gcaaaacgaa	aaaataaaaag	aatatacgga	aattatgact	tagaggaatt	actacctgat	3600
attccatttt	ctgatgtgag	aagagccatt	atggattcgt	cagaggaatt	aatagataat	3660
tatcaggatg	atgaaaccaa	ctctatatta	actttatgcc	gtatgatttt	aactatggac	3720
acgggtaaaa	tcataccaaa	agatatgtcg	ggaaatgcag	tggctgaatc	ttctccatta	3780
gaacataggg	agagaatttt	gtagcagtt	cgtagtatc	ttggagagaa	tattgaatgg	3840
actaatgaaa	atgtaaattt	aactataaac	tatttaaata	acagattaaa	aaaattataa	3900
aaaaattgaa	aaaatggtgg	aaacactttt	ttcaattttt	ttagatcttg	agcaaaaggc	3960
cagcaaaagg	ccaggaaccg	taaaaaggcc	gcgttgctgg	cgtttttcca	taggctccgc	4020
ccccctgacg	agcatcacia	aatcgacgc	tcaagtcaga	ggtggcgaaa	cccgacagga	4080
ctataaagat	accaggcggt	ttcccctgga	agctccctcg	tgcgctctcc	tgttccgacc	4140
ctgccgctta	ccggatacct	gtccgccttt	ctcccttcgg	gaagcgtggc	gctttctcat	4200
agctcacgct	gtaggtatct	cagttcgggt	taggtcgttc	gctccaagct	gggctgtgtg	4260
cacgaacccc	ccgttcagcc	cgaccgctgc	gccttatccg	gtaactatcg	tcttgagtcc	4320
aacccggtaa	gacacgactt	atcgccactg	gcagcagcca	ctggtaacag	gattagcaga	4380
gcgaggtatg	taggcgggtg	tacagagttc	ttgaagtggg	ggcctaacta	cggctacact	4440
agaagaacag	tatttggtat	ctgcgctctg	ctgaagccag	ttaccttcgg	aaaaagagtt	4500
ggtagctctt	gatccggcaa	acaaaccacc	gctggtagcg	gtggtttttt	tgtttgcaag	4560
cagcagatta	cgcgcagaaa	aaaaggatct	caagaagatc	ctttgatctt	ttctac	4616

<210> 16
 <211> 4442
 <212> DNA
 <213> Artificial

<220>
 <223> phIFNg33

<400> 16	
ggatccgtct	tcctgctggc
ctatgcattg	ggttccgcag
tgcccactcc	aggcgggtctg
ggcgggtgtg	aagcggcgct
gacattcgcg	ttcgtggcgg
tcggagtgcc	gcagggcgctg
gcgctttccg	ccactttgct
gcaccgcgtg	gtgttctact
ggctgcgcat	tccgctgggc
gcggcggcca	tgaagtggct
tgacaagcat	aatcttgtct
gattcgtcta	ttttcatacc
cccttcgggg	aaatagatgt
gaaaaccctt	ataaaacgcg
ggttttcgca	gaaacatgcg
ctagtatcat	tgatgacaac
atggactaag	caaaagtgct
tgtcccctga	ccaagaagg
atgctttatg	aattattttac
gacaaaaaat	ttcggctagt
gctatcgcg	tggtgtcgac
ttgtgggttg	attttggcgc
caatgccggt	ctttgcggat
gattcaacgc	catcttcaac
gccatcggat	ggcagttaca
ccacgactga	tagcggtcag
gacccgtacg	tcaaggaagc
cgaaaacctg	aagaagtact
tcaacgccgg	ccatagcgat
gtcgccgata	acggcaccct
	60
	120
	180
	240
	300
	360
	420
	480
	540
	600

Sequence Listings_ASCII.txt

gttcctgggc	atcctgaaga	actggaagga	agagtccgac	cgcaagatca	tgcagtccca	660
gacgtgagc	ttctacttca	agctgttcaa	gaacttcaag	gacgatcagt	cgatccagaa	720
gtccgtggag	accatcaagg	aagacatgaa	cgtcaagttc	ttcaacagca	acaagaagaa	780
gcgcgacgat	ttcgagaagc	tgaccaacta	ctccgtgacc	gatctgaacg	tccagcgtaa	840
ggccatccac	gagctgatcc	aggatcatggc	cgaactgtcc	ccggccgcca	agaccggcaa	900
gcgtaagcgt	tcccagatgc	tggtccgtgg	ccgtcgcgcc	tcccagcacc	atcatcacca	960
ccactgacct	tctgctcgta	gcgattactt	cgagcattac	tgacgacaaa	gaccccgacc	1020
gagatggtcg	gggtcttttt	gttggtggtg	tgtgacgtgt	tgtccaaccg	tattattccg	1080
gactagtcct	ccaggacctc	gtctacgagg	cgctgagcga	ggaatggcgc	aaaagggacg	1140
gcgagatcag	cgacccatgg	gccaacgacg	aggcggacgg	ataccagccg	ccctcatacg	1200
agccggtcaa	ccccgaacgc	aggactcccc	agacgccctc	cgatggcctg	atctgacgtc	1260
cgaaaaaagg	cgctgtgcgc	cctttttaaa	tcttttataa	atctttttac	attcttttag	1320
cccctccgca	gccttactct	cccaacgggt	ttcagccgaa	acctacacca	aaaggggagc	1380
gaacctacac	caaaagggga	gcgaacctac	acaaaaaggg	gagcgaacct	acaccaaaag	1440
gggagctata	tacacctttt	gttattttaag	gtgcaagttg	tgctatgctg	aggccatgtc	1500
caatgagatc	gtgaagttca	gcaaccagtt	caacaacgtc	gcgctgaaga	agttcgacgc	1560
cgtgcacctg	gacgtgctca	tggcgatcgc	ctcaaggggtg	agggagaagg	gcacggccac	1620
ggtggagttc	tcgttcgagg	agctgcgcgg	cctcatgcga	ttgaggaaga	acctgaccaa	1680
caagcagctg	gccgacaaga	tcgtgcagac	gaacgcgcgc	ctgctggcgc	tgaactacat	1740
gttcgaggat	tcgggcaaga	tcatccagtt	cgcgctgttc	acgaagttcg	tcaccgaccc	1800
gcaggaggcg	actctcgcgg	ttgggggtcaa	cgaggagttc	gcgttcctgc	tcaacgacct	1860
gaccagccag	ttcacgcgct	tcgagctggc	cgagttcgcc	gacctcaaga	gcaagtacgc	1920
caaggagttc	taccgcaggg	ccaagcagta	ccgcagctcc	ggaatctgga	agatcggccg	1980
cgacgagttc	tgccgactgc	ttggcggttc	accgtcggca	ataaaccaga	cacgatatct	2040
gaatcagaag	gttcttcagc	caattcagga	ggagtgtggg	cctctccttg	gcctgaagat	2100
cgagcgccag	tacgtgaaac	gcaggctgtc	gggcttcgtg	ttcacattcg	cccgcgagac	2160
ccctccggtg	atcgacgcca	ggcccgtgga	ggcgagggaag	acggacggcg	acggcaaggg	2220
ccattggacg	agcgttgccg	ggtacggcga	ggtgttcacg	accacggcgt	tgttcgacgt	2280
gacggccgcc	cgggctcact	tcgacggcac	cgttgaagcc	ggggagtgcc	gtttctgcgc	2340
gtttgacgcg	cgcaaccgcg	aacatcatgc	gcggaacgcc	ggaaggctgt	tctagcggcc	2400
gtgtccgcgc	ctctggggcg	gttgcgccctg	ccatgggtcg	atctgccgct	gttcggcctc	2460
acgctggtct	gtgcgctgcc	tgatctccct	gagcaggctg	gccttggtcc	tgggggcgct	2520
tcgctcctcg	aacgggcccgc	tctccccag	gtcctcgggc	tcgctcaggt	ccaacggctc	2580
gtcaccggac	ggctcggggc	ggttctctcc	ctgtgccggg	ttctccgcct	gtgcgcgttg	2640

Sequence Listings_ASCII.txt

```

ttcggccatg cgcagtgcga gggccttcac ctgttcgggg cttgtcgact cgatttttcgt 2700
tcgtgaatac atgtttataat aactataact aataacgtaa cgtgactggc aagagatatt 2760
tttaaaacaa tgaatagggtt tacacttact ttagttttat ggaaatgaaa gatcatatca 2820
tatataatct agaataaaat taactaaaat aattattatc tagataaaaa atttagaagc 2880
caatgaaatc tataaataaa ctaaattaag tttattttaat taacaactat ggatataaaa 2940
taggtactaa tcaaaatagt gaggaggata tatttgaata catacgaaca aattaataaa 3000
gtgaaaaaaa tacttcggaa acatttaaaa aataacctta ttggtactta catgtttgga 3060
tcaggagttg agagtggact aaaaccaa atgtgatcttg acttttttagt cgtcgtatct 3120
gaaccattga cagatcaaag taaagaaata cttatacaaa aaattagacc tatttcaaaa 3180
aaaataggag ataaaagcaa cttacgatat attgaattaa caattattat tcagcaagaa 3240
atggtaccgt ggaatcatcc tcccaacaa gaatttattt atggagaatg gttacaagag 3300
ctttatgaac aaggatacat tcctcagaag gaattaaatt cagatttaac cataatgctt 3360
taccaagcaa aacgaaaaaa taaaagaata tacggaaatt atgacttaga ggaattacta 3420
cctgatattc ctttttctga tgtgagaaga gccattatgg attcgtcaga ggaattaata 3480
gataattatc aggatgatga aaccaactct atattaactt tatgccgtat gattttaact 3540
atggacacgg gtaaaatcat accaaaagat attgcgggaa atgcagtggc tgaatcttct 3600
ccattagaac atagggagag aattttgtta gcagttcgta gttatcttgg agagaatatt 3660
gaatggacta atgaaaatgt aaatttaact ataaactatt taaataacag attaaaaaaa 3720
ttataaaaaa attgaaaaaa tggtggaac acttttttca atttttttag atcttgagca 3780
aaaggccagc aaaaggccag gaaccgtaaa aaggccgcgt tgctggcggt tttccatagg 3840
ctccgcccc ctgacgagca tcacaaaaat cgacgctcaa gtcagaggtg gcgaaacccg 3900
acaggactat aaagatacca ggcgtttccc cctggaagct ccctcgtgcg ctctcctgtt 3960
ccgaccctgc cgcttaccgg atacctgtcc gcctttctcc cttcggaag cgtggcgctt 4020
tctcatagct cacgctgtag gtatctcagt tcggtgtagg tcgttcgctc caagctgggc 4080
tgtgtgcacg aacccccctg tcagcccgac cgctgcgcct tatccggtaa ctatcgtctt 4140
gagtccaacc cggtaaagaca cgacttatcg ccactggcag cagccactgg taacaggatt 4200
agcagagcga ggtatgtagg cggtgctaca gagttcttga agtgggtggc taactacggc 4260
tacactagaa gaacagtatt tggatatctgc gctctgctga agccagttac cttcgaaaaa 4320
agagttggta gctcttgatc cggcaacaa accaccgtg gtagcggtgg tttttttgtt 4380
tgcaagcagc agattacgcg cagaaaaaaa ggatctcaag aagatccttt gatcttttct 4440
ac 4442

```

```

<210> 17
<211> 5697
<212> DNA
<213> Artificial

```

Sequence Listings_ASCII.txt

<220>

<223> pHG-1

<400> 17

tagccggcat	tttcgcgata	cattcccccg	aatgttgcg	aacggggaac	gcgcaccaca	60
ccgcaaccac	agtgcgccac	gcccagtccg	gccctgtgcg	ctataatagg	tcagttattc	120
gcgcgcgcgt	ggcgccctct	acacccccgag	ccgcgaggac	acgtggattc	cggacggcca	180
tgccccacat	ggcaaaccga	gaacccgcac	acctagcatt	acaaggagag	ccattatggc	240
gttgatgatg	agcgttaaga	ctattatttc	cacatcagtg	gcgattatcg	ccacgggtgc	300
catgttttgcg	tgcgtagccc	cgtttgcctc	tgccgattcc	gcgcagacga	gtgctgtggt	360
gtcctcacgt	tctttcccga	aggcgagttc	ggtggaagtg	cagctggtcg	aatcgggcg	420
cggcctggtg	cagccggg	gctccctgcg	tctgtcgtgc	gccgcctcgg	gcttcaacat	480
caaggatacc	tacatccact	gggtgcgcca	ggccccgggc	aagggcctgg	aatgggtggc	540
ccgtatctac	ccgaccaacg	gctacacccg	ctacgccgat	tccgtgaagg	gccgcttcac	600
catctccgcc	gataccagca	agaacaccgc	ctacctgcag	atgaactccc	tgcgcgccga	660
agataccgcc	gtgtactact	gctcgcgctg	gggcggcgac	ggcttctacg	ccatggacta	720
ctggggccag	ggcacccctg	tgaccgtgtc	cagcggcggc	ggcggctccg	gcggcggcgg	780
ctcgggcggc	ggcggctccg	acatccagat	gacccagtcc	ccgtcgtccc	tgagcgcctc	840
ggtgggcgat	cgcgtgacca	tcacctgccg	cgccctcccag	gatgtgaaca	ccgccgtggc	900
ctggtaccag	cagaagccgg	gcaaggcccc	gaagctgctg	atctactcgg	cctccttcct	960
gtactccggc	gtgccgtccc	gtttctccgg	ctcccgctcg	ggcaccgact	tcaccctgac	1020
catctcgtcc	ctgcagccgg	aagacttcgc	cacctactac	tgccagcagc	attacaccac	1080
cccgccgacc	ttcggccagg	gcaccaaggt	ggaaatcaag	catcatcatc	atcatcactg	1140
accttctgct	cgtagcgatt	acttcgagca	ttactgacga	caaagacccc	gaccgagatg	1200
gtcggggtct	ttttgttgtg	gtgctgtgac	gtgttgtcca	accgtattat	tccggggatc	1260
cgtcttcctg	ctggcctatg	cattgggttc	cgcagtgccc	actccaggcg	gtctgggcgg	1320
tgtggaagcg	gcgctgacat	tcgcgttcgt	ggcggtcgga	gtgccgcagg	gcgtggcgct	1380
ttccgccact	ttgctgcacc	gcgtggtgtt	ctactggctg	cgcatccgc	tgggcgcggc	1440
ggccatgaag	tggcttgaca	agcataatct	tgtctgattc	gtctattttc	ataccccctt	1500
cggggaaata	gatgtgaaaa	cccttataaa	acgcgggttt	tcgcagaaac	atgcgctagt	1560
atcattgatg	acaacatgga	ctaagcaaaa	gtgcttgtcc	cctgacccaa	gaaggatgct	1620
ttatgaatta	tttacgacaa	aaaatttcgg	ctagtgtctat	cgcggtgttg	tcgacttgtg	1680
ggttgatttt	ggcgccaatg	ccggtctttg	cggatgattc	aacgccatct	tcaacgccat	1740
cggatggcag	ttacaccacg	actgatagcg	gtcaggaccc	gtacgtcaag	gaagccgaaa	1800
acctgaagaa	gtacttcaac	gccggccata	gcgatgtcgc	cgataacggc	accctgttcc	1860
tgggcatacct	gaagaactgg	aaggaagagt	ccgaccgcaa	gatcatgcag	tcccagatcg	1920

Sequence Listings_ASCII.txt

tgagcttcta	cttcaagctg	ttcaagaact	tcaaggacga	tcagtcgatc	cagaagtccg	1980
tggagaccat	caaggaagac	atgaacgtca	agttcttcaa	cagcaacaag	aagaagcgcg	2040
acgatttcga	gaagctgacc	aactactccg	tgaccgatct	gaacgtccag	cgtaaggcca	2100
tccacgagct	gatccaggtc	atggccgaac	tgtccccggc	cgccaagacc	ggcaagcgta	2160
agcgttccca	gatgctgttc	cgtggccgtc	gcgccctcca	gcaccatcat	caccaccact	2220
gaccttctgc	tcgtagcgat	tacttcgagc	attactgacg	acaaagaccc	cgaccgagat	2280
ggtcgggggc	tttttgttgt	gggtgtgtga	cgtgttgctc	aaccgtatta	ttccggacta	2340
gtcctccagg	acctcgctta	cgaggcgctg	agcgaggaat	ggcgcaaaaag	ggacggcgag	2400
atcagcgacc	catggggcaa	cgacgaggcg	gacggatacc	agccgccctc	atacgagccg	2460
gtcaaccccg	aacgcaggac	tccccagacg	ccctccgatg	gcctgatctg	acgtccgaaa	2520
aaaggcgctg	tgcgcccttt	ttaaattcttt	tataaatctt	tttacattct	tttagcccct	2580
ccgcagcctt	actctcccaa	cggggtttcag	ccgaaaccta	caccaaaaag	ggagcgaacc	2640
tacacaaaaa	ggggagcgaa	cctacaccaa	aaggggagcg	aacctacacc	aaaaggggag	2700
ctatatacac	cttttgttat	ttaaggtgca	agttgtgcta	tgctgaggcc	atgtccaatg	2760
agatcgtgaa	gttcagcaac	cagttcaaca	acgtcgcgct	gaagaagttc	gacgccgtgc	2820
acctggacgt	gctcatggcg	atcgccctca	gggtgagggg	gaagggcacg	gccacggtgg	2880
agttctcggt	cgaggagctg	cgcggcctca	tgcgattgag	gaagaacctg	accaacaagc	2940
agctggccga	caagatcgtg	cagacgaacg	cgcgccctgct	ggcgctgaac	tacatgttcg	3000
aggattcggg	caagatcatc	cagttcgcgc	tgttcacgaa	gttcgtcacc	gacccgcagg	3060
aggcgactct	cgcggttggg	gtcaacgagg	agttcgcgtt	cctgctcaac	gacctgacca	3120
gccagttcac	gcgcttcgag	ctggccgagt	tcgccgacct	caagagcaag	tacgccaagg	3180
agttctaccg	cagggccaag	cagtaccgca	gctccggaat	ctggaagatc	ggccgcgacg	3240
agttctgccg	actgcttggc	gttccaccgt	cggcaataac	ccagacacga	tatctgaatc	3300
agaaggttct	tcagccaatt	caggaggagt	gtgggcctct	ccttggcctg	aagatcgagc	3360
gccagtacgt	gaaacgcagg	ctgtcgggct	tcgtgttcac	attcgcccgc	gagaccctc	3420
cggtagatga	cgccaggccc	gtggaggcga	ggaagacgga	cggcgacggc	aagggccatt	3480
ggacgagcgt	tgccgggtac	ggcgagggtg	tcacgaccac	ggcgttgttc	gacgtgacgg	3540
ccgcccgggc	tcacttcgac	ggcaccgttg	aagccgggga	gtgccgtttc	tgcgcgtttg	3600
acgcgcgcaa	ccgcgaacat	catgcgcgga	acgccggaag	gctgttctag	cggccgtgtc	3660
cgcgccctct	gggcggttgc	gcctgccatg	ggtcgatctg	ccgctgttcg	gcctcacgct	3720
ggctctgtgc	ctgcctgatc	tccctgagca	ggtcggcctt	ggctcctggg	gcgcttcgct	3780
cctcgaacgg	gccgctctcc	cccaggctct	cgggctcgct	caggtccaac	ggctcgtcac	3840
cggacggctc	gggcccgttc	tctccctgtg	ccgggttctc	cgccctgtgc	cgttgttcgg	3900
ccatgcgcag	tgcgagggcc	ttcacctgtt	cggggcctgt	cgactcgatt	ttcgttcgtg	3960

Sequence Listings_ASCII.txt

```

aatacatggtt ataataacta taactaataa cgtaacgtga ctggcaagag atatTTTTTaa 4020
aacaatgaat aggttttacac ttacttttagt tttatggaaa tgaaagatca tatcatatat 4080
aatctagaat aaaattaact aaaataatta ttatctagat aaaaaattta gaagccaatg 4140
aaatctataa ataaactaaa ttaagtttat ttaattaaca actatggata taaaataggt 4200
actaatcaaa atagtgagga ggatatatTTT gaatacacatc gaacaaatta ataaagtgaa 4260
aaaaatactt cggaacatt taaaaataa ccttattggt acttacatgt ttggatcagg 4320
agttgagagt ggactaaaac caaatagtga tcttgacttt ttagtcgtcg tatctgaacc 4380
attgacagat caagtaaag aaatacttat acaaaaaatt agacctatTTT caaaaaaaat 4440
aggagataaa agcaacttac gatatatTTga attaacaatt attattcagc aagaaatggt 4500
accgtggaat catcctcca aacaagaatt tatttatgga gaatggttac aagagcttta 4560
tgaacaagga tacattcctc agaaggaatt aaattcagat ttaaccataa tgctttacca 4620
agcaaaacga aaaaataaaa gaatatacgg aaattatgac ttagaggaat tactacctga 4680
tattccattt tctgatgtga gaagagccat tatggattcg tcagaggaat taatagataa 4740
ttatcaggat gatgaaacca actctatatt aactttatgc cgtatgattt taactatgga 4800
cacgggtaaa atcatacca aagatattgc gggaaatgca gtggctgaat cttctccatt 4860
agaacatagg gagagaattt tgtagcagt tcgtagttat cttggagaga atattgaatg 4920
gactaatgaa aatgtaaatt taactataaa ctatttaaat aacagattaa aaaaattata 4980
aaaaaattga aaaaatggtg gaaacacttt tttcaatttt tttagatctt gagcaaaagg 5040
ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg 5100
ccccctgac gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg 5160
actataaaga taccaggcgt tttccccctg aagctccctc gtgcgctctc ctgttccgac 5220
cctgccgctt accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgcttttca 5280
tagctcacgc tgtaggtatc tcagttcggg gtaggtcgtt cgctccaagc tgggctgtgt 5340
gcacgaaccc ccggttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc 5400
caaccggta agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag 5460
agcgagggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac 5520
tagaagaaca gtatttggtg tctgcgctct gctgaagcca gttaccttcg gaaaaagagt 5580
tggtagctct tgatccggca aacaaaccac cgctggtagc ggtggTTTTT ttgtttgcaa 5640
gcagcagatt acgcgagaa aaaaaggatc tcaagaagat cttttgatct tttctac 5697

```

```

<210> 18
<211> 33
<212> DNA
<213> Artificial

```

```

<220>
<223> GA1_primer

```

Sequence Listings_ASCII.txt

<400> 18
gagcagaagg tcactgggag gcgcgacggc cac 33

<210> 19
<211> 21
<212> DNA
<213> Artificial

<220>
<223> GA2_primer

<400> 19
agtgaccttc tgctcgtagc g 21

<210> 20
<211> 21
<212> DNA
<213> Artificial

<220>
<223> GA5_primer_rev

<400> 20
ggtatgtagg cggtgctaca g 21

<210> 21
<211> 20
<212> DNA
<213> Artificial

<220>
<223> GA6_primer

<400> 21
caccgcctac atacctcgct 20

<210> 22
<211> 25
<212> DNA
<213> Artificial

<220>
<223> GA100_primer

<400> 22
cggtggtgcg ctcctcctcc cgtac 25

<210> 23
<211> 18
<212> DNA
<213> Artificial

<220>
<223> GA101_primer

<400> 23
tcacagggcg atgatgcc 18

<210> 24
<211> 28
<212> DNA
<213> Artificial

Sequence Listings_ASCII.txt

```

<220>
<223> GA103_primer

<400> 24
aggagcgcac caccgaactc gccttcgg                28

<210> 25
<211> 39
<212> DNA
<213> Artificial

<220>
<223> GA104_primer

<400> 25
atcatcgccc tgtgaaaccg cttctcattt ccatttgcg        39

<210> 26
<211> 27
<212> DNA
<213> Artificial

<220>
<223> GA113_primer

<400> 26
cggtgcacac tagtcctcca ggacctc                    27

<210> 27
<211> 25
<212> DNA
<213> Artificial

<220>
<223> GA116_primer

<400> 27
gactagtgtg caccgaatcg cgctg                        25

<210> 28
<211> 34
<212> DNA
<213> Artificial

<220>
<223> IFNG1_primer

<400> 28
gaaggatgct ttatgcagga cccgtacgtc aagg            34

<210> 29
<211> 34
<212> DNA
<213> Artificial

<220>
<223> IFNG2_primer

<400> 29
catcatcacc accactgacc ttctgctcgt agcg            34

```

Sequence Listings_ASCII.txt

```

<210> 30
<211> 36
<212> DNA
<213> Artificial

<220>
<223> IFNG3_primer

<400> 30
gtggtggtga tgatggtgct gggaggcgcg acggcc 36

<210> 31
<211> 19
<212> DNA
<213> Artificial

<220>
<223> hIFNG4_primer

<400> 31
caggaccgt acgtcaagg 19

<210> 32
<211> 43
<212> DNA
<213> Artificial

<220>
<223> SP69-ins_F1_primer

<400> 32
caagaaggat gctttatgaa ttatttacga caaaaaattt cgg 43

<210> 33
<211> 38
<212> DNA
<213> Artificial

<220>
<223> SP69-ins_R2_primer

<400> 33
gacgtacggg tcctgaccgc tatcagtcgt ggtgtaac 38

<210> 34
<211> 24
<212> DNA
<213> Artificial

<220>
<223> pCDshuttle_R1_primer

<400> 34
cataaagcat ccttcttggg tcag 24

<210> 35
<211> 22
<212> DNA
<213> Artificial

<220>
<223> Hu-mCCL21-vecR1_primer

```

Sequence Listings_ASCII.txt

<400> 35
aaagcatcct tcttggtca gg 22

<210> 36
<211> 30
<212> DNA
<213> Artificial

<220>
<223> Ins-hPD-1scFv03-F1

<400> 36
caggtccagc tggtcgaatc gggcggcggc 30

<210> 37
<211> 36
<212> DNA
<213> Artificial

<220>
<223> Ins-hPD-1scFv03-R1

<400> 37
acgagcagaa ggtcagtggg ggtgatgatg gtgctt 36

<210> 38
<211> 24
<212> DNA
<213> Artificial

<220>
<223> TGA-Hu-Terminator-F

<400> 38
tgaccttctg ctcgtagcga ttac 24

<210> 39
<211> 36
<212> DNA
<213> Artificial

<220>
<223> vec-SP7L20-R1

<400> 39
gaccagctgg acctgcaccg aactcgcctt cgggaa 36

<210> 40
<211> 30
<212> DNA
<213> Artificial

<220>
<223> Ins-hCTLA-4scFv02-F1

<400> 40
caggtccagc tggtcgaatc gggcggcggc 30

<210> 41
<211> 36
<212> DNA
<213> Artificial

Sequence Listings_ASCII.txt

```

<220>
<223>  Ins-hCTLA-4scFv02-R1

<400>  41
acgagcagaa ggtcagtgat gatgatgatg atgctt                                     36

<210>  42
<211>  45
<212>  DNA
<213>  Artificial

<220>
<223>  hCTLA-4scFv02-FLAG-F1

<400>  42
gactacaagg acgacgacga caagtgacct tctgctcgta gcgat                               45

<210>  43
<211>  33
<212>  DNA
<213>  Artificial

<220>
<223>  hCTLA-4scFv02-FLAG-R1

<400>  43
gtcgtccttg tagtccttga tttccacctt ggt                                           33

<210>  44
<211>  30
<212>  DNA
<213>  Artificial

<220>
<223>  InF_pTB6 rep_F1

<400>  44
actagtcctc caggacctcg tctacgaggc                                               30

<210>  45
<211>  30
<212>  DNA
<213>  Artificial

<220>
<223>  InF_Hu Prom_F1

<400>  45
gtcttcctgc tggcctatgc attgggttcc                                             30

<210>  46
<211>  35
<212>  DNA
<213>  Artificial

<220>
<223>  InF_Hu Term-Hu Prom_R1

<400>  46
ggccagcagg aagacccgga ataatacggg tggac                                         35

```

Sequence Listings_ASCII.txt

```

<210> 47
<211> 35
<212> DNA
<213> Artificial

<220>
<223> InF_Hu Term-pTB6_R1

<400> 47
tcctggagga ctagtccgga ataatacggt tggac 35

<210> 48
<211> 25
<212> DNA
<213> Artificial

<220>
<223> pTB6_Vec_F1

<400> 48
actagtcctc caggacctcg tctac 25

<210> 49
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Hu-term_Vec_R1

<400> 49
ccggaataat acggttggac aac 23

<210> 50
<211> 34
<212> DNA
<213> Artificial

<220>
<223> Hu-HuT_ins_F1

<400> 50
accgtattat tccggggatc cgtcttcctg ctgg 34

<210> 51
<211> 38
<212> DNA
<213> Artificial

<220>
<223> HuT-pTB6_ins_R1

<400> 51
tcctggagga ctagtccgga ataatacggt tggacaac 38

<210> 52
<211> 19
<212> DNA
<213> Artificial

<220>
<223> Hu_Vec_F1

```

Sequence Listings_ASCII.txt

```

<400> 52
ggatccgtct tcctgctgg                                     19

<210> 53
<211> 25
<212> DNA
<213> Artificial

<220>
<223> bHER2-His_Vec_R1

<400> 53
tcagtgatga tgatgatgat gcttg                               25

<210> 54
<211> 37
<212> DNA
<213> Artificial

<220>
<223> d0013+T_ins_F1

<400> 54
catcatcatc actgaaaccg cttctcattt ccatttg                 37

<210> 55
<211> 32
<212> DNA
<213> Artificial

<220>
<223> d0013+T_ins_R1

<400> 55
caggaagacg gatccgtgca ccgaatcgcg ct                      32

<210> 56
<211> 99
<212> DNA
<213> Bifidobacterium spp.

<220>
<221> CDS
<222> (1)..(99)
<223>

<220>
<221> misc_feature
<223> SP7

<400> 56
atg gcg ttg atg atg agc gtt aag act att att tcc aca tca gtg gcg      48
Met Ala Leu Met Met Ser Val Lys Thr Ile Ile Ser Thr Ser Val Ala
1      5      10      15

att atc gcc acg ggt gcc atg ttt gcg tgc gta gcc ccg ttt gcc tct      96
Ile Ile Ala Thr Gly Ala Met Phe Ala Cys Val Ala Pro Phe Ala Ser
20     25     30

gcc
Ala                                         99

```

Sequence Listings_ASCII.txt

<210> 57
 <211> 33
 <212> PRT
 <213> Bifidobacterium spp.

<400> 57

Met Ala Leu Met Met Ser Val Lys Thr Ile Ile Ser Thr Ser Val Ala
 1 5 10 15

Ile Ile Ala Thr Gly Ala Met Phe Ala Cys Val Ala Pro Phe Ala Ser
 20 25 30

Ala

<210> 58
 <211> 102
 <212> DNA
 <213> Bifidobacterium spp.

<220>
 <221> CDS
 <222> (1)..(102)
 <223>

<220>
 <221> misc_feature
 <223> SP45

<400> 58
 atg aag cac ctc tcc cac cgc acc atc gcc atc atc gtc gcg ttg ctc 48
 Met Lys His Leu Ser His Arg Thr Ile Ala Ile Ile Val Ala Leu Leu
 1 5 10 15

tcc acg ctg tca ctg gca ctt gcc gtc atc tcc ctt ccg cac cag gcg 96
 Ser Thr Leu Ser Leu Ala Leu Ala Val Ile Ser Leu Pro His Gln Ala
 20 25 30

tac gca 102
 Tyr Ala

<210> 59
 <211> 34
 <212> PRT
 <213> Bifidobacterium spp.

<400> 59

Met Lys His Leu Ser His Arg Thr Ile Ala Ile Ile Val Ala Leu Leu
 1 5 10 15

Ser Thr Leu Ser Leu Ala Leu Ala Val Ile Ser Leu Pro His Gln Ala
 20 25 30

Tyr Ala

Sequence Listings_ASCII.txt

<210> 60
 <211> 168
 <212> DNA
 <213> Bifidobacterium spp.

<220>
 <221> CDS
 <222> (1)..(168)
 <223>

<220>
 <221> misc_feature
 <223> SP50

<400> 60
 atg atc gtg gcc tac ccg cac aca gtg cag tat gcg ggg aaa cgt acc 48
 Met Ile Val Ala Tyr Pro His Thr Val Gln Tyr Ala Gly Lys Arg Thr
 1 5 10 15
 agg aaa gga cga atg atg ata acg aca tgg cgg caa cgg ggc atg gcc 96
 Arg Lys Gly Arg Met Met Ile Thr Thr Trp Arg Gln Arg Gly Met Ala
 20 25 30
 atc gta gcg atg ctg acc ggt ctg ata ata atg gtg gga gtg gtg ttc 144
 Ile Val Ala Met Leu Thr Gly Leu Ile Ile Met Val Gly Val Val Phe
 35 40 45
 ggc tcg gcg aat acg gcg tat gcc 168
 Gly Ser Ala Asn Thr Ala Tyr Ala
 50 55

<210> 61
 <211> 56
 <212> PRT
 <213> Bifidobacterium spp.

<400> 61
 Met Ile Val Ala Tyr Pro His Thr Val Gln Tyr Ala Gly Lys Arg Thr
 1 5 10 15
 Arg Lys Gly Arg Met Met Ile Thr Thr Trp Arg Gln Arg Gly Met Ala
 20 25 30
 Ile Val Ala Met Leu Thr Gly Leu Ile Ile Met Val Gly Val Val Phe
 35 40 45
 Gly Ser Ala Asn Thr Ala Tyr Ala
 50 55

<210> 62
 <211> 105
 <212> DNA
 <213> Bifidobacterium spp.

<220>
 <221> CDS
 <222> (1)..(105)
 <223>

<220>
 <221> misc_feature

Sequence Listings_ASCII.txt

<223> SP52

<400> 62

atg	agt	ttc	cat	gta	tcc	gcg	caa	tcg	gtt	cgc	gcg	gtg	gcc	ggt	gga	48
Met	Ser	Phe	His	Val	Ser	Ala	Gln	Ser	Val	Arg	Ala	Val	Ala	Gly	Gly	
1				5					10				15			

ctc	gtc	gcc	gca	gcg	aca	ttg	ctg	tca	ggc	ctt	gcc	ctt	gcg	ccg	acc	96
Leu	Val	Ala	Ala	Ala	Thr	Leu	Leu	Ser	Gly	Leu	Ala	Leu	Ala	Pro	Thr	
			20					25					30			

gca	atg	gcc														105
Ala	Met	Ala														
		35														

<210> 63

<211> 35

<212> PRT

<213> Bifidobacterium spp.

<400> 63

Met	Ser	Phe	His	Val	Ser	Ala	Gln	Ser	Val	Arg	Ala	Val	Ala	Gly	Gly	
1				5					10					15		

Leu	Val	Ala	Ala	Ala	Thr	Leu	Leu	Ser	Gly	Leu	Ala	Leu	Ala	Pro	Thr	
			20					25					30			

Ala	Met	Ala														
		35														

<210> 64

<211> 144

<212> DNA

<213> Bifidobacterium spp.

<220>

<221> CDS

<222> (1)..(144)

<223>

<220>

<221> misc_feature

<223> SP55

<400> 64

atg	gtt	cgt	cgc	gcc	cag	gct	gct	ctt	cgg	tcc	gtt	gaa	cac	acc	agc	48
Met	Val	Arg	Arg	Ala	Gln	Ala	Ala	Leu	Arg	Ser	Val	Glu	His	Thr	Ser	
1				5					10					15		

gtg	agg	cag	ctg	cga	gtc	ctg	gct	gcg	att	gta	ttt	ctg	ttc	gcc	atg	96
Val	Arg	Gln	Leu	Arg	Val	Leu	Ala	Ala	Ile	Val	Phe	Leu	Phe	Ala	Met	
			20					25					30			

gtc	atc	gcc	act	gtg	gct	cct	gca	gtc	acg	gct	ccg	atg	gcc	ttc	gcc	144
Val	Ile	Ala	Thr	Val	Ala	Pro	Ala	Val	Thr	Ala	Pro	Met	Ala	Phe	Ala	
		35					40					45				

<210> 65

<211> 48

<212> PRT

Sequence Listings_ASCII.txt

<213> Bifidobacterium spp.

<400> 65

Met Val Arg Arg Ala Gln Ala Ala Leu Arg Ser Val Glu His Thr Ser
1 5 10 15

Val Arg Gln Leu Arg Val Leu Ala Ala Ile Val Phe Leu Phe Ala Met
20 25 30

Val Ile Ala Thr Val Ala Pro Ala Val Thr Ala Pro Met Ala Phe Ala
35 40 45

<210> 66

<211> 96

<212> DNA

<213> Bifidobacterium spp.

<220>

<221> CDS

<222> (1)..(96)

<223>

<220>

<221> misc_feature

<223> SP58

<400> 66

atg gca atg gca cgg cgt tgg acc ccg cag cgg ttt gtt aca ctg cgt 48
Met Ala Met Ala Arg Arg Trp Thr Pro Gln Arg Phe Val Thr Leu Arg
1 5 10 15

cgc atc cgc gta atc gcc tgt atc gcg gcg acc agt atc gcg ctg gct 96
Arg Ile Arg Val Ile Ala Cys Ile Ala Ala Thr Ser Ile Ala Leu Ala
20 25 30

<210> 67

<211> 32

<212> PRT

<213> Bifidobacterium spp.

<400> 67

Met Ala Met Ala Arg Arg Trp Thr Pro Gln Arg Phe Val Thr Leu Arg
1 5 10 15

Arg Ile Arg Val Ile Ala Cys Ile Ala Ala Thr Ser Ile Ala Leu Ala
20 25 30

<210> 68

<211> 93

<212> DNA

<213> Bifidobacterium spp.

<220>

<221> CDS

<222> (1)..(93)

<223>

<220>

<221> misc_feature

Sequence Listings_ASCII.txt

<223> SP64

<400> 68
 atg aag tca cta atc agg aat gta gcg gcg ggc gtc ctc gca gcc gcc 48
 Met Lys Ser Leu Ile Arg Asn Val Ala Ala Gly Val Leu Ala Ala Ala
 1 5 10 15

acg atg ctc ggc atc gcc ggc ctc ggc gcc acc acc gcc tcc gcg 93
 Thr Met Leu Gly Ile Ala Gly Leu Gly Ala Thr Thr Ala Ser Ala
 20 25 30

<210> 69

<211> 31

<212> PRT

<213> Bifidobacterium spp.

<400> 69

Met Lys Ser Leu Ile Arg Asn Val Ala Ala Gly Val Leu Ala Ala Ala
 1 5 10 15

Thr Met Leu Gly Ile Ala Gly Leu Gly Ala Thr Thr Ala Ser Ala
 20 25 30

<210> 70

<211> 78

<212> DNA

<213> Bifidobacterium spp.

<220>

<221> CDS

<222> (1)..(78)

<223>

<220>

<221> misc_feature

<223> SP66

<400> 70
 gtg aag cat tgg aag aag atg gca gca tcg ttg att gca ata tca acg 48
 Val Lys His Trp Lys Lys Met Ala Ala Ser Leu Ile Ala Ile Ser Thr
 1 5 10 15

atg gtg gca gta gtt ccg acg acg tat gcc 78
 Met Val Ala Val Val Pro Thr Thr Tyr Ala
 20 25

<210> 71

<211> 26

<212> PRT

<213> Bifidobacterium spp.

<400> 71

Val Lys His Trp Lys Lys Met Ala Ala Ser Leu Ile Ala Ile Ser Thr
 1 5 10 15

Met val Ala val val Pro Thr Thr Tyr Ala
 20 25

Sequence Listings_ASCII.txt

<210> 72
<211> 99
<212> DNA
<213> Bifidobacterium spp.

<220>
<221> CDS
<222> (1)..(99)
<223>

<220>
<221> misc_feature
<223> SP67

<400> 72
atg aag ata aac aat aag ggc aag ggc gct ctt atc gcg gca att acc 48
Met Lys Ile Asn Asn Lys Gly Lys Gly Ala Leu Ile Ala Ala Ile Thr
1 5 10 15

gcc gcg gca acg cta ttg tca tgc ggg ctg gcc gct gca agt gcc agt 96
Ala Ala Ala Thr Leu Leu Ser Cys Gly Leu Ala Ala Ala Ser Ala Ser
20 25 30

gcg 99
Ala

<210> 73
<211> 33
<212> PRT
<213> Bifidobacterium spp.

<400> 73
Met Lys Ile Asn Asn Lys Gly Lys Gly Ala Leu Ile Ala Ala Ile Thr
1 5 10 15

Ala Ala Ala Thr Leu Leu Ser Cys Gly Leu Ala Ala Ala Ser Ala Ser
20 25 30

Ala

<210> 74
<211> 129
<212> DNA
<213> Bifidobacterium spp.

<220>
<221> CDS
<222> (1)..(129)
<223>

<220>
<221> misc_feature
<223> SP68

<400> 74
atg gtt tat aac att cac ata ttg caa aca agg aaa acc ggt cgt gtg 48
Met Val Tyr Asn Ile His Ile Leu Gln Thr Arg Lys Thr Gly Arg Val
1 5 10 15

Sequence Listings_ASCII.txt

gtt gct gct gcg gct gca tcc gtg ctg tgt tgc atg ggg gct gta ttt 96
Val Ala Ala Ala Ala Ala Ser Val Leu Cys Cys Met Gly Ala Val Phe
20 25 30

cca gcg act atc gga gtg act gcg gcg tcg gcc 129
Pro Ala Thr Ile Gly Val Thr Ala Ala Ser Ala
35 40

<210> 75
<211> 43
<212> PRT
<213> Bifidobacterium spp.

<400> 75

Met Val Tyr Asn Ile His Ile Leu Gln Thr Arg Lys Thr Gly Arg Val
1 5 10 15

Val Ala Ala Ala Ala Ala Ser Val Leu Cys Cys Met Gly Ala Val Phe
20 25 30

Pro Ala Thr Ile Gly Val Thr Ala Ala Ser Ala
35 40

<210> 76
<211> 90
<212> DNA
<213> Bifidobacterium spp.

<220>
<221> CDS
<222> (1)..(90)
<223>

<220>
<221> misc_feature
<223> SP69

<400> 76 48
atg aat tat tta cga caa aaa att tcg gct agt gct atc gcg gtg ttg
Met Asn Tyr Leu Arg Gln Lys Ile Ser Ala Ser Ala Ile Ala Val Leu
1 5 10 15

tcg act tgt ggg ttg att ttg gcg cca atg ccg gtc ttt gcg 90
Ser Thr Cys Gly Leu Ile Leu Ala Pro Met Pro Val Phe Ala
20 25 30

<210> 77
<211> 30
<212> PRT
<213> Bifidobacterium spp.

<400> 77

Met Asn Tyr Leu Arg Gln Lys Ile Ser Ala Ser Ala Ile Ala Val Leu
1 5 10 15

Ser Thr Cys Gly Leu Ile Leu Ala Pro Met Pro Val Phe Ala
20 25 30

Sequence Listings_ASCII.txt

<210> 78
 <211> 90
 <212> DNA
 <213> Bifidobacterium spp.

<220>
 <221> CDS
 <222> (1)..(90)
 <223>

<220>
 <221> misc_feature
 <223> Linker peptide (SP7)

<400> 78
 gat tcc gcg cag acg agt gct gtg gtg tcc tca cgt tct ttc ccg aag 48
 Asp Ser Ala Gln Thr Ser Ala Val Val Ser Ser Arg Ser Phe Pro Lys
 1 5 10 15
 gcg agt tcg gtg aag aag aat ttg ttc gcc gaa tcc acc tcc 90
 Ala Ser Ser Val Lys Lys Asn Leu Phe Ala Glu Ser Thr Ser
 20 25 30

<210> 79
 <211> 30
 <212> PRT
 <213> Bifidobacterium spp.

<400> 79
 Asp Ser Ala Gln Thr Ser Ala Val Val Ser Ser Arg Ser Phe Pro Lys
 1 5 10 15
 Ala Ser Ser Val Lys Lys Asn Leu Phe Ala Glu Ser Thr Ser
 20 25 30

<210> 80
 <211> 90
 <212> DNA
 <213> Bifidobacterium spp.

<220>
 <221> CDS
 <222> (1)..(90)
 <223>

<220>
 <221> misc_feature
 <223> Linker peptide (SP45)

<400> 80
 gtc gac ggc aca gac ggc aca agc ggc acg aac agt acg tct cag gga 48
 Val Asp Gly Thr Asp Gly Thr Ser Gly Thr Asn Ser Thr Ser Gln Gly
 1 5 10 15
 agc gac ggc gat tcc gcg cca atc gcc ggc ccg gtg ccg aac 90
 Ser Asp Gly Asp Ser Ala Pro Ile Ala Gly Pro Val Pro Asn
 20 25 30

<210> 81
 <211> 30
 <212> PRT

Sequence Listings_ASCII.txt

<213> Bifidobacterium spp.

<400> 81

Val Asp Gly Thr Asp Gly Thr Ser Gly Thr Asn Ser Thr Ser Gln Gly
1 5 10 15

Ser Asp Gly Asp Ser Ala Pro Ile Ala Gly Pro Val Pro Asn
20 25 30

<210> 82

<211> 90

<212> DNA

<213> Bifidobacterium spp.

<220>

<221> CDS

<222> (1)..(90)

<223>

<220>

<221> misc_feature

<223> Linker peptide (SP50)

<400> 82

gcg acg ttg acg ccc gcc gac gaa aga tat cac gtg gcg ttt cca tac 48
Ala Thr Leu Thr Pro Ala Asp Glu Arg Tyr His Val Ala Phe Pro Tyr
1 5 10 15

aac gat atg gaa tat tac gtc ggt gtc gcg ggg ctg gac gct 90
Asn Asp Met Glu Tyr Tyr Val Gly Val Ala Gly Leu Asp Ala
20 25 30

<210> 83

<211> 30

<212> PRT

<213> Bifidobacterium spp.

<400> 83

Ala Thr Leu Thr Pro Ala Asp Glu Arg Tyr His Val Ala Phe Pro Tyr
1 5 10 15

Asn Asp Met Glu Tyr Tyr Val Gly Val Ala Gly Leu Asp Ala
20 25 30

<210> 84

<211> 90

<212> DNA

<213> Bifidobacterium spp.

<220>

<221> CDS

<222> (1)..(90)

<223>

<220>

<221> misc_feature

<223> Linker peptide (SP52)

<400> 84

Sequence Listings_ASCII.txt

gcc gat tca gcc acc gct gac aac gcg ccc agc gtt gcc ggt cac gcg 48
Ala Asp Ser Ala Thr Ala Asp Asn Ala Pro Ser Val Ala Gly His Ala
1 5 10 15

tat aac gaa ctg ccg tat aac aat cct gat gtc acc gtc acc 90
Tyr Asn Glu Leu Pro Tyr Asn Asn Pro Asp Val Thr Val Thr
20 25 30

<210> 85
<211> 30
<212> PRT
<213> Bifidobacterium spp.

<400> 85

Ala Asp Ser Ala Thr Ala Asp Asn Ala Pro Ser Val Ala Gly His Ala
1 5 10 15

Tyr Asn Glu Leu Pro Tyr Asn Asn Pro Asp Val Thr Val Thr
20 25 30

<210> 86
<211> 90
<212> DNA
<213> Bifidobacterium spp.

<220>
<221> CDS
<222> (1)..(90)
<223>

<220>
<221> misc_feature
<223> Linker peptide (SP55)

<400> 86
gac agc agc acc agc tcg tcc agt tca tca agc tcg tcc agc gtt gac 48
Asp Ser Ser Thr Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Val Asp
1 5 10 15

tac gcc acc tgg gcc gaa gtc tcc aag gcg atg gac aag cag 90
Tyr Ala Thr Trp Ala Glu Val Ser Lys Ala Met Asp Lys Gln
20 25 30

<210> 87
<211> 30
<212> PRT
<213> Bifidobacterium spp.

<400> 87

Asp Ser Ser Thr Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Val Asp
1 5 10 15

Tyr Ala Thr Trp Ala Glu Val Ser Lys Ala Met Asp Lys Gln
20 25 30

<210> 88
<211> 90
<212> DNA
<213> Bifidobacterium spp.

Sequence Listings_ASCII.txt

```

<220>
<221> CDS
<222> (1)..(90)
<223>

<220>
<221> misc_feature
<223> Linker peptide (SP58)

<400> 88
gga tca ttc gcg ttc acc gcg cgt aaa tcc gtg gcc ctg aac atc aac      48
Gly Ser Phe Ala Phe Thr Ala Arg Lys Ser Val Ala Leu Asn Ile Asn
1          5          10          15

ggg caa acc acc caa gtc acc aca tat gcg atg acg gcc acc      90
Gly Gln Thr Thr Gln Val Thr Thr Tyr Ala Met Thr Ala Thr
          20          25          30

<210> 89
<211> 30
<212> PRT
<213> Bifidobacterium spp.

<400> 89
Gly Ser Phe Ala Phe Thr Ala Arg Lys Ser Val Ala Leu Asn Ile Asn
1          5          10          15

Gly Gln Thr Thr Gln Val Thr Thr Tyr Ala Met Thr Ala Thr
          20          25          30

<210> 90
<211> 90
<212> DNA
<213> Bifidobacterium spp.

<220>
<221> CDS
<222> (1)..(90)
<223>

<220>
<221> misc_feature
<223> Linker peptide (SP64)

<400> 90
gaa gat gct acc ggc acg ctg acc gtc acc agc tcg gat gcc gcg ttc      48
Glu Asp Ala Thr Gly Thr Leu Thr Val Thr Ser Ser Asp Ala Ala Phe
1          5          10          15

aac ggc aag aag gtg aac gcc tac cag atg ttc tcc gct tcc      90
Asn Gly Lys Lys Val Asn Ala Tyr Gln Met Phe Ser Ala Ser
          20          25          30

<210> 91
<211> 30
<212> PRT
<213> Bifidobacterium spp.

<400> 91

```

Sequence Listings_ASCII.txt

Glu Asp Ala Thr Gly Thr Leu Thr Val Thr Ser Ser Asp Ala Ala Phe
1 5 10 15

Asn Gly Lys Lys Val Asn Ala Tyr Gln Met Phe Ser Ala Ser
20 25 30

<210> 92
<211> 90
<212> DNA
<213> Bifidobacterium spp.

<220>
<221> CDS
<222> (1)..(90)
<223>

<220>
<221> misc_feature
<223> Linker peptide (SP66)

<400> 92
atg gaa tcg gaa gat tcc caa cca cag aca acc gat acc gcg aca gtg 48
Met Glu Ser Glu Asp Ser Gln Pro Gln Thr Thr Asp Thr Ala Thr Val
1 5 10 15

cag act act aag gct gct gaa ccg acg ctg ctc gcc agc tgg 90
Gln Thr Thr Lys Ala Ala Glu Pro Thr Leu Leu Ala Ser Trp
20 25 30

<210> 93
<211> 30
<212> PRT
<213> Bifidobacterium spp.

<400> 93
Met Glu Ser Glu Asp Ser Gln Pro Gln Thr Thr Asp Thr Ala Thr Val
1 5 10 15

Gln Thr Thr Lys Ala Ala Glu Pro Thr Leu Leu Ala Ser Trp
20 25 30

<210> 94
<211> 90
<212> DNA
<213> Bifidobacterium spp.

<220>
<221> CDS
<222> (1)..(90)
<223>

<220>
<221> misc_feature
<223> Linker peptide (SP67)

<400> 94
gca ggt gtg gat tac ctg cct acc atc ggc caa gtg ccg aca tac acc 48
Ala Gly Val Asp Tyr Leu Pro Thr Ile Gly Gln Val Pro Thr Tyr Thr
1 5 10 15

aag ttc cag ccc aca gcc gat ccg ggc aag aac gct agc gat 90
 Lys Phe Gln Pro Thr Ala Asp Pro Gly Lys Asn Ala Ser Asp
 20 25 30

<210> 95
 <211> 30
 <212> PRT
 <213> Bifidobacterium spp.

<400> 95

Ala Gly Val Asp Tyr Leu Pro Thr Ile Gly Gln Val Pro Thr Tyr Thr
 1 5 10 15

Lys Phe Gln Pro Thr Ala Asp Pro Gly Lys Asn Ala Ser Asp
 20 25 30

<210> 96
 <211> 90
 <212> DNA
 <213> Bifidobacterium spp.

<220>
 <221> CDS
 <222> (1)..(90)
 <223>

<220>
 <221> misc_feature
 <223> Linker peptide (SP68)

<400> 96 48
 gat gaa ccc gtc gaa ttg gtc gtc aac ggc gga ttc gaa gac gat ctt
 Asp Glu Pro Val Glu Leu Val Val Asn Gly Gly Phe Glu Asp Asp Leu
 1 5 10 15

aat ggt tgg aag tct gga acg gtg tgg aat agc tcc gca tcg 90
 Asn Gly Trp Lys Ser Gly Thr Val Trp Asn Ser Ser Ala Ser
 20 25 30

<210> 97
 <211> 30
 <212> PRT
 <213> Bifidobacterium spp.

<400> 97

Asp Glu Pro Val Glu Leu Val Val Asn Gly Gly Phe Glu Asp Asp Leu
 1 5 10 15

Asn Gly Trp Lys Ser Gly Thr Val Trp Asn Ser Ser Ala Ser
 20 25 30

<210> 98
 <211> 90
 <212> DNA
 <213> Bifidobacterium spp.

<220>
 <221> CDS
 <222> (1)..(90)

Sequence Listings_ASCII.txt

<223>

<220>

<221> misc_feature

<223> Linker peptide (SP69)

<400> 98

gat	gat	tca	acg	cca	tct	tca	acg	cca	tcg	gat	ggc	agt	tac	acc	acg		48
Asp	Asp	Ser	Thr	Pro	Ser	Ser	Thr	Pro	Ser	Asp	Gly	Ser	Tyr	Thr	Thr		
1				5				10						15			

act	gat	agc	ggg	gat	ggc	acg	tat	tcc	att	ccc	atg	ttg	aac				90
Thr	Asp	Ser	Gly	Asp	Gly	Thr	Tyr	Ser	Ile	Pro	Met	Leu	Asn				
			20					25					30				

<210> 99

<211> 30

<212> PRT

<213> Bifidobacterium spp.

<400> 99

Asp	Asp	Ser	Thr	Pro	Ser	Ser	Thr	Pro	Ser	Asp	Gly	Ser	Tyr	Thr	Thr	
1				5				10						15		

Thr	Asp	Ser	Gly	Asp	Gly	Thr	Tyr	Ser	Ile	Pro	Met	Leu	Asn			
			20					25					30			

<210> 100

<211> 5697

<212> DNA

<213> Artificial

<220>

<223> pHG-2

<400> 100

tagccggcat	tttcgcgata	cattccccgg	aatgttgcg	aacggggaac	gcgcaccaca		60
ccgcaaccac	agtgcgccac	gcccagtcg	gccctgtgcg	ctataatagg	tcagttattc		120
gcgcgcgcgt	ggcgccctct	acaccccgag	ccgcgaggac	acgtggattc	cggacggcca		180
tgccccacat	ggcaaaccga	gaaccgcac	acctagcatt	acaaggagag	ccattatggc		240
gttgatgatg	agcgtaaga	ctattatttc	cacatcagtg	gcgattatcg	ccacgggtgc		300
catgtttgcg	tgcgtagccc	cgtttgcctc	tgccgattcc	gcgcagacga	gtgctgtggt		360
gtcctcacgt	tctttcccga	aggcgagttc	ggtggaagtg	cagctggtcg	aatcgggcgg		420
cggcctgggtg	cagccgggcg	gctccctgcg	tctgtcgtgc	gccgcctcgg	gcttcaacat		480
caaggatacc	tacatccact	gggtgcgcca	ggccccgggc	aagggcctgg	aatgggtggc		540
ccgtatctac	ccgaccaacg	gctacacccg	ctacgccgat	tccgtgaagg	gccgcttcac		600
catctccgcc	gataccagca	agaacaccgc	ctacctgcag	atgaactccc	tgcgcgccga		660
agataccgcc	gtgtactact	gctcgcgctg	gggcggcgac	ggcttctacg	ccatggacta		720
ctggggccag	ggcaccctgg	tgaccgtgtc	cagcggcggc	ggcggctccg	gcggcggcgg		780
ctcgggcggc	ggcggctccg	acatccagat	gacccagtc	ccgtcgtccc	tgagcgcctc		840

Sequence Listings_ASCII.txt

```

ggtgggcgat cgcgtagacca tcacctgccg cgccctcccag gatgtgaaca ccgccgtggc 900
ctggtaccag cagaagccgg gcaaggcccc gaagctgctg atctactcgg cctccttcct 960
gtactccggc gtgccgtccc gtttctccgg ctcccgtctg ggcaccgact tcaccctgac 1020
catctcgtcc ctgcagccgg aagacttcgc cacctactac tgccagcagc attacaccac 1080
cccgccgacc ttcggccagg gcaccaaggt ggaaatcaag catcatcatc atcatcactg 1140
aaaccgcttc tcatttccat ttgcgatatg gtctgaatac gacgaaaccc cggcgcgagg 1200
ccgggggttc gtaagctgtg cgtgactata gcacgaccag cgcgattcgg tgcacggatc 1260
cgtcttcctg ctggcctatg cattgggttc cgcagtgcgc actccaggcg gtctgggagg 1320
tgtggaagcg gcgctgacat tcgcgttcgt ggcggctcga gtgccgcagg gcgtggcgct 1380
ttccgccact ttgctgcacc gcgtggtgtt ctactggctg cgcatccgc tgggcgcggc 1440
ggccatgaag tggcttgaca agcataatct tgtctgattc gtctattttc atacccccctt 1500
cggggaaata gatgtgaaaa cccttataaa acgcgggttt tcgcagaaac atgcgctagt 1560
atcattgatg acaacatgga ctaagcaaaa gtgcttgctc cctgacccaa gaaggatgct 1620
ttatgaatta ttacgacaa aaaatttcgg ctagtgctat cgcggtgttg tcgacttggt 1680
ggttgatttt ggcgccaatg ccgggtcttt cggtatgattc aacgccatct tcaacgccat 1740
cggtatggcag ttacaccacg actgatagcg gtcaggaccc gtacgtcaag gaagccgaaa 1800
acctgaagaa gtacttcaac gccggccata gcgatgtcgc cgataacggc acctgtttcc 1860
tgggcatcct gaagaactgg aaggaagagt ccgaccgcaa gatcatgcag tcccagatcg 1920
tgagcttcta cttcaagctg ttcaagaact tcaaggacga tcagtcgatc cagaagtccg 1980
tgagagaccat caaggaagac atgaacgtca agttcttcaa cagcaacaag aagaagcgcg 2040
acgatttcga gaagctgacc aactactccg tgaccgatct gaacgtccag cgtaaggcca 2100
tccacgagct gatccaggtc atggccgaac tgtccccggc cgccaagacc ggcaagcgta 2160
agcgttccca gatgctgttc cgtggccgtc gcgcctccca gcaccatcat caccaccact 2220
gaccttctgc tcgtagcgat tacttcgagc attactgacg acaaagaccc cgaccgagat 2280
ggtcggggtc tttttgttgt ggtgctgtga cgtgtgtgcc aaccgtatta ttccggacta 2340
gtcctccagg acctcgtcta cgaggcgctg agcgaggaat ggcgcaaaag ggacggcgag 2400
atcagcgacc catgggcca cgcagaggcg gacggatacc agccgccctc atacgagccg 2460
gtcaaccccg aacgcaggac tccccagacg ccctccgatg gcctgatctg acgtccgaaa 2520
aaaggcgctg tgcgcccttt ttaaattctt tataaatctt ttacattct tttagcccct 2580
ccgcagcctt actctcccaa cgggtttcag ccgaaacct caccaaaagg ggagcgaacc 2640
tacacaaaaa ggggagcgaa cctacaccaa aaggggagcg aacctacacc aaaaggggag 2700
ctatatacac cttttgttat ttaaggtgca agttgtgcta tgctgaggcc atgtccaatg 2760
agatcgtgaa gttcagcaac cagttcaaca acgtcgcgct gaagaagttc gacgccgtgc 2820
acctggacgt gctcatggcg atcgcctcaa ggggtgaggga gaagggcacg gccacgggtg 2880

```

Sequence Listings_ASCII.txt

agttctcggtt	cgaggagctg	cgcggcctca	tgcgattgag	gaagaacctg	accaacaagc	2940
agctggccga	caagatcgtg	cagacgaacg	cgcgcttgct	ggcgctgaac	tacatgttcg	3000
aggattcggg	caagatcatc	cagttcgcgc	tgttcacgaa	gttcgtcacc	gacccgcagg	3060
aggcgactct	cgcggttggg	gtcaacgagg	agttcgcgtt	cctgctcaac	gacctgacca	3120
gccagttcac	gcgcttcgag	ctggccgagt	tcgccgacct	caagagcaag	tacgccaagg	3180
agttctaccg	cagggccaag	cagtaccgca	gctccggaat	ctggaagatc	ggccgcgacg	3240
agttctgccg	actgcttggc	gttccaccgt	cggcaataac	ccagacacga	tatctgaatc	3300
agaaggttct	tcagccaatt	caggaggagt	gtgggcctct	ccttggcctg	aagatcgagc	3360
gccagtacgt	gaaacgcagg	ctgtcgggct	tcgtgttcac	attcgcccgc	gagacccctc	3420
cggtgatcga	cgccaggccc	gtggaggcga	ggaagacgga	cggcgacggc	aagggccatt	3480
ggacgagcgt	tgccgggtac	ggcgagggtg	tcacgaccac	ggcgttgttc	gacgtgacgg	3540
ccgcccgggc	tcacttcgac	ggcaccgttg	aagccgggga	gtgccgtttc	tgcgcgtttg	3600
acgcgcgcaa	ccgcgaacat	catgcgcgga	acgccggaag	gctgttctag	cggccgtgtc	3660
cgcgcctctg	gggcgggttg	gcctgccatg	ggtcgatctg	ccgctgttcg	gcctcacgct	3720
ggtctgtgcg	ctgcctgata	tccctgagca	ggtcggcctt	ggtcctgggg	gcgcttcgct	3780
cctcgaacgg	gccgctctcc	cccaggctct	cgggctcgct	caggtccaac	ggctcgtcac	3840
cggacggctc	gggcccgttc	tctccctgtg	ccgggttctc	cgcctgtgcg	cgttgttcgg	3900
ccatgcgcag	tgcgagggcc	ttcacctgtt	cggggcctgt	cgactcgatt	ttcgttcgtg	3960
aatacatgtt	ataataacta	taactaataa	cgtaacgtga	ctggcaagag	atatttttaa	4020
aacaatgaat	aggttttacac	ttacttttagt	tttatggaaa	tgaaagatca	tatcatatat	4080
aatctagaat	aaaattaact	aaaataatta	ttatctagat	aaaaaattta	gaagccaatg	4140
aaatctataa	ataaactaaa	ttaagtttat	ttaattaaca	actatggata	taaaataggt	4200
actaatcaaa	atagtgagga	ggatatatatt	gaatacatac	gaacaaatta	ataaagtga	4260
aaaaataactt	cggaaacatt	taaaaaataa	ccttattggg	acttacatgt	ttggatcagg	4320
agttgagagt	ggactaaaac	caaatagtga	tcttgacttt	ttagtcgtcg	tatctgaacc	4380
attgacagat	caaagtaaag	aaatacttat	acaaaaaatt	agacctattt	caaaaaaaat	4440
aggagataaa	agcaacttac	gatataattga	attaacaatt	attattcagc	aagaaatggg	4500
accgtggaat	catcctccca	aacaagaatt	tatttatgga	gaatgggttac	aagagcttta	4560
tgaacaagga	tacattcctc	agaaggaatt	aaattcagat	ttaaccataa	tgctttacca	4620
agcaaaacga	aaaaataaaa	gaatatacgg	aaattatgac	ttagaggaat	tactacctga	4680
tattccattt	tctgatgtga	gaagagccat	tatggattcg	tcagaggaat	taatagataa	4740
ttatcaggat	gatgaaacca	actctatatt	aactttatgc	cgtatgattt	taactatgga	4800
cacgggtaaa	atcataccaa	aagatattgc	gggaaatgca	gtggctgaat	cttctccatt	4860
agaacatagg	gagagaattt	tgttagcagt	tcgtagttat	cttggagaga	atattgaatg	4920

Sequence Listings_ASCII.txt

```

gactaatgaa aatgtaaatt taactataaa ctattttaaat aacagattaa aaaaattata 4980
aaaaaattga aaaaatggtg gaaacacttt tttcaatttt tttagatctt gagcaaaagg 5040
ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg 5100
ccccctgac gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg 5160
actataaaga taccaggcgt ttccccctgg aagctccctc gtgcgctctc ctgttccgac 5220
cctgccgctt accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgcttttctca 5280
tagctcacgc tgtaggatc tcagttcggg gtaggtcgtt cgctccaagc tgggctgtgt 5340
gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc 5400
caacccggta agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag 5460
agcgaggat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac 5520
tagaagaaca gtatttggtg tctgcgctct gctgaagcca gttaccttcg gaaaaagagt 5580
tggtagctct tgatccggca aacaaaccac cgctggtagc ggtgggtttt ttgtttgcaa 5640
gcagcagatt acgcgagaa aaaaaggatc tcaagaagat cctttgatct tttctac 5697

```

```

<210> 101
<211> 129
<212> DNA
<213> Artificial

```

```

<220>
<223> T2 terminator

```

```

<400> 101
ccaggcatca aataaaacga aaggctcagt cgaaagactg ggcctttcgt tttatctggt 60
gtttgtcggg gaacgctctc tactagagtc aactggctc accttcgggt gggcctttct 120
gcgtttata 129

```

```

<210> 102
<211> 22
<212> DNA
<213> Artificial

```

```

<220>
<223> PC1_primer

```

```

<400> 102
actagtcctc caggacctcg tc 22

```

```

<210> 103
<211> 20
<212> DNA
<213> Artificial

```

```

<220>
<223> PC2_primer

```

```

<400> 103
ccggaataat acggttgac 20

```

Sequence Listings_ASCII.txt

```

<210> 104
<211> 46
<212> DNA
<213> Artificial

<220>
<223> PC3_primer

<400> 104
accgtattat tccggccagg catcaaataa aacgaaaggc tcagtc 46

<210> 105
<211> 36
<212> DNA
<213> Artificial

<220>
<223> PC4_primer

<400> 105
tcctggagga ctagttataa acgcagaaag gcccac 36

<210> 106
<211> 34
<212> DNA
<213> Artificial

<220>
<223> vec_F5_primer

<400> 106
acaaggagag ccattatggc gttgatgatg agcg 34

<210> 107
<211> 43
<212> DNA
<213> Artificial

<220>
<223> vec_R2_primer

<400> 107
ggctaggatc cgtagaaaag atcaaaggat cttcttgaga tcc 43

<210> 108
<211> 36
<212> DNA
<213> Artificial

<220>
<223> P30_F1_primer

<400> 108
ctacggatcc tagccggcat tttcgcgata cattcc 36

<210> 109
<211> 24
<212> DNA
<213> Artificial

<220>
<223> P30_R1_primer

```

Sequence Listings_ASCII.txt

<400> 109
aatggctctc cttgtaatgc tagg 24

<210> 110
<211> 21
<212> DNA
<213> Artificial

<220>
<223> hCTLA3_primer

<400> 110
caggtccagc tggtcgaatc g 21

<210> 111
<211> 33
<212> DNA
<213> Artificial

<220>
<223> SP50-ins_F2_primer

<400> 111
acaaggagag ccattatgat cgtggcctac ccg 33

<210> 112
<211> 39
<212> DNA
<213> Artificial

<220>
<223> SP50-ins_R6_primer

<400> 112
gaccagctgg acctgttcca tatcgttgta tggaaacgc 39

<210> 113
<211> 40
<212> DNA
<213> Artificial

<220>
<223> SP67-ins_F2_primer

<400> 113
acaaggagag ccattatgaa gataaacaat aagggcaagg 40

<210> 114
<211> 37
<212> DNA
<213> Artificial

<220>
<223> SP67-ins_R6_primer

<400> 114
gaccagctgg acctggggct ggaacttggt gtatgtc 37

<210> 115
<211> 44
<212> DNA
<213> Artificial

Sequence Listings_ASCII.txt

```

<220>
<223> SP68-ins_F2_primer

<400> 115
acaaggagag ccattatggt ttataacatt cacatattgc aaac
44

<210> 116
<211> 40
<212> DNA
<213> Artificial

<220>
<223> SP68-ins_R6_primer

<400> 116
gaccagctgg acctgcttcc aaccattaag atcgtcttcg
40

<210> 117
<211> 20
<212> DNA
<213> Artificial

<220>
<223> GA6_primer

<400> 117
caccgcctac atacctcgct
20

<210> 118
<211> 21
<212> DNA
<213> Artificial

<220>
<223> GA5_primer_rev

<400> 118
ggtatgtagg cggtgctaca g
21

<210> 119
<211> 39
<212> DNA
<213> Artificial

<220>
<223> hCTLA16_primer

<400> 119
tcgtcgtcgt ccttgtagtc cttgatctcg accttggtg
39

<210> 120
<211> 38
<212> DNA
<213> Artificial

<220>
<223> hCTLA15_primer

<400> 120
caaggacgac gacgacaagt gaccttctgc tcgtagcg
38

```

Sequence Listings_ASCII.txt

```

<210> 121
<211> 37
<212> DNA
<213> Artificial

<220>
<223> PC5_primer

<400> 121
aagtgaccag gcatcaaata aaacgaaagg ctcagtc 37

<210> 122
<211> 41
<212> DNA
<213> Artificial

<220>
<223> PC6_primer

<400> 122
accgtattat tccggtagcc ggcattttcg cgatacattc c 41

<210> 123
<211> 27
<212> DNA
<213> Artificial

<220>
<223> PC7_primer

<400> 123
gatgcctggg cacttgtcgt cgtcgtc 27

<210> 124
<211> 37
<212> DNA
<213> Artificial

<220>
<223> PC8_primer

<400> 124
aagtgaccag gcatcaaata aaacgaaagg ctcagtc 37

<210> 125
<211> 31
<212> DNA
<213> Artificial

<220>
<223> PC9_primer

<400> 125
gatgcctggg cacttgatct cgaccttggt g 31

<210> 126
<211> 19
<212> DNA
<213> Artificial

<220>
<223> pCDshuttle_F1_primer

```

Sequence Listings_ASCII.txt

<400> 126
 tgaccttctg ctcgtagcg 19

<210> 127
 <211> 35
 <212> DNA
 <213> Artificial

<220>
 <223> hPD1scFv03-1_primer

<400> 127
 acgagcagaa ggtcacttga tctcgacctt ggtgc 35

<210> 128
 <211> 31
 <212> DNA
 <213> Artificial

<220>
 <223> SP50L5-ins_R1_hPD1_03

<400> 128
 gaccagctgg acctggggcg tcaacgtcgc g 31

<210> 129
 <211> 30
 <212> DNA
 <213> Artificial

<220>
 <223> SP68L1-ins_R1_hPD1_03

<400> 129
 gaccagctgg acctgatcgg ccgacgccgc 30

<210> 130
 <211> 32
 <212> DNA
 <213> Artificial

<220>
 <223> SP67L1-ins_R1_hPD1_03

<400> 130
 gaccagctgg acctgtgccg cactggcact tg 32

<210> 131
 <211> 2618
 <212> DNA
 <213> Artificial

<220>
 <223> pPC2 scFv expression cassettes sequence

<400> 131
 gtcttcctgc tggcctatgc attgggttcc gcagtgccca ctccaggcgg tctgggcggt 60
 gtggaagcgg cgctgacatt cgcgttcgtg gcggtcggag tgccgcaggg cgtggcgctt 120
 tccgccactt tgctgcaccg cgtggtgttc tactggctgc gcattccgct gggcgcgggc 180
 gccatgaagt ggcttgacaa gcataatctt gtctgattcg tctatittca tacccttc 240

Sequence Listings_ASCII.txt

ggggaaatag	atgtgaaaac	ccttataaaa	cgcggggtttt	cgcagaaaca	tgcgctagta	300
tcattgatga	caacatggac	taagcaaaaag	tgcttggtccc	ctgacccaag	aaggatgctt	360
tatgatcgtg	gcctacccgc	acacagtgca	gtatgcgggg	aaacgtacca	ggaaaggacg	420
aatgatgata	acgacatggc	ggcaacgggg	catggccatc	gtagcgatgc	tgaccggtct	480
gataataatg	gtgggagtgg	tggttcggctc	ggcgaatacg	gcgtatgccg	cgacgttgac	540
gccccaggtc	cagctgggtcg	aatcggggcgg	cggcgctcgtc	cagccggggcc	gttccctgcg	600
tctggattgc	aaggcctcgg	gcatcacctt	ctcgaactcc	ggcatgcact	gggtgcgcca	660
ggccccgggc	aagggcctgg	aatgggtcgc	cgtgatctgg	tacgatggct	cgaagcgcta	720
ctacgccgat	tccgtgaagg	gccgcttcac	catctcgcgc	gacaactcca	agaacaccct	780
gttcctgcag	atgaactccc	tgcgcgccga	agacaccgcc	gtgtactact	gcgccaccaa	840
cgatgactac	tggggccagg	gcaccctggt	caccgtgtcc	agcggcgggc	gcggctccgg	900
cggcgggcgg	tcgggcggcg	gcggcagcga	aatcgtgctg	acccagtccc	cggccaccct	960
gtccctgtcc	ccgggcgaac	gtgccaccct	gtcgtgccgc	gcctcccagt	cgggtgtccag	1020
ctacctggcc	tgggtaccag	agaagccggg	ccaggccccc	cgtctgctga	tctacgacgc	1080
ctccaaccgc	gccaccggca	tcccggcccc	cttctccggc	tcgggctccg	gcaccgactt	1140
caccctgacc	atctcgtccc	tggaaaccga	ggacttcgcc	gtctactact	gccagcagtc	1200
ctcgaactgg	ccgcgcacct	tcggccaggg	caccaaggtc	gagatcaagc	accatcatca	1260
ccaccactga	ccttctgctc	gtagcgatta	cttcgagcat	tactgacgac	aaagaccccc	1320
accgagatgg	tcgggggtctt	tttgttggtg	tgctgtgacg	tggtgtccaa	ccgtattatt	1380
ccggtagccg	gcattttcgc	gatacattcc	ccggaatgtt	gcgcaacggg	gaacgcgcac	1440
cacaccgcaa	ccacagtgcg	ccacgcccag	tccggcccctg	tgcgctataa	taggtcagtt	1500
attcgcgcgc	gcgtggcgcc	ctctacaccc	cgagccgcga	ggacacgtgg	attccggacg	1560
gccatgcccc	acatggcaaa	ccgagaaccc	gcacacctag	cattacaagg	agagccatta	1620
tgaagataaa	caataagggc	aagggcgctc	ttatcgcggc	aattaccgcc	gcggcaacgc	1680
tattgtcatg	cgggctggcc	gctgcaagtg	ccagtgcggc	acagggtccag	ctggtcgaat	1740
cgggcggcgg	cgtcgtccag	ccgggccgtt	ccctgcgtct	gtcgtgcgcc	gcctcgggct	1800
tcaccttctc	cagctacggc	atgcactggg	tgcgtcaggc	cccgggcaag	ggcctggagt	1860
gggtggccgt	catctggtac	gacggctcca	acaagtacta	cgccgattcc	gtcaagggcc	1920
gcttcacat	ctcgcgtgac	aactccaaga	acaccctgta	cctgcagatg	aactccctgc	1980
gtgccgaaga	caccgccgtg	tactactgcg	cccgcgatcc	gcgtggcgcc	accctgtact	2040
actactacta	cggcatggat	gtctggggcc	agggcaccac	cgtgaccgtc	tcgtccggcg	2100
gcggcggtc	cggcgggcgg	ggcagcggcg	gcggcggtc	cgacatccag	atgaccagtc	2160
ccccgagctc	gctgagcgcc	tcgggtggcg	atcgcgtcac	catcacctgc	cgtgcctccc	2220
agagcatcaa	ctcctacctg	gactgggtacc	agcagaagcc	gggcaaggcc	ccgaagctgc	2280

Sequence Listings_ASCII.txt

tgatctacgc	cgctccagc	ctgcagagcg	gcgtgccgtc	gcgcttctcg	ggctccggca	2340
gcggcaccga	cttcaccctg	accatctcgt	ccctgcagcc	ggaggatttc	gccacctact	2400
actgccagca	gtactactcc	accccgttca	ccttcggccc	gggcaccaag	gtcgagatca	2460
aggactacaa	ggacgacgac	gacaagtgac	caggcatcaa	ataaaacgaa	aggctcagtc	2520
gaaagactgg	gcctttcgtt	ttatctgttg	tttgtcggtg	aacgctctct	actagagtca	2580
cactggctca	ccttcgggtg	ggcctttctg	cgtttata			2618

<210> 132
 <211> 2648
 <212> DNA
 <213> Artificial

<220>
 <223> pPC3 scFv expression cassettes sequence

<400> 132	
gtcttcctgc	60
tggaagcgg	120
tccgccactt	180
gccatgaagt	240
ggggaaatag	300
tcattgatga	360
tatgatcgtg	420
aatgatgata	480
gataataatg	540
gccccaggtc	600
tctggattgc	660
ggccccgggc	720
ctacgccgat	780
gttcctgcag	840
cgatgactac	900
cggcggcggc	960
gtccctgtcc	1020
ctacctggcc	1080
ctccaaccgc	1140
cacctgacc	1200
ctcgaactgg	1260
ccaccactga	1320
accgagatgg	1380

Sequence Listings_ASCII.txt

```

ccggtagccg gcattttcgc gatacattcc ccggaatggt gcgcaacggg gaacgcgcac 1440
cacaccgcaa ccacagtgcg ccacgcccag tccggccctg tgcgctataa taggtcagtt 1500
attcgcgcg cgcgtggcgcc ctctacaccc cgagccgcga ggacacgtgg attccggacg 1560
gccatgcccc acatggcaaa ccgagaaccc gcacacctag cattacaagg agagccatta 1620
tggtttataa cattcacata ttgcaaacia ggaaaaccgg tcgtgtgggt gctgctgcgg 1680
ctgcatccgt gctgtgttgc atgggggctg tatttccagc gactatcggg gtgactgcgg 1740
cgtcggccga tcaggtccag ctggtcgaat cgggcggcgg cgtcgtccag ccggggccgtt 1800
ccctgcgtct gtcgtgcgcc gcctcgggct tcaccttctc cagctacggc atgcactggg 1860
tgcgtcaggc cccgggcaag ggcctggagt ggggtggcgt catctggtac gacggctcca 1920
acaagtacta cgccgattcc gtcaagggcc gcttcaccat ctgcgtgac aactccaaga 1980
acaccctgta cctgcagatg aactccctgc gtgccgaaga caccgccgtg tactactgcg 2040
cccgcgatcc gcggtggcgcc accctgtact actactacta cggcatggat gtctggggcc 2100
agggcaccac cgtgaccgtc tcgtccggcg gcggcggtc cggcggcggc ggcagcggcg 2160
gcggcggtc cgacatccag atgaccagc ccccgagctc gctgagcgcc tcggtgggcg 2220
atcgcgtcac catcacctgc cgtgcctccc agagcatcaa ctctacctg gactggtacc 2280
agcagaagcc gggcaaggcc ccgaagctgc tgatctacgc cgcctccagc ctgcagagcg 2340
gcgtgccgtc gcgcttctcg ggctccggca gcggcaccga cttcaccctg accatctcgt 2400
ccctgcagcc ggaggatttc gccacctact actgccagca gtactactcc accccgttca 2460
ccttcggccc gggcaccaag gtcgagatca aggactacaa ggacgacgac gacaagtgc 2520
caggcatcaa ataaaacgaa aggctcagtc gaaagactgg gcctttcgtt ttatctgttg 2580
tttgtcggtg aacgctctct actagagtca cactggctca ccttcgggtg ggcctttctg 2640
cgtttata 2648

```

```

<210> 133
<211> 2645
<212> DNA
<213> Artificial

```

```

<220>
<223> pPC4 scFv expression cassettes sequence

```

```

<400> 133
gtcttcctgc tggcctatgc attgggttcc gcagtgccca ctccaggcgg tctgggcggt 60
gtggaagcgg cgctgacatt cgcgttcgtg gcggtcggag tgccgcaggg cgtggcgctt 120
tccgccactt tgctgcaccg cgtggtgttc tactggctgc gcattccgct gggcgcgggc 180
gccatgaagt ggcttgacaa gcataatctt gtctgattcg tctattttca tacccttctc 240
ggggaaatag atgtgaaaac cttataaaa cgcggtttt cgagaaaca tgcgctagta 300
tcattgatga caacatggac taagcaaaag tgcttgctcc ctgaccaag aaggatgctt 360
tatgaagata aacaataagg gcaagggcgc tcttatcgcg gcaattaccg ccgcggaac 420

```

Sequence Listings_ASCII.txt

gctattgtca	tgcgggctgg	ccgctgcaag	tgccagtgcg	gcaggtgtgg	attacctgcc	480
taccatcggc	caggtccagc	tggtcgaatc	gggcggcggc	gtcgtccagc	cgggccgttc	540
cctgcgtctg	gattgcaagg	cctcgggcat	caccttctcg	aactccggca	tgactgggt	600
gcgccaggcc	ccgggcaagg	gcctggaatg	ggtcgccgtg	atctggtacg	atggctcgaa	660
gcgctactac	gccgattccg	tgaagggccg	cttcaccatc	tcgcgcgaca	actccaagaa	720
caccctgttc	ctgcagatga	actccctgcg	cgccgaagac	accgccgtgt	actactgcgc	780
caccaacgat	gactactggg	gccagggcac	cctggtcacc	gtgtccagcg	gcggcggcgg	840
ctccggcggc	ggcggctcgg	gcggcggcgg	cagcgaaatc	gtgctgaccc	agtccccggc	900
caccctgtcc	ctgtccccgg	gcgaacgtgc	caccctgtcg	tgccgcgcct	ccagtcggt	960
gtccagctac	ctggcctggt	accagcagaa	gccgggccag	gccccgcgtc	tgctgatcta	1020
cgacgcctcc	aaccgcgcca	ccggcatccc	ggccccgttc	tccggctcgg	gctccggcac	1080
cgacttcacc	ctgaccatct	cgccccctgga	accggaggac	ttcgccgtct	actactgcca	1140
gcagtcctcg	aactggccgc	gcaccttcgg	ccagggcacc	aaggtcgaga	tcaagcacca	1200
tcatcaccac	cactgacctt	ctgctcgtag	cgattacttc	gagcattact	gacgacaaag	1260
accccgaccg	agatggtcgg	ggctctttttg	ttgtggtgct	gtgacgtgtt	gtccaaccgt	1320
attattccgg	tagccggcat	tttcgcgata	cattccccgg	aatgttgcg	aacggggaac	1380
gcgcaccaca	ccgaaccac	agtgcgccac	gcccagtcgg	gccctgtgcg	ctataatagg	1440
tcagttattc	gcgcgcgcgt	ggcgccctct	acaccccgag	ccgcgaggac	acgtggattc	1500
cggacggcca	tgccccacat	ggcaaaccga	gaacccgcac	acctagcatt	acaaggagag	1560
ccattatgat	cgtggcctac	ccgcacacag	tgagtatg	ggggaaacgt	accaggaaag	1620
gacgaatgat	gataacgaca	tggcggcaac	ggggcatggc	catcgtagcg	atgctgaccg	1680
gtctgataat	aatggtggga	gtggtgttcg	gctcggcgaa	tacggcgat	gccgcgacgt	1740
tgacgcccc	ggtccagctg	gtcgaatcgg	gcggcggcgt	cgccagccg	ggccgttccc	1800
tgcgctctgtc	gtgcgcgcgc	tcgggcttca	ccttctccag	ctacggcatg	cactgggtgc	1860
gtcaggcccc	gggcaagggc	ctggagtggg	tggccgtcat	ctggtacgac	ggctccaaca	1920
agtactacgc	cgattccgtc	aagggccgct	tcaccatctc	gcgtgacaac	tccaagaaca	1980
ccctgtacct	gcagatgaac	tcctgcgtg	ccgaagacac	cgccgtgtac	tactgcgccc	2040
gcgatccgcg	tggcgccacc	ctgtactact	actactacgg	catggatgtc	tggggccagg	2100
gcaccaccgt	gaccgtctcg	tccggcggcg	gcggctccgg	cggcggcggc	agcggcggcg	2160
gcggctccga	catccagatg	accagtccc	cgagctcgct	gagcgcctcg	gtgggcgatc	2220
gcgtcaccat	cacctgccgt	gcctcccaga	gcatcaactc	ctacctggac	tggtaccagc	2280
agaagccggg	caaggccccg	aagctgctga	tctacgccgc	ctccagcctg	cagagcggcg	2340
tgccgtcgcg	cttctcgggc	tccggcagcg	gcaccgactt	caccctgacc	atctcgtccc	2400
tgagccggga	ggatttcgcc	acctactact	gccagcagta	ctactccacc	ccgttcacct	2460

Sequence Listings_ASCII.txt

tcggccccggg	caccaaggtc	gagatcaagg	actacaagga	cgacgacgac	aagtgaccag	2520
gcatcaaata	aaacgaaagg	ctcagtcgaa	agactggggcc	tttcgtttta	tctgttgttt	2580
gtcggatgaac	gctctctact	agagtcacac	tggctcacct	tcgggtgggc	ctttctgcgt	2640
ttata						2645

<210> 134
 <211> 2594
 <212> DNA
 <213> Artificial

<220>
 <223> pPC5 scFv expression cassettes sequence

<400> 134						
gtcttcctgc	tggcctatgc	attgggttcc	gcagtgccca	ctccaggcgg	tctgggcggt	60
gtggaagcgg	cgctgacatt	cgcggttcgtg	gcggtcggag	tgccgcaggg	cgtggcgctt	120
tccgccactt	tgctgcaccg	cgtgggtgttc	tactggctgc	gcattccgct	gggcgcggcg	180
gccatgaagt	ggcttgacaa	gcataatctt	gtctgattcg	tctattttca	tacccccctt	240
ggggaaatag	atgtgaaaac	ccttataaaa	cgcggtgttt	cgcagaaaca	tgcgctagta	300
tcattgatga	caacatggac	taagcaaaaag	tgcttgctccc	ctgacccaag	aaggatgctt	360
tatgaagata	aacaataagg	gcaagggcgc	tcttatcgcg	gcaattaccg	ccgcggcaac	420
gctattgtca	tgcgggctgg	ccgctgcaag	tgccagtgcg	gcagggtgtg	attacctgcc	480
taccatcggc	caggtccagc	tggtcgaatc	gggcggcggc	gtcgtccagc	cgggccgttc	540
cctgcgtctg	gattgcaagg	cctcgggcat	caccttctcg	aactccggca	tgactgggt	600
gcgccaggcc	ccgggcaagg	gcctggaatg	ggtcgccgtg	atctggtacg	atggctcgaa	660
gcgctactac	gccgattccg	tgaagggccg	cttcaccatc	tcgcgcgaca	actccaagaa	720
caccctgttc	ctgcagatga	actccctgcg	cgccgaagac	accgccgtgt	actactgcgc	780
caccaacgat	gactactggg	gccagggcac	cctggtcacc	gtgtccagcg	gcggcgggcg	840
ctccggcggc	ggcggtcgg	gcggcgggcg	cagcgaaaatc	gtgctgaccc	agtccccggc	900
caccctgtcc	ctgtcccccg	gcgaacgtgc	caccctgtcg	tgccgcgcct	cccagtcggt	960
gtccagctac	ctggcctggt	accagcagaa	gccggggccag	gccccgcgtc	tgctgatcta	1020
cgacgcctcc	aaccgcgcca	ccggcatccc	ggccccgttc	tccgggtcgg	gctccggcac	1080
cgacttcacc	ctgaccatct	cgctccctgga	accggaggac	ttcgccgtct	actactgcca	1140
gcagtcctcg	aactggccgc	gcaccttcgg	ccagggcacc	aaggctcgaga	tcaagcacca	1200
tcatcaccac	cactgacctt	ctgctcgtag	cgattacttc	gagcattact	gacgacaaag	1260
accccgaccg	agatgggtcgg	ggcttttttg	ttgtgggtgct	gtgacgtgtt	gtccaaccgt	1320
attattccgg	tagccggcat	tttcgcgata	cattccccgg	aatgttgcg	aacggggaac	1380
gcgcaccaca	ccgcaaccac	agtgcgccac	gcccagtccg	gccctgtgcg	ctataatagg	1440
tcagttattc	gcgcgcgcgt	ggcgccctct	acaccccgag	ccgcgaggac	acgtggattc	1500

Sequence Listings_ASCII.txt

```

cggacggcca tgccccacat ggcaaaccga gaacccgcac acctagcatt acaaggagag 1560
ccattatggt ttataacatt cacatatgtc aaacaaggaa aaccggtcgt gtggttgctg 1620
ctgcggctgc atccgtgctg tgttgcatgg gggctgtatt tccagcgact atcggagtga 1680
ctgcggcgtc ggccgatcag gtccagctgg tcgaatcggg cggcggcgtc gtccagccgg 1740
gccgtttccct gcgtctgtcg tgcgccgcct cgggcttcac cttctccagc tacggcatgc 1800
actgggtgcg tcaggccccg ggcaaggggc tggagtgggt ggccgcatc tggtagcagc 1860
gctccaacaa gtactacgcc gattccgtca agggccgctt caccatctcg cgtgacaact 1920
ccaagaacac cctgtacctg cagatgaact ccctgcgtgc cgaagacacc gccgtgtact 1980
actgcgcccg cgatccgctg ggcgccaccc tgtactacta ctactacggc atggatgtct 2040
ggggccaggg caccaccgtg accgtctcgt ccggcggcgg cggctccggc ggcggcggca 2100
gcggcggcgg cggctccgac atccagatga ccagtcgcc gagctcgctg agcgcctcgg 2160
tgggcgatcg cgtcaccatc acctgccgtg cctcccagag catcaactcc tacctggact 2220
ggtaccagca gaagccgggc aaggccccga agctgctgat ctacgccgcc tccagcctgc 2280
agagcggcgt gccgtcgcgc ttctcgggct ccggcagcgg caccgacttc accctgacca 2340
tctcgtccct gcagccggag gatttcgcca cctactactg ccagcagtac tactccaccc 2400
cgttcacctt cggcccgggc accaaggctc agatcaagga ctacaaggac gacgacgaca 2460
agtgaccagg catcaaataa aacgaaaggc tcagtcgaaa gactgggcct ttcgttttat 2520
ctgttgtttg tcggtgaacg ctctctacta gagtcacact ggctcacctt cgggtggggc 2580
tttctgcgtt tata 2594

```

```

<210> 135
<211> 2609
<212> DNA
<213> Artificial

```

```

<220>
<223> pPC6 scFv expression cassettes sequence

```

```

<400> 135
gtcttcctgc tggcctatgc attgggttcc gcagtgccca ctccaggcgg tctgggcggt 60
gtggaagcgg cgctgacatt cgcgttcgtg gcggtcggag tgccgcaggg cgtggcgctt 120
tccgccactt tgctgcaccg cgtggtgttc tactggctgc gcattccgct gggcgcggcg 180
gccatgaagt ggcttgacaa gcataatctt gtctgattcg tctattttca tacccttctc 240
ggggaaatag atgtgaaaac cttataaaa cgcgggtttt cgcagaaaca tgcgctagta 300
tcattgatga caacatggac taagcaaaaag tgcttgctcc ctgaccaag aaggatgctt 360
tatgaattat ttacgacaaa aaatttcggc tagtgctatc gcggtgttgt cgacttgtgg 420
gttgattttg gcgccaatgc cggctcttgc ggatcaggtc cagctggctg aatcgggcgg 480
cggcgtcgtc cagccggggc gttccctgcg tctggattgc aaggcctcgg gcatcacctt 540
ctcgaactcc ggcatgcact ggggtgcgcca ggccccgggc aagggcctgg aatgggtcgc 600

```

Sequence Listings_ASCII.txt

cgtgatctgg	tacgatggct	cgaagcgcta	ctacgccgat	tccgtgaagg	gccgcttcac	660
catctcgcgc	gacaactcca	agaacaccct	gttcctgcag	atgaactccc	tgcgcgccga	720
agacaccgcc	gtgtactact	gcgccaccaa	cgatgactac	tggggccagg	gcaccctggt	780
caccgtgtcc	agcggcgggc	gcggctccgg	cggcgggcgc	tcgggcggcg	gcggcagcga	840
aatcgtgctg	accagatccc	cggccaccct	gtccctgtcc	ccgggcgaac	gtgccaccct	900
gtcgtgccgc	gcctcccagt	cggtgtccag	ctacctggcc	tggtaccagc	agaagccggg	960
ccaggccccg	cgtctgctga	tctacgacgc	ctccaaccgc	gccaccggca	tcccggcccc	1020
cttctccggc	tcgggctccg	gcaccgactt	caccctgacc	atctcgtccc	tggaaccgga	1080
ggacttcgcc	gtctactact	gccagcagtc	ctcgaactgg	ccgcgcacct	tcggccaggg	1140
caccaaggtc	gagatcaagc	accatcatca	ccaccactga	ccttctgctc	gtagcgatta	1200
cttcgagcat	tactgacgac	aaagaccccc	accgagatgg	tcgggggtctt	tttgttgtgg	1260
tgctgtgacg	tgttgtccaa	ccgtattatt	ccggtagccg	gcattttcgc	gatacattcc	1320
ccggaatggt	gcgcaacggg	gaacgcgcac	cacaccgcaa	ccacagtgcg	ccacgcccag	1380
tccggccctg	tgcgctataa	taggtcagtt	attcgcgcgc	gcgtggcgcc	ctctacaccc	1440
cgagccgcga	ggacacgtgg	attccggacg	gccatgcccc	acatggcaaa	ccgagaaccc	1500
gcacacctag	cattacaagg	agagccatta	tgatcgtggc	ctacccgcac	acagtgcagt	1560
atgcggggaa	acgtaccagg	aaaggacgaa	tgatgataac	gacatggcgg	caacggggca	1620
tggccatcgt	agcgatgctg	accggtctga	taataatggt	gggagtgggtg	ttcggctcgg	1680
cgaatacggc	gtatgccgcg	acgttgacgc	cccaggcca	gctggtcgaa	tcgggcggcg	1740
gcgtcgtcca	gccggggcgt	tccctgcgtc	tgctcgtcgc	cgcctcgggc	ttcaccttct	1800
ccagctacgg	catgcactgg	gtgcgtcagg	ccccgggcaa	gggcctggag	tgggtggccg	1860
tcattctggta	cgacggctcc	aacaagtact	acgccgattc	cgtcaagggc	cgcttcacca	1920
tctcgcgtga	caactccaag	aacaccctgt	acctgcagat	gaactccctg	cgtgccgaag	1980
acaccgccgt	gtactactgc	gcccgcgac	cgcgtggcgc	caccctgtac	tactactact	2040
acggcatgga	tgtctggggc	cagggcacca	ccgtgaccgt	ctcgtccggc	ggcggcggct	2100
ccggcggcgg	cggcagcggc	ggcggcggct	ccgacatcca	gatgaccag	tccccgagct	2160
cgctgagcgc	ctcgggtggc	gatcgcgtca	ccatcacctg	ccgtgcctcc	cagagcatca	2220
actcctacct	ggactgggtac	cagcagaagc	cgggcaaggc	cccgaagctg	ctgatctacg	2280
ccgcctccag	cctgcagagc	ggcgtgccgt	cgcgcttctc	gggctccggc	agcggcaccg	2340
acttcaccct	gaccatctcg	tccctgcagc	cggaggatct	cgccacctac	tactgccagc	2400
agtactactc	caccccgttc	accttcggcc	cgggcaccaa	ggtcgagatc	aaggactaca	2460
aggacgacga	cgacaagtga	ccaggcatca	aataaaacga	aaggctcagt	cgaaagactg	2520
ggcctttcgt	tttatctggt	gtttgtcgg	gaacgctctc	tactagagtc	acactggctc	2580
accttcgggt	gggcctttct	gcgtttata				2609

Sequence Listings_ASCII.txt

<210> 136
<211> 2528
<212> DNA
<213> Artificial

<220>
<223> pPC7 scFv expression cassettes sequence

```
<400> 136
gtcttcctgc tggcctatgc attgggttcc gcagtgccca ctccaggcgg tctgggcggt      60
gtggaagcgg cgctgacatt cgcgttcgtg gcggtcggag tgccgcaggg cgtggcgctt      120
tccgccactt tgctgcaccg cgtggtgttc tactggctgc gcattccgct gggcgcgggcg      180
gccatgaagt ggcttgacaa gcataatctt gtctgattcg tctattttca tacccttc      240
ggggaaatag atgtgaaaac cttataaaa cgcgggtttt cgagaaaca tgcgctagta      300
tcattgatga caacatggac taagcaaaag tgcttgcccc ctgacccaag aaggatgctt      360
tatgaattat ttacgacaaa aaatttcggc tagtgctatc gcggtgttgt cgacttgtgg      420
gttgattttg gcgccaatgc cggctcttgc ggatcaggtc cagctggctc aatcgggcgg      480
cggcgtcgtc cagccggggc gttccctgcg tctggattgc aaggcctcgg gcatcacctt      540
ctcgaactcc ggcatgcact ggggtgcgcca ggccccgggc aagggcctgg aatgggtcgc      600
cgtgatctgg tacgatggct cgaagcgcta ctacgccgat tccgtgaagg gccgcttcac      660
catctcgcgc gacaactcca agaacaccct gttcctgcag atgaactccc tgcgcgccga      720
agacaccgcc gtgtactact gcgccaccaa cgatgactac tggggccagg gcaccctggt      780
caccgtgtcc agcggcgggc gcggctccgg cggcgggcggc tcgggcggcg gcggcagcga      840
aatcgtgctg acccagtccc cggccaccct gtccctgtcc ccggggcgaac gtgccaccct      900
gtcgtgccgc gcctcccagt cgggtgtccag ctacctggcc tggtagcagg agaagccggg      960
ccaggccccg cgtctgctga tctacgacgc ctccaaccgc gccaccggca tcccggcccc      1020
cttctccggc tcgggctccg gcaccgactt caccctgacc atctcgtccc tggaaccgga      1080
ggacttcgcc gtctactact gccagcagtc ctcgaactgg ccgcgcacct tcggccaggg      1140
caccaaggtc gagatcaagc accatcatca ccaccactga cttctgctc gtagcgatta      1200
cttcgagcat tactgacgac aaagaccccc accgagatgg tcgggggtctt tttgttgtgg      1260
tgctgtgacg tgttgtccaa ccgtattatt ccggtagccg gcattttcgc gatacattcc      1320
ccggaatggt gcgcaacggg gaacgcgcac cacaccgcaa ccacagtgcg ccacgcccag      1380
tccggccctg tgcgctataa taggtcagtt attcgcgcgc gcgtggcgcc ctctacaccc      1440
cgagccgcga ggacacgtgg attccggacg gccatgcccc acatggcaaa ccgagaaccc      1500
gcacacctag cattacaagg agagccatta tgaagataaa caataagggc aaggcgctc      1560
ttatcgcggc aattaccgcc gcggcaacgc tattgtcatg cgggctggcc gctgcaagtg      1620
ccagtgcggc acagggtccag ctggtcgaat cgggcggcgg cgtcgtccag ccgggccgtt      1680
ccctgcgtct gtcgtgcgcc gcctcgggct tcaccttctc cagctacggc atgcactggg      1740
```

Sequence Listings_ASCII.txt

tgcgtcaggc	cccgggcaag	ggcctggagt	gggtggccgt	catctggtac	gacgggtcca	1800
acaagtacta	cgccgattcc	gtcaagggcc	gcttcaccat	ctcgcgtagc	aactccaaga	1860
acaccctgta	cctgcagatg	aactccctgc	gtgccgaaga	caccgccgtg	tactactgcg	1920
cccgcgatcc	gcgtggcgcc	accctgtact	actactacta	cggcatggat	gtctggggcc	1980
agggcaccac	cgtgaccgtc	tcgtccggcg	gcggcggtc	cggcggcggc	ggcagcggcg	2040
gcggcggtc	cgacatccag	atgacccagt	ccccgagctc	gctgagcgcc	tcggtgggcg	2100
atcgcgtcac	catcacctgc	cgtgcctccc	agagcatcaa	ctcctacctg	gactggtacc	2160
agcagaagcc	gggcaaggcc	ccgaagctgc	tgatctacgc	cgctccagc	ctgcagagcg	2220
gcgtgccgtc	gcgcttctcg	ggctccggca	gcggcaccga	cttcaccctg	accatctcgt	2280
ccctgcagcc	ggaggatttc	gccacctact	actgccagca	gtactactcc	accccgttca	2340
ccttcggccc	gggcaccaag	gtcgagatca	aggactacaa	ggacgacgac	gacaagtgc	2400
caggcatcaa	ataaaacgaa	aggctcagtc	gaaagactgg	gcctttcgtt	ttatctgttg	2460
tttgtcgggtg	aacgctctct	actagagtca	cactgggtca	ccttcgggtg	ggcctttctg	2520
cgtttata						2528

<210> 137
 <211> 2558
 <212> DNA
 <213> Artificial

<220>
 <223> pPC8 scFv expression cassettes sequence

<400> 137	
gtcttcctgc	60
tggaagcgg	120
tccgccactt	180
gccatgaagt	240
ggggaaatag	300
tcattgatga	360
tatgaattat	420
gttgattttg	480
cggcgtcgtc	540
ctcgaactcc	600
cgtgatctgg	660
catctcgcg	720
agacaccgcc	780
caccgtgtcc	840
aatcgtgctg	900

Sequence Listings_ASCII.txt

```

gtcgtgccgc gcctcccagt cggtgtccag ctacctggcc tggtagcagc agaagccggg 960
ccaggccccg cgtctgctga tctacgacgc ctccaaccgc gccaccggca tcccggcccc 1020
cttctccggc tcgggctccg gcaccgactt caccctgacc atctcgtccc tggaaccgga 1080
ggacttcgcc gtctactact gccagcagtc ctcgaactgg ccgcgcacct tcggccaggg 1140
caccaaggtc gagatcaagc accatcatca ccaccactga ctttctgctc gtagcgatta 1200
cttcgagcat tactgacgac aaagaccccc accgagatgg tcggggtctt tttgttgtgg 1260
tgctgtgacg tgttgtccaa ccgtattatt ccggtagccg gcattttcgc gatacattcc 1320
ccggaatggt gcgcaacggg gaacgcgcac cacaccgcaa ccacagtgcg ccacgcccag 1380
tccggccctg tgcgctataa taggtcagtt attcgcgcgc gcgtggcgcc ctctacaccc 1440
cgagccgcga ggacacgtgg attccggacg gccatgcccc acatggcaaa ccgagaaccc 1500
gcacacctag cattacaagg agagccatta tggtttataa cattcacata ttgcaaacia 1560
ggaaaaccgg tcgtgtgggt gctgctgcgg ctgcatccgt gctgtgttgc atgggggctg 1620
tatttccagc gactatcgga gtgactgcgg cgtcggccga tcaggccag ctggtcgaat 1680
cgggaggcgg cgtcgtccag ccgggccgtt ccctgcgtct gtcgtgcgcc gcctcgggct 1740
tcaccttctc cagctacggc atgcactggg tgcgtcaggc cccgggcaag ggcctggagt 1800
gggtggccgt catctggtac gacggctcca acaagtacta cgccgattcc gtcaagggcc 1860
gcttcaccat ctcgcgtgac aactccaaga acacctgta cctgcagatg aactccctgc 1920
gtgccgaaga caccgccgtg tactactgcg cccgcgatcc gcgtggcgcc accctgtact 1980
actactacta cggcatggat gtctggggcc agggcaccac cgtgaccgtc tcgtccggcg 2040
gcggcgggctc cggcggcggc ggcagcggcg gcggcggtc cgacatccag atgaccagc 2100
ccccgagctc gctgagcgcc tcggtgggcg atcgcgtcac catcacctgc cgtgcctccc 2160
agagcatcaa ctctacctg gactggtacc agcagaagcc gggcaaggcc ccgaagctgc 2220
tgatctacgc cgctccagc ctgcagagcg gcgtgccgtc gcgcttctcg ggctccggca 2280
gcggcaccga cttcacctg accatctcgt ccctgcagcc ggaggatttc gccacctact 2340
actgccagca gtactactcc acccgttca cttcggccc gggcaccaag gtcgagatca 2400
aggactacaa ggacgacgac gacaagtgc caggcatcaa ataaaacgaa aggtcagtc 2460
gaaagactgg gcctttcggt ttatctgttg tttgtcggtg aacgctctct actagagtca 2520
cactggctca cttcgggtg ggcctttctg cgtttata 2558

```

<210> 138
 <211> 2576
 <212> DNA
 <213> Artificial

<220>
 <223> pPC2TL scFv expression cassettes sequence

```

<400> 138
gtcttctcgc tggcctatgc attgggttcc gcagtgccca ctccaggcgg tctgggagggt 60

```

Sequence Listings_ASCII.txt

gtggaagcgg	cgctgacatt	cgcgttcgtg	gcggtcggag	tgccgcaggg	cgtaggcgctt	120
tccgccactt	tgctgcaccg	cgtaggtgttc	tactggctgc	gcattccgct	gggcgcggcg	180
gccatgaagt	ggcttgacaa	gcataatctt	gtctgattcg	tctattttca	tacccccttc	240
ggggaaatag	atgtgaaaac	ccttataaaa	cgcggtttt	cgcagaaaca	tgcgctagta	300
tcattgatga	caacatggac	taagcaaaaag	tgcttgcccc	ctgacccaag	aaggatgctt	360
tatgatcgtg	gcctacccgc	acacagtgc	gtatgcgggg	aaacgtacca	ggaaaggacg	420
aatgatgata	acgacatggc	ggcaacgggg	catggccatc	gtagcgatgc	tgaccggtct	480
gataataatg	gtgggagtgg	tggttcggctc	ggcgaatacg	gcgtatgccg	cgacgttgac	540
gccccaggtc	cagctggctg	aatcggggcg	cggcgtcgtc	cagccggggc	gttccctgcg	600
tctggattgc	aaggcctcgg	gcatcacctt	ctcgaactcc	ggcatgcact	gggtgcgcca	660
ggccccgggc	aagggcctgg	aatgggtcgc	cgtgatctgg	tacgatggct	cgaagcgcta	720
ctacgccgat	tccgtgaagg	gccgcttcac	catctcgcgc	gacaactcca	agaacaccct	780
gttcctgcag	atgaactccc	tgcgcgccga	agacaccgcc	gtgtactact	gcgccaccaa	840
cgatgactac	tggggccagg	gcaccctggg	caccgtgtcc	agcggcggcg	gcggctccgg	900
cggcggcggc	tcgggcggcg	gcggcagcga	aatcgtgctg	acccagtccc	cggccaccct	960
gtccctgtcc	ccgggcgaac	gtgccaccct	gtcgtgccgc	gcctcccagt	cggtgtccag	1020
ctacctggcc	tgggtaccagc	agaagccggg	ccaggccccg	cgtctgctga	tctacgacgc	1080
ctccaaccgc	gccaccggca	tcccggcccc	cttctccggc	tcgggctccg	gcaccgactt	1140
caccctgacc	atctcgtccc	tggaaaccgga	ggacttcgcc	gtctactact	gccagcagtc	1200
ctcgaactgg	ccgcgcacct	tcggccaggg	caccaaggtc	gagatcaagt	gaccttctgc	1260
tcgtagcgat	tacttcgagc	attactgacg	acaaagaccc	cgaccgagat	ggtcggggtc	1320
tttttgttgt	ggtgctgtga	cgtgttgtcc	aaccgtatta	ttccggtagc	cggcattttc	1380
gcgatacatt	ccccggaatg	ttgcgcaacg	gggaacgcgc	accacaccgc	aaccacagtg	1440
cgccacgccc	agtcgggccc	tgtgcgctat	aataggctcag	ttattcgcgc	gcgcgtggcg	1500
ccctctacac	cccagaccgc	gaggacacgt	ggattccgga	cggccatgcc	ccacatggca	1560
aaccgagaac	ccgcacacct	agcattacaa	ggagagccat	tatgaagata	aacaataagg	1620
gcaagggcgc	tcttatcgcg	gcaattaccg	ccgcggcaac	gctattgtca	tgcgggctgg	1680
ccgctgcaag	tgccagtgcg	gcacaggctc	agctggtcga	atcgggcggc	ggcgtcgtcc	1740
agccggggcg	ttccctgcgt	ctgtcgtgcg	ccgcctcggg	cttcaccttc	tccagctacg	1800
gcatgcactg	ggtgcgtcag	gccccgggca	agggcctgga	gtgggtggcc	gtcatctggt	1860
acgacggctc	caacaagtac	tacgccgatt	ccgtcaaggg	ccgcttcacc	atctcgcgtg	1920
acaactccaa	gaacaccctg	tacctgcaga	tgaactccct	gcgtgccgaa	gacaccgccg	1980
tgtactactg	cggccgcgat	ccgcgtggcg	ccaccctgta	ctactactac	tacggcatgg	2040
atgtctgggg	ccagggcacc	accgtgaccg	tctcgtccgg	cggcggcggc	tccggcggcg	2100

Sequence Listings_ASCII.txt

gcggcagcgg	cggcggcggc	tccgacatcc	agatgaccca	gtccccgagc	tcgctgagcg	2160
cctcgggtggg	cgatcgcgtc	accatcacct	gccgtgcctc	ccagagcatc	aactcctacc	2220
tggactggta	ccagcagaag	ccgggcaagg	ccccgaagct	gctgatctac	gccgcctcca	2280
gcctgcagag	cggcgtgccg	tcgcgcttct	cgggctccgg	cagcggcacc	gacttcaccc	2340
tgaccatctc	gtccctgcag	ccggaggatt	tcgccaccta	ctactgccag	cagtactact	2400
ccaccccgtt	caccttcggc	ccgggcacca	aggtcgagat	caagtgacca	ggcatcaaat	2460
aaaacgaaag	gctcagtcga	aagactgggc	ctttcgtttt	atctgttggt	tgtcggtgaa	2520
cgctctctac	tagagtcaca	ctggctcacc	ttcgggtggg	cctttctgcg	tttata	2576

<210> 139
 <211> 2606
 <212> DNA
 <213> Artificial

<220>
 <223> pPC3TL scFv expression cassettes sequence

<400> 139	
gtcttcctgc	60
gtggaagcgg	120
tccgccactt	180
gccatgaagt	240
ggggaaatag	300
tcattgatga	360
tatgatcgtg	420
aatgatgata	480
gataataatg	540
gccccaggtc	600
tctggattgc	660
ggccccgggc	720
ctacgccgat	780
gttcctgcag	840
cgatgactac	900
cggcggcggc	960
gtccctgtcc	1020
ctacctggcc	1080
ctccaaccgc	1140
cacctgacc	1200
ctcgaactgg	1260

Sequence Listings_ASCII.txt

tcgtagcgat	tacttcgagc	attactgacg	acaaagaccc	cgaccgagat	ggtcgggggtc	1320
tttttgttgt	ggtgctgtga	cggtgtgtcc	aaccgtatta	ttccggtagc	cggcatttttc	1380
gcgatacatt	ccccggaatg	ttgcgcaacg	gggaacgcgc	accacaccgc	aaccacagtg	1440
cgccacgccc	agtccggccc	tgtgcgctat	aatagggtcag	ttattcgcgc	gcgcgtggcg	1500
ccctctacac	cccgagccgc	gaggacacgt	ggattccgga	cggccatgcc	ccacatggca	1560
aaccgagaac	ccgcacacct	agcattacaa	ggagagccat	tatggtttat	aacattcaca	1620
tattgcaaac	aaggaaaacc	ggtcgtgtgg	ttgctgctgc	ggctgcatcc	gtgctgtgtt	1680
gcatgggggc	tgtattttca	gcgactatcg	gagtgactgc	ggcgtcggcc	gatcagggtcc	1740
agctgggtcga	atcgggcggc	ggcgtcgtcc	agccgggccc	ttccctgcgt	ctgtcgtgcg	1800
ccgcctcggg	cttcaccttc	tccagctacg	gcatgcactg	ggcgcgtcag	gccccgggca	1860
agggcctgga	gtgggtggcc	gtcatctggt	acgacggctc	caacaagtac	tacgccgatt	1920
ccgtcaaggg	ccgcttcacc	atctcgcgtg	acaactccaa	gaacaccctg	tacctgcaga	1980
tgaactccct	gcgtgccgaa	gacaccgccg	tgtactactg	cgcccgcgat	ccgcgtggcg	2040
ccaccctgta	ctactactac	tacggcatgg	atgtctgggg	ccagggcacc	accgtgaccg	2100
tctcgtccgg	cggcgggcgg	tccggcgggc	gcggcagcgg	cggcgggcgg	tccgacatcc	2160
agatgaccca	gtccccgagc	tcgctgagcg	cctcgggtgg	cgatcgcgtc	accatcacct	2220
gccgtgcctc	ccagagcatc	aactcctacc	tggactggta	ccagcagaag	ccgggcaagg	2280
ccccgaagct	gctgatctac	gccgcctcca	gcctgcagag	cggcgtgccg	tcgcgcttct	2340
cgggctccgg	cagcggcacc	gacttcaccc	tgaccatctc	gtccctgcag	ccggaggatt	2400
tcgccaccta	ctactgccag	cagtactact	ccaccccggt	caccttcggc	ccgggaccca	2460
aggtcgagat	caagtgacca	ggcatcaaat	aaaacgaaa	gctcagtcga	aagactgggc	2520
ctttcgtttt	atctgttgtt	tgtcgggtgaa	cgctctctac	tagagtcaca	ctggctcacc	2580
ttcgggtggg	cctttctgcg	tttata				2606

<210> 140
 <211> 2603
 <212> DNA
 <213> Artificial

<220>
 <223> pPC4TL scFv expression cassettes sequence

<400> 140	
gtcttcctgc	tggcctatgc attgggttcc gcagtgccca ctccaggcgg tctgggcggt 60
gtggaagcgg	cgctgacatt cgcgttcgtg gcggtcggag tgccgcaggg cgtggcgctt 120
tccgccactt	tgctgcaccg cgtgggtgtt tactggctgc gattccgct gggcgcgggc 180
gccatgaagt	ggcttgacaa gcataatctt gtctgattcg tctattttca tacccttc 240
ggggaaatag	atgtgaaaac cttataaaa cgcggtttt cgagaaaca tgcgctagta 300
tcattgatga	caacatggac taagcaaaa tgcttgctcc ctgacccaag aaggatgctt 360

Sequence Listings_ASCII.txt

tatgaagata	aacaataagg	gcaagggcgc	tcttatcgcg	gcaattaccg	ccgcggcaac	420
gctattgtca	tgcgggctgg	ccgctgcaag	tgccagtgcg	gcaggtgtgg	attacctgcc	480
taccatcggc	caggtccagc	tggtcgaatc	gggcggcggc	gtcgtccagc	cgggccgttc	540
cctgcgtctg	gattgcaagg	cctcgggcat	caccttctcg	aactccggca	tgactgggt	600
gcgccaggcc	ccgggcaagg	gcctggaatg	ggtcgccgtg	atctggtacg	atggctcgaa	660
gcgctactac	gccgattccg	tgaagggccg	cttcaccatc	tcgcgcgaca	actccaagaa	720
caccctgttc	ctgcagatga	actccctgcg	cgccgaagac	accgccgtgt	actactgcgc	780
caccaacgat	gactactggg	gccagggcac	cctggtcacc	gtgtccagcg	gcggcggcgg	840
ctccggcggc	ggcggctcgg	gcggcggcgg	cagcgaaatc	gtgctgacct	agtccccggc	900
caccctgtcc	ctgtccccgg	gcgaacgtgc	caccctgtcg	tgccgcgcct	cccagtcggt	960
gtccagctac	ctggcctggg	accagcagaa	gccggggccag	gccccgcgtc	tgctgatcta	1020
cgacgcctcc	aaccgcgcca	ccggcatccc	ggccccgctt	tccggctcgg	gtccggcac	1080
cgacttcacc	ctgaccatct	cgtccctgga	accggaggac	ttcgccgtct	actactgcca	1140
gcagtcctcg	aactggccgc	gcaccttcgg	ccagggcacc	aaggtcgaga	tcaagtgacc	1200
ttctgctcgt	agcgattact	tcgagcatta	ctgacgacaa	agaccccgc	cgagatgggt	1260
ggggtctttt	tgttggtggg	ctgtgacgtg	ttgtccaacc	gtattattcc	ggtagccggc	1320
atcttcgcga	tacattcccc	ggaatgttgc	gcaacgggga	acgcgcacca	caccgcaacc	1380
acagtgcgcc	acgcccagtc	cggccctgtg	cgctataata	ggtcagttat	tcgcgcgcgc	1440
gtggcgcctt	ctacacccc	agccgcgagg	acacgtggat	tccggacggc	catgccccac	1500
atggcaaacc	gagaacccgc	acacctagca	ttacaaggag	agccattatg	atcgtggcct	1560
acccgcacac	agtgcagtat	gcggggaaac	gtaccaggaa	aggacgaatg	atgataacga	1620
catggcggca	acggggcatg	gccatcgtag	cgatgctgac	cggctctgata	ataatggtgg	1680
gagtgggtgt	cggctcggcg	aatacggcgt	atgccgcgac	gttgacgccc	caggtccagc	1740
tggtcgaatc	gggcggcggc	gtcgtccagc	cgggccgttc	cctgcgtctg	tcgtgcgccg	1800
cctcgggctt	caccttctcc	agctacggca	tgactgggt	gcgtcaggcc	ccgggcaagg	1860
gcctggagtg	ggtggccgtc	atctggtacg	acggctccaa	caagtactac	gccgattccg	1920
tcaagggccg	cttcaccatc	tcgcgtgaca	actccaagaa	caccctgtac	ctgcagatga	1980
actccctgcg	tgccgaagac	accgccgtgt	actactgcgc	ccgcgatccg	cgtggcgcca	2040
ccctgtacta	ctactactac	ggcatggatg	tctggggcca	gggcaccacc	gtgaccgtct	2100
cgtccggcgg	cggcggctcc	ggcggcggcg	gcagcggcgg	cggcggctcc	gacatccaga	2160
tgacccagtc	cccagctcg	ctgagcgcct	cgggtgggca	tcgcgtcacc	atcacctgcc	2220
gtgcctccca	gagcatcaac	tcctacctgg	actggtacca	gcagaagccg	ggcaaggccc	2280
cgaagctgct	gatctacgcc	gcctccagcc	tgagagcg	cgtgccgtcg	cgcttctcgg	2340
gctccggcag	cggcaccgac	ttcaccctga	ccatctcgtc	cctgcagccg	gaggatttcg	2400

Sequence Listings_ASCII.txt

```
ccacctacta ctgccagcag tactactcca ccccggtcac cttcggtccc ggcaccaagg 2460
tcgagatcaa gtgaccaggc atcaaataaa acgaaaaggct cagtcgaaaag actgggcctt 2520
tcgtttttatc tgttggttgt cggtgaacgc tctctactag agtcacactg gctcaccttc 2580
gggtgggcct ttctgcgttt ata 2603
```

```
<210> 141
<211> 2552
<212> DNA
<213> Artificial
```

```
<220>
<223> pPC5TL scFv expression cassettes sequence
```

```
<400> 141
gtcttcctgc tggcctatgc attgggttcc gcagtgccca ctccaggcgg tctgggcggt 60
gtggaagcgg cgctgacatt cgcgttcgtg gcggtcggag tgccgcaggg cgtggcgctt 120
tccgccactt tgctgcaccg cgtggtgttc tactggctgc gcattccgct gggcgcggcg 180
gccatgaagt ggcttgacaa gcataatctt gtctgattcg tctattttca tacccttc 240
ggggaaatag atgtgaaaac cttataaaa cgcgggtttt cgcagaaaca tgcgctagta 300
tcattgatga caacatggac taagcaaaaag tgcttgctcc ctgacccaag aaggatgctt 360
tatgaagata aacaataagg gcaagggcgc tcttatcgcg gcaattaccg ccgcggaac 420
gctattgtca tgcgggctgg ccgctgcaag tgccagtgcg gcagggtgtg attacctgcc 480
taccatcggc cagggtccagc tggtcgaatc gggcggcggc gtcgtccagc cgggccgttc 540
cctgcgtctg gattgcaagg cctcgggcat caccttctcg aactccggca tgactgggt 600
gcgccaggcc ccgggcaagg gcctggaatg ggtcgccgtg atctggtacg atggctcgaa 660
gcgctactac gccgattccg tgaagggccg cttcaccatc tcgcgcgaca actccaagaa 720
caccctgttc ctgcagatga actccctgcg cggcgaagac accgccgtgt actactgcgc 780
caccaacgat gactactggg gccagggcac cctggtcacc gtgtccagcg gcggcggcgg 840
ctccggcggc ggcggctcgg gcggcggcgg cagcgaaatc gtgctgacct agtccccggc 900
caccctgtcc ctgtccccgg gcgaacgtgc caccctgtcg tgccgcgcct ccagtcggt 960
gtccagctac ctggcctggt accagcagaa gccgggccag gccccgcgtc tgctgatcta 1020
cgacgcctcc aaccgcgcca ccggcatccc ggccccgttc tccggctcgg gctccggcac 1080
cgacttcacc ctgaccatct cgtccctgga accggaggac ttcgccgtct actactgcca 1140
gcagtcctcg aactggccgc gcaccttcgg ccagggcacc aaggctcaga tcaagtgacc 1200
ttctgctcgt agcgattact tcgagcatta ctgacgacaa agaccccgac cgagatgggtc 1260
ggggtctttt tgttggtgtg ctgtgacgtg ttgtccaacc gtattattcc ggtagccggc 1320
atcttcgcga tacattcccc ggaatgttgc gcaacgggga acgcgcacca caccgcaacc 1380
acagtgcgcc acgcccagtc cggccctgtg cgctataata ggtcagttat tcgcgcgcgc 1440
gtggcgccct ctacaccccg agccgcgagg acacgtggat tccggacggc catgccccac 1500
```

Sequence Listings_ASCII.txt

```

atggcaaacc gagaacccgc acacctagca ttacaaggag agccattatg gtttataaca 1560
ttcacatatt gcaaacaagg aaaaccgggtc gtgtgggttgc tgctgcggct gcatccgtgc 1620
tgtgttgcat gggggctgta tttccagcga ctatcggagt gactgcggcg tcggccgac 1680
aggtccagct ggtcgaatcg ggcggcggcg tcgtccagcc gggccgttcc ctgctgtgt 1740
cgtgcgccgc ctccgggttc accttctcca gctacggcat gcactgggtg cgtcaggccc 1800
cgggcaaggg cctggagtgg gtggccgtca tctggtacga cggctccaac aagtactacg 1860
ccgattccgt caagggccgc ttcaccatct cgcgtgacaa ctccaagaac accctgtacc 1920
tgcagatgaa ctccctgcgt gccgaagaca ccgccgtgta ctactgcgcc cgcgatccgc 1980
gtggcgccac cctgtactac tactactacg gcatggatgt ctggggccag ggcaccaccg 2040
tgaccgtctc gtccggcggc ggcggctccg gcggcggcgg cagcggcggc ggcggctccg 2100
acatccagat gaccagtc ccgagctcgc tgagcgctc ggtgggcgat cgcgtcacca 2160
tcacctgccg tgcctcccag agcatcaact cctacctgga ctggtaccag cagaagccgg 2220
gcaaggcccc gaagctgctg atctacgccg cctccagcct gcagagcggc gtgccgtcgc 2280
gcttctcggg ctccggcagc ggcaccgact tcacctgac catctcgtcc ctgcagccgg 2340
aggatttcgc cacctactac tgccagcagt actactccac cccgttcacc ttcggccccg 2400
gcaccaaggt cgagatcaag tgaccaggca tcaaataaaa cgaaaggctc agtcgaaaga 2460
ctgggccttt cgttttatct gttgtttgtc ggtgaacgct ctctactaga gtcacactgg 2520
ctcaccttcg ggtgggcctt tctgcgttta ta 2552

```

```

<210> 142
<211> 2567
<212> DNA
<213> Artificial

```

```

<220>
<223> pPC6TL scFv expression cassettes sequence

```

```

<400> 142
gtcttcctgc tggcctatgc attgggttcc gcagtgccca ctccaggcgg tctgggcgggt 60
gtggaagcgg cgctgacatt cgcgttcgtg gcggtcggag tgccgcaggg cgtggcgctt 120
tccgccactt tgctgcaccg cgtggtgttc tactggctgc gcattccgct gggcgcgggc 180
gccatgaagt ggcttgacaa gcataatctt gtctgattcg tctattttca tacccttctc 240
ggggaaatag atgtgaaaac cttataaaa cgcgggtttt cgcagaaaca tgcgctagta 300
tcattgatga caacatggac taagcaaaag tgcttgctcc ctgacccaag aaggatgctt 360
tatgaattat ttacgacaaa aaatttcggc tagtgctatc gcggtgttgt cgacttggtg 420
gttgattttg gcgccaatgc cggctcttgc ggatcaggtc cagctggtcg aatcgggcgg 480
cggcgtcgtc cagccggggc gttccctgcg tctggattgc aaggcctcgg gcatcacctt 540
ctcgaactcc ggcattgcact ggggtgcgcca ggccccgggc aagggcctgg aatgggtcgc 600
cgtgatctgg tacgatggct cgaagcgcta ctacgccgat tccgtgaagg gccgcttcac 660

```

Sequence Listings_ASCII.txt

catctcgcgc	gacaactcca	agaacaccct	gttcctgcag	atgaactccc	tgcgcgccga	720
agacaccgcc	gtgtactact	gcgccaccaa	cgatgactac	tggggccagg	gcaccctggt	780
caccgtgtcc	agcggcgggc	gcggctccgg	cggcgggcgg	tcgggcggcg	gcggcagcga	840
aatcgtgctg	acccagtccc	cggccaccct	gtccctgtcc	ccgggcgaac	gtgccaccct	900
gtcgtgccgc	gcctcccagt	cggtgtccag	ctacctggcc	tgggtaccagc	agaagccggg	960
ccaggccccg	cgtctgctga	tctacgacgc	ctccaaccgc	gccaccggca	tcccggcccc	1020
cttctccggc	tcgggctccg	gcaccgactt	caccctgacc	atctcgtccc	tggaaaccgga	1080
ggacttcgcc	gtctactact	gccagcagtc	ctcgaactgg	ccgcgcacct	tcggccaggg	1140
caccaaggtc	gagatcaagt	gaccttctgc	tcgtagcgat	tacttcgagc	attactgacg	1200
acaaagacct	cgaccgagat	ggtcgggggc	tttttgttgt	ggtgctgtga	cgtgttgtcc	1260
aaccgtatta	ttccggtagc	cggcattttc	gcgatacatt	ccccggaatg	ttgcgcaacg	1320
gggaacgcgc	accacaccgc	aaccacagtg	cgccacgccc	agtccggccc	tgtgcgctat	1380
aataggtcag	ttattcgcgc	gcgcgtggcg	ccctctacac	cccagaccgc	gaggacacgt	1440
ggattccgga	cggccatgcc	ccacatggca	aaccgagaac	ccgcacacct	agcattacaa	1500
ggagagccat	tatgatcgtg	gcctacccgc	acacagtgcg	gtatgcgggg	aaacgtacca	1560
ggaaaggacg	aatgatgata	acgacatggc	ggcaacgggg	catggccatc	gtagcgatgc	1620
tgaccggtct	gataataatg	gtgggagtg	tggtcggctc	ggcgaatacg	gcgtatgccg	1680
cgacgttgac	gccccagggt	cagctgggtc	aatcggggcg	cggcgtcgtc	cagccggggc	1740
gttcctcgcg	tctgtcgtgc	gccgcctcgg	gcttcacctt	ctccagctac	ggcatgcact	1800
gggtgcgtca	ggccccgggc	aagggcctgg	agtgggtggc	cgtcatctgg	tacgacggct	1860
ccaacaagta	ctacgccgat	tccgtcaagg	gccgcttcac	catctcgcgt	gacaactcca	1920
agaacaccct	gtacctgcag	atgaactccc	tgcgtgccga	agacaccgcc	gtgtactact	1980
gcgcccgcga	tccgcgtggc	gccaccctgt	actactacta	ctacggcatg	gatgtctggg	2040
gccagggcac	caccgtgacc	gtctcgtccg	gcggcgggcg	ctccggcggc	ggcggcagcg	2100
gcggcgggcg	ctccgacatc	cagatgaccc	agtccccgag	ctcgtgagc	gcctcgggtg	2160
gcgatcgcgt	caccatcacc	tgccgtgcct	cccagagcat	caactcctac	ctggactggt	2220
accagcagaa	gccgggcaag	gccccgaagc	tgctgatcta	cgccgcctcc	agcctgcaga	2280
gcggcggtgc	gtcgcgcttc	tcgggctccg	gcagcggcac	cgacttcacc	ctgaccatct	2340
cgtccctgca	gccggaggat	ttgccacct	actactgcca	gcagtactac	tccaccccg	2400
tcaccttcgg	cccgggcacc	aaggctcgaga	tcaagtgacc	aggcatcaaa	taaaacgaaa	2460
ggctcagtcg	aaagactggg	cctttcgttt	tatctgttgt	ttgtcgggtg	acgctctcta	2520
ctagagtcac	actggctcac	cttcgggtgg	gcctttctgc	gtttata		2567

<210> 143
<211> 2486

Sequence Listings_ASCII.txt

<212> DNA

<213> Artificial

<220>

<223> pPC7TL scFv expression cassettes sequence

<400> 143

gtcttcctgc	tggcctatgc	attgggttcc	gcagtgccca	ctccaggcgg	tctgggcggt	60
gtggaagcgg	cgctgacatt	cgcggttcgtg	gcggtcggag	tgccgcaggg	cgtaggcgctt	120
tccgccactt	tgctgcaccg	cgtgggtgttc	tactggctgc	gcattccgct	gggcgcggcg	180
gcatgaagt	ggcttgacaa	gcataatctt	gtctgattcg	tctattttca	tacccccctt	240
ggggaaatag	atgtgaaaac	ccttataaaa	cgcggttttt	cgcagaaaaca	tgcgctagta	300
tcattgatga	caacatggac	taagcaaaaag	tgcttgctccc	ctgacccaag	aaggatgctt	360
tatgaattat	ttacgacaaa	aaatttcggc	tagtgctatc	gcggtgttgt	cgacttgtag	420
gttgattttg	gcgccaatgc	cggtctttgc	ggatcaggtc	cagctggctc	aatcgggcgg	480
cggcgtcgtc	cagccggggc	gttccctgcg	tctggattgc	aaggcctcgg	gcatcacctt	540
ctcgaactcc	ggcatgcact	gggtgcgcca	ggccccgggc	aagggcctgg	aatgggtcgc	600
cgtgatctgg	tacgatggct	cgaagcgcta	ctacgccgat	tccgtgaagg	gccgcttcac	660
catctcgcgc	gacaactcca	agaacaccct	gttcctgcag	atgaactccc	tgcgcgccga	720
agacaccgcc	gtgtactact	gcgccaccaa	cgatgactac	tggggccagg	gcaccctggt	780
caccgtgtcc	agcggcgggc	gcggctccgg	cggcggcggc	tcgggcggcg	gcggcagcga	840
aatcgtgctg	accagtgccc	cggccaccct	gtccctgtcc	ccgggcgaac	gtgccaccct	900
gtcgtgccgc	gcctcccagt	cggtgtccag	ctacctggcc	tggtaccagc	agaagccggg	960
ccaggccccg	cgtctgctga	tctacgacgc	ctccaaccgc	gccaccggca	tcccggcccc	1020
cttctccggc	tcgggctccg	gcaccgactt	caccctgacc	atctcgtccc	tggaaccgga	1080
ggacttcgcc	gtctactact	gccagcagtc	ctcgaactgg	ccgcgcacct	tcggccaggg	1140
caccaaggtc	gagatcaagt	gaccttctgc	tcgtagcgat	tacttcgagc	attactgacg	1200
acaaagaccc	cgaccgagat	ggtcggggtc	tttttgttgt	ggtgctgtga	cgtgttgtcc	1260
aaccgtatta	ttccggtagc	cggcattttc	gcgatacatt	ccccggaatg	ttgcgcaacg	1320
gggaacgcgc	accacaccgc	aaccacagtg	cgccacgccc	agtccggccc	tgtgcgctat	1380
aataggctcag	ttattcgcgc	gcgcgtggcg	ccctctacac	cccagaccgc	gaggacacgt	1440
ggattccgga	cggccatgcc	ccacatggca	aaccgagaac	ccgcacacct	agcattacaa	1500
ggagagccat	tatgaagata	aacaataagg	gcaagggcgc	tcttatcgcg	gcaattaccg	1560
ccgcggcaac	gctattgtca	tgcgggctgg	ccgctgcaag	tgccagtgcg	gcacaggtcc	1620
agctggctga	atcgggcggc	ggcgtcgtcc	agccggggcc	ttccctgcgt	ctgtcgtgcg	1680
ccgcctcggg	cttcaccttc	tccagctacg	gcatgcactg	ggtgcgtcag	gccccgggca	1740
agggcctgga	gtgggtggcc	gtcatctggt	acgacggctc	caacaagtac	tacgccgatt	1800
ccgtcaaggg	ccgcttcacc	atctcgcgtg	acaactccaa	gaacaccctg	tacctgcaga	1860

Sequence Listings_ASCII.txt

tgaactccct	gcgtgccgaa	gacaccgccg	tgtactactg	cggccgcgat	ccgcgtggcg	1920
ccaccctgta	ctactactac	tacggcatgg	atgtctgggg	ccagggcacc	accgtgaccg	1980
tctcgtccgg	cggcgggcggc	tccggcgggc	gcggcagcgg	cggcgggcggc	tccgacatcc	2040
agatgaccca	gtccccgagc	tcgctgagcg	cctcgggtggg	cgatcgcgtc	accatcacct	2100
gccgtgcctc	ccagagcatc	aactcctacc	tggactggta	ccagcagaag	ccgggcaagg	2160
ccccgaagct	gctgatctac	gccgcctcca	gcctgcagag	cggcgtgccg	tcgcgcttct	2220
cgggctccgg	cagcggcacc	gacttcaccc	tgaccatctc	gtccctgcag	ccggaggatt	2280
tcgccaccta	ctactgccag	cagtactact	ccaccccggt	caccttcggc	ccgggcacca	2340
aggtcgagat	caagtgacca	ggcatcaaat	aaaacgaaag	gctcagtcga	aagactgggc	2400
ctttcgtttt	atctgttggt	tgtcggtgaa	cgctctctac	tagagtcaca	ctggctcacc	2460
ttcgggtggg	cctttctgcg	tttata				2486

<210> 144
 <211> 2516
 <212> DNA
 <213> Artificial

<220>
 <223> pPC8TL scFv expression cassettes sequence

<400> 144	
gtcttcctgc	60
gtggaagcgg	120
tccgccactt	180
gccatgaagt	240
ggggaaatag	300
tcattgatga	360
tatgaattat	420
gttgattttg	480
cggcgtcgtc	540
ctcgaactcc	600
cgtgatctgg	660
catctcgcgc	720
agacaccgcc	780
caccgtgtcc	840
aatcgtgctg	900
gtcgtgccgc	960
ccaggccccg	1020
cttctccggc	1080

Sequence Listings_ASCII.txt

ggacttcgcc	gtctactact	gccagcagtc	ctcgaactgg	ccgcgcacct	tcggccaggg	1140
caccaagggtc	gagatcaagt	gaccttctgc	tcgtagcgat	tacttcgagc	attactgacg	1200
acaaagaccc	cgaccgagat	ggtcgggggtc	tttttgttgt	ggtgctgtga	cggtgtgtcc	1260
aaccgtatta	ttccggtagc	cggcattttc	gcgatacatt	ccccggaatg	ttgcgcaacg	1320
gggaacgcgc	accacaccgc	aaccacagtg	cgccacgccc	agtccggccc	tgtgcgctat	1380
aataggtcag	ttattcgcg	gcgcgtggcg	ccctctacac	cccagagccg	gaggacacgt	1440
ggattccgga	cggccatgcc	ccacatggca	aaccgagaac	ccgcacacct	agcattacaa	1500
ggagagccat	tatggtttat	aacattcaca	tattgcaaac	aaggaaaacc	ggtcgtgtgg	1560
ttgctgctgc	ggctgcatcc	gtgctgtgtt	gcatgggggc	tgtatttcca	gcgactatcg	1620
gagtgactgc	ggcgtcggcc	gatcagggtcc	agctggtcga	atcgggcggc	ggcgtcgtcc	1680
agccggggccg	ttccctgcgt	ctgtcgtgcg	ccgcctcggg	cttcaccttc	tccagctacg	1740
gcatgcactg	ggtgcgtcag	gccccgggca	agggcctgga	gtgggtggcc	gtcatctggt	1800
acgacggctc	caacaagtac	tacgccgatt	ccgtcaaggg	ccgcttcacc	atctcgcgtg	1860
acaactccaa	gaacaccctg	tacctgcaga	tgaactccct	gcgtgccgaa	gacaccgccg	1920
tgtactactg	cgcccgcgat	ccgcgtggcg	ccaccctgta	ctactactac	tacggcatgg	1980
atgtctgggg	ccagggcacc	accgtgaccg	tctcgtccgg	cggcggcggc	tccggcggcg	2040
gcggcagcgg	cggcggcggc	tccgacatcc	agatgaccca	gtccccgagc	tcgctgagcg	2100
cctcgggtggg	cgatcgcgtc	accatcacct	gccgtgcctc	ccagagcatc	aactcctacc	2160
tggactggta	ccagcagaag	ccgggcaagg	ccccgaagct	gctgatctac	gccgcctcca	2220
gcctgcagag	cggcgtgccg	tcgcgcttct	cgggctccgg	cagcggcacc	gacttcaccc	2280
tgaccatctc	gtccctgcag	ccggaggatt	tcgccaccta	ctactgccag	cagtactact	2340
ccaccccgtt	caccttcggc	ccgggcacca	aggtcgagat	caagtgacca	ggcatcaaat	2400
aaaacgaaag	gctcagtcga	aagactgggc	ctttcgtttt	atctgttgtt	tgtcgggtgaa	2460
cgctctctac	tagagtcaca	ctggctcacc	ttcgggtggg	cctttctgcg	tttata	2516